,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,855980,35370,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,361,1,2,,855980,35370,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
2,364,1,3,,855980,35370,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Assay,Confirmatory,,
3,368,2,3,,855980,35370,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
4,371,1,1,,855980,35370,Inactive,,,,,Human A549 Lung Tumor Cell Growth Inhibition Assay,Screening,,
5,373,1,4,,855980,35370,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
6,374,2,3,,855980,35370,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
7,375,2,3,,855980,35370,Inactive,90108679.0,,,,Mycobacterium tuberculosis Pantothenate Synthetase Assay,Confirmatory,,
8,411,2,1,,855980,35370,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
9,421,1,3,,17390027,35370,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
10,422,1,5,,855980,35370,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
11,425,3,2,,855980,35370,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
12,426,1,2,,17390027,35370,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
13,427,1,1,,17390027,35370,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
14,429,1,5,,855980,35370,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
15,429,1,5,,855980,35370,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
16,430,2,4,,855980,35370,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7 cells),Confirmatory,,
17,431,2,4,,855980,35370,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HPDE-C7K cells),Confirmatory,,
18,432,2,4,,855980,35370,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
19,433,1,1,,17390027,35370,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
20,434,1,2,,17390027,35370,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
21,435,1,2,,17390027,35370,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
22,436,2,1,,855980,35370,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
23,438,1,4,,855980,35370,Inactive,223468676.0,5970.0,,,Cellular assay for TNF alpha induced NFkappaB translocation,Screening,,
24,440,3,3,,855980,35370,Inactive,4503779.0,2357.0,,,Primary HTS Assay for Formylpeptide Receptor (FPR) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide-Like-1 (FPRL1) Ligands,Screening,,
25,441,3,3,,855980,35370,Inactive,54112388.0,2358.0,,,Primary HTS Assay for Formylpeptide Receptor-Like-1 (FPRL1) Ligands and Primary HTS Counter-Screen Assay for Formylpeptide Receptor (FPR) Ligands,Screening,,
26,444,1,1,,855980,35370,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
27,445,3,1,,17390027,35370,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
28,446,1,1,,855980,35370,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
29,449,1,5,,855980,35370,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
30,450,1,2,,855980,35370,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
31,453,2,2,,855980,35370,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
32,454,1,7,,855980,35370,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
33,455,1,7,,855980,35370,Inactive,,,,,VCAM-1 Plate Reader Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression,Screening,,
34,456,1,7,,855980,35370,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Inhibition of TNFa induced VCAM-1 cell surface expression,Screening,,
35,457,1,7,,855980,35370,Inactive,,,,,VCAM-1 Imaging Assay in Pooled HUVECs: Augmentation of TNFa induced VCAM-1 cell surface expression.,Screening,,
36,460,2,2,,855980,35370,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
37,461,1,7,,855980,35370,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression,Screening,,
38,483,1,6,,855980,35370,Inactive,296434520.0,3064.0,,,Aggregation and Clearance of Mutant Huntingtin Protein,Screening,,
39,485,1,8,,855980,35370,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
40,487,1,2,,855980,35370,Inactive,,,,,TNFalpha Induced E-Selectin Expression -  Primary screen,Screening,,
41,488,2,1,,855980,35370,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
42,501,2,2,,855980,35370,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
43,518,2,6,,855980,35370,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
44,521,2,5,,855980,35370,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
45,522,1,2,,855980,35370,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
46,524,1,3,,855980,35370,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
47,525,1,3,,855980,35370,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
48,527,3,1,,855980,35370,Inactive,,,,,Primary HTS Assay for Inhibitors of Bacterial Quorum Sensing,Screening,,
49,528,1,4,,855980,35370,Inactive,67191027.0,3676.0,,,Allosteric Agonists for the VLA-4 Integrin,Screening,,
50,529,1,4,,855980,35370,Inactive,67191027.0,3676.0,,,Allosteric Antagonists for the VLA-4 Integrin,Screening,,
51,530,1,1,,17390027,35370,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
52,538,2,2,,855980,35370,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
53,539,1,2,,855980,35370,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
54,540,1,1,,17390027,35370,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
55,541,1,1,,17390027,35370,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
56,542,1,1,,17390027,35370,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
57,543,1,1,,17390027,35370,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
58,544,2,1,,17390027,35370,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
59,545,1,1,,17390027,35370,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
60,546,1,1,,17390027,35370,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
61,552,1,3,,855980,35370,Active,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type),Screening,,
62,555,1,2,,855980,35370,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
63,556,1,3,,855980,35370,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
64,559,2,2,,855980,35370,Inactive,147728.0,,,,RNA polymerase,Screening,,
65,560,1,2,,855980,35370,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
66,561,1,3,,855980,35370,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
67,565,1,4,,855980,35370,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
68,567,1,4,,855980,35370,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
69,568,1,7,,855980,35370,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
70,568,1,7,,855980,35370,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
71,570,1,4,,855980,35370,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
72,571,1,4,,855980,35370,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
73,572,1,5,,855980,35370,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay (Pilot Screen),Screening,,
74,573,1,4,,855980,35370,Inactive,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
75,574,1,3,,855980,35370,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
76,575,1,4,,855980,35370,Inactive,,,,,Human Endothelial Cell Proliferation Assay,Screening,,
77,576,1,2,,855980,35370,Inactive,67191027.0,3676.0,,,Auto-fluorescence of compounds effecting screening of VLA-4 Integrin,Other,,
78,577,1,1,,855980,35370,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
79,580,1,5,,855980,35370,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay,Screening,,
80,581,2,2,,855980,35370,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
81,583,2,6,,855980,35370,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
82,584,1,3,,17390027,35370,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
83,585,1,4,,17390027,35370,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
84,587,1,5,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
85,588,1,4,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
86,589,1,3,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
87,590,1,3,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
88,591,1,4,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
89,592,1,6,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
90,593,1,4,,855980,35370,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
91,594,1,4,,855980,35370,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
92,595,1,3,,17390027,35370,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
93,596,1,2,,17390027,35370,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
94,597,1,3,,855980,35370,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
95,598,1,4,,855980,35370,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
96,601,1,4,,855980,35370,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance Pilot Screen,Screening,,
97,602,1,4,,855980,35370,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
98,603,1,2,,17390027,35370,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
99,604,1,3,,855980,35370,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
100,605,1,2,,17390027,35370,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
101,606,1,3,,855980,35370,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
102,606,1,3,,855980,35370,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
103,609,1,2,,855980,35370,Inactive,,,,,Chemical Complementation Assay for MKP-3,Screening,,
104,614,1,6,,855980,35370,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
105,615,1,6,,855980,35370,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
106,618,2,6,,855980,35370,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
107,620,2,5,,855980,35370,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
108,622,1,2,,855980,35370,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Negative Modulator Primary Screen,Screening,,
109,623,1,3,,855980,35370,Inactive,499328.0,29738.0,,,Voltage-Dependent Potassium Channel Beta Subunit (KvBeta) Positive Modulator: Primary Screen,Screening,,
110,624,1,2,,855980,35370,Inactive,,,,,Measurement of GPCR-mediated thallium flux through GIRK channels: Primary Screen,Screening,,
111,625,1,2,,855980,35370,Inactive,,,,,Discovery of Novel Allosteric Agonists of the M4 Muscarinic Receptor: Primary Screen,Screening,,
112,626,1,3,,855980,35370,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
113,628,2,4,,855980,35370,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
114,629,1,3,,855980,35370,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
115,630,1,1,,855980,35370,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
116,631,1,4,,855980,35370,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
117,631,1,4,,855980,35370,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
118,633,1,3,,855980,35370,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
119,639,1,2,,855980,35370,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
120,641,1,4,,855980,35370,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
121,645,1,4,,855980,35370,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
122,648,1,3,,855980,35370,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
123,654,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
124,655,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
125,656,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
126,657,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
127,658,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
128,659,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
129,660,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
130,661,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
131,662,1,1,,17390027,35370,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
132,663,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
133,664,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
134,665,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
135,666,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
136,667,1,1,,17390027,35370,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
137,680,1,10,,855980,35370,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
138,684,1,12,,855980,35370,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
139,686,1,1,,855980,35370,Inactive,,,,,Zebrafish Lipid Metabolism Assay---Primary Screen,Screening,,
140,687,1,17,,855980,35370,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
141,701,1,17,,855980,35370,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
142,708,1,4,,855980,35370,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
143,709,1,2,,855980,35370,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
144,719,1,3,,855980,35370,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
145,731,1,5,,855980,35370,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
146,731,1,5,,855980,35370,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
147,746,1,1,,855980,35370,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
148,750,1,3,,855980,35370,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
149,751,1,3,,855980,35370,Inactive,,,,,Disassembly of the 26S Proteasome (ATP Hydrolysis-dependent),Screening,,
150,757,1,4,,855980,35370,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
151,758,1,4,,855980,35370,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
152,759,1,4,,855980,35370,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
153,760,1,4,,855980,35370,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
154,761,1,4,,855980,35370,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
155,764,1,4,,855980,35370,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
156,770,1,1,,855980,35370,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (24 Hour Treatment Protocol),Screening,,
157,771,1,2,,855980,35370,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (48 Hour Treatment Protocol),Screening,,
158,772,1,2,,855980,35370,Inactive,,,,,Cell Growth High Content Screening Assay of Human HT29 Colon Tumor Cells (72 Hour Treatment Protocol),Screening,,
159,774,1,2,,855980,35370,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
160,775,1,3,,855980,35370,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
161,781,1,1,,855980,35370,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
162,782,1,2,,855980,35370,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
163,782,1,2,,855980,35370,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
164,784,1,4,,855980,35370,Inactive,55584151.0,2629.0,,,Primary Cell Based High Throughput Screening Assay for Enhancers of Beta-Glucosidase Activity,Screening,,
165,793,1,2,,855980,35370,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
166,795,1,1,,855980,35370,Inactive,,,,,MLSCN Assay for Activators of Prostate Cell Differentiation,Screening,,
167,797,1,1,,855980,35370,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
168,798,2,12,,855980,35370,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
169,799,1,5,,855980,35370,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
170,800,2,11,,855980,35370,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
171,803,1,4,,855980,35370,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
172,804,1,3,,855980,35370,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
173,813,1,4,,855980,35370,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
174,817,1,1,,855980,35370,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
175,818,1,2,,855980,35370,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
176,827,1,2,,855980,35370,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
177,828,1,5,,855980,35370,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
178,834,1,3,,855980,35370,Inactive,,,,,C. albicans biofilm killing,Screening,,
179,841,1,1,,855980,35370,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
180,847,1,2,,855980,35370,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
181,861,1,1,,855980,35370,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
182,862,1,2,,855980,35370,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
183,868,1,3,,855980,35370,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
184,871,1,2,,855980,35370,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
185,873,1,13,,855980,35370,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
186,875,1,2,,17390027,35370,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
187,878,1,2,,855980,35370,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
188,880,2,1,,855980,35370,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
189,880,2,1,,855980,35370,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
190,880,2,1,,17390027,35370,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
191,880,2,1,,17390027,35370,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
192,881,2,2,,17390027,35370,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
193,884,1,2,,17390027,35370,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
194,885,1,2,,17390027,35370,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
195,886,1,2,,17390027,35370,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
196,886,1,2,,17390027,35370,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
197,887,1,2,,17390027,35370,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
198,889,1,3,,17390027,35370,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
199,892,1,2,,17390027,35370,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
200,893,1,2,,17390027,35370,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
201,893,1,2,,17390027,35370,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
202,894,2,1,,855980,35370,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
203,894,2,1,,17390027,35370,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
204,898,1,1,,855980,35370,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
205,900,1,3,,17390027,35370,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
206,902,1,2,,17390027,35370,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
207,912,1,2,,17390027,35370,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
208,914,1,3,,855980,35370,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
209,915,1,3,,855980,35370,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
210,920,1,2,,855980,35370,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
211,921,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
212,923,1,2,,17390027,35370,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
213,924,1,2,,17390027,35370,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
214,925,1,2,,17390027,35370,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
215,926,1,2,,17390027,35370,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
216,932,1,4,,855980,35370,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
217,938,1,2,,17390027,35370,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
218,940,1,2,,855980,35370,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
219,940,1,2,,26612305,35370,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
220,946,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
221,947,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
222,948,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
223,950,1,1,,855980,35370,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
224,951,1,1,,855980,35370,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
225,952,1,1,,855980,35370,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
226,955,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
227,960,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
228,961,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
229,962,1,2,,17390027,35370,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
230,963,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
231,964,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
232,965,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
233,966,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
234,967,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
235,968,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
236,969,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
237,970,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
238,971,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
239,972,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
240,973,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
241,974,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
242,975,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
243,976,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
244,977,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
245,978,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
246,979,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
247,980,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
248,981,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
249,982,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
250,983,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
251,984,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
252,985,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
253,986,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
254,987,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
255,988,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
256,989,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
257,993,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
258,994,1,2,,17390027,35370,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
259,995,1,2,,17390027,35370,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
260,1001,2,2,,855980,35370,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
261,1006,1,6,,855980,35370,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
262,1007,1,1,,855980,35370,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
263,1008,1,2,,855980,35370,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
264,1009,1,2,,855980,35370,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
265,1012,1,4,,855980,35370,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
266,1016,1,4,,855980,35370,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
267,1018,2,5,,855980,35370,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
268,1019,1,4,,855980,35370,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
269,1020,1,5,,855980,35370,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
270,1021,1,1,,855980,35370,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
271,1022,1,1,,855980,35370,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
272,1027,1,3,,855980,35370,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
273,1030,2,1,,855980,35370,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
274,1030,2,1,,17390027,35370,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
275,1032,1,2,,855980,35370,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
276,1032,1,2,,855980,35370,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
277,1040,1,2,,855980,35370,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
278,1046,1,6,,855980,35370,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
279,1048,1,1,,855980,35370,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
280,1048,1,1,,855980,35370,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
281,1049,1,1,,855980,35370,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
282,1049,1,1,,855980,35370,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
283,1051,1,1,,855980,35370,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
284,1051,1,1,,855980,35370,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
285,1063,1,1,,855980,35370,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
286,1066,1,2,,855980,35370,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
287,1085,1,1,,855980,35370,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
288,1135,1,3,,855980,35370,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
289,1136,1,3,,855980,35370,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
290,1189,1,5,,48413256,35370,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
291,1194,1,3,,48413256,35370,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
292,1195,1,2,,48416710,35370,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
293,1199,1,3,,48413256,35370,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
294,1203,1,3,,855980,35370,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
295,1205,1,4,,48413256,35370,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
296,1208,1,3,,48413256,35370,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
297,1209,2,2,,855980,35370,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
298,1214,1,4,,855980,35370,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
299,1216,1,5,,855980,35370,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
300,1217,1,4,,855980,35370,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
301,1220,2,2,,855980,35370,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
302,1222,1,6,,855980,35370,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
303,1229,1,3,,855980,35370,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
304,1235,1,2,,855980,35370,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
305,1236,1,1,,855980,35370,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
306,1239,1,3,,855980,35370,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
307,1239,1,3,,855980,35370,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
308,1242,1,1,,855980,35370,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
309,1251,1,1,,855980,35370,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
310,1273,1,1,,855980,35370,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
311,1274,1,2,,855980,35370,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
312,1276,1,1,,855980,35370,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
313,1285,1,1,,855980,35370,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
314,1296,1,1,,855980,35370,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
315,1304,1,2,,855980,35370,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
316,1321,1,2,,855980,35370,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
317,1325,1,2,,855980,35370,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
318,1326,1,4,,855980,35370,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
319,1359,1,4,,855980,35370,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
320,1362,1,2,,855980,35370,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
321,1376,1,2,,855980,35370,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
322,1377,1,1,,855980,35370,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
323,1379,1,2,,855980,35370,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
324,1381,1,1,,855980,35370,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
325,1385,2,2,,855980,35370,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
326,1415,1,2,,855980,35370,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
327,1415,1,2,,855980,35370,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
328,1416,1,2,,855980,35370,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
329,1422,1,1,,855980,35370,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
330,1422,1,1,,26612305,35370,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
331,1423,1,2,,855980,35370,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
332,1423,1,2,,855980,35370,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
333,1424,1,1,,855980,35370,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
334,1430,1,1,,855980,35370,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
335,1434,2,3,,855980,35370,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
336,1434,2,3,,855980,35370,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
337,1439,1,1,,855980,35370,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
338,1439,1,1,,855980,35370,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
339,1440,1,1,,855980,35370,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
340,1440,1,1,,855980,35370,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
341,1441,1,1,,855980,35370,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
342,1441,1,1,,855980,35370,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
343,1443,1,3,,855980,35370,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
344,1445,1,1,,855980,35370,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
345,1446,1,3,,855980,35370,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
346,1448,1,3,,855980,35370,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
347,1452,1,1,,855980,35370,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
348,1452,1,1,,17390027,35370,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
349,1456,1,1,,855980,35370,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
350,1457,1,1,,855980,35370,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
351,1457,1,1,,17390027,35370,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
352,1458,1,1,,855980,35370,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
353,1458,1,1,,17390027,35370,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
354,1460,1,3,,855980,35370,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
355,1461,1,2,,855980,35370,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
356,1463,1,1,,855980,35370,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
357,1465,1,1,,855980,35370,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
358,1466,1,2,,855980,35370,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
359,1468,1,1,,855980,35370,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
360,1469,1,1,,855980,35370,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
361,1469,1,1,,17390027,35370,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
362,1469,1,1,,26751584,35370,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
363,1471,2,1,,17390027,35370,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
364,1471,2,1,,26751584,35370,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
365,1476,2,1,,855980,35370,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
366,1476,2,1,,17390027,35370,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
367,1477,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
368,1477,1,1,,17390027,35370,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
369,1478,2,1,,855980,35370,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
370,1478,2,1,,17390027,35370,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
371,1479,1,2,,855980,35370,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
372,1479,1,2,,17390027,35370,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
373,1479,1,2,,26751584,35370,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
374,1481,1,2,,855980,35370,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
375,1486,1,3,,855980,35370,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
376,1487,1,1,,855980,35370,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
377,1490,2,1,,855980,35370,Inactive,10954339.0,,25.1189,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
378,1490,2,1,,26751584,35370,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
379,1496,1,4,,855980,35370,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
380,1496,1,4,,855980,35370,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
381,1509,1,2,,855980,35370,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
382,1510,1,3,,855980,35370,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
383,1511,1,3,,855980,35370,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
384,1515,1,2,,855980,35370,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
385,1527,1,3,,855980,35370,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
386,1529,1,1,,855980,35370,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
387,1530,1,1,,855980,35370,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
388,1531,1,1,,855980,35370,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
389,1532,1,1,,855980,35370,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
390,1554,1,1,,855980,35370,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
391,1556,1,4,,855980,35370,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
392,1565,2,2,,855980,35370,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
393,1566,2,3,,855980,35370,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
394,1578,3,2,,855980,35370,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
395,1580,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
396,1581,1,1,,8149829,35370,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
397,1582,1,1,,8149829,35370,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
398,1583,1,1,,8149829,35370,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
399,1584,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
400,1585,1,1,,8149829,35370,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
401,1586,1,1,,8149829,35370,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
402,1587,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
403,1588,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
404,1589,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
405,1590,1,1,,8149829,35370,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
406,1593,1,1,,8149829,35370,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
407,1594,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
408,1595,1,1,,8149829,35370,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
409,1596,1,1,,8149829,35370,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
410,1597,1,1,,8149829,35370,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
411,1598,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
412,1599,1,1,,8149829,35370,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
413,1600,1,1,,8149829,35370,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
414,1601,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
415,1602,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
416,1603,1,1,,8149829,35370,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
417,1604,1,1,,8149829,35370,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
418,1605,1,1,,8149829,35370,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
419,1606,1,1,,8149829,35370,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
420,1607,1,1,,8149829,35370,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
421,1608,1,1,,8149829,35370,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
422,1609,1,1,,8149829,35370,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
423,1610,1,1,,8149829,35370,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
424,1612,1,1,,8149829,35370,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
425,1613,1,1,,8149829,35370,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
426,1614,1,1,,8149829,35370,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
427,1616,1,1,,8149829,35370,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
428,1619,1,2,,855980,35370,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
429,1621,1,2,,855980,35370,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
430,1626,1,2,,855980,35370,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
431,1631,3,1,,855980,35370,Inconclusive,33286418.0,5315.0,39.8107,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
432,1634,3,1,,855980,35370,Inactive,33286418.0,5315.0,39.8107,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
433,1654,2,2,,855980,35370,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
434,1656,2,2,,855980,35370,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
435,1662,1,2,,855980,35370,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
436,1663,1,2,,855980,35370,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
437,1665,2,2,,855980,35370,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
438,1672,1,3,,855980,35370,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
439,1688,1,1,,855980,35370,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
440,1688,1,1,,26751584,35370,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
441,1700,1,2,,855980,35370,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
442,1706,1,2,,855980,35370,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
443,1721,1,2,,855980,35370,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
444,1722,1,2,,855980,35370,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
445,1766,1,1,,855980,35370,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
446,1766,1,1,,855980,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
447,1766,1,1,,26751584,35370,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
448,1766,1,1,,26751584,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
449,1768,1,1,,855980,35370,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
450,1768,1,1,,855980,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
451,1768,1,1,,26751584,35370,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
452,1768,1,1,,26751584,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
453,1775,1,2,,855980,35370,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
454,1776,1,2,,855980,35370,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
455,1777,3,2,,855980,35370,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
456,1778,3,3,,855980,35370,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
457,1779,2,2,,855980,35370,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
458,1789,1,2,,855980,35370,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
459,1800,1,2,,855980,35370,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
460,1813,1,2,,855980,35370,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
461,1814,1,2,,855980,35370,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
462,1817,2,2,,855980,35370,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
463,1822,1,3,,855980,35370,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
464,1825,1,1,,855980,35370,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
465,1832,2,1,,855980,35370,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
466,1845,1,2,,855980,35370,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
467,1850,2,1,,855980,35370,Active,,,29.32,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
468,1861,2,1,,855980,35370,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
469,1862,1,4,,855980,35370,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
470,1863,2,1,,855980,35370,Active,,,150.0,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
471,1865,1,1,,855980,35370,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
472,1867,1,4,,855980,35370,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
473,1868,1,4,,855980,35370,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
474,1870,1,4,,855980,35370,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
475,1873,1,4,,855980,35370,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
476,1875,2,1,,855980,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
477,1885,2,1,,855980,35370,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
478,1887,1,4,,855980,35370,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
479,1899,1,3,,855980,35370,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
480,1903,2,3,,855980,35370,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
481,1906,1,3,,855980,35370,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
482,1910,1,2,,855980,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
483,1947,1,2,,855980,35370,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
484,1948,1,1,,17390027,35370,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
485,1950,1,3,,855980,35370,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
486,1956,1,1,,855980,35370,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
487,1961,2,2,,855980,35370,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
488,1962,1,2,,855980,35370,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
489,1974,1,2,,855980,35370,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
490,1981,2,1,,855980,35370,Inactive,,,,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,Confirmatory,,
491,1984,1,3,,855980,35370,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
492,1985,2,1,,855980,35370,Inactive,,,,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,Confirmatory,,
493,1986,1,2,,855980,35370,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
494,1987,1,2,,855980,35370,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
495,1996,2,2,,49718184,35370,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
496,2006,3,2,,855980,35370,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
497,2006,3,2,,855980,35370,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
498,2006,3,2,,855980,35370,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
499,2012,3,2,,855980,35370,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
500,2013,2,2,,855980,35370,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
501,2014,3,2,,855980,35370,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
502,2016,1,3,,855980,35370,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
503,2023,1,3,,855980,35370,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
504,2025,1,3,,855980,35370,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
505,2029,1,3,,855980,35370,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
506,2052,2,1,,855980,35370,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
507,2057,1,2,,855980,35370,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
508,2058,3,2,,855980,35370,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
509,2066,1,4,,855980,35370,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
510,2071,2,2,,855980,35370,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
511,2073,2,3,,855980,35370,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
512,2073,2,3,,855980,35370,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
513,2094,1,2,,855980,35370,Inconclusive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
514,2094,1,2,,855980,35370,Inconclusive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
515,2094,1,2,,855980,35370,Inconclusive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
516,2097,1,2,,855980,35370,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
517,2098,1,1,,855980,35370,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
518,2099,1,1,,855980,35370,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
519,2100,1,1,,855980,35370,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
520,2101,1,1,,855980,35370,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
521,2101,1,1,,17390027,35370,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
522,2107,1,1,,855980,35370,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
523,2107,1,1,,17390027,35370,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
524,2112,1,1,,855980,35370,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
525,2112,1,1,,17390027,35370,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
526,2120,1,1,,17390027,35370,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
527,2129,1,2,,855980,35370,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
528,2130,1,3,,855980,35370,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
529,2147,1,1,,855980,35370,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
530,2156,2,2,,855980,35370,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
531,2174,1,3,,855980,35370,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
532,2177,1,3,,855980,35370,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
533,2205,1,1,,855980,35370,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
534,2216,1,3,,855980,35370,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
535,2221,1,2,,855980,35370,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
536,2227,1,2,,855980,35370,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
537,2234,1,2,,855980,35370,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
538,2235,1,2,,855980,35370,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
539,2237,1,2,,855980,35370,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
540,2239,1,2,,855980,35370,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
541,2240,1,1,,85788843,35370,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
542,2241,1,1,,85788843,35370,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
543,2242,1,1,,855980,35370,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
544,2247,1,2,,855980,35370,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
545,2252,1,1,,855980,35370,Active,,,50.0,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,Confirmatory,,
546,2253,1,1,,855980,35370,Inactive,,,,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,Confirmatory,,
547,2275,1,1,,85788843,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
548,2280,2,3,,855980,35370,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
549,2288,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
550,2289,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
551,2300,1,3,,855980,35370,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
552,2313,1,1,,85788843,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
553,2314,1,2,,855980,35370,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
554,2314,1,2,,855980,35370,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
555,2315,1,2,,855980,35370,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
556,2315,1,2,,855980,35370,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
557,2322,1,1,,85788843,35370,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
558,2326,1,1,,855980,35370,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
559,2330,1,1,,85788843,35370,Inconclusive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
560,2380,1,2,,49718184,35370,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
561,2384,1,1,,855980,35370,Active,,,64.59,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
562,2391,1,1,,855980,35370,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
563,2401,1,2,,855980,35370,Inactive,,,,IC50,A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
564,2417,1,1,,855980,35370,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
565,2435,1,2,,855980,35370,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
566,2445,1,2,,855980,35370,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
567,2451,1,2,,855980,35370,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
568,2462,1,1,,855980,35370,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
569,2462,1,1,,855980,35370,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
570,2472,1,2,,855980,35370,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
571,2517,2,1,,855980,35370,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
572,2517,2,1,,17390027,35370,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
573,2520,1,4,,49718184,35370,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
574,2521,1,3,,49718184,35370,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
575,2523,1,1,,855980,35370,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
576,2524,1,2,,49718184,35370,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
577,2528,1,2,,855980,35370,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
578,2528,1,2,,26751584,35370,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
579,2540,1,2,,49718184,35370,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
580,2544,1,2,,49718184,35370,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
581,2546,1,1,,855980,35370,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
582,2546,1,1,,17390027,35370,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
583,2546,1,1,,26751584,35370,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
584,2549,1,1,,855980,35370,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
585,2549,1,1,,17390027,35370,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
586,2550,1,3,,855980,35370,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
587,2551,1,1,,855980,35370,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
588,2551,1,1,,17390027,35370,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
589,2551,1,1,,26751584,35370,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
590,2553,1,2,,855980,35370,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
591,2557,1,3,,855980,35370,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
592,2563,1,1,,855980,35370,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
593,2599,1,2,,49718184,35370,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
594,2606,1,2,,855980,35370,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
595,2629,1,1,,855980,35370,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
596,2629,1,1,,49718184,35370,Active,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
597,2642,1,2,,855980,35370,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
598,2648,1,2,,855980,35370,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
599,2650,2,1,,855980,35370,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
600,2660,1,1,,90341185,35370,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
601,2661,1,1,,855980,35370,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
602,2662,2,1,,855980,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
603,2662,2,1,,26751584,35370,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
604,2666,1,1,,90341185,35370,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
605,2667,1,1,,90341185,35370,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
606,2668,1,1,,90341185,35370,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
607,2674,1,1,,855980,35370,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
608,2675,1,1,,855980,35370,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
609,2676,1,2,,855980,35370,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
610,2685,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
611,2690,1,2,,855980,35370,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
612,2706,1,1,,855980,35370,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
613,2716,1,1,,855980,35370,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
614,2716,1,1,,49718184,35370,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
615,2717,1,2,,855980,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
616,2718,1,1,,855980,35370,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
617,2732,1,1,,855980,35370,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
618,2751,2,2,,855980,35370,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
619,2796,1,4,,855980,35370,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
620,2797,1,2,,855980,35370,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
621,2805,2,2,,49718184,35370,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
622,2806,2,2,,49718184,35370,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
623,2825,1,2,,49718184,35370,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
624,3007,8,3,,103188975,35370,Inconclusive,,,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Other,,
625,3011,8,3,,103188975,35370,Inconclusive,,,,,Cytotoxicity in 2.2.15 cells; Not determined,Other,,
626,3044,6,1,,103188975,35370,Active,,,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Other,8496903.0,
627,3046,6,1,,103188975,35370,Unspecified,,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Other,8496903.0,
628,7699,6,2,,103188975,35370,Active,,,0.01,IC50,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Confirmatory,1573638.0,
629,7783,3,4,,103188975,35370,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
630,8002,5,2,,103188975,35370,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
631,8449,8,2,,103188975,35370,Inconclusive,,,,,Tested in vitro for anticancer activity against 9L cells; Not determined,Other,10072683.0,
632,9851,4,4,,103188975,35370,Unspecified,,,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Other,7543578.0,
633,9852,4,4,,103188975,35370,Unspecified,,,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Other,7543578.0,
634,13511,5,2,,103188975,35370,Unspecified,,,,,AUC in brain,Other,2374145.0,
635,13512,5,2,,103188975,35370,Unspecified,,,,,AUC in serum,Other,2374145.0,
636,14573,5,1,,103188975,35370,Unspecified,,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,Other,8627600.0,
637,14728,4,1,,103188975,35370,Unspecified,,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,Other,8632406.0,
638,15235,3,3,,103188975,35370,Unspecified,,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Other,8632406.0,
639,15236,3,4,,103188975,35370,Unspecified,,,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Other,8632406.0,
640,15237,3,3,,103188975,35370,Unspecified,,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Other,8632406.0,
641,15238,3,4,,103188975,35370,Unspecified,,,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Other,8632406.0,
642,15239,3,3,,103188975,35370,Unspecified,,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Other,8632406.0,
643,15240,3,4,,103188975,35370,Unspecified,,,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Other,8632406.0,
644,15241,3,3,,103188975,35370,Unspecified,,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Other,8632406.0,
645,15242,3,4,,103188975,35370,Unspecified,,,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Other,8632406.0,
646,16366,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Other,8632406.0,
647,16367,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Other,8632406.0,
648,16516,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Other,8632406.0,
649,16517,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Other,8632406.0,
650,16518,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Other,8632406.0,
651,16519,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Other,8632406.0,
652,16520,3,4,,103188975,35370,Unspecified,,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Other,8632406.0,
653,18608,3,3,,103188975,35370,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
654,19209,3,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,9925728.0,
655,19628,4,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,10229629.0,
656,19629,3,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,10229630.0,
657,19636,4,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP) (1-pentanol),Other,7473592.0,
658,19826,3,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,7707321.0,
659,20867,3,4,,103188975,35370,Unspecified,,,,,Concentration in 1-octanol / concentration in water,Other,7996541.0,
660,20871,3,4,,103188975,35370,Unspecified,,,,,Partition coefficient (P) in 1-octanol and 0.1 M Na3PO4 at pH 7,Other,2153206.0,
661,21032,3,4,,103188975,35370,Unspecified,,,,,Partition coefficient which is the ratio of its concentration in octanol to concentration in water,Other,7932583.0,
662,21045,3,4,,103188975,35370,Unspecified,,,,,Evaluated for Partition coefficient in n-octanol and phosphate buffer pH 7.4,Other,2329572.0,
663,21084,3,3,,103188975,35370,Unspecified,,,,,Compound was evaluated for the partition coefficient measured for 1-octanol and 0.01 M potassium phosphate buffer (pH 7.0),Other,2033586.0,
664,21236,3,4,,103188975,35370,Unspecified,,,,,Partition coefficient for 1-octanol/water was evaluated,Other,8632406.0,
665,21904,5,1,,103188975,35370,Unspecified,,,,,Concentration in mouse blood 15 min post injection at a dose 240 mocromol/kg,Other,8632406.0,
666,21905,5,1,,103188975,35370,Unspecified,,,,,Concentration in mouse blood 20 min post injection at a dose 240 mocromol/kg,Other,8632406.0,
667,21906,5,1,,103188975,35370,Unspecified,,,,,Concentration in mouse blood 60 min post injection at a dose 240 mocromol/kg,Other,8632406.0,
668,22007,6,2,,103188975,35370,Unspecified,,,,,"Solubility was determined with phosphate buffer (0.10M, 5 mL).",Other,7473592.0,
669,22061,5,1,,103188975,35370,Unspecified,,,,,Concentration in mouse blood 90 min post injection at a dose 240 mocromol/kg,Other,8632406.0,
670,22170,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index calculated from IC50 and EC50 values of the compound,Other,8627600.0,
671,23239,3,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,11087582.0,
672,23323,3,3,,103188975,35370,Unspecified,,,,,Relative brain exposure of the compound,Other,2374145.0,
673,23362,7,2,,103188975,35370,Inconclusive,,,,,Hydrolysis half life in glycine/HCl buffer at the specified pH; Not available,Other,10229629.0,
674,23366,6,2,,103188975,35370,Inconclusive,,,,,Hydrolysis half life in phosphate buffer at the specified pH; Not available,Other,10229629.0,
675,23368,6,2,,103188975,35370,Inconclusive,,,,,Hydrolysis half life in phosphate buffer; Not available,Other,10229630.0,
676,24309,3,3,,103188975,35370,Unspecified,,,,,Time taken to decrease plasma concentration to half of its initial concentration after ip administration,Other,8627600.0,
677,24685,5,2,,103188975,35370,Unspecified,,,,,"Concentration in plasma after intravenous administration of (5S,6S-IMAZT)",Other,8632406.0,
678,25126,4,3,,103188975,35370,Unspecified,,,,,Half life of the compound,Other,2374145.0,
679,25129,3,3,,103188975,35370,Unspecified,,,,,Half life of the compound,Other,2374145.0,
680,25912,5,2,,103188975,35370,Unspecified,,,,,Half-life for the compound after intravenous administration into BALB/c Mice in plasma samples.,Other,8632406.0,
681,26304,4,4,,103188975,35370,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
682,26380,3,3,,103188975,35370,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
683,26769,4,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,2033591.0,
684,28722,3,3,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,11262088.0,
685,28922,3,3,,103188975,35370,Unspecified,,,,,In vitro Apparent partition coefficients of mixed aryl phosphodiester was determined,Other,12593658.0,
686,28964,4,4,,103188975,35370,Unspecified,,,,,Partition coefficient (logP),Other,11520210.0,
687,28980,3,4,,103188975,35370,Inconclusive,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
688,29360,4,3,,103188975,35370,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
689,31740,5,3,,103188975,35370,Unspecified,,,,,Compound was evaluated as inhibitor of avian myeloblastosis virus (AMV) reverse transcriptase,Other,,
690,32065,8,1,,103188975,35370,Active,,,2.4,ED50,Protection of ATH8 cells against the cytopathic effect of HIV.,Confirmatory,3497272.0,
691,32066,8,1,,103188975,35370,Active,,,45.0,ID50,Required dose to reduce viability of normal uninfected ATH8 cells.,Confirmatory,3497272.0,
692,32074,6,2,,103188975,35370,Active,,,0.4,IC50,The compound was tested for anti HIV-activity (active) against ATH8 cell line,Confirmatory,10450963.0,
693,32208,6,1,,103188975,35370,Unspecified,,,,,Concentration required to suppress the growth of target ATH8 cells,Other,2033586.0,
694,32212,8,1,,103188975,35370,Active,,,5.0,ED50,Concentration required to inhibit the cytopathic effect of HIV-1 on ATH8 cells,Confirmatory,2033586.0,
695,32214,5,2,,103188975,35370,Inconclusive,,,,,Concentration required to inhibit the cytopathic effect of HIV-2 on ATH8 cells; ND=Not determined,Other,2033586.0,
696,32218,5,1,,103188975,35370,Unspecified,,,,,Protection of ATH8 cells against the cytopathic effect of HIV isolate HTLF IIIB,Other,2918509.0,
697,32219,8,1,,103188975,35370,Active,,,,,"Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase",Other,2427720.0,
698,32220,3,4,,103188975,35370,Unspecified,,,,,Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC),Other,2427720.0,
699,32831,6,2,,103188975,35370,Active,,,0.01,IC50,Inhibitory activity against HIV in Alex cells,Confirmatory,2165163.0,
700,38035,6,2,,103188975,35370,Active,,,0.001,EC50,Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay,Confirmatory,7932526.0,
701,40035,8,1,,103188975,35370,Unspecified,,,200.0,TC50,Antiviral activity against Ba-L monocyte tropic isolate strain in monocyte,Confirmatory,11708913.0,
702,41896,3,7,,103188975,35370,Unspecified,,,,,Beta-blocking activity measured by applying the stepwise linear discriminate analysis; Inactive,Other,,
703,42384,7,1,,103188975,35370,Active,,,,,Effective dose which reduces the HIV-1 yield in C8166 cells by 90%,Other,1548681.0,
704,42385,5,1,,103188975,35370,Unspecified,,,,,Pprotection of C8166 cells against the cytopathic effect of HIV isolate RF,Other,2918509.0,
705,42386,6,1,,103188975,35370,Unspecified,,,,,Protection of C8166 cells against the cytopathic effect of HIV isolate CBL-1,Other,2918509.0,
706,42390,6,2,,103188975,35370,Active,,,0.0085,IC50,Antiviral activity against HIV-1 (RF strain) in C8166 cells,Confirmatory,2165161.0,
707,42393,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Concentration which results in 50% survival of uninfected untreated control C8166 cells (cytotoxicity of the compound),Confirmatory,11462972.0,
708,42398,6,2,,103188975,35370,Active,,,0.02,EC50,Inhibition of p24 antigen formation in infected C8166-cells,Confirmatory,7504733.0,
709,42399,6,2,,103188975,35370,Active,,,0.03,EC50,Inhibition of syncytia formation in infected C8166-cells,Confirmatory,7504733.0,
710,42400,4,4,,103188975,35370,Unspecified,,,,,Selectivity index in HIV-1 infected C8166 (human CD4) cells.,Other,11020296.0,
711,42620,6,2,,103188975,35370,Active,,,2.9,EC50,Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes,Confirmatory,9258355.0,
712,42621,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes,Confirmatory,9258355.0,
713,42622,6,2,,103188975,35370,Active,,,0.013000000000000001,EC50,Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes,Confirmatory,9258355.0,
714,43654,6,3,,103188975,35370,Unspecified,,,20.0,CC50,Compound was evaluated cytotoxicity against moloney sarcoma virus (MSV) infected C3H cell cultures.,Confirmatory,,
715,43655,8,2,,103188975,35370,Active,,,,,Compound was evaluated minimum inhibitory concentration against moloney sarcoma virus (MSV) infected C3H cell cultures.,Other,,
716,43810,8,1,,103188975,35370,Unspecified,,,,,Minimal inhibitory concentration was measured as compound concentration that causes a microscopically visible alteration of C3H cell morphology.,Other,2016718.0,
717,43940,6,2,,103188975,35370,Active,,,0.6,IC50,Compound was tested for inhibitory activity against erythroid (BFU-E) progenitor cells,Confirmatory,8057301.0,
718,43981,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for anti-retroviral activity against moloney murine sarcoma virus (MSV) in murine C3H/3T3 embryo fibroblast cell culture,Other,8831773.0,
719,43986,6,2,,103188975,35370,Active,,,0.02,EC50,Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.,Confirmatory,2016718.0,
720,43987,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Effect of compound against Moloney murine sarcoma virus (MSV)-induced transformation of C3H/3T3 embryo murine fibroblasts,Confirmatory,10229629.0,
721,44591,6,2,,103188975,35370,Active,,,0.055,EC50,Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay,Confirmatory,7932526.0,
722,44608,6,3,,103188975,35370,Active,,,0.04,EC50,Compound was evaluated for the inhibition of p24 viral antigen production in C-8166 cells.,Confirmatory,,
723,44610,6,3,,103188975,35370,Active,,,0.03,EC50,Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells,Confirmatory,,
724,44648,8,1,,103188975,35370,Active,,,0.01,ED50,Compound was tested for its ability to inhibit the replication of HIV-1 in C8166 T-cells,Confirmatory,,
725,44650,7,1,,103188975,35370,Unspecified,,,200.0,TD50,Toxic dose required to inhibit the replication of HIV-1 in C8166 T-cells,Confirmatory,,
726,44657,6,2,,103188975,35370,Unspecified,,,500.0,CC50,Ability to reduce 50% viability of C8166 cells acutely infected with HIV-2 strain IIIB,Confirmatory,8642557.0,
727,44658,6,3,,103188975,35370,Unspecified,,,1000.0,CC50,Cytotoxicity in C8166 cell lines,Confirmatory,,
728,44660,6,3,,103188975,35370,Unspecified,,,1000.0,CC50,Concentration of compound required to reduce viability of C8166 cells by 50%.,Confirmatory,,
729,44661,6,3,,103188975,35370,Unspecified,,,1000.0,CC50,Concentration which reduces the viability of uninfected C8166 cells by 50%,Confirmatory,,
730,44662,6,3,,103188975,35370,Unspecified,,,1400.0,CC50,Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line,Confirmatory,,
731,44664,6,2,,103188975,35370,Active,,,0.015,EC50,Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells,Confirmatory,9154967.0,
732,44666,6,3,,103188975,35370,Active,,,0.016,EC50,Anti-HIV activity against HIV-1 infected C8166 cell lines,Confirmatory,,
733,44667,6,3,,103188975,35370,Active,,,0.016,EC50,Compound was evaluated for anti-HIV activity against HIV-1 infected C8166 cell lines,Confirmatory,,
734,44668,6,3,,103188975,35370,Active,,,0.016,EC50,Compound was evaluated for inhibitory activity against HIV-1 infected C8166 cells.,Confirmatory,,
735,44791,6,2,,103188975,35370,Active,,,0.006,EC50,Effective dose to achieve 50% protection of C8166 cells acutely infected with HIV-2 strain IIIB,Confirmatory,8642557.0,
736,44794,6,3,,103188975,35370,Active,,,0.016,EC50,Inhibitory activity against HIV-111B in C8166 cells,Confirmatory,,
737,44795,6,3,,103188975,35370,Active,,,0.016,EC50,"Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA",Confirmatory,,
738,44802,6,3,,103188975,35370,Active,,,0.004,IC50,Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain,Confirmatory,,
739,44809,8,1,,103188975,35370,Unspecified,,,1000.0,TC50,Compound was evaluated for its cytotoxicity against C8166 cell line,Confirmatory,,
740,44810,8,1,,103188975,35370,Unspecified,,,1000.0,TC50,Compound was tested for toxicity against HIV-111B in C8166 cells,Confirmatory,,
741,44815,6,1,,103188975,35370,Unspecified,,,,,Concentration of compound that inhibits incorporation of radiolabeled amino acids by 50 %,Other,2165161.0,
742,44827,6,2,,103188975,35370,Active,,,0.4,EC50,Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control C8166 cells,Confirmatory,11462972.0,
743,44830,6,2,,103188975,35370,Active,,,0.03,EC50,Inhibitory effects on HIV-1 induced syncytium formation in C8166 cells,Confirmatory,8230098.0,
744,45006,7,1,,103188975,35370,Active,,,,,Concentration required to reduce the viability of uninfected cells (CEM-CL13) by 50% on day 11.,Other,1712047.0,
745,45007,7,1,,103188975,35370,Active,,,,,Concentration required to reduce the viability of uninfected cells (CEM-CL13) by 50% on day 19.,Other,1712047.0,
746,45008,7,1,,103188975,35370,Active,,,,,Concentration required to reduce the viability of uninfected cells (CEM-CL13) by 50% on day 22.,Other,1712047.0,
747,45009,7,1,,103188975,35370,Active,,,,,Concentration required to reduce the viability of uninfected cells (CEM-CL13) by 50% on day 7.,Other,1712047.0,
748,45010,8,1,,103188975,35370,Active,,,0.12,ED50,Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.,Confirmatory,1712047.0,
749,45011,8,1,,103188975,35370,Active,,,0.18,ED50,Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.,Confirmatory,1712047.0,
750,45012,8,1,,103188975,35370,Active,,,0.45,ED50,Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.,Confirmatory,1712047.0,
751,45013,8,1,,103188975,35370,Active,,,0.12,ED50,Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.,Confirmatory,1712047.0,
752,45016,6,2,,103188975,35370,Active,,,0.1,IC50,Concentration of compound required to inhibit 50% of viral replication of human immunodeficiency virus in CEM-F cells,Confirmatory,2754712.0,
753,45017,7,1,,103188975,35370,Active,,,,,Concentration of compound required to inhibit 50% of host cell replication of human immunodeficiency virus in CEM-F cells,Other,2754712.0,
754,45022,6,7,,103188975,35370,Unspecified,82310930.0,,100.0,CC50,Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%,Confirmatory,10821705.0,
755,45023,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells,Confirmatory,12593658.0,
756,45025,6,2,,103188975,35370,Unspecified,,,,EC50,Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.,Confirmatory,10821705.0,
757,45026,6,7,,103188975,35370,Active,82310930.0,,0.002,EC50,Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.,Confirmatory,10821705.0,
758,45027,6,2,,103188975,35370,Active,,,0.003,EC50,Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells,Confirmatory,12593658.0,
759,45033,6,2,,103188975,35370,Unspecified,,,1.0,CC50,Tested for cytotoxic concentration in CEM-SS cell culture,Confirmatory,11087582.0,
760,45035,6,2,,103188975,35370,Active,,,0.003,EC50,Tested for anti-HIV -1 Activity in CEM-SS cell culture,Confirmatory,11087582.0,
761,45038,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%,Confirmatory,7562927.0,
762,45041,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration required to reduce viability of uninfected cells in CEM-SS cell line,Confirmatory,14521418.0,
763,45176,6,2,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.,Confirmatory,9240351.0,
764,45180,5,3,,103188975,35370,Unspecified,,,100.0,CC50,Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line,Confirmatory,11052800.0,
765,45185,5,3,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against wild type HIV-1-IIIB strain infected CEMSS cells.,Confirmatory,7473595.0,
766,45188,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 100, Add at infection",Other,10212126.0,
767,45192,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 100, Pretreat with 100 uM",Other,10212126.0,
768,45193,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 1000, Add at infection",Other,10212126.0,
769,45197,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 1000, Pretreat with 100 uM",Other,10212126.0,
770,45198,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 333, Add at infection",Other,10212126.0,
771,45201,3,4,,103188975,35370,Unspecified,,,,,"Compound was evaluated for the effect of Order of Addition on Cytoprotection against HIV-1RF at dilution 333, Pretreat with 100 uM",Other,10212126.0,
772,45373,6,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined,Confirmatory,7562927.0,
773,45534,6,2,,103188975,35370,Active,,,0.0045,EC50,Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.,Confirmatory,9240351.0,
774,45541,6,2,,103188975,35370,Active,,,0.0019,EC50,Effective concentration against 50% survival of HIV -1 infected cells relative to uninfected untreated control (in vitro anti HIV-1 activity),Confirmatory,8709096.0,
775,45542,6,2,,103188975,35370,Active,,,0.0063,EC50,Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells,Confirmatory,14698189.0,
776,45550,6,3,,103188975,35370,Active,,,0.3,EC50,Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells,Confirmatory,,
777,45551,6,3,,103188975,35370,Active,,,0.02,EC50,Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells,Confirmatory,,
778,45552,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay,Confirmatory,7932526.0,
779,45553,6,2,,103188975,35370,Active,,,0.095,EC50,Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay,Confirmatory,7932526.0,
780,45681,6,2,,103188975,35370,Unspecified,,,500.0,CC50,cytotoxic activity in CEM/0 cell line,Confirmatory,8478904.0,
781,45682,6,2,,103188975,35370,Active,,,0.003,EC50,Anti HIV-1 activity in human lymphocyte CEM/0 cell line,Confirmatory,8478904.0,
782,45683,6,2,,103188975,35370,Active,,,0.004,EC50,Anti HIV-2 activity in human lymphocyte CEM/0 cell line,Confirmatory,8478904.0,
783,45706,6,2,,103188975,35370,Active,,,0.0038,EC50,The compound was tested for anti HIV activity in CEM-SS cell lines,Confirmatory,10411486.0,
784,45808,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity in HIV-2 infected CEM cells which are deficient in Thymidine Kinase,Confirmatory,8478904.0,
785,45817,6,3,,103188975,35370,Unspecified,,,10.0,CC50,Compound was evaluated for cytotoxicity against CEM SS cells infected with HIV-1(LAI strain).,Confirmatory,,
786,45818,6,3,,103188975,35370,Active,,,3.0,IC50,Compound was evaluated for antiviral activity against CEM SS cells infected with HIV-1(LAI strain).,Confirmatory,,
787,45822,5,2,,103188975,35370,Inconclusive,,,,,The compound was evaluated for percent reduction of H2O2-induced H2DCFDA fluorescence in human CEM T-cells;No data,Other,10636251.0,
788,45836,7,1,,103188975,35370,Unspecified,,,,,Tested for intracellular levels of AZT phosphate against CEM cell lines.,Other,10841805.0,
789,45842,6,3,,103188975,35370,Unspecified,,,100.0,CC50,Compound was evaluated for cytotoxic activity against CEM cells.,Confirmatory,,
790,45843,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Compound was evaluated for cytotoxicity against thymidine kinase deficient CEM cell line infected with HIV-1,Confirmatory,9871705.0,
791,45844,6,3,,103188975,35370,Unspecified,,,100.0,CC50,Compound was evaluated for the cytotoxic concentration to inhibit HIV replication in CEM cells.,Confirmatory,,
792,45853,6,2,,103188975,35370,Unspecified,,,500.0,CC50,Cytotoxic concentration against HIV-1 infected CEM cell lines,Confirmatory,7837220.0,
793,45893,6,3,,103188975,35370,Unspecified,,,1887.0,IC50,Compound was evaluated for inhibitory activity against cell growth,Confirmatory,,
794,45898,6,2,,103188975,35370,Active,,,0.0026,IC50,Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells,Confirmatory,9548815.0,
795,45902,6,2,,103188975,35370,Active,,,1.9,IC50,Compounds were tested for cytotoxicity against CEM-SS cells in terms of incorporation of [3H]dThd,Confirmatory,9548815.0,
796,45989,6,2,,103188975,35370,Unspecified,,,,,Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.,Other,9046339.0,
797,45990,6,2,,103188975,35370,Unspecified,,,14300.0,CC50,Cytotoxic concentration required to inhibit 50% of HIV-1 in CEM cells,Confirmatory,9341906.0,
798,45991,6,2,,103188975,35370,Unspecified,,,,,Cytotoxic concentration required to reduce CEM cell viability by 50%,Other,8709116.0,
799,45996,7,1,,103188975,35370,Active,,,,,Cytotoxic activity against CEM cell lines.,Other,10841805.0,
800,46001,6,2,,103188975,35370,Unspecified,,,,,50% effective concentration of compound which is required to protect human CEM cells against HIV-1 induced giant cell formation.,Other,9046339.0,
801,46002,6,2,,103188975,35370,Unspecified,,,,,50% effective concentration of compound which is required to protect human CEM cells against HIV-2 induced giant cell formation.,Other,9046339.0,
802,46007,6,2,,103188975,35370,Active,,,0.023,EC50,Anti-HIV activity against HIV-I RFII strain in CEM cell line,Confirmatory,8632437.0,
803,46017,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Compound was evaluated for anti-HIV activity against thymidine kinase deficient CEM cell line infected with HIV-1,Confirmatory,9871705.0,
804,46018,6,3,,103188975,35370,Active,,,0.005,EC50,Compound was evaluated for antiviral activity against HIV-1 (IIIB) infected CEM cells.,Confirmatory,,
805,46019,6,3,,103188975,35370,Active,,,0.008,EC50,Compound was evaluated for antiviral activity against HIV-2 (ROD) infected CEM cells.,Confirmatory,,
806,46020,6,3,,103188975,35370,Active,,,0.005,EC50,Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.,Confirmatory,,
807,46021,6,3,,103188975,35370,Active,,,0.008,EC50,Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.,Confirmatory,,
808,46022,6,3,,103188975,35370,Unspecified,,,100.0,EC50,Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.,Confirmatory,,
809,46033,6,7,,103188975,35370,Active,82310930.0,,0.003,EC50,Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls,Confirmatory,7996541.0,
810,46036,6,2,,103188975,35370,Unspecified,,,1.0,IC50,Cytotoxic concentration against 50% survival of uninfected untreated control CEM-SS cells,Confirmatory,8709096.0,
811,46042,6,2,,103188975,35370,Active,,,0.002,IC50,Inhibitory activity against the HIV-1-induced cytopathic effect in CEM-SS cell line,Confirmatory,7650678.0,
812,46043,6,2,,103188975,35370,Active,,,0.002,IC50,Inhibitory activity against the cytopathic effect of HIV-1 IIIB strain in CEM-SS cells,Confirmatory,7650678.0,
813,46044,6,2,,103188975,35370,Active,,,0.004,IC50,Inhibitory activity against the cytopathic effect of HIV-1 LAV strain in CEM-SS cells,Confirmatory,7650678.0,
814,46045,6,2,,103188975,35370,Active,,,0.003,IC50,Inhibitory activity against the cytopathic effect of HIV-1 RFstrain in CEM-SS cells,Confirmatory,7650678.0,
815,46046,6,2,,103188975,35370,Active,,,0.005,IC50,Inhibitory activity against the cytopathic effect of HIV-2 A17 (pyridinone-res) strain in CEM-SS cells,Confirmatory,7650678.0,
816,46047,6,2,,103188975,35370,Unspecified,,,1.0,IC50,Inhibitory activity against the cytopathic effect of HIV-2 G910-6(AZT-res) strain in CEM-SS cells,Confirmatory,7650678.0,
817,46048,6,2,,103188975,35370,Active,,,0.03,IC50,Inhibitory activity against the cytopathic effect of HIV-2 MS strain in CEM-SS cells,Confirmatory,7650678.0,
818,46049,6,2,,103188975,35370,Active,,,0.005,IC50,Inhibitory activity against the cytopathic effect of HIV-2 ROD strain in CEM-SS cells,Confirmatory,7650678.0,
819,46051,4,4,,103188975,35370,Active,,,0.003,IC50,Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line,Confirmatory,11052800.0,
820,46053,6,2,,103188975,35370,Unspecified,,,1.0,IC50,The compound was tested for anti HIV activity in CEM-SS cell lines,Confirmatory,10411486.0,
821,46059,4,4,,103188975,35370,Active,,,0.003,IC50,Inhibition of wild type HIV-1-IIIB strain replication in CEM-SS cells,Confirmatory,7473595.0,
822,46079,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index value of the cpmpound against CEM-SS cells,Other,10411486.0,
823,46082,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Compound was tested for cytotoxicity against HIV-1 in CEM-SS cells,Confirmatory,9873664.0,
824,46174,6,3,,103188975,35370,Active,,,0.18600000000000003,EC50,Effective concentration against HIV-1-infected CEM cells in mice administered intraperitoneally,Confirmatory,8627600.0,
825,46191,4,5,,103188975,35370,Active,,,0.003,EC50,In vitro inhibitory activity against replication of HIV-1 in human lymphocyte CEM cells,Confirmatory,,
826,46192,4,5,,103188975,35370,Active,,,0.0035,EC50,In vitro inhibitory activity against replication of HIV-2 in human lymphocyte CEM cells,Confirmatory,,
827,46193,4,5,,103188975,35370,Unspecified,,,100.0,EC50,In vitro inhibitory activity against replication of HIV-2 in human lymphocyte thymidine kinase deficient CEM cells,Confirmatory,,
828,46197,6,3,,103188975,35370,Active,,,0.011000000000000001,EC50,Inhibitory effect against HIV-1 replication in CEM cells.,Confirmatory,7538589.0,
829,46198,6,2,,103188975,35370,Unspecified,,,35.0,EC50,Inhibitory effect against HIV-2 replication in CEM /TK-(thymidine kinase deficient) cells.,Confirmatory,7538589.0,
830,46199,6,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Inhibitory effect against HIV-2 replication in CEM cells.,Confirmatory,7538589.0,
831,46200,6,2,,103188975,35370,Active,,,0.003,EC50,Tested for in vitro drug concentration which produces 50% survival of HIV-1 infected CEM cells relative to uninfected untreated controls,Confirmatory,7932583.0,
832,46204,6,2,,103188975,35370,Active,,,0.003,EC50,Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells,Confirmatory,7527463.0,
833,46205,6,2,,103188975,35370,Active,,,0.004,EC50,Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells,Confirmatory,7527463.0,
834,46250,6,2,,103188975,35370,Active,,,0.0019,EC50,Concentration which produces a 50% survival of HIV-1 infected cells relative to uninfected control CEM-SS cells (in vitro anti-HIV activity),Confirmatory,11462972.0,
835,46255,4,4,,103188975,35370,Active,,,0.011000000000000001,EC50,Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 2),Confirmatory,10206539.0,
836,46370,6,3,,103188975,35370,Unspecified,,,191.0,IC50,Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration,Confirmatory,8627600.0,
837,46371,6,2,,103188975,35370,Unspecified,,,301.6,IC50,Anti-HIV activity against HIV-I RFII strain in CEM cell line,Confirmatory,8632437.0,
838,46372,6,2,,103188975,35370,Unspecified,,,375.0,IC50,Antiproliferative activity was determined against human T-lymphocyte cells-CEM,Confirmatory,12801219.0,
839,46374,6,2,,103188975,35370,Active,,,0.87,IC50,Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells,Confirmatory,11708913.0,
840,46375,6,2,,103188975,35370,Active,,,0.08199999999999999,IC50,Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells,Confirmatory,11708913.0,
841,46376,6,2,,103188975,35370,Active,,,0.046,IC50,Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells,Confirmatory,11708913.0,
842,46377,6,2,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells,Confirmatory,11708913.0,
843,46378,6,2,,103188975,35370,Active,,,0.006,IC50,Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells,Confirmatory,11708913.0,
844,46379,6,2,,103188975,35370,Active,,,0.04,IC50,Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells,Confirmatory,11708913.0,
845,46380,6,2,,103188975,35370,Active,,,0.013999999999999999,IC50,Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells,Confirmatory,11708913.0,
846,46381,6,2,,103188975,35370,Active,,,0.02,IC50,Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells,Confirmatory,11708913.0,
847,46382,6,2,,103188975,35370,Active,,,0.08,IC50,Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells,Confirmatory,11708913.0,
848,46383,6,2,,103188975,35370,Active,,,0.087,IC50,Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells,Confirmatory,11708913.0,
849,46384,6,2,,103188975,35370,Active,,,0.008,IC50,Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells,Confirmatory,11708913.0,
850,46385,6,2,,103188975,35370,Active,,,0.017,IC50,Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells,Confirmatory,11708913.0,
851,46390,6,2,,103188975,35370,Active,,,13.0,IC50,Compound was evaluated for its toxicity by Calorimetric assay in CEM,Confirmatory,9357530.0,
852,46395,6,2,,103188975,35370,Unspecified,,,,,Inhibition of human immunodeficiency virus-1 (HIV-1) induced cytopathicity in CEM cells,Other,8831773.0,
853,46399,6,2,,103188975,35370,Unspecified,,,,,Inhibition of human immunodeficiency virus-2 (HIV-2) induced cytopathicity in CEM cells,Other,8831773.0,
854,46442,6,2,,103188975,35370,Active,,,0.006,IC50,Compound was tested for inhibitory activity against HIV-1 replication in CEM-SS cells,Confirmatory,9873664.0,
855,46446,6,2,,103188975,35370,Unspecified,,,1.0,IC50,Concentration which results in 50% survival of uninfected untreated control CEM-SS cells (cytotoxicity of the compound),Confirmatory,11462972.0,
856,46447,8,2,,103188975,35370,Inconclusive,,,,,Cytotoxicity on CEM cells; Not tested,Other,9438017.0,
857,46561,6,2,,103188975,35370,Active,,,13.0,IC50,Cytotoxic concentration against CEM cells was determined on day 6,Confirmatory,8057301.0,
858,46565,6,3,,103188975,35370,Active,,,14.0,IC50,Cytotoxicity in CEM cells,Confirmatory,,
859,46587,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Inhibitory concentration (cytotoxic activity) which results in a 50% survival of HIV-1-infected CEM cells relative to uninfected untreated control cells,Confirmatory,7996541.0,
860,46589,6,2,,103188975,35370,Active,,,0.01,IC50,Inhibitory concentration against HIV-1 infected CEM cell lines,Confirmatory,7837220.0,
861,46599,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Tested for in vitro drug concentration which results in 50% survival of uninfected untreated control CEM cells,Confirmatory,7932583.0,
862,46608,6,2,,103188975,35370,Active,,,5.6,IC50,In vitro inhibition of CEM-SS cell growth by 50 %,Confirmatory,2016713.0,
863,46613,3,5,,103188975,35370,Unspecified,,,,,Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells relative to AZT,Other,10206539.0,
864,46636,6,2,,103188975,35370,Unspecified,,,5.0,CC50,Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells,Confirmatory,9154976.0,
865,46637,6,2,,103188975,35370,Active,,,0.003,EC50,Inhibition of HIV-1 LA1 cytopathic effects on CEM-CL13 cells in vitro.,Confirmatory,9154976.0,
866,46640,6,2,,103188975,35370,Unspecified,,,500.0,CC50,Cytotoxic concentration against CEM cells (in vitro),Confirmatory,8648614.0,
867,46641,6,3,,103188975,35370,Unspecified,,,250.0,CC50,Concentration required to reduce cell viability of CEM/0 cells by 50%,Confirmatory,,
868,46642,6,3,,103188975,35370,Unspecified,,,250.0,CC50,Concentration of compound required to reduce viability of CEM/0 cells by 50%.,Confirmatory,,
869,46643,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Concentration required to reduce 50% of the number of CEM/O cells in the mock infected cell cultures.,Confirmatory,8765527.0,
870,46644,6,2,,103188975,35370,Unspecified,,,500.0,CC50,Concentration required to reduce CEM/0 cell viability by 50%,Confirmatory,11356105.0,
871,46645,6,3,,103188975,35370,Active,,,0.003,EC50,Anti-HIV activity against HIV-1 infected CEM/0 cell lines.,Confirmatory,,
872,46646,6,3,,103188975,35370,Active,,,0.006,EC50,Anti-HIV activity against HIV-2 infected CEM/0 cell lines.,Confirmatory,,
873,46647,6,3,,103188975,35370,Active,,,0.003,EC50,Compound was evaluated for anti-HIV activity against HIV-1 infected CEM/0 cell lines.,Confirmatory,,
874,46648,6,3,,103188975,35370,Active,,,0.006,EC50,Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/0 cell lines.,Confirmatory,,
875,46649,6,2,,103188975,35370,Active,,,0.003,EC50,Activity against HIV-1 in CEM cells (in vitro),Confirmatory,8648614.0,
876,46651,6,2,,103188975,35370,Active,,,0.004,EC50,Activity against HIV-2 in CEM cells (in vitro),Confirmatory,8648614.0,
877,46656,6,2,,103188975,35370,Active,,,0.0064,EC50,Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.,Confirmatory,11356105.0,
878,46657,6,2,,103188975,35370,Active,,,0.006,EC50,Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.,Confirmatory,11356105.0,
879,46767,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against CEM cell lines,Other,2165162.0,
880,46800,6,2,,103188975,35370,Active,,,0.006,EC50,Concentration required to reduce 50% of the number of CEM/O cells in the HIV-1 infected cell cultures.,Confirmatory,8765527.0,
881,46801,6,2,,103188975,35370,Active,,,0.004,EC50,Concentration required to reduce 50% of the number of CEM/O cells in the HIV-2 infected cell cultures.,Confirmatory,8765527.0,
882,46818,6,2,,103188975,35370,Unspecified,,,100.0,CC50,The cytotoxicity was measured on wild type CEM/O cells.,Confirmatory,9554875.0,
883,46819,6,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity was measured on HIV-1 in wild-type CEM/O cells,Confirmatory,9554875.0,
884,46823,6,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity was measured on HIV-2 in wild-type CEM/O cells,Confirmatory,9554875.0,
885,46837,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells,Confirmatory,12593658.0,
886,46838,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells,Confirmatory,12593658.0,
887,46839,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%,Confirmatory,7562927.0,
888,46840,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration required to reduce viability of uninfected cells in CEM/TK cell line,Confirmatory,14521418.0,
889,46843,6,3,,103188975,35370,Unspecified,,,250.0,EC50,Anti-HIV activity against HIV-2 infected CEM/TK- cell lines.,Confirmatory,,
890,46845,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined,Confirmatory,7562927.0,
891,46846,6,3,,103188975,35370,Unspecified,,,250.0,EC50,Compound was evaluated for anti-HIV activity against HIV-2 infected CEM/TK- cell lines.,Confirmatory,,
892,46847,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Activity against HIV-1 in CEM/TK cells (in vitro),Confirmatory,8648614.0,
893,46848,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Concentration required to reduce 50% of the number of CEM/TK cells in the HIV-2 infected cell cultures.,Confirmatory,8765527.0,
894,46937,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against CEM cell lines,Other,2165162.0,
895,46940,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio between IC50/EC50 of HIV-I RFII strain in CEM cell line,Other,8632437.0,
896,46953,6,3,,103188975,35370,Active,,,14.3,CC50,Cytotoxic concentration towards CEM cells,Confirmatory,,
897,46970,6,2,,103188975,35370,Active,,,6.0,CC50,Concentration required to reduce the viability of mock-infected CEM cells by 50%,Confirmatory,11714616.0,
898,46975,6,2,,103188975,35370,Unspecified,,,100.0,CC50,In vitro cytotoxic concentration in CEM cells.,Confirmatory,10229629.0,
899,46983,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Tested for cytotoxic concentration in CEM/TK- cell culture,Confirmatory,11087582.0,
900,46985,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Tested for anti-HIV -1 Activity in CEM/TK- cell culture,Confirmatory,11087582.0,
901,46988,6,2,,103188975,35370,Unspecified,,,,,Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.,Other,9046339.0,
902,46990,6,2,,103188975,35370,Unspecified,,,,,50% effective concentration of compound which is required to protect Thymidine kinase deficient human CEM (CEM/TK-) cells against HIV-2.,Other,9046339.0,
903,46995,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Compound was tested for cytotoxicity against HIV-1 in CEM/TK- cells,Confirmatory,9873664.0,
904,46996,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity was measured on HIV-2 in mutant thymidine kinase-deficient CEM/TK- cells,Confirmatory,9554875.0,
905,47002,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Compound was tested for inhibitory activity against HIV-1 replication in CEM/TK- cells,Confirmatory,9873664.0,
906,47009,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%,Confirmatory,11356105.0,
907,47062,4,5,,103188975,35370,Inconclusive,,,,,Inhibition of p24 expression was measured at 1 uM using vVK/CV-1 assay,Other,8295217.0,
908,47105,6,2,,103188975,35370,Unspecified,,,,,compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells,Other,9548818.0,
909,47111,6,2,,103188975,35370,Active,,,0.006999999999999999,EC50,In vitro inhibition of HIV-1 replication in human T-lymphocytic cells (CEM).,Confirmatory,10229629.0,
910,47113,6,2,,103188975,35370,Active,,,0.006,EC50,In vitro inhibition of HIV-2 replication in human T-lymphocytic cells (CEM).,Confirmatory,10229629.0,
911,47139,6,2,,103188975,35370,Active,,,0.001,EC50,Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells,Confirmatory,11170632.0,
912,47140,6,7,,103188975,35370,Active,82310930.0,,0.003,EC50,Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells,Confirmatory,11714616.0,
913,47141,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells,Confirmatory,11714616.0,
914,47288,6,3,,103188975,35370,Active,,,14.0,IC50,Compound was evaluated for cytotoxicity against CEM cells,Confirmatory,,
915,47289,6,2,,103188975,35370,Active,,,14.0,IC50,Compound was evaluated for its cytotoxicity against CEM cells.,Confirmatory,9873395.0,
916,47300,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for its inhibitory activity against HIV replication in CEM cells.,Other,1738145.0,
917,47301,6,2,,103188975,35370,Active,,,14.2,IC50,Concentration required to kill 50% of CEM cells,Confirmatory,11170632.0,
918,47303,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against CEM cells,Confirmatory,12383014.0,
919,47305,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against CEM cells,Confirmatory,11882000.0,
920,47307,6,2,,103188975,35370,Active,,,30.9,IC50,Cytotoxicity against uninfected PHA-stimulated CEM cells was determined.,Confirmatory,8421287.0,
921,47311,6,2,,103188975,35370,Active,,,30.9,IC50,"Cytotoxicity was determined in CEM cells, relative to RVT",Confirmatory,15081000.0,
922,47336,6,2,,103188975,35370,Active,,,1.5,IC50,Compound was tested for inhibitory activity against human myeloid cells (CFU-GM),Confirmatory,8057301.0,
923,47426,6,2,,103188975,35370,Active,,,29.0,IC50,Evaluated in vitro for their potential toxic effects human CEM cells,Confirmatory,12540238.0,
924,47432,6,2,,103188975,35370,Active,,,14.3,IC50,Inhibitory activity was evaluated on mitochondrial DNA content of CEM cells,Confirmatory,10197975.0,
925,47445,6,2,,103188975,35370,Active,,,14.3,IC50,In vitro cytotoxicity in CEM cells.,Confirmatory,11689085.0,
926,47449,6,2,,103188975,35370,Active,,,30.9,IC50,Tested in vitro for anticancer activity against CEM cells,Confirmatory,10072683.0,
927,47450,6,2,,103188975,35370,Unspecified,,,,,compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells,Other,9548818.0,
928,47454,5,1,,103188975,35370,Unspecified,,,,,Antiviral test was performed against HIV (LAV strain) on CEM cells using 30 tissue culture infectious units. T,Other,2165162.0,
929,47455,5,1,,103188975,35370,Unspecified,,,,,Antiviral test was performed against HIV (LAV strain) on CEM cells using 50 tissue culture infectious units.,Other,2165162.0,
930,47460,5,1,,103188975,35370,Unspecified,,,,,Evaluated for the anticellular activity against CEM cells by dye-exclusion method,Other,2157012.0,
931,47462,8,1,,103188975,35370,Active,,,0.1,ID50,In vitro antiviral test was performed on HIV(LAV strain) infected CEM cells,Confirmatory,2536441.0,
932,47474,3,4,,103188975,35370,Unspecified,,,,,Percent reduction in p24 gag expression in CEM cells,Other,2296018.0,
933,47476,3,4,,103188975,35370,Unspecified,,,,,Total viral index (TAI) is the area between the cytotoxicity and the antiviral activity curve for CEM cells.,Other,1738145.0,
934,47612,5,1,,103188975,35370,Unspecified,,,,,Minimum compound concentration that reduced cell viability by 25% for HIV replication in CEM cells.,Other,1738145.0,
935,47625,7,1,,103188975,35370,Active,,,,,The 90% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells,Other,2536441.0,
936,47634,3,4,,103188975,35370,Unspecified,,,,,Inhibitory effect against synthesis of p24 gag protein in CEM cells.,Other,2296018.0,
937,47640,6,2,,103188975,35370,Active,,,0.00032,EC50,Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells.,Confirmatory,2153206.0,
938,47641,6,2,,103188975,35370,Unspecified,,,100.0,IC50,"Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in CEM cells.",Confirmatory,2153206.0,
939,47657,6,2,,103188975,35370,Active,,,0.006,EC50,Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.,Confirmatory,8385224.0,
940,47658,6,2,,103188975,35370,Active,,,20.0,IC50,Antiviral activity measured in lymphocytic cell line (CEM-C113) infected with HIV-1 cell free supernatants,Confirmatory,8385224.0,
941,51036,6,2,,103188975,35370,Active,,,45.0,CC50,Drug concentration which inhibits 50% of growth of cord blood mononuclear cells (CBMCs),Confirmatory,7837220.0,
942,52553,8,4,,103188975,35370,Inconclusive,,,,,Inhibitory activity based on the inhibition of [Ca2+] mobilization induced by human SDF-1alpha stimulation through CXCR4; N.T. means not tested,Other,11958995.0,
943,53666,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Inhibitory activity against DNA polymerase-alpha derived from peripheral blood mononuclear cells,Confirmatory,1720175.0,
944,54867,5,2,,103188975,35370,Inconclusive,,,,,Inhibitory concentration against Cryptococcus neoformans; Not tested,Other,15214779.0,
945,56385,3,3,,103188975,35370,Unspecified,,,,,Selective index is the ratio of inhibitory concentrations of cellular DNA polymerase alpha to HIV-1 reverse transcriptase,Other,7512142.0,
946,56389,3,7,,103188975,35370,Unspecified,,,,,Selective index is the ratio of inhibitory concentrations of cellular DNA polymerase delta to HIV-1 reverse transcriptase,Other,7512142.0,
947,56582,4,7,,103188975,35370,Unspecified,,,,,Inhibitory activity against deoxycytidine kinase from L1210 cells,Other,6644738.0,
948,70382,3,4,,103188975,35370,Inconclusive,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 0.3 mM in experiment-1; ND= No data,Other,,
949,70383,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 0.3 mM in experiment-2,Other,,
950,70384,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 100 mM in experiment-1,Other,,
951,70387,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 10 mM in experiment-1,Other,,
952,70389,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 10 mM in experiment-2,Other,,
953,70390,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 1 mM in experiment-1,Other,,
954,70392,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 1 mM in experiment-2,Other,,
955,70521,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 30 mM in experiment-1,Other,,
956,70522,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 30 mM in experiment-2,Other,,
957,70527,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 3 mM in experiment-1,Other,,
958,70528,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as burst forming unit for erythrocyte at a compound concentration of 3 mM in experiment-2,Other,,
959,71777,6,2,,103188975,35370,Active,,,0.035,EC50,Concentration that reduces Friend murine leukemia virus titer by 50%,Confirmatory,1992143.0,
960,72042,6,2,,103188975,35370,Unspecified,,,203.0,IC50,Inhibitory effect of compound on the proliferation of murine mammary carcinoma cells FM3A/0,Confirmatory,11356105.0,
961,74862,3,4,,103188975,35370,Inconclusive,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 0.3 mM in experiment-1; ND= No data,Other,,
962,74863,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 0.3 mM in experiment-2,Other,,
963,74864,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 100 mM in experiment-1,Other,,
964,74867,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 10 mM in experiment-1,Other,,
965,74869,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 10 mM in experiment-2,Other,,
966,74870,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 1 mM in experiment-1,Other,,
967,74872,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 1 mM in experiment-2,Other,,
968,74877,3,4,,103188975,35370,Inconclusive,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 30 mM in experiment-1; ND= No data,Other,,
969,74878,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 30 mM in experiment-2,Other,,
970,74883,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 3 mM in experiment-1,Other,,
971,74995,3,4,,103188975,35370,Unspecified,,,,,Tested for bone marrow cell toxicity expressed as colony forming unit of granulocyte -macrophage at a compound concentration of 3 mM in experiment-2,Other,,
972,78738,6,2,,103188975,35370,Unspecified,,,1872.0,IC50,Concentration required to inhibit uninfected H9 cell growth by 50%,Confirmatory,14736256.0,
973,78752,6,2,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxic concentration against HIV-1 infected H9 cell lines,Confirmatory,7837220.0,
974,78759,6,3,,103188975,35370,Active,,,0.045,EC50,Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%,Confirmatory,,
975,78760,6,2,,103188975,35370,Active,,,0.037000000000000005,EC50,Anti-HIV activity was measured in H9-cells by MAGI assay,Confirmatory,9804704.0,
976,78761,6,2,,103188975,35370,Active,,,0.015,EC50,Anti-HIV activity was measured in H9-cells.,Confirmatory,9804704.0,
977,78770,6,3,,103188975,35370,Active,,,0.15,EC50,Effective concentration against HIV-1 replication in H9 lymphocyte cells was determined,Confirmatory,,
978,78779,6,3,,103188975,35370,Active,,,0.009000000000000001,EC50,Evaluation for anti-HIV activity using T cell line (H9).,Confirmatory,,
979,78783,6,2,,103188975,35370,Active,,,0.15,EC50,Toxic concentration on HIV-1 mock infected H9 lymphocyte cells,Confirmatory,8676334.0,
980,78924,5,1,,103188975,35370,Unspecified,,,,,Effective dose required to inhibit virus replication growth by 50%,Other,8642556.0,
981,78935,6,3,,103188975,35370,Unspecified,,,1875.0,IC50,Compound was tested for inhibitory activity against HIV-1 replication in H9 lymphocyte cells,Confirmatory,,
982,78942,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Inhibitory activity against HIV-1 replication in mock infected H9 cells,Confirmatory,8676334.0,
983,78943,6,3,,103188975,35370,Unspecified,,,1875.0,IC50,Inhibitory activity against gorwth of uninfected H9 cell growth by 50%,Confirmatory,,
984,78946,6,2,,103188975,35370,Active,,,0.07,IC50,Inhibitory concentration against HIV-1 infected H9 cell lines,Confirmatory,7837220.0,
985,78947,6,2,,103188975,35370,Unspecified,,,,,Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%,Other,8642556.0,
986,78948,6,3,,103188975,35370,Unspecified,,,500.0,IC50,Cytotoxicity against H9 cell line,Confirmatory,,
987,78958,3,4,,103188975,35370,Unspecified,,,,,Compound was tested for the cytotoxicity in H-9 cells infected with HIV-IIIB over 7 days,Other,8978856.0,
988,78959,3,4,,103188975,35370,Unspecified,,,,,Compound was tested for the cytotoxicity in H-9 cells infected with HIV-IIIB over 9 days,Other,8978856.0,
989,79107,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration which destroyed HIV-1 LAV infected H9 cells completely,Other,1573638.0,
990,79108,7,1,,103188975,35370,Active,,,,,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 25 percent,Other,1573638.0,
991,79110,6,2,,103188975,35370,Active,,,,,Compound was evaluated for antiviral activity against H9 cells. Cell culture inhibitor concentration (CIC95) is defined as those which inhibited by >95% the spread of HIV-1 IIIb infection in susceptible cell culture,Other,1279173.0,
992,79112,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV-1(IIIB) infected H9 cell lines.,Other,11720855.0,
993,79114,6,2,,103188975,35370,Active,,,0.045,EC50,Concentration required to inhibit HIV-1 replication in H9 lymphocyte cells,Confirmatory,10843202.0,
994,79116,6,2,,103188975,35370,Active,,,0.045,EC50,Evaluated for the anti-HIV activity against HIV-1 replication in H9 lymphocyte cells,Confirmatory,11206454.0,
995,79117,6,2,,103188975,35370,Active,,,0.045,EC50,Inhibitory concentration against HIV-1 replication in acutely infected H9 lymphocytes,Confirmatory,11527717.0,
996,79119,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%,Confirmatory,9873504.0,
997,79123,6,2,,103188975,35370,Unspecified,,,,,Concentration which was toxic to 50% of the mock-infected H9 lymphocyte.,Other,11720855.0,
998,79125,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Concentration required to inhibit uninfected H9 cell growth,Confirmatory,10843202.0,
999,79128,6,2,,103188975,35370,Unspecified,,,1873.0,IC50,Evaluated for the anti-HIV activity against HIV-1 replication in mock-infected H9 cells,Confirmatory,11206454.0,
1000,79129,6,2,,103188975,35370,Active,,,0.03,IC50,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent,Confirmatory,1573638.0,
1001,79132,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%,Confirmatory,11527717.0,
1002,79235,4,5,,103188975,35370,Active,,,0.05,IC50,Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay,Confirmatory,,
1003,79276,6,2,,103188975,35370,Active,,,0.045,EC50,Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%,Confirmatory,9873374.0,
1004,79277,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%,Confirmatory,9873374.0,
1005,79278,6,3,,103188975,35370,Active,,,0.04,EC50,Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined,Confirmatory,,
1006,79281,6,3,,103188975,35370,Unspecified,,,2000.0,IC50,Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined,Confirmatory,,
1007,79283,6,2,,103188975,35370,Active,,,0.045,EC50,Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes,Confirmatory,12699758.0,
1008,79284,6,2,,103188975,35370,Unspecified,,,,,Effective concentration against HIV-1 replication in H9 lymphocytic cells,Other,12729671.0,
1009,79286,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Concentration that inhibits HIV-1 replication in cell growth in H9 lymphocytes,Confirmatory,12699758.0,
1010,79287,6,2,,103188975,35370,Unspecified,,,,,Concentration that inhibits uninfected H9 cell growth by 50%.,Other,12729671.0,
1011,79291,6,2,,103188975,35370,Active,,,0.015,EC50,Compound was evaluated for anti-HIV activity in H9 lymphocytes,Confirmatory,9871747.0,
1012,79293,6,2,,103188975,35370,Active,,,0.045,EC50,Compound was evaluated for anti-HIV activity in acutely infected H9 Lymphocytes,Confirmatory,9873504.0,
1013,79295,6,2,,103188975,35370,Active,,,0.015,EC50,Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.,Confirmatory,9804704.0,
1014,79297,6,2,,103188975,35370,Active,,,0.15,EC50,Anti-HIV activity in acutely infected H9 lymphocytes.,Confirmatory,7525962.0,
1015,79299,6,2,,103188975,35370,Unspecified,,,45000.0,EC50,Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes,Confirmatory,15149703.0,
1016,79303,6,2,,103188975,35370,Active,,,4.5,EC50,Inhibitory activity against HIV-1 replication in H9 lymphocytes,Confirmatory,11262077.0,
1017,79304,6,2,,103188975,35370,Unspecified,,,,,Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%,Other,10021911.0,
1018,79305,6,2,,103188975,35370,Active,,,4.5,EC50,Antiviral activity against HIV-1 in H9 lymphocytes.,Confirmatory,10411486.0,
1019,79307,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Compound was evaluated for cytotoxicity in H9 lymphocytes,Confirmatory,9871747.0,
1020,79309,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.,Confirmatory,9804704.0,
1021,79435,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Concentration required to inhibit uninfected H9 cell growth by 50%,Confirmatory,15149703.0,
1022,79436,6,2,,103188975,35370,Unspecified,,,150.0,IC50,Evaluated in vitro for the concentration required to produce 50% inhibition of proliferation of H9 lymphocytes,Confirmatory,2329572.0,
1023,79437,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Inhibition of HIV replication was determined in H9 lymphocytes,Confirmatory,11262077.0,
1024,79438,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Anti-HIV activity in H9 lymphocytes.,Confirmatory,10411486.0,
1025,79440,4,3,,103188975,35370,Unspecified,,,,,Tested for in vitro therapeutic index as the ratio of IC50 to EC50 in acutely infected H9 Lymphocytes,Other,7525962.0,
1026,79442,4,4,,103188975,35370,Unspecified,,,,,Therapeutic index in H9 lymphocytes.,Other,10411486.0,
1027,79444,6,2,,103188975,35370,Unspecified,,,,,Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%,Other,10021911.0,
1028,79450,6,2,,103188975,35370,Unspecified,,,20.0,EC50,Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells,Confirmatory,9154967.0,
1029,79634,6,2,,103188975,35370,Unspecified,,,10.0,EC50,Antiviral activity against Hepatitis-B virus 2.2.15(HBV),Confirmatory,9357530.0,
1030,80086,5,2,,103188975,35370,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HCMV; Not determined,Other,9871553.0,
1031,80886,6,2,,103188975,35370,Active,,,0.016,EC50,Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).,Confirmatory,1992136.0,
1032,81067,6,2,,103188975,35370,Active,,,16.5,CC50,Cytotoxicity against HIV-1 (human immunodeficiency virus type 1),Confirmatory,10091689.0,
1033,81069,7,1,,103188975,35370,Active,,,,,Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells.,Other,3172142.0,
1034,81085,6,2,,103188975,35370,Active,,,0.075,EC50,Anti HIV-1 activity against the virus NL4-3 using MAGI assay,Confirmatory,12213068.0,
1035,81086,6,2,,103188975,35370,Unspecified,,,75.0,EC50,Anti HIV-1 activity against the virus NL4-3 using fusion assay,Confirmatory,12213068.0,
1036,81089,6,2,,103188975,35370,Active,,,0.004,EC50,Anti-HIV activity was determined,Confirmatory,11882000.0,
1037,81099,6,2,,103188975,35370,Active,,,0.02,EC50,In vitro antiviral activity against HIV-1 IIIB in C8166 (human CD4) cells.,Confirmatory,11020296.0,
1038,81100,6,2,,103188975,35370,Active,,,0.0017,EC50,Antiviral activity against HIV-1 (human immunodeficiency virus type 1),Confirmatory,10091689.0,
1039,81233,6,2,,103188975,35370,Unspecified,,,,,Compound was evaluated for the antiviral activity against HIV-1,Other,9871553.0,
1040,81235,6,2,,103188975,35370,Unspecified,,,1.0,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate 4 x AZT with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1041,81236,6,2,,103188975,35370,Active,,,0.005,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate K101E with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1042,81237,6,2,,103188975,35370,Active,,,0.004,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate K103E with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1043,81239,6,2,,103188975,35370,Active,,,0.003,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate L100I with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1044,81240,6,2,,103188975,35370,Active,,,0.01,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate M184I with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1045,81241,6,2,,103188975,35370,Active,,,0.02,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate P236L with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1046,81242,6,2,,103188975,35370,Active,,,0.04,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate T1391 with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1047,81243,6,2,,103188975,35370,Active,,,0.004,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate V1081 with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1048,81244,6,2,,103188975,35370,Active,,,0.006,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate Y181C with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1049,81245,6,2,,103188975,35370,Active,,,0.03,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate Y181C/K103N with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1050,81246,6,2,,103188975,35370,Active,,,0.003,EC50,Compound was evaluated for the antiviral activity against compound resistant virus isolate Y188H with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1051,81247,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Compound was evaluated for the antiviral activity against resistant virus isolate IIIB with amino acid changes in the HIV-1 reverse transcriptase (RT),Confirmatory,9873509.0,
1052,81251,6,2,,103188975,35370,Active,,,0.006,EC50,Effective concentration required to inhibit HIV-1 replication in CEM-SS cell line,Confirmatory,14521418.0,
1053,81252,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Effective concentration required to inhibit HIV-1 replication in CEM/TK cell line,Confirmatory,14521418.0,
1054,81253,6,2,,103188975,35370,Active,,,0.017,EC50,Effective concentration required to inhibit HIV-1 replication in MT-4 cell line,Confirmatory,14521418.0,
1055,81254,6,3,,103188975,35370,Active,,,0.016,EC50,Compound was tested for the drug concentration which reduces viral antigen production by 50%,Confirmatory,,
1056,81263,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration against cytopathicity of HIV-1 strain (HTLV IIIB) in CEM cell line,Confirmatory,12801219.0,
1057,81266,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration against HIV-1,Confirmatory,15214779.0,
1058,81411,6,2,,103188975,35370,Active,,,0.002,EC50,Inhibition of HIV-1 replication in human peripheral blood mononuclear cells.,Confirmatory,3339606.0,
1059,81413,6,2,,103188975,35370,Active,,,0.004,EC50,Inhibitory effect against HIV-1 in human peripheral blood monocyte cells(PBMC) (EC50 ->0.273 ug/mL),Confirmatory,1495008.0,
1060,81417,6,2,,103188975,35370,Active,,,0.004,EC50,Evaluated for anti-HIV activity,Confirmatory,10197975.0,
1061,81438,8,1,,103188975,35370,Active,,,0.004,ED50,Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.,Confirmatory,3172142.0,
1062,81442,8,1,,103188975,35370,Active,,,0.001,ED50,Inhibition of HIV-1 D34 replication in human peripheral blood mononuclear cells.,Confirmatory,7684450.0,
1063,81443,8,1,,103188975,35370,Active,,,0.07,ED50,Inhibition of HIV-1 IIIB replication in MT2 (human lymphocyte) cells.,Confirmatory,7684450.0,
1064,81605,6,2,,103188975,35370,Unspecified,,,10.0,IC50,Compound was tested for antiviral activity against matched pairs of HIV-1 resistant to AZT,Confirmatory,9548815.0,
1065,81606,6,2,,103188975,35370,Active,,,0.002,IC50,Compound was tested for antiviral activity against matched pairs of HIV-1 sensitive to AZT,Confirmatory,9548815.0,
1066,81946,8,1,,103188975,35370,Unspecified,,,500.0,TC50,In vitro toxicity to C8166 (human CD4) cells.,Confirmatory,11020296.0,
1067,81964,3,4,,103188975,35370,Unspecified,,,,,Protection of MT-4 lymphocytes by the compound against HIV-1 infectivity in vitro at a concentration of 0.008 ug/mL (0.00003 uM/mL),Other,1495008.0,
1068,81965,3,4,,103188975,35370,Unspecified,,,,,Protection of MT-4 lymphocytes by the compound against HIV-1 infectivity in vitro at a concentration of 0.016 ug/mL (0.00006 uM/mL),Other,1495008.0,
1069,81966,3,4,,103188975,35370,Unspecified,,,,,Protection of MT-4 lymphocytes by the compound against HIV-1 infectivity in vitro at a concentration of 0.032 ug/mL (0.0012 uM/mL),Other,1495008.0,
1070,82064,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration,Confirmatory,7562946.0,
1071,82109,5,1,,103188975,35370,Unspecified,,,,,Evaluated for the antiretroviral activity against Human immunodeficiency virus type 1,Other,2157012.0,
1072,82129,6,2,,103188975,35370,Active,,,0.006,IC50,Compound was evaluated for anti-retrovirus activity against HIV-1 (D34) Diagen strain.,Confirmatory,8496903.0,
1073,82137,6,2,,103188975,35370,Active,,,0.01,EC50,Inhibition of HIV-1 (strain A17)-infected MT-4 cells,Confirmatory,7504733.0,
1074,82282,7,1,,103188975,35370,Active,,,0.126,EC50,Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1),Confirmatory,10206539.0,
1075,82283,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Tested in vitro against MT-4 cells using MTT assay,Confirmatory,11087576.0,
1076,82284,6,7,,103188975,35370,Active,82310930.0,,0.038,EC50,Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay,Confirmatory,11087576.0,
1077,82287,6,7,,103188975,35370,Active,82310930.0,,24.9,EC50,Tested in vitro against HIV-1 MDR using MAGI assay,Confirmatory,11087576.0,
1078,82562,8,1,,103188975,35370,Active,,,6.7,ID50,The 50% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells,Confirmatory,2536441.0,
1079,82563,8,1,,103188975,35370,Active,,,1.0,ID50,Cellular toxicity was measured in CEM cells after 8 days by using a [3H]- thymidine uptake assay,Confirmatory,2536441.0,
1080,82565,7,1,,103188975,35370,Active,,,,,The 90% inhibitory concentration expresses cellular toxicity measured against normal human granulocyte-monocyte cells,Other,2536441.0,
1081,82618,8,6,,103188975,35370,Inconclusive,75593047.0,,,,Inhibitory activity against HIV-1 protease; No data,Other,,
1082,82918,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 15 days at a concentration 0.2 uM,Other,1712047.0,
1083,82919,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 15 days at a concentration 1 uM,Other,1712047.0,
1084,82920,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 15 days at a concentration 25 uM,Other,1712047.0,
1085,82921,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 15 days at a concentration 5 uM,Other,1712047.0,
1086,82922,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 22 days at a concentration 0.2 uM,Other,1712047.0,
1087,82923,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 22 days at a concentration 1 uM,Other,1712047.0,
1088,82924,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 22 days at a concentration 25 uM,Other,1712047.0,
1089,82925,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 22 days at a concentration 5 uM,Other,1712047.0,
1090,82926,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 26 days at a concentration 0.2 uM,Other,1712047.0,
1091,82927,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 26 days at a concentration 1 uM,Other,1712047.0,
1092,82928,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 26 days at a concentration 25 uM,Other,1712047.0,
1093,82929,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 26 days at a concentration 5 uM,Other,1712047.0,
1094,82930,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 7 days at a concentration 0.2 uM,Other,1712047.0,
1095,82931,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 7 days at a concentration 1 uM,Other,1712047.0,
1096,82932,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 7 days at a concentration 25 uM,Other,1712047.0,
1097,82933,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of CEM-CL13 on at 7 days at a concentration 5 uM,Other,1712047.0,
1098,82965,9,3,,103188975,35370,Active,,,0.01,IC50,Tested for the inhibition towards HIV-reverse transcriptase,Confirmatory,,
1099,82981,6,2,,103188975,35370,Unspecified,,,96.0,IC50,Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.,Confirmatory,1695683.0,
1100,83055,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 0.2 uM,Other,1712047.0,
1101,83056,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 1 uM,Other,1712047.0,
1102,83057,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 25 uM,Other,1712047.0,
1103,83058,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 5 uM,Other,1712047.0,
1104,83059,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 0.2 uM,Other,1712047.0,
1105,83060,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 1 uM,Other,1712047.0,
1106,83061,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 25 uM,Other,1712047.0,
1107,83062,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 5 uM,Other,1712047.0,
1108,83063,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 0.2 uM,Other,1712047.0,
1109,83065,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 1 uM,Other,1712047.0,
1110,83066,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 25 uM,Other,1712047.0,
1111,83067,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 5 uM,Other,1712047.0,
1112,83068,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 10 days at a concentration 1 uM,Other,1712047.0,
1113,83069,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 10 days at a concentration 25 uM,Other,1712047.0,
1114,83070,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 10 days at a concentration 5 uM,Other,1712047.0,
1115,83071,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 14 days at a concentration 1 uM,Other,1712047.0,
1116,83073,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 14 days at a concentration 25 uM,Other,1712047.0,
1117,83074,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 14 days at a concentration 5 uM,Other,1712047.0,
1118,83075,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 21 days at a concentration 1 uM,Other,1712047.0,
1119,83077,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 21 days at a concentration 25 uM,Other,1712047.0,
1120,83078,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 21 days at a concentration 5 uM,Other,1712047.0,
1121,83079,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 7 days at a concentration 1 uM,Other,1712047.0,
1122,83080,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 7 days at a concentration 25 uM,Other,1712047.0,
1123,83081,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compound ability to inhibit the production of HIV reverse transcriptase (RT) in preinfected PBL (peripheral blood lymphocytes) at 7 days at a concentration 5 uM,Other,1712047.0,
1124,83082,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity at 0 days of culture,Other,1712047.0,
1125,83108,6,2,,103188975,35370,Active,,,0.006,EC50,Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.,Confirmatory,1732552.0,
1126,83112,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration against cytopathicity of HIV-2 strain (ROD) in CEM cell line,Confirmatory,12801219.0,
1127,83210,6,7,,103188975,35370,Inconclusive,82310930.0,,,,Compounds were evaluated for anti-RT activity at 13 days of culture; Not determined,Other,1712047.0,
1128,83211,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity at 7 days of culture,Other,1712047.0,
1129,83212,7,1,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity at 9 days of culture,Other,1712047.0,
1130,83213,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and % cell / viability was reported at 13 days of culture,Other,1712047.0,
1131,83214,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and % cell / viability was reported at 7 days of culture,Other,1712047.0,
1132,83215,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and % cell / viability was reported at 9 days of culture,Other,1712047.0,
1133,83217,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition evaluated for anti-RT activity at 7 days of culture,Other,1712047.0,
1134,83218,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition evaluated for anti-RT activity at 9 days of culture,Other,1712047.0,
1135,83219,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 0.2 uM,Other,1712047.0,
1136,83220,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 1 uM,Other,1712047.0,
1137,83221,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 25 uM,Other,1712047.0,
1138,83222,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 11 days at a concentration 5 uM,Other,1712047.0,
1139,83223,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 0.2 uM,Other,1712047.0,
1140,83224,9,1,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 1 uM,Other,1712047.0,
1141,83225,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 25 uM,Other,1712047.0,
1142,83226,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 14 days at a concentration 5 uM,Other,1712047.0,
1143,83227,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 0.2 uM,Other,1712047.0,
1144,83228,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 1 uM,Other,1712047.0,
1145,83229,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 25 uM,Other,1712047.0,
1146,83230,4,9,,103188975,35370,Unspecified,82310930.0,,,,Percent inhibition measured as the production of HIV reverse transcriptase (RT) in culture supernatant of monocytic U937 on at 7 days at a concentration 5 uM,Other,1712047.0,
1147,83231,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and %protection was reported at 13 days of culture,Other,1712047.0,
1148,83232,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and %protection was reported at 7 days of culture,Other,1712047.0,
1149,83234,4,9,,103188975,35370,Unspecified,82310930.0,,,,Compounds were evaluated for anti-RT activity by MTT dose and %protection was reported at 9 days of culture,Other,1712047.0,
1150,83250,6,2,,103188975,35370,Active,,,0.002,EC50,Effective concentration required for antiviral activity against HIV strain MS (HIV-2) by XTT assay,Confirmatory,7932526.0,
1151,83265,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Effective concentration required for antiviral activity against HIV strain 205 by XTT assay,Confirmatory,7932526.0,
1152,83266,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Effective concentration required for antiviral activity against HIV strain 214 by XTT assay,Confirmatory,7932526.0,
1153,83267,6,2,,103188975,35370,Active,,,0.002,EC50,Effective concentration required for antiviral activity against HIV strain A17 (pyridinone-resistant strain) by XTT assay,Confirmatory,7932526.0,
1154,83268,6,2,,103188975,35370,Active,,,0.01,EC50,Effective concentration required for antiviral activity against HIV strain BAKI (syncytia inducing) by XTT assay,Confirmatory,7932526.0,
1155,83283,6,2,,103188975,35370,Active,,,0.002,EC50,Effective concentration required for antiviral activity against HIV strain G by XTT assay,Confirmatory,7932526.0,
1156,83284,6,4,,103188975,35370,Unspecified,,,0.1,EC50,Effective concentration required for antiviral activity against HIV strain G9106 (AZT-resistant strain) by XTT assay,Confirmatory,7932526.0,
1157,83393,6,2,,103188975,35370,Active,,,0.0041,EC50,Antiviral activity against Human immunodeficiency virus type-1,Confirmatory,10425099.0,
1158,83394,6,2,,103188975,35370,Active,,,3.2,IC50,Antiviral activity against Human immunodeficiency virus type-1,Confirmatory,10425099.0,
1159,83397,7,3,,103188975,35370,Unspecified,,,,,Evaluated for minimum inhibitory concentration (MIC) against MT-4 cells of human immunodeficiency virus type-1 (HIV-1),Other,2158560.0,
1160,83398,6,3,,103188975,35370,Active,,,0.12,IC50,Evaluated in vitro for the concentration required to produce 50% inhibition of replication of HIV-1,Confirmatory,2329572.0,
1161,83399,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage toxicity at 1 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1162,83401,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage toxicity at 100 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1163,83416,6,2,,103188975,35370,Active,,,0.008,EC50,Effective concentration required for antiviral activity against HIV strain LAV by XTT assay,Confirmatory,7932526.0,
1164,83417,6,2,,103188975,35370,Active,,,0.002,EC50,Effective concentration required for antiviral activity against HIV strain MCK by XTT assay,Confirmatory,7932526.0,
1165,83418,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration required for antiviral activity against HIV strain MN by XTT assay,Confirmatory,7932526.0,
1166,83419,6,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Effective concentration required for antiviral activity against HIV strain PM16 by XTT assay,Confirmatory,7932526.0,
1167,83420,6,2,,103188975,35370,Active,,,0.004,EC50,Effective concentration required for antiviral activity against HIV strain RF by XTT assay,Confirmatory,7932526.0,
1168,83424,6,2,,103188975,35370,Active,,,0.013000000000000001,EC50,Effective concentration required for antiviral activity against HIV strain SKI by XTT assay,Confirmatory,7932526.0,
1169,83425,6,2,,103188975,35370,Active,,,0.006,EC50,Effective concentration required for antiviral activity against HIV strain TP1 by XTT assay,Confirmatory,7932526.0,
1170,83426,6,2,,103188975,35370,Active,,,0.02,EC50,Effective concentration required for antiviral activity against HIV strain VIHU (nonsyncytia inducing) by XTT assay,Confirmatory,7932526.0,
1171,83427,6,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Effective concentration required for antiviral activity against HIV strain WEJO (syncytia inducing) by XTT assay,Confirmatory,7932526.0,
1172,83428,6,2,,103188975,35370,Active,,,0.006,EC50,Effective concentration required for antiviral activity against HIV strain WOME (syncytia inducing) by XTT assay,Confirmatory,7932526.0,
1173,83436,4,3,,103188975,35370,Active,,,0.0025,IC50,"Inhibitory activity against wild type strain,HIV104pre.",Confirmatory,12699395.0,
1174,83538,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage toxicity at 20 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1175,83541,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage toxicity at 5 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1176,83555,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage protection at 1 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1177,83557,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage protection at 100 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1178,83563,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage protection at 20 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1179,83566,3,4,,103188975,35370,Unspecified,,,,,Tested for the determination of percentage protection at 5 uM concentrations against HIV-1 in ATH8 Cells,Other,2329551.0,
1180,84646,8,1,,103188975,35370,Active,,,0.23,ED50,"Activity against HTLV-III/LAV/AAV, was determined in vitro.",Confirmatory,3643284.0,
1181,84778,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity against Herpes simplex virus type-2,Confirmatory,9357530.0,
1182,84930,5,2,,103188975,35370,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HSV-2; Not determined,Other,9871553.0,
1183,85880,6,2,,103188975,35370,Inconclusive,,,,,Cytotoxicity against HSV-1 (herpes simplex virus); Not determined,Other,10091689.0,
1184,85885,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity against Herpes simplex virus type-1,Confirmatory,9357530.0,
1185,85887,8,2,,103188975,35370,Inconclusive,,,,,Antiviral activity against HSV-1 (herpes simplex virus); Not determined,Other,10091689.0,
1186,85889,5,2,,103188975,35370,Inconclusive,,,,,Compound was evaluated for the antiviral activity against HSV-1; Not determined,Other,9871553.0,
1187,86697,8,2,,103188975,35370,Inconclusive,,,,,The compound was tested in vitro for anticancer activity against HepG2 cells; Not determined,Other,10072683.0,
1188,86854,6,2,,103188975,35370,Unspecified,,,10.0,EC50,The EC50 value was measured on hepatitis B virus,Confirmatory,10197975.0,
1189,87480,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for antiviral activity against HSV-1,Other,12161143.0,
1190,87598,6,2,,103188975,35370,Active,,,0.002,EC50,Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay,Confirmatory,11087576.0,
1191,87665,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for antiviral activity against HSV-2,Other,12161143.0,
1192,88999,6,2,,103188975,35370,Active,,,0.004,EC50,Concentration of compound required to inhibit HIV-1 replication in MT-4 cells by 50%,Confirmatory,2016718.0,
1193,89000,6,2,,103188975,35370,Active,,,0.004,IC50,In vitro inhibition of HIV-1 plaque formation,Confirmatory,2016713.0,
1194,89003,6,2,,103188975,35370,Active,,,4.0,IC50,Anti-HIV-1 activity against syncytial plaque formation,Confirmatory,1901911.0,
1195,89026,7,1,,103188975,35370,Active,,,,,Antiviral activity against drug-resistant HIV-1 virus (M184v) in Human peripheral blood mononuclear (PBM) cells,Other,15027854.0,
1196,89028,7,1,,103188975,35370,Active,,,,,Antiviral activity against wild type HIV virus(xxBRU) in Human peripheral blood mononuclear (PBM) cells,Other,15027854.0,
1197,89030,8,1,,103188975,35370,Active,,,0.001,ED50,Effective antiviral dose required to block the spread of HIV-1D34 infection in human peripheral blood mononuclear cells,Confirmatory,7512142.0,
1198,89134,6,2,,103188975,35370,Unspecified,,,5100.0,IC50,Concentration of compound required to 50% growth inhibition of HIV-1 in CEM-SS cells,Confirmatory,1901911.0,
1199,89135,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0003 uM,Other,1901911.0,
1200,89136,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0007 uM,Other,1901911.0,
1201,89139,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0015 uM,Other,1901911.0,
1202,89143,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003 uM,Other,1901911.0,
1203,89147,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006 uM,Other,1901911.0,
1204,89150,3,3,,103188975,35370,Unspecified,,,,,Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.012 uM,Other,1901911.0,
1205,89158,6,2,,103188975,35370,Active,,,0.0027,EC50,Effective concentration against M184V HIV-1 virus in human peripheral blood mononuclear cells,Confirmatory,15189036.0,
1206,89159,6,2,,103188975,35370,Active,,,0.0041,EC50,Effective concentration against Wild Type HIV-1 virus in human peripheral blood mononuclear cells,Confirmatory,15189036.0,
1207,89166,6,2,,103188975,35370,Active,,,7.8,CC50,Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells against the HIV-1 (HTLV-IIIB)induced cytopathic effect,Confirmatory,2016715.0,
1208,89167,6,2,,103188975,35370,Active,,,0.003,EC50,Inhibitory activity against HIV-1 (HTLV-IIIB strain) replication in MT-4 cells,Confirmatory,2016715.0,
1209,89170,6,2,,103188975,35370,Active,,,0.187,EC50,Concentration required to inhibit HIV-1 replication in acutely infected H9 lymphocytes by 50%,Confirmatory,14736256.0,
1210,89309,6,2,,103188975,35370,Active,,,0.0028,EC50,Inhibitory activity against HIV-2(LAV-2ROD strain) replication in MT-4 cells,Confirmatory,2016715.0,
1211,89656,5,3,,103188975,35370,Unspecified,,,66.0,CC50,"In vitro cytotoxicity in CD4+ human T-cells (c8166), using HIV-1 RT enzyme assay",Confirmatory,1712395.0,
1212,90921,4,3,,103188975,35370,Unspecified,,,,,"Bone marrow toxicity was measured against human colony forming units-granulocyte monocyte (CFU-GM), concentration is 1.0 uM",Other,2165162.0,
1213,90922,3,3,,103188975,35370,Unspecified,,,,,"Bone marrow toxicity was measured against human colony forming units-granulocyte monocyte (CFU-GM), concentration is 10.0 uM",Other,2165162.0,
1214,91481,4,7,,103188975,35370,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
1215,91919,6,3,,103188975,35370,Unspecified,,,1000.0,CC50,Concentration required to reduce cell viability of JM cells by 50%,Confirmatory,,
1216,91923,6,3,,103188975,35370,Unspecified,,,200.0,EC50,Anti-HIV activity against HIV-1 infected JM cell lines,Confirmatory,,
1217,91930,8,1,,103188975,35370,Unspecified,,,100.0,ED50,Effective dose of compound that decreases antigen production in HIV-1 infected JM cells to 50% of control,Confirmatory,,
1218,91932,8,1,,103188975,35370,Unspecified,,,1000.0,TD50,Toxic dose of compound which causes 50% cytotoxicity towards HIV-1 uninfected JM cells,Confirmatory,,
1219,95276,6,2,,103188975,35370,Unspecified,,,500.0,CC50,Cytotoxic concentration against HIV-1 infected Jurkat cell lines,Confirmatory,7837220.0,
1220,95292,6,2,,103188975,35370,Active,,,0.01,IC50,Inhibitory concentration against HIV-1 infected Jurkat cell lines,Confirmatory,7837220.0,
1221,99154,6,2,,103188975,35370,Active,,,6.18,IC50,Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/0.,Confirmatory,11356105.0,
1222,99185,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Inhibitory effect of compound on the proliferation of murine leukemia cells L1210/TK-,Confirmatory,11356105.0,
1223,100404,8,2,,103188975,35370,Inconclusive,,,,,The compound was tested in vitro for anticancer activity against LNCaP cells; Not determined,Other,10072683.0,
1224,102615,6,2,,103188975,35370,Unspecified,,,10.0,IC50,Tested in vitro for anticancer activity against MCF-7 cells,Confirmatory,10072683.0,
1225,103003,6,2,,103188975,35370,Active,,,0.015,EC50,Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay,Confirmatory,7932526.0,
1226,103518,7,1,,103188975,35370,Unspecified,,,,,Tested for intracellular levels of AZT phosphate against MCF-7 cell lines.,Other,10841805.0,
1227,103548,7,1,,103188975,35370,Active,,,,,Cytotoxic activity against MCF-7 cell lines.,Other,10841805.0,
1228,104235,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio between IC50/EC50 of HIV-I A17 strain in MT2 cell line,Other,8632437.0,
1229,104237,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio between IC50/EC50 of HIV-I H112-2 strain in MT2 cell line,Other,8632437.0,
1230,104238,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio between IC50/EC50 of HIV-I IIIB strain in MT2 cell line,Other,8632437.0,
1231,104240,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration which destroyed HIV-1 LAV infected MT-2 cells completely,Other,1573638.0,
1232,104242,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 25 percent,Other,1573638.0,
1233,104243,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Anti-HIV activity based on reduction of the viability of mock-infected MT-2 cells.,Confirmatory,12699395.0,
1234,104244,6,2,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxic concentration against MT-2 cells,Confirmatory,7684450.0,
1235,104249,7,1,,103188975,35370,Active,,,,,The compound was tested for its antiviral activity against HIV-1LAV virus infected MT-2 cells,Other,,
1236,104251,4,4,,103188975,35370,Active,,,0.027000000000000003,IC50,Anti-HIV activity based on inhibition of HIV-1 induced cytopathogenicity in MT-2 cells.,Confirmatory,12699395.0,
1237,104256,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.,Other,1738145.0,
1238,104258,6,2,,103188975,35370,Active,,,10.0,IC50,In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent,Confirmatory,1573638.0,
1239,104259,6,2,,103188975,35370,Active,,,0.22,IC50,In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent,Confirmatory,1573638.0,
1240,104260,6,2,,103188975,35370,Active,,,31.0,IC50,In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent,Confirmatory,1573638.0,
1241,104261,6,2,,103188975,35370,Active,,,0.2,IC50,In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent,Confirmatory,1573638.0,
1242,104262,6,2,,103188975,35370,Active,,,0.16,IC50,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent,Confirmatory,1573638.0,
1243,104272,4,8,,103188975,35370,Active,,,0.0079,EC50,Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay,Confirmatory,11459656.0,
1244,104274,6,2,,103188975,35370,Active,,,0.003,EC50,Effective concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1,Confirmatory,1469700.0,
1245,104283,6,2,,103188975,35370,Active,,,0.02,EC50,Inhibition of cytopathic effect of HIV-1 strain RF in MT-4 cell culture,Confirmatory,8230098.0,
1246,104285,4,3,,103188975,35370,Active,,,0.025,EC50,Inhibition of HIV-1 (BRU) cytopathicity in MT-4 (human leukemia).,Confirmatory,11262088.0,
1247,104287,8,2,,103188975,35370,Unspecified,,,,,Inhibitory activity toward HIV replication in MT-4 cells,Other,1323681.0,
1248,104297,6,2,,103188975,35370,Active,,,0.0064,EC50,The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-1(IIIB),Confirmatory,11858989.0,
1249,104298,6,2,,103188975,35370,Active,,,0.006,EC50,The compound was tested for effective concentration required to protect MT-4 cells against the cytopathicity of HIV-2(ROD),Confirmatory,11858989.0,
1250,104308,8,1,,103188975,35370,Active,,,0.004,ED50,"Cytopathogenicity against HIV-1 induced, replication in MT-4 cells was determined",Confirmatory,2299647.0,
1251,104309,8,1,,103188975,35370,Active,,,0.004,ED50,Cytopathogenicity against HIV-2 induced replication in MT-4 cells was determined,Confirmatory,2299647.0,
1252,104310,8,1,,103188975,35370,Active,,,0.003,ED50,Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV,Confirmatory,2342078.0,
1253,104311,8,1,,103188975,35370,Active,,,0.04,ED50,Effective dose required for 50% inhibition of HIV-1 antigen production in MT-4 cultures,Confirmatory,9457243.0,
1254,104315,6,2,,103188975,35370,Active,,,0.004,IC50,Ability to block replication of HIV-1 virus in mock infected MT-4 cells,Confirmatory,1956037.0,
1255,104399,3,4,,103188975,35370,Unspecified,,,,,Total viral index (TAI) is the area between the cytotoxicity and the antiviral activity curve for MT-2 cell line.,Other,1738145.0,
1256,104403,5,1,,103188975,35370,Unspecified,,,,,Minimum compound concentration that reduced cell viability by 25% for HIV replication in MT-2 cells.,Other,1738145.0,
1257,104415,6,2,,103188975,35370,Active,,,0.18,EC50,Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in MT-2 cells.,Confirmatory,2153206.0,
1258,104416,6,2,,103188975,35370,Unspecified,,,970.0,IC50,"Concentration of the drug resulting in 50% growth inhibition of normal, uninfected cells against HIV-1 replication in MT-2 cells.",Confirmatory,2153206.0,
1259,104420,6,2,,103188975,35370,Active,,,42.0,CC50,Conc. required to cause 50% death of uninfected MT-4 cells,Confirmatory,11520210.0,
1260,104421,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%,Confirmatory,10821705.0,
1261,104423,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells,Confirmatory,12593658.0,
1262,104427,4,4,,103188975,35370,Active,,,0.012,EC50,Conc. required to inhibit the cytopathicity on HIV-1 by 50% on MT-4 cells,Confirmatory,11520210.0,
1263,104429,6,2,,103188975,35370,Active,,,0.02,EC50,Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay,Confirmatory,10821705.0,
1264,104430,6,2,,103188975,35370,Active,,,0.015,EC50,Effective concentration required to inhibit the replication of HIV-1 by 50% in MT-4 cells,Confirmatory,12593658.0,
1265,104432,3,4,,103188975,35370,Active,,,,,In vitro anti viral activity against HIV-1(IIIB) in MT-4 T-lymphoid cell culture by p-24-ELISA assay,Other,1588551.0,
1266,104440,4,4,,103188975,35370,Active,,,0.06,IC50,Average antiviral activity against HIV-1 in MT-4 cells using cell-protection assay,Confirmatory,1380561.0,
1267,104458,8,4,,103188975,35370,Inconclusive,,,,,Inhibitory concentration determined on an HIV infection model mediated by CXCR4; Not tested,Other,11459656.0,
1268,104464,4,1,,103188975,35370,Unspecified,,,,,Inhibitory concentration against HIV-1 in MT-4 cell line.,Other,,
1269,104577,6,2,,103188975,35370,Active,,,20.0,CC50,Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,1992136.0,
1270,104594,6,2,,103188975,35370,Unspecified,,,1.0,CC50,Tested for cytotoxic concentration in MT-4 cell culture,Confirmatory,11087582.0,
1271,104596,6,1,,103188975,35370,Unspecified,,,,,The concentration required to cause a 50% inhibition of cell proliferation was determined in MT-4 cell culture.,Other,11881997.0,
1272,104597,6,2,,103188975,35370,Active,,,0.015,EC50,Tested for anti-HIV -1 Activity in MT-4 cell culture,Confirmatory,11087582.0,
1273,104600,8,1,,103188975,35370,Active,,,0.004,ID50,The concentration required to cause a 50% inhibition of HIV reproduction was determined in MT-4 cell culture for free forms,Confirmatory,11881997.0,
1274,104612,3,4,,103188975,35370,Unspecified,,,,,Antigen p24 content in culture fluid at 10e-4 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1275,104613,3,4,,103188975,35370,Unspecified,,,,,Antigen p24 content in culture fluid at 10e-5 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1276,104616,6,2,,103188975,35370,Unspecified,,,150.0,CC50,Ability to reduce 50% viability of MT-4 cells acutely infected with HIV-1 strain IIIB,Confirmatory,8642557.0,
1277,104755,6,2,,103188975,35370,Unspecified,,,75.0,CC50,Antiviral activity in MT-4 cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%,Confirmatory,7562927.0,
1278,104757,6,2,,103188975,35370,Unspecified,,,20.0,CC50,Compound dose required to reduce the viability of mock-infected cells by 50%,Confirmatory,7650679.0,
1279,104760,6,2,,103188975,35370,Unspecified,,,80.0,CC50,Dose required to reduce the viability of mock-infected cells by 50%,Confirmatory,9154967.0,
1280,104762,6,3,,103188975,35370,Unspecified,,,113.0,CC50,Compound was evaluated for the concentration required to reduce the viability of MT-4 cells.,Confirmatory,,
1281,104763,6,2,,103188975,35370,Active,,,6.0,CC50,Cytotoxic concentration against MT-4 cells (in vitro),Confirmatory,8648614.0,
1282,104765,6,2,,103188975,35370,Unspecified,,,75.0,CC50,Cytotoxic concentration required to reduce viability of uninfected cells in MT-4 cell line,Confirmatory,14521418.0,
1283,104766,6,2,,103188975,35370,Unspecified,,,190.0,CC50,Compound was tested for reduction of the viability of mock infected MT-4 cell in test-I,Confirmatory,11128640.0,
1284,104767,6,2,,103188975,35370,Active,,,20.0,CC50,Compound was tested for reduction of the viability of mock infected MT-4 cell in test-II,Confirmatory,11128640.0,
1285,104769,6,2,,103188975,35370,Unspecified,,,50.0,CC50,Concentration required to cause 50% death of uninfected MT-4 cells,Confirmatory,9925728.0,
1286,104772,6,2,,103188975,35370,Unspecified,,,20.0,CC50,Concentration required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,8558522.0,
1287,104773,6,2,,103188975,35370,Unspecified,,,80.0,CC50,Concentration required to reduce the viability of mock-infected MT-4 cells by 50% (4 days),Confirmatory,7523675.0,
1288,104782,6,2,,103188975,35370,Unspecified,,,110.0,CC50,Cytotoxic concentration against HIV-1 infected MT-4 cell lines,Confirmatory,7837220.0,
1289,104785,6,2,,103188975,35370,Active,,,3.2,CC50,Cytotoxic concentration based on the reduction of viability of mock-infected cells,Confirmatory,7540208.0,
1290,104790,6,2,,103188975,35370,Unspecified,,,,,Cytotoxic concentration which is required to reduce human MT-4 cell viability by 50%.,Other,9046339.0,
1291,104791,6,2,,103188975,35370,Active,,,9.3,CC50,Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.,Confirmatory,1995896.0,
1292,104792,6,2,,103188975,35370,Unspecified,,,20.0,CC50,Cytotoxic concentration required to reduce viability of mock-infected MT-4 cells (4 days),Confirmatory,7562935.0,
1293,104796,5,4,,103188975,35370,Active,,,6.0,CC50,Cytotoxicity against human lymphocyte MT-4 cells,Confirmatory,,
1294,104799,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against MT-4 cells,Other,14505657.0,
1295,104800,6,2,,103188975,35370,Active,,,35.6,CC50,"Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.",Confirmatory,9767646.0,
1296,104804,6,2,,103188975,35370,Active,,,6.0,CC50,Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells,Confirmatory,7527463.0,
1297,104935,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against (monocyte macrophages) cell lines,Other,2165162.0,
1298,104936,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against (monocyte macrophages) cell lines,Other,2165162.0,
1299,104938,6,2,,103188975,35370,Active,,,7.8,CC50,Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,7636846.0,
1300,104939,6,2,,103188975,35370,Active,,,7.8,CC50,The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus A012D strain,Confirmatory,7636846.0,
1301,104940,6,2,,103188975,35370,Active,,,7.8,CC50,The cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50% on HIV-1 virus LAV-2ROD strain,Confirmatory,7636846.0,
1302,104943,6,1,,103188975,35370,Unspecified,,,,,50% inhibition of MT-4 cell proliferation.,Other,15214788.0,
1303,104944,6,1,,103188975,35370,Unspecified,82310930.0,,,,Concentration which reduced the viability of the HIV-1 infected MT-4 cells to 50% compared to untreated control cells,Other,8523406.0,
1304,104945,7,1,,103188975,35370,Unspecified,,,,,Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells,Other,8691437.0,
1305,104946,7,1,,103188975,35370,Active,,,,,Cytotoxicity was determined as the dose required to reduce the viability of uninfected MT-4 cells by 50%,Other,3499515.0,
1306,104961,3,4,,103188975,35370,Unspecified,,,,,Cytotoxic concentration for 50% death of MT-4 cell culture infected by HIV-1,Other,7520081.0,
1307,104967,6,2,,103188975,35370,Unspecified,,,,,50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-1.,Other,9046339.0,
1308,104968,6,2,,103188975,35370,Unspecified,,,,,50% effective concentration of compound which is required to protect human MT-4 cells against cytopathogenicity of HIV-2.,Other,9046339.0,
1309,104970,6,2,,103188975,35370,Active,,,0.017,EC50,Antiviral activity in MT-4 cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined,Confirmatory,7562927.0,
1310,104980,6,2,,103188975,35370,Active,,,0.01,EC50,Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity,Confirmatory,7650679.0,
1311,104997,6,2,,103188975,35370,Active,,,0.03,EC50,Effective concentration required to protect MT-2 cells against cytopathogenicity of HIV-1 LAI,Confirmatory,12852759.0,
1312,105007,6,2,,103188975,35370,Active,,,6.0,CC50,cytotoxic activity in MT-4 cell line,Confirmatory,8478904.0,
1313,105008,6,2,,103188975,35370,Active,,,0.002,EC50,Anti HIV-1 activity in human lymphocyte MT-4 cell line,Confirmatory,8478904.0,
1314,105009,6,2,,103188975,35370,Active,,,0.003,EC50,Anti HIV-2 activity in human lymphocyte MT-4 cell line,Confirmatory,8478904.0,
1315,105023,6,3,,103188975,35370,Active,,,3.2,CC50,Tested for 50% cytotoxic concentration based on the reduction of viability in mock-infected MT-4 cells,Confirmatory,,
1316,105123,6,2,,103188975,35370,Active,,,0.01,EC50,Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells,Confirmatory,9154967.0,
1317,105125,6,2,,103188975,35370,Unspecified,,,,,Compound was evaluated for its inhibitory effect on the replication of HIV-1(IIIB) in MT-4 cells,Other,14505657.0,
1318,105126,6,2,,103188975,35370,Unspecified,,,,,Compound was evaluated for its inhibitory effect on the replication of HIV-2 (ROD) in MT-4 cells,Other,14505657.0,
1319,105127,6,2,,103188975,35370,Active,,,0.004,EC50,Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells,Confirmatory,7540208.0,
1320,105129,6,3,,103188975,35370,Active,,,0.04,EC50,Compound was evaluated for the inhibition of HIV-1 induced cytopathic effect in MT-4 cells.,Confirmatory,,
1321,105131,6,2,,103188975,35370,Active,,,0.002,EC50,Activity against HIV-1 in MT-4 cells (in vitro),Confirmatory,8648614.0,
1322,105132,6,2,,103188975,35370,Active,,,0.003,EC50,Activity against HIV-2 in MT-4 cells (in vitro),Confirmatory,8648614.0,
1323,105135,5,6,,103188975,35370,Active,46577576.0,7852.0,0.048,EC50,Inhibition of HIV-induced cytopathogenicity in MT-4 cell,Confirmatory,11128640.0,
1324,105136,6,2,,103188975,35370,Active,,,0.05,EC50,Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells,Confirmatory,9925728.0,
1325,105137,6,2,,103188975,35370,Active,,,0.005,EC50,Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-1 (IIIa),Confirmatory,10212126.0,
1326,105138,6,2,,103188975,35370,Active,,,0.005,EC50,Concentration of compound required to protect 50% of MT-4 cells against retroviral cytopathic effects by HIV-2 (ROD),Confirmatory,10212126.0,
1327,105150,6,3,,103188975,35370,Active,,,0.035,EC50,Concentration required to inhibit HIV-1-induced cytopathic effect by 50% in MT-4 cells,Confirmatory,,
1328,105153,6,2,,103188975,35370,Active,,,0.0007,EC50,"Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.",Confirmatory,9767646.0,
1329,105154,6,3,,103188975,35370,Active,,,0.002,EC50,Dose required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1,Confirmatory,,
1330,105155,6,2,,103188975,35370,Active,,,0.01,EC50,Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells,Confirmatory,8558522.0,
1331,105158,6,2,,103188975,35370,Active,,,0.01,EC50,Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1 (4 days),Confirmatory,7523675.0,
1332,105159,6,2,,103188975,35370,Active,,,0.04,EC50,Effective concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-2 (8 days),Confirmatory,7523675.0,
1333,105165,6,2,,103188975,35370,Active,,,0.085,EC50,Effective concentration required for antiviral activity against T (HTLV-1+)cell line of MT-4 cells of Human by XTT assay,Confirmatory,7932526.0,
1334,105180,6,2,,103188975,35370,Active,,,0.0099,EC50,Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells,Confirmatory,14698189.0,
1335,105186,5,3,,103188975,35370,Unspecified,,,,,In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in MT-4 cells by indirect immunofluorescence assay,Other,,
1336,105190,6,3,,103188975,35370,Active,,,0.004,EC50,Tested for 50% effective concentration based on the inhibition of HIV-I induced cytopathic effect in MT-4 cells,Confirmatory,,
1337,105205,6,2,,103188975,35370,Active,,,0.04,IC50,Potency against non nucleoside reverse transcriptor was determined in MT-4 cells,Confirmatory,15109677.0,
1338,105322,6,2,,103188975,35370,Active,,,0.005,EC50,Effective dose to achieve 50% protection of MT-4 cells from acutely infected HIV-1 strain IIIB,Confirmatory,8642557.0,
1339,105328,4,5,,103188975,35370,Active,,,0.0025,EC50,In vitro inhibitory activity against replication of HIV-1 in human lymphocyte MT-4 cells,Confirmatory,,
1340,105329,4,5,,103188975,35370,Active,,,0.0026,EC50,In vitro inhibitory activity against replication of HIV-2 in human lymphocyte MT-4 cells,Confirmatory,,
1341,105344,6,2,,103188975,35370,Active,,,0.01,EC50,Protection of MT-4 cells against the cytopathic effect of HIV-1 (4 days),Confirmatory,7562935.0,
1342,105345,6,2,,103188975,35370,Active,,,0.04,EC50,Protection of MT-4 cells against the cytopathic effect of HIV-2 (8 days),Confirmatory,7562935.0,
1343,105347,7,2,,103188975,35370,Active,,,0.004,EC50,Tested for in vitro cytopathic effect of HIV for MT-4 cells,Confirmatory,7932583.0,
1344,105348,6,2,,103188975,35370,Active,,,0.002,EC50,Tested for the inhibitory activity of HIV-1 infected MT-4 cells,Confirmatory,7527463.0,
1345,105349,6,2,,103188975,35370,Active,,,0.003,EC50,Tested for the inhibitory activity of HIV-2 infected MT-4 cells,Confirmatory,7527463.0,
1346,105373,6,1,,103188975,35370,Active,,,,,Concentration required to reduce the number of viable cells in the untreated MT-4 cell culture,Other,1527788.0,
1347,105374,6,1,,103188975,35370,Unspecified,,,,,Cytotoxic activity was determined against HIV-1 infected MT-4 cells.,Other,,
1348,105376,7,1,,103188975,35370,Active,,,,,Cytotoxic dose in MT-4 cells,Other,2754700.0,
1349,105399,6,2,,103188975,35370,Active,,,0.006,EC50,"AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).",Confirmatory,1695683.0,
1350,105400,6,2,,103188975,35370,Active,,,0.0045,EC50,"AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay",Confirmatory,1695683.0,
1351,105513,6,2,,103188975,35370,Active,,,0.003,EC50,Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.,Confirmatory,7636846.0,
1352,105514,6,2,,103188975,35370,Active,,,0.3,EC50,The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus A012D strain,Confirmatory,7636846.0,
1353,105515,6,2,,103188975,35370,Active,,,0.0028,EC50,The effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-2 virus LAV-2ROD,Confirmatory,7636846.0,
1354,105521,8,1,,103188975,35370,Active,,,0.006,ED50,Anti-HIV activity was determined as dose required to protect 50% of the HIV-infected MT-4 cells against destruction,Confirmatory,3499515.0,
1355,105522,8,1,,103188975,35370,Active,82310930.0,,0.006999999999999999,ED50,Concentration which reduced the cytopathic effect of HIV-1 in MT-4 infected cells,Confirmatory,8523406.0,
1356,105530,8,1,,103188975,35370,Active,,,0.04,ED50,Effective dose of compound required to inhibit 50% of HIV-1 antigen production in MT-4 cultures.,Confirmatory,8691437.0,
1357,105554,6,2,,103188975,35370,Active,,,0.02,EC50,Effective concentration required to protect MT-4 cells against cytopathogenicity of HIV-1 LAI,Confirmatory,12852759.0,
1358,105578,8,1,,103188975,35370,Active,,,0.004,ED50,Concentration required to affect a 50% reduction in the cytopathic effect of HIV for MT-4 cells,Confirmatory,1527788.0,
1359,105579,8,1,,103188975,35370,Active,,,0.06,ED50,Concentration that inhibits cellular growth of MT-4 cells acutely infected with HIV-1 RFstrain by 50%,Confirmatory,,
1360,105582,8,1,,103188975,35370,Active,82310930.0,,0.003,ED50,Inhibitory activity against HIV-1 replication in MT-4 cells,Confirmatory,2754700.0,
1361,105590,6,2,,103188975,35370,Unspecified,,,53.0,IC50,Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.,Confirmatory,1695683.0,
1362,105691,7,1,,103188975,35370,Active,,,,,Inhibitory activity against resistant HIV-1 strain MC639r was determined.,Other,9154967.0,
1363,105692,7,1,,103188975,35370,Active,,,,,Inhibitory activity against resistant HIV-1 strain NevR was determined.,Other,9154967.0,
1364,105746,3,4,,103188975,35370,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.00032 uM concentration; Range is 10-40,Other,3497272.0,
1365,105749,3,4,,103188975,35370,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.008 uM concentration; Range is 40-60,Other,3497272.0,
1366,105750,4,4,,103188975,35370,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration,Other,3497272.0,
1367,105753,4,4,,103188975,35370,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration,Other,3497272.0,
1368,105756,3,4,,103188975,35370,Unspecified,,,,,Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration.,Other,3497272.0,
1369,105759,3,4,,103188975,35370,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.00032 uM concentration,Other,3497272.0,
1370,105760,3,4,,103188975,35370,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.008 uM concentration,Other,3497272.0,
1371,105762,4,4,,103188975,35370,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration,Other,3497272.0,
1372,105764,4,4,,103188975,35370,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration,Other,3497272.0,
1373,105766,4,4,,103188975,35370,Unspecified,,,,,Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration,Other,3497272.0,
1374,105869,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Concentration of compound required to reduce MT-4 cell viability by 50%,Confirmatory,10212126.0,
1375,105872,7,2,,103188975,35370,Unspecified,,,,,Concentration required to reduce the number of viable uninfected cells by 50%,Other,7473592.0,
1376,106024,6,1,,103188975,35370,Unspecified,,,,,Compound was evaluated for the inhibition of cell replication of human fibroblast (MRC-5) cells.,Other,8496903.0,
1377,106037,6,2,,103188975,35370,Active,,,0.0015,IC50,Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.,Confirmatory,1995896.0,
1378,106044,7,2,,103188975,35370,Unspecified,,,,,Inhibitory Effect against HIV-1 (IIIB) in CEM cells,Other,7473592.0,
1379,106080,6,2,,103188975,35370,Active,,,0.005,IC50,Inhibitory concentration against HIV-1 infected MT-4 cell lines,Confirmatory,7837220.0,
1380,106239,6,2,,103188975,35370,Active,,,0.0041,IC50,Concentration required for 50% protection of MT-4 cells against the cytopathic effect of HIV-1,Confirmatory,7877144.0,
1381,106240,8,1,,103188975,35370,Active,,,0.017,ID50,50% inhibition of HIV replication in MT-4 cells,Confirmatory,15214788.0,
1382,106241,7,1,,103188975,35370,Active,,,,,90% inhibition of HIV replication in MT-4 cells,Other,15214788.0,
1383,106410,3,5,,103188975,35370,Unspecified,,,,,Number of infected cells at 10e-4 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1384,106411,3,5,,103188975,35370,Unspecified,,,,,Number of infected cells at 10e-5 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1385,106423,3,4,,103188975,35370,Unspecified,,,,,Content of viable cells at 10e-4 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1386,106424,3,4,,103188975,35370,Unspecified,,,,,Content of viable cells at 10e-5 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1387,106586,6,2,,103188975,35370,Active,,,20.0,CC50,Concentration of compound required to reduce MT-4 cells viability by 50%.,Confirmatory,2016718.0,
1388,106587,6,2,,103188975,35370,Active,,,7.8,CC50,Concentration of compound required to reduce the viability of mock infected MT-4 cells against HIV-1 by 50%,Confirmatory,2016729.0,
1389,106588,6,2,,103188975,35370,Active,,,7.8,CC50,Concentration required to reduce the viability of mock-infected MT-4 cells by 50%.,Confirmatory,1732552.0,
1390,106591,6,3,,103188975,35370,Unspecified,,,20.0,CC50,Concentration required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,,
1391,106592,6,2,,103188975,35370,Active,,,7.8,CC50,Concentration to required to reduce viability of Mock infected MT-4 cells,Confirmatory,1469700.0,
1392,106594,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Concentration required to cause 50% death of uninfected MT-4 cells (expressed in AZT equivalent),Confirmatory,11881996.0,
1393,106596,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against MT-4 (human leukemia) cells.,Confirmatory,11262088.0,
1394,106598,6,2,,103188975,35370,Active,,,12.0,CC50,Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I,Confirmatory,11459656.0,
1395,106599,6,2,,103188975,35370,Active,,,20.0,CC50,Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,2479745.0,
1396,106606,6,3,,103188975,35370,Unspecified,,,113.0,CC50,Cytotoxic concentration required to reduce the viability of MT-4 cells,Confirmatory,,
1397,106607,6,2,,103188975,35370,Active,,,4.8,CC50,Cytotoxic concentration required to reduce the viability of normal uninfected MT-4 cells by 50%,Confirmatory,1697345.0,
1398,106633,6,2,,103188975,35370,Active,,,0.4,IC50,Inhibitory activity against the HIV-1-induced cytopathic effect in Macrophage,Confirmatory,7650678.0,
1399,106749,6,2,,103188975,35370,Active,,,12.0,CC50,Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method,Confirmatory,11958995.0,
1400,106755,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity indicative of 50% survival concentration in virus-uninfected MT-4 cells.,Other,12161143.0,
1401,106758,6,2,,103188975,35370,Unspecified,,,500.0,CC50,The compound was tested for cytotoxic concentration required to reduce the viability of MT-4 cells,Confirmatory,11858989.0,
1402,106764,4,1,,103188975,35370,Unspecified,,,,,Cytotoxic activity against MT-4 cell line,Other,,
1403,106767,6,1,,103188975,35370,Unspecified,,,,,Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells by 50%,Other,9457243.0,
1404,106768,6,1,,103188975,35370,Active,,,,,Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%,Other,2342078.0,
1405,106771,6,1,,103188975,35370,Active,,,,,Cytotoxic dose to reduce the viability of MT-4 cells by 50 % was determined,Other,2299647.0,
1406,106776,6,2,,103188975,35370,Active,,,,,Compound was evaluated for antiviral activity against MT-4 cells. Cell culture inhibitor concentration (CIC95) is defined as those which inhibited by >95% the spread of HIV-1 IIIb infection in susceptible cell culture; value ranges from 0.012-0.025 uM,Other,1279173.0,
1407,106886,6,2,,103188975,35370,Unspecified,,,123.0,CC50,Tested for the drug concentration required to decrease HIV-1IIIb infected MT-2 cell viability compared to uninfected controls,Confirmatory,7512142.0,
1408,106890,6,2,,103188975,35370,Active,,,0.013999999999999999,EC50,Anti-HIV activity against HIV-I A17 strain in MT2 cell line,Confirmatory,8632437.0,
1409,106892,6,2,,103188975,35370,Active,,,0.037000000000000005,EC50,Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line,Confirmatory,8632437.0,
1410,106893,6,2,,103188975,35370,Active,,,0.028999999999999998,EC50,Anti-HIV activity against HIV-I IIIB strain in MT2 cell line,Confirmatory,8632437.0,
1411,106901,6,2,,103188975,35370,Active,,,0.003,EC50,Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay,Confirmatory,7932526.0,
1412,106910,8,1,,103188975,35370,Active,,,0.07,ED50,Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia,Confirmatory,7512142.0,
1413,106916,6,2,,103188975,35370,Unspecified,,,83.44,IC50,Anti-HIV activity against HIV-I A17 strain in MT2 cell line,Confirmatory,8632437.0,
1414,106917,6,2,,103188975,35370,Unspecified,,,131.71,IC50,Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line,Confirmatory,8632437.0,
1415,106918,6,2,,103188975,35370,Unspecified,,,119.84,IC50,Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line,Confirmatory,8632437.0,
1416,106919,6,2,,103188975,35370,Unspecified,,,51.64,IC50,Anti-HIV activity against HIV-I IIIB strain in MT2 cell line,Confirmatory,8632437.0,
1417,106929,6,2,,103188975,35370,Active,,,0.006,IC50,Inhibitory activity against the HIV-1-induced cytopathic effect in MT-2 cell line,Confirmatory,7650678.0,
1418,106948,6,2,,103188975,35370,Active,,,0.3,EC50,Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method,Confirmatory,11958995.0,
1419,106959,6,2,,103188975,35370,Unspecified,,,,,Compound was tested for antiviral activity indicative of 50% cytopathic concentration in virus (HIV-1) infected MT-4 cells.,Other,12161143.0,
1420,106964,6,2,,103188975,35370,Active,,,0.003,EC50,Concentration of compound required to achieve 50% protection of MT-4 cells against HIV-1 virus induced cytopathic effect,Confirmatory,2016729.0,
1421,106965,6,2,,103188975,35370,Active,,,0.016,EC50,Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1,Confirmatory,2479745.0,
1422,106966,6,3,,103188975,35370,Active,,,0.01,EC50,Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1,Confirmatory,,
1423,106968,6,2,,103188975,35370,Active,,,0.0028,EC50,Concentration required to inhibit replication of HIV-2 LAV-2rod strain in MT-4 cells,Confirmatory,1469700.0,
1424,106971,4,4,,103188975,35370,Active,,,0.025,EC50,Concentration required to inhibit the cytopathicity of HIV-1 strain BRU by 50% in MT-4 cells (expressed in AZT equivalent),Confirmatory,11881996.0,
1425,106972,4,4,,103188975,35370,Active,,,0.012,EC50,Concentration required to inhibit the cytopathicity of HIV-1 strain IIIB by 50% in MT-4 cells (expressed in AZT equivalent),Confirmatory,11881996.0,
1426,106976,6,2,,103188975,35370,Active,,,0.003,EC50,Effective concentration achieving 50% protection of MT-4 cells against the cytopathic effect of HIV-1,Confirmatory,1697345.0,
1427,125167,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration in mock-infected A3.01 cells.,Other,1573638.0,
1428,125169,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration in mock-infected A3.01 cells - 100% toxicity.,Other,1573638.0,
1429,125177,8,1,,103188975,35370,Active,,,0.02,ED50,"In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus",Confirmatory,3643284.0,
1430,125353,4,4,,103188975,35370,Active,,,0.0062,EC50,Compound was evaluated for anti-HIV activity against HIV-1Lal inoculated with Molt-4 cells,Confirmatory,10866387.0,
1431,125500,6,2,,103188975,35370,Unspecified,,,62.8,IC50,Inhibitory effect of compound on the proliferation of human T-lymphocyte cells Molt4/C8,Confirmatory,11356105.0,
1432,125503,6,2,,103188975,35370,Unspecified,,,375.0,IC50,Antiproliferative activity was determined against human T-lymphocyte cells -Molt4/C8,Confirmatory,12801219.0,
1433,133198,3,3,,103188975,35370,Unspecified,,,,,"Quantity of anylate in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Other,8632406.0,
1434,133199,3,4,,103188975,35370,Unspecified,,,,,"Quantity of anylate in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Other,8632406.0,
1435,133200,3,3,,103188975,35370,Unspecified,,,,,Quantity of anylate in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Other,8632406.0,
1436,133201,3,3,,103188975,35370,Unspecified,,,,,Quantity of anylate in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Other,8632406.0,
1437,134516,2,4,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, expressed as percent inhibition at a dose of 12 mg/kg",Other,,
1438,134517,2,4,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, expressed as percent inhibition at a dose of 40 mg/kg",Other,,
1439,134518,2,4,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, expressed as percent inhibition at a dose of 4 mg/kg",Other,,
1440,137764,2,5,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, spleen weights at a dose of 12 mg/kg",Other,,
1441,137765,2,5,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, spleen weights at a dose of 40 mg/kg",Other,,
1442,137766,2,5,,103188975,35370,Unspecified,,,,,"Effect of compound on Friend Complex Murine Leukemia Virus (F-MuLV) induced splenomegaly, spleen weights at a dose of 4 mg/kg",Other,,
1443,141778,6,2,,103188975,35370,Unspecified,,,,,Concentration inhibiting moloney murine leukemia retrovirus,Other,1322989.0,
1444,141779,5,1,,103188975,35370,Unspecified,,,,,Inhibitory activity on moloney murine leukemia retrovirus.,Other,1322989.0,
1445,142319,3,3,,103188975,35370,Unspecified,,,,,Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 0.05 uM,Other,7636846.0,
1446,142320,3,3,,103188975,35370,Unspecified,,,,,Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 0.5 uM,Other,7636846.0,
1447,142321,3,3,,103188975,35370,Unspecified,,,,,Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 50 uM,Other,7636846.0,
1448,142323,3,3,,103188975,35370,Unspecified,,,,,Reduced GM-CSF dependent colony formation in murine bone marrow progenitor cells at 5uM,Other,7636846.0,
1449,142324,3,3,,103188975,35370,Unspecified,,,,,Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 0.05 uM,Other,7636846.0,
1450,142325,3,3,,103188975,35370,Unspecified,,,,,Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 0.5 uM,Other,7636846.0,
1451,142326,3,3,,103188975,35370,Unspecified,,,,,Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 50 uM,Other,7636846.0,
1452,142328,3,3,,103188975,35370,Unspecified,,,,,Reduced IL-3 dependent colony formation in murine bone marrow progenitor cells at 5uM,Other,7636846.0,
1453,142331,6,2,,103188975,35370,Unspecified,,,1330.0,Ki,Thymidine Influx Inhibition constant for the compound in fresh Murine Erythrocytes,Confirmatory,8632406.0,
1454,142441,6,2,,103188975,35370,Unspecified,,,594.0,IC50,Cytotoxicity was evaluated,Confirmatory,1992143.0,
1455,144029,5,2,,103188975,35370,Inconclusive,,,,,Inhibitory concentration against Mycobacterium intracellular; Not tested,Other,15214779.0,
1456,144633,5,2,,103188975,35370,Inconclusive,,,,,The compound was evaluated for percent reduction of H2O2-induced H2DCFDA fluorescence in NALM-6-B-cells;No data,Other,10636251.0,
1457,152613,6,3,,103188975,35370,Active,,,0.004,EC50,In vitro anti-HIV activity was evaluated in human peripheral blood mononuclear (PBM) cells,Confirmatory,,
1458,152614,6,3,,103188975,35370,Active,,,0.004,EC50,In vitro anti-HIV activity against HIV-1 in human peripheral blood mononuclear (PBM) cells,Confirmatory,,
1459,152615,6,2,,103188975,35370,Active,,,0.004,EC50,In vitro anti-HIV activity was determined in PBM cells infected with HIV-1,Confirmatory,12540238.0,
1460,152616,8,1,,103188975,35370,Active,,,2.0,EC50,In vitro anti-HIV activity was determined in peripheral blood mononuclear cells.,Confirmatory,2374145.0,
1461,152618,6,3,,103188975,35370,Active,,,0.004,EC50,Median effective dose required for anti HIV-1 activity in PBM cells(Human lymphocytes),Confirmatory,,
1462,152621,6,2,,103188975,35370,Unspecified,,,1000.0,EC50,The antiviral fold-increase activity of the compound (AZT-sensitive to AZT-resistant),Confirmatory,1597854.0,
1463,152622,6,2,,103188975,35370,Active,,,0.004,EC50,In vitro antiviral activity against HIV-1 in human PBM cells.,Confirmatory,11689085.0,
1464,152623,6,2,,103188975,35370,Active,,,1.2,EC50,The compound was tested for antiviral activity against AZT resistant strain 9F HIV in PBM cells.,Confirmatory,1597854.0,
1465,152624,6,2,,103188975,35370,Active,,,0.0012,EC50,The compound was tested for antiviral activity against AZT sensitive strain 9F HIV in PBM cells.,Confirmatory,1597854.0,
1466,152625,6,3,,103188975,35370,Active,,,0.002,EC50,Tested in vitro for anti HIV-1 activity against PBM cells,Confirmatory,10072683.0,
1467,152626,7,1,,103188975,35370,Active,,,,,"Activity against Lamivudine-resistant virus (HIV-1M184V) in human PBM cells, expressed as EC90",Other,12852755.0,
1468,152627,7,1,,103188975,35370,Active,,,,,Antiviral activity against (HIV-1M184V) mutant strain in human PBM cells,Other,12383014.0,
1469,152628,7,1,,103188975,35370,Active,,,,,Antiviral activity against HIV-1xxBRU mutant strain in human PBM cells,Other,12383014.0,
1470,152629,7,1,,103188975,35370,Unspecified,,,,,The antiviral fold-increase activity of the compound (AZT-sensitive to AZT-resistant),Other,1597854.0,
1471,152630,7,1,,103188975,35370,Active,,,,,The compound was tested for antiviral activity against AZT resistant strain 10 HIV in PBM cells.,Other,1597854.0,
1472,152631,7,1,,103188975,35370,Active,,,,,The compound was tested for antiviral activity against AZT sensitive 10 HIV in PBM cells.,Other,1597854.0,
1473,152632,7,1,,103188975,35370,Active,,,,,Tested in vitro for anti HIV-1 activity against PBM cells,Other,10072683.0,
1474,152637,6,4,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for cytotoxicity against human lymphocytes (PBM cells),Confirmatory,,
1475,152640,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxic activity against HIV-1 in peripheral blood mononuclear (PBM) cells,Confirmatory,,
1476,152642,6,2,,103188975,35370,Unspecified,,,200.0,IC50,Cytotoxic effect in uninfected human peripheral blood mononuclear (PBM) cells,Confirmatory,2918508.0,
1477,152644,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human peripheral blood mononuclear (PBM) cells infected with HIV-I,Confirmatory,8423591.0,
1478,152646,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against uninfected PHA-stimulated human peripheral blood mononuclear (PBM) cells was determined.,Confirmatory,8421287.0,
1479,152649,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity in peripheral blood mononuclear cells (PBM).,Confirmatory,1597854.0,
1480,152651,6,4,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity in human peripheral blood mononuclear (PBM) cells,Confirmatory,,
1481,152652,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Evaluated in vitro for their potential toxic effects on uninfected PHA-stimulated human PBM cells,Confirmatory,12540238.0,
1482,152653,6,3,,103188975,35370,Unspecified,,,100.0,IC50,In vitro anti-HIV activity assessed by measuring [3H]-thymidine uptake in human peripheral blood mononuclear (PBM) cells,Confirmatory,,
1483,152655,6,3,,103188975,35370,Unspecified,,,100.0,IC50,In vitro cytotoxicity against human peripheral blood mononuclear (PBM) cells,Confirmatory,12383014.0,
1484,152656,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Inhibition of cell growth against HIV-1 infected PBM (Human peripheral blood mononuclear) cells,Confirmatory,8410975.0,
1485,152657,6,3,,103188975,35370,Active,,,0.004,IC50,Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17 variant.,Confirmatory,10386942.0,
1486,152659,6,3,,103188975,35370,Active,,,0.006,IC50,Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17.,Confirmatory,10386942.0,
1487,152661,6,3,,103188975,35370,Active,,,0.004,IC50,Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain HTLV IIIB wild type.,Confirmatory,10386942.0,
1488,152775,6,3,,103188975,35370,Active,,,0.15,IC50,Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain RT-MDR.,Confirmatory,10386942.0,
1489,152780,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Inhibitory activity was evaluated in human peripheral blood mononuclear (PBM) cells infected with Human immunodeficiency virus-1,Confirmatory,10197975.0,
1490,152792,6,2,,103188975,35370,Unspecified,,,100.0,IC50,In vitro cytotoxicity in PBM cells.,Confirmatory,11689085.0,
1491,152794,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Tested in vitro for cytotoxicity against PBM cells,Confirmatory,10072683.0,
1492,152819,4,3,,103188975,35370,Active,,,0.064,IC50,Anti-HIV activity against multidrug resistant HIV JSL strain by inhibition of HIV p24 antigen expression in peripheral blood mononuclear cells(PBMC),Confirmatory,12699395.0,
1493,152820,4,3,,103188975,35370,Active,,,0.037000000000000005,IC50,Anti-HIV activity against multidrug resistant HIV MM strain by inhibition of HIV p24 antigen expression in peripheral blood mononuclear cells(PBMC),Confirmatory,12699395.0,
1494,152932,4,3,,103188975,35370,Active,,,0.043,IC50,Anti-HIV activity against multidrug resistant HIV TM strain by inhibition of HIV p24 antigen expression in peripheral blood mononuclear cells(PBMC),Confirmatory,12699395.0,
1495,152935,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxic effect in human peripheral blood monocyte cells(PBMC),Confirmatory,1495008.0,
1496,152970,6,2,,103188975,35370,Active,,,0.024,EC50,Effective concentration of compound against HIV-1 89.6 strain in PBMC cells,Confirmatory,14698189.0,
1497,153100,6,3,,103188975,35370,Active,,,11.0,CC50,Cytotoxicity against human peripheral blood mononuclear cells.,Confirmatory,11262088.0,
1498,153101,6,3,,103188975,35370,Active,,,8.0,CC50,Cytotoxicity against human peripheral blood mononuclear cells.,Confirmatory,11262088.0,
1499,153102,6,2,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxic concentration against PBMC cells,Confirmatory,7684450.0,
1500,153105,4,3,,103188975,35370,Active,,,0.011000000000000001,EC50,Inhibition of HIV-1 (BaL) cytopathicity in human peripheral blood mononuclear cells.,Confirmatory,11262088.0,
1501,153106,4,3,,103188975,35370,Active,,,0.0075,EC50,Inhibition of HIV-1 (IIIB) cytopathicity in human peripheral blood mononuclear cells.,Confirmatory,11262088.0,
1502,153131,6,2,,103188975,35370,Active,,,15.0,CC50,Conc. required to cause 50% death of uninfected PBMCs,Confirmatory,11520210.0,
1503,153132,4,4,,103188975,35370,Active,,,0.055999999999999994,EC50,Conc. required to inhibit HIV-1 replication on PBMCs by 50%,Confirmatory,11520210.0,
1504,153133,7,1,,103188975,35370,Unspecified,,,,,Intracellular of AZT-TP concentrations in LAI/HIV-1 infected PMBCs was determined at a conc of 10 uM),Other,11170632.0,
1505,153134,7,1,,103188975,35370,Unspecified,,,,,Intracellular of AZT-TP concentrations in LAI/HIV-1 infected PMBCs was determined at a conc of 10 uM),Other,11170632.0,
1506,153135,6,2,,103188975,35370,Active,,,0.01,EC50,Concentration required to kill 50% of activated PBMCs,Confirmatory,11170632.0,
1507,153136,6,2,,103188975,35370,Active,,,0.006,EC50,Effective concentration of required to inhibit the replication of HIV-1 BY 50% in PMBCs from donor 1,Confirmatory,11170632.0,
1508,153137,6,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Effective concentration of required to inhibit the replication of HIV-1 BY 50% in PMBCs from donor 2,Confirmatory,11170632.0,
1509,153140,6,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Effective concentration required to inhibit the replication of HIV-1 by 50% in PMBCs in the absence of thymidine,Confirmatory,11170632.0,
1510,153141,6,2,,103188975,35370,Active,,,0.3,EC50,Effective concentration required to inhibit the replication of HIV-1 by 50% in PMBCs in the presence of thymidine,Confirmatory,11170632.0,
1511,153143,6,2,,103188975,35370,Active,,,1.0,EC50,Effective concentration required to inhibit the replication of HIV-1 with 2 hr pretreatment of activated PBMCs,Confirmatory,11170632.0,
1512,153144,6,2,,103188975,35370,Active,,,0.015,EC50,Effective concentration required to inhibit the replication of HIV-1 with no pretreatment of activated PBMCs,Confirmatory,11170632.0,
1513,153147,7,1,,103188975,35370,Active,,,,,Concentration required to kill 100% of unactivated PBMCs,Other,11170632.0,
1514,154640,6,2,,103188975,35370,Active,,,0.028999999999999998,EC50,Effective concentration required for antiviral activity against lymphocyte cell line of PBL cells of Human by XTT assay,Confirmatory,7932526.0,
1515,154763,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against PBL cell lines,Other,2165162.0,
1516,154765,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against PBL cell lines,Other,2165162.0,
1517,154767,6,2,,103188975,35370,Active,,,26.0,CC50,Concentration required to reduce viability of Mock infected PBL (peripheral blood lymphocytes) cells.,Confirmatory,1469700.0,
1518,154769,6,2,,103188975,35370,Active,,,0.0014,EC50,Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells,Confirmatory,1469700.0,
1519,154770,6,2,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against Ba-L monocyte tropic isolate strain in monocyte,Confirmatory,11708913.0,
1520,154771,6,3,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against ROJO virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1521,154772,6,3,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against SLKA virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1522,154773,6,3,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against TEKI virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1523,154774,6,3,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against WEJO virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1524,154776,6,3,,103188975,35370,Active,,,0.025,IC50,Antiviral activity against multi drug resistant MDR 769 strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1525,154778,6,3,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against subtype isolate A strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1526,154780,6,3,,103188975,35370,Active,,,0.009000000000000001,IC50,Antiviral activity against subtype isolate B strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1527,154782,6,3,,103188975,35370,Active,,,0.004,IC50,Antiviral activity against subtype isolate C strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1528,154784,6,3,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against subtype isolate D strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1529,154786,6,3,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against subtype isolate E strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1530,154788,6,3,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against subtype isolate F strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1531,154790,6,3,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against subtype isolate G strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1532,154792,6,3,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against subtype isolate O strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1533,154794,8,1,,103188975,35370,Unspecified,,,190.0,TC50,Antiviral activity against ROJO virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1534,154795,8,1,,103188975,35370,Unspecified,,,190.0,TC50,Antiviral activity against SLKA virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1535,154796,8,1,,103188975,35370,Unspecified,,,190.0,TC50,Antiviral activity against TEKI virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1536,154797,8,1,,103188975,35370,Unspecified,,,190.0,TC50,Antiviral activity against WEJO virus strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1537,154798,8,1,,103188975,35370,Unspecified,,,172.0,TC50,Antiviral activity against multi drug resistant MDR 769 strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1538,154799,8,1,,103188975,35370,Unspecified,,,180.0,TC50,Antiviral activity against subtype isolate A strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1539,154800,8,1,,103188975,35370,Unspecified,,,200.0,TC50,Antiviral activity against subtype isolate B strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1540,154801,8,1,,103188975,35370,Unspecified,,,200.0,TC50,Antiviral activity against subtype isolate C strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1541,154802,8,1,,103188975,35370,Unspecified,,,200.0,TC50,Antiviral activity against subtype isolate D strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1542,154803,8,1,,103188975,35370,Unspecified,,,170.0,TC50,Antiviral activity against subtype isolate E strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1543,154804,8,1,,103188975,35370,Unspecified,,,200.0,TC50,Antiviral activity against subtype isolate F strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1544,154805,8,1,,103188975,35370,Unspecified,,,170.0,TC50,Antiviral activity against subtype isolate G strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1545,154806,8,1,,103188975,35370,Unspecified,,,170.0,TC50,Antiviral activity against subtype isolate O strain in PBLs (peripheral blood lymphocytes),Confirmatory,11708913.0,
1546,154809,6,2,,103188975,35370,Unspecified,,,75.0,CC50,Cytotoxic concentration which reduces the cell viability of HIV-1 IIIB infected PBM (peripheral blood mononuclear) cells,Confirmatory,10821705.0,
1547,154811,6,2,,103188975,35370,Active,,,0.004,EC50,Anti-HIV activity against human peripheral blood mononuclear (PBM) cell lines infected with M184V Pitt (FTC resistant isolate),Confirmatory,11882000.0,
1548,154931,6,2,,103188975,35370,Active,,,0.005,EC50,Anti-HIV activity against human peripheral blood mononuclear (PBM) cell lines infected with XxBRU Pitt (FTC sensitive isolate),Confirmatory,11882000.0,
1549,154932,6,2,,103188975,35370,Active,,,0.001,EC50,Effective conc. required to achieve 50% inhibition of HIV-1 IIIB multiplication in PBM (peripheral blood mononuclear) cells,Confirmatory,10821705.0,
1550,154933,6,2,,103188975,35370,Active,,,0.006,EC50,Effective conc. required to achieve 50% inhibition of HIV-2 D194 multiplication in PBM (peripheral blood mononuclear) cells,Confirmatory,10821705.0,
1551,154934,6,3,,103188975,35370,Active,,,0.004,EC50,Effective concentration against HIV-1 strain LAV in human peripheral blood mononuclear (PBM) cells.,Confirmatory,8496934.0,
1552,154939,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Toxicity against human peripheral blood mononuclear (PBM) cells,Confirmatory,11882000.0,
1553,154940,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against uninfected PHA-stimulated peripheral blood mononuclear (PBM) cells,Confirmatory,8496934.0,
1554,154941,6,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV-1 strain LAI in PBM cells on day 6,Confirmatory,8057301.0,
1555,154942,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxic concentration against PBM cells was determined on day 6,Confirmatory,8057301.0,
1556,154943,6,2,,103188975,35370,Active,,,0.004,IC50,The compound was tested for anti HIV-activity (active) against PBM cell line,Confirmatory,10450963.0,
1557,154948,6,2,,103188975,35370,Inconclusive,,,,,Cytotoxic concentration of compound determined by the tyran blue exclusion staining method in PBMC by test II; Not tested,Other,11459656.0,
1558,154954,6,2,,103188975,35370,Active,,,0.003,EC50,"Activity against Lamivudine-resistant virus (HIV-1M184V) in human PBM cells, expressed as EC50",Confirmatory,12852755.0,
1559,154955,6,2,,103188975,35370,Active,,,0.01,EC50,"Activity against Lamivudine-resistant virus (HIV-1XXBRU) in human PBM cells, expressed as EC50",Confirmatory,12852755.0,
1560,154956,6,2,,103188975,35370,Active,,,0.004,EC50,Anti-HIV-1 activity against human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV,Confirmatory,8423591.0,
1561,154958,6,2,,103188975,35370,Active,,,0.004,EC50,Anti-viral activity against HIV-1 in human PBM cells,Confirmatory,12383014.0,
1562,154960,6,2,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV I strain (LAV) in human peripheral blood mononuclear (PBM) cells; Range is 0.002 - 0.009,Confirmatory,2918508.0,
1563,154969,6,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity was evaluated in mitogen-stimulated human peripheral blood mononuclear (PBM) cells infected with HIV-1 strain LAV.,Confirmatory,8421287.0,
1564,154973,6,3,,103188975,35370,Active,,,0.009000000000000001,EC50,Effective concentration against HIV-1 in peripheral blood mononuclear cells(PBM).,Confirmatory,1597854.0,
1565,154974,6,2,,103188975,35370,Active,,,0.004,EC50,Concentration required for antiviral activity in PBMC (human peripheral blood mononuclear cells) infected with HIV-1 strain LAV,Confirmatory,8410975.0,
1566,154976,6,3,,103188975,35370,Active,,,0.004,EC50,In vitro anti-HIV activity in human peripheral blood mononuclear (PBM) cells acutely infected with HIV-1 LAI,Confirmatory,,
1567,155102,6,3,,103188975,35370,Unspecified,,,80.0,EC50,Effective concentration required to inhibit 50% of HIV-1 in peripheral blood mononuclear cells (PBMC),Confirmatory,9341906.0,
1568,155104,6,3,,103188975,35370,Active,,,0.08,EC50,Effective molar concentration required to inhibit the replication of HIV-1 in human peripheral blood mononuclear cells by 50% (PBMC) was determined,Confirmatory,,
1569,155105,6,2,,103188975,35370,Active,,,0.002,EC50,"The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT",Confirmatory,15081000.0,
1570,155118,5,2,,103188975,35370,Inconclusive,,,,,Compound was evaluated for its anti-HIV activity in vitro in peripheral blood mononuclear (PBM) cells; Not determined,Other,9873395.0,
1571,155119,7,1,,103188975,35370,Active,,,,,"The anti-HIV-1 activity was assayed in activated human peripheral blood mononuclear (PBM) cells, relative to RVT",Other,15081000.0,
1572,155133,6,2,,103188975,35370,Active,,,0.006,IC50,Ability to inhibit the replication of A17 (Y181C) strain of HIV-1 p24 antigen production in PBMC,Confirmatory,10617082.0,
1573,155270,6,2,,103188975,35370,Active,,,0.004,IC50,"Ability to inhibit the replication of A17 variant (Y181C,K103N) strain of HIV-1 p24 antigen production in PBMC",Confirmatory,10617082.0,
1574,155272,6,2,,103188975,35370,Active,,,0.004,IC50,Ability to inhibit the replication of HTLV IIIb strain of HIV-1 p24 antigen production in PBMC,Confirmatory,10617082.0,
1575,155273,6,2,,103188975,35370,Active,,,0.2,IC50,Ability to inhibit the replication of RT-MDR (V106A) strain of HIV-1 p24 antigen production in PBMC,Confirmatory,10617082.0,
1576,155274,6,3,,103188975,35370,Active,,,0.006,IC50,Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 (Y181C) in peripheral blood mononuclear cells (PBMC),Confirmatory,10509923.0,
1577,155276,6,3,,103188975,35370,Active,,,0.004,IC50,"Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 variant (Y181C,K103N) in peripheral blood mononuclear cells (PBMC)",Confirmatory,10509923.0,
1578,155278,6,3,,103188975,35370,Active,,,0.004,IC50,Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain HTLV IIIB in peripheral blood mononuclear cells (PBMC),Confirmatory,10509923.0,
1579,155280,6,3,,103188975,35370,Active,,,0.2,IC50,Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain RT-MDR(V106A) in peripheral blood mononuclear cells (PBMC),Confirmatory,10509923.0,
1580,155287,6,2,,103188975,35370,Unspecified,,,50.0,IC50,Compound was evaluated for cellular proliferation (on viability of peripheral blood mononuclear cells) using microculture tetrazolium assay (MTA).,Confirmatory,9873515.0,
1581,155288,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for cytotoxic activity against peripheral blood mononuclear cells using microculture tetrazolium assay,Confirmatory,9873370.0,
1582,155289,6,2,,103188975,35370,Active,,,0.004,IC50,Compound was evaluated for inhibition of p24 production in HIV infected peripheral blood mononuclear cells,Confirmatory,9873370.0,
1583,155292,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for its cytotoxicity against peripheral blood mononuclear (PBM) cells.,Confirmatory,9873395.0,
1584,155293,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for its toxicity by Calorimetric assay in PBM,Confirmatory,9357530.0,
1585,155294,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for the toxicity in human PBM cells,Confirmatory,,
1586,155299,6,2,,103188975,35370,Unspecified,,,100.0,IC50,"Cytotoxicity was determined in PBM cells, relative to RVT",Confirmatory,15081000.0,
1587,155460,6,2,,103188975,35370,Active,,,0.006,IC50,Inhibitory effect on p24 production in HIV-infected peripheral blood mononuclear cells.,Confirmatory,9873515.0,
1588,155467,6,3,,103188975,35370,Unspecified,,,100.0,IC50,The compound was tested for toxicity in peripheral blood mononuclear cells,Confirmatory,1720175.0,
1589,155624,3,4,,103188975,35370,Unspecified,,,,,Inhibition of p24 expression in HIVD34-infected PBMC assay on day 4 at concentration of 4 nM,Other,8295217.0,
1590,155625,3,4,,103188975,35370,Unspecified,,,,,Inhibition of p24 expression in HIVD34-infected PBMC assay on day 4 at concentration of 40 nM,Other,8295217.0,
1591,155631,3,4,,103188975,35370,Unspecified,,,,,Inhibition of viral RNA in HIVD34-infected PBMC assay on day 4 at concentration of 4 nM,Other,8295217.0,
1592,155632,3,4,,103188975,35370,Unspecified,,,,,Inhibition of viral RNA in HIVD34-infected PBMC assay on day 4 at concentration of 40 nM,Other,8295217.0,
1593,155823,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Concentration required to kill 50% of PBMCs,Confirmatory,11170632.0,
1594,156335,8,2,,103188975,35370,Inconclusive,,,,,The compound was tested in vitro for anticancer activity against PC-3 cells; Not determined,Other,10072683.0,
1595,157393,6,2,,103188975,35370,Unspecified,,,83.0,CC50,Cytotoxic concentration based on the reduction of viability of mock-infected peripheral blood lymphocytes (PBL),Confirmatory,7540208.0,
1596,157399,6,2,,103188975,35370,Active,,,12.0,CC50,The cytotoxic concentration of compound required to reduce the viability of mock-infected PBL cells by 50% on HIV-1 virus HTLV-IIIB strain,Confirmatory,7636846.0,
1597,157403,6,2,,103188975,35370,Active,,,0.003,EC50,Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in peripheral blood lymphocytes (PBL).,Confirmatory,7540208.0,
1598,157405,6,2,,103188975,35370,Active,,,0.002,EC50,The effective concentration required to achieve 50% protection of human peripheral blood lymphocytes against the cytopathic effect of HIV-1 virus HTLV-IIIB strain,Confirmatory,7636846.0,
1599,157412,6,2,,103188975,35370,Active,,,0.02,IC50,Inhibitory activity against the HIV-1-induced cytopathic effect in fresh human peripheral blood lymphocytes,Confirmatory,7650678.0,
1600,157416,7,1,,103188975,35370,Unspecified,,,,,In vitro Cytotoxic concentration which destroyed HIV-1 LAV infected peripheral blood lymphocytes (PBL) completely,Other,1573638.0,
1601,157417,7,1,,103188975,35370,Active,,,,,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected peripheral blood lymphocytes (PBL) by 25 percent,Other,1573638.0,
1602,157418,6,2,,103188975,35370,Active,,,0.08,IC50,In vitro Cytotoxic concentration which reduced HIV-1 LAV infected peripheral blood lymphocytes by 50 percent,Confirmatory,1573638.0,
1603,157554,6,2,,103188975,35370,Active,,,0.004,EC50,Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells,Confirmatory,15027854.0,
1604,157555,7,1,,103188975,35370,Active,,,,,Anti-HIV activity in Human peripheral blood mononuclear (PBM) cells,Other,15027854.0,
1605,157556,6,2,,103188975,35370,Unspecified,,,149.0,CC50,Cytotoxic concentration for inhibition of HIV-1 replication in human peripheral Blood mononuclear cells.(PBMCs),Confirmatory,9240351.0,
1606,157557,6,3,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration towards peripheral blood mononuclear cells,Confirmatory,,
1607,157558,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration was evaluated using microculture tetrazolium assay (MTA),Confirmatory,10617082.0,
1608,157559,6,3,,103188975,35370,Unspecified,,,100000.0,CC50,Cytotoxic concentration required to inhibit 50% of HIV-1 in peripheral blood mononuclear cells (PBMC),Confirmatory,9341906.0,
1609,157561,6,2,,103188975,35370,Active,,,10.0,CC50,Tested for the drug concentration required to decrease HIV-1D4 infected human peripheral blood mononuclear cell viability compared to uninfected controls,Confirmatory,7512142.0,
1610,157568,6,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against human immunodeficiency virus type-1 (HIV-1) in PBM cells,Confirmatory,9357530.0,
1611,157569,6,2,,103188975,35370,Active,,,0.004,EC50,"Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-1(strain LAV)",Confirmatory,1720175.0,
1612,157571,6,2,,103188975,35370,Active,,,0.002,EC50,"Antiviral activity against human peripheral blood mononuclear cells, infected with HIV-2(strain ROD-2)",Confirmatory,1720175.0,
1613,157574,6,2,,103188975,35370,Active,,,0.004,EC50,Compound was evaluated for its anti-HIV activity in vitro in peripheral blood mononuclear (PBM) cells,Confirmatory,9873395.0,
1614,157575,6,3,,103188975,35370,Active,,,0.004,EC50,Compound was evaluated for the anti-HIV-1 activity in human peripheral blood mononuclear cells infected with HIV-1LA1.,Confirmatory,,
1615,157581,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Effective concentration for inhibition of HIV-1 replication in human peripheral Blood mononuclear cells.(PBMCs),Confirmatory,9240351.0,
1616,160452,7,2,,103188975,35370,Inconclusive,,,,Ki,In vitro inhibitory activity against biotinylated human HIV-1 protease,Confirmatory,8295217.0,
1617,160635,3,7,,103188975,35370,Unspecified,,,,,"Relative potency of compound to that of parent HIV Protease inhibitor, KNI-727 was determined",Other,10866387.0,
1618,163315,6,2,,103188975,35370,Active,,,0.023,IC50,Concentration of compound required to inhibit 50% of viral replication of Rauscher-Murine leukemia virus,Confirmatory,2754712.0,
1619,163316,7,1,,103188975,35370,Unspecified,,,,,Concentration of compound required to inhibit 50% of host cell replication of Rauscher-Murine leukemia virus,Other,2754712.0,
1620,163320,5,1,,103188975,35370,Unspecified,,,,,Evaluated for the antiretroviral activity against Rauscher murine leukemia virus (R-MuLV),Other,2157012.0,
1621,197658,6,2,,103188975,35370,Active,,,0.046,EC50,Concentration that reduces Rauscher murine leukemia virus titer by 50%,Confirmatory,1992143.0,
1622,197772,6,7,,103188975,35370,Unspecified,82310930.0,,100.0,IC50,Inhibition of HIV-1 reverse transcriptase.,Confirmatory,,
1623,197773,6,5,,103188975,35370,Unspecified,,,100.0,IC50,Inhibition of HIV-1 reverse transcriptase,Confirmatory,,
1624,197785,9,5,,103188975,35370,Unspecified,82310930.0,,100.0,IC50,Inhibition of recombinant HIV-1 reverse transcriptase,Confirmatory,10636251.0,
1625,197808,8,4,,103188975,35370,Inconclusive,,,,,In vitro inhibition of HIV-1 reverse transcriptase; NA = not applicable,Other,7684450.0,
1626,197924,9,2,,103188975,35370,Active,,,0.04,IC50,Concentration required to inhibit HIV reverse transcriptase,Confirmatory,1527788.0,
1627,197946,11,2,,103188975,35370,Active,82310930.0,,0.006,IC50,In vitro inhibitory activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT),Confirmatory,1712395.0,
1628,198229,9,5,,103188975,35370,Unspecified,82310930.0,,100.0,IC50,Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system,Confirmatory,10617082.0,
1629,198232,8,4,,103188975,35370,Inconclusive,,,,,Inhibitory activity of compound against purified recombinant HIV-1 reverse transcriptase; Not determined,Other,10386942.0,
1630,198262,9,2,,103188975,35370,Active,,,0.017,IC50,Inhibitory concentration against human immunodeficiency virus type 1 (HIV-1 strain IIIB RT) reverse transcriptase was determined by triplicate assay at high (~1 pfu/cell) multiplicity of injection (moi),Confirmatory,9438017.0,
1631,198384,9,2,,103188975,35370,Active,,,0.003,IC50,Inhibitory concentration against human immunodeficiency virus type 1 (HIV-1 strain IIIB RT) reverse transcriptase was determined by triplicate assay at low (~0.1 pfu/cell) multiplicity of injection (moi),Confirmatory,9438017.0,
1632,198387,9,2,,103188975,35370,Active,,,0.006,IC50,"Inhibitory effect on HIV-1 RT activity using template primer,poly (rA)-oligo (dT)",Confirmatory,7540208.0,
1633,198570,9,2,,103188975,35370,Active,,,0.011000000000000001,IC50,antiviral activity in Human immunodeficiency virus-1 as reverse transcriptase activity in culture supernatant,Confirmatory,7562946.0,
1634,198594,6,4,,103188975,35370,Inconclusive,,,,,In vitro inhibition of HIV-1 reverse transcriptase at 100 uM; NA = not applicable,Other,7684450.0,
1635,199075,3,3,,103188975,35370,Unspecified,,,,,RT activity in culture fluid at 10e-4 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1636,199076,3,3,,103188975,35370,Unspecified,,,,,RT activity in culture fluid at 10e-5 concentration of compound was tested on MT-4 cells infected by HIV-1/IIB,Other,7520081.0,
1637,199660,6,3,,103188975,35370,Active,,,0.1,IC50,Inhibition of HIV-1 reverse transcriptase from peripheral blood mononuclear cells,Confirmatory,1720175.0,
1638,199672,6,5,,103188975,35370,Unspecified,,,,,Compound was evaluated as inhibitor of recombinant HIV-l reverse transcriptase,Other,,
1639,199849,9,1,,103188975,35370,Active,,,0.0031,IC50,Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells,Confirmatory,9548815.0,
1640,199850,9,2,,103188975,35370,Active,,,0.01,EC50,Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by reverse transcriptase (RT) assay.,Confirmatory,8385224.0,
1641,199851,9,2,,103188975,35370,Active,,,0.003,EC50,"Reverse transcriptase activity was measured in the culture supernatant, concentration that reduces by 50% the HIV produced in the supernatant.",Confirmatory,9154976.0,
1642,199981,4,7,,103188975,35370,Active,,,,,Inhibition of HIV-1 reverse transcriptase; + = active,Other,7520081.0,
1643,200005,9,5,,103188975,35370,Active,82310930.0,,0.003,EC50,Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay,Confirmatory,7504733.0,
1644,200148,9,2,,103188975,35370,Active,,,0.03,IC50,Ability to inhibit the HIV-1 reverse transcriptase in cord blood mononuclear cells.,Confirmatory,7837220.0,
1645,200172,7,2,,103188975,35370,Active,,,0.016,IC50,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RTS (K103 N),Confirmatory,7683725.0,
1646,200173,7,2,,103188975,35370,Active,,,0.023,IC50,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RTS (Y181C),Confirmatory,7683725.0,
1647,200175,9,2,,103188975,35370,Unspecified,,,100.0,IC50,Compound was evaluated for enzymatic inhibitory activity against recombinant HIV reverse transcriptase,Confirmatory,9873370.0,
1648,201966,6,2,,103188975,35370,Unspecified,,,10.0,IC50,The compound was tested in vitro for anticancer activity against SK-MEL-28 cells,Confirmatory,10072683.0,
1649,202327,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Tested in vitro for anticancer activity against SK-MES-1 cells,Confirmatory,10072683.0,
1650,206707,5,2,,103188975,35370,Inconclusive,,,,,Inhibitory concentration against Staphylococcus aureus; Not tested,Other,15214779.0,
1651,206710,5,2,,103188975,35370,Inconclusive,,,,,Inhibitory concentration against methicillin-resistant Staphylococcus aureus; Not tested,Other,15214779.0,
1652,208555,6,2,,103188975,35370,Active,,,0.0007,EC50,In vitro effective concentration against HIV-1 cytopathic effect in T4 cells,Confirmatory,10956199.0,
1653,208557,6,2,,103188975,35370,Active,,,35.6,IC50,In vitro inhibitory activity against uninfected T4 cells,Confirmatory,10956199.0,
1654,209161,4,5,,103188975,35370,Active,,,0.05,IC50,Tested for the inhibitory activity against HIV-1 in Sup T1 cell lines assessed by syncytium formation and reverse transcriptase assay,Confirmatory,,
1655,209368,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxic concentration to inhibit HIV replication in TK CEM-SS cell line,Confirmatory,11425558.0,
1656,209370,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Effective concentration to inhibit HIV replication in TK CEM-SS cell line,Confirmatory,11425558.0,
1657,210286,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against T-cells,Other,2165162.0,
1658,210290,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against T-cells,Other,2165162.0,
1659,210592,8,1,,103188975,35370,Unspecified,,,1000.0,TC50,Compound was tested for the drug concentration which reduces the viability of uninfected C8166 cells by 50%,Confirmatory,,
1660,210597,3,4,,103188975,35370,Unspecified,,,,,Therapeutic Index is the average of the IC50 to that of EC50,Other,9804704.0,
1661,210869,4,7,,103188975,35370,Unspecified,,,,,Inhibitory activity against thymidine kinase (TK) from L1210 cells,Other,6644738.0,
1662,210881,9,3,,103188975,35370,Active,,,2.9,Ki,Inhibitory affect against rabbit thymus thymidine kinase and represented as molt/4F kinase.,Confirmatory,2153206.0,
1663,210882,9,3,,103188975,35370,Active,,,7.0,Ki,Inhibitory affect against rabbit thymus thymidine kinase,Confirmatory,2153206.0,
1664,210897,9,5,,103188975,35370,Active,614088749.0,888740.0,28.0,Ki,In Vitro inhibition of Thymidine Monophosphatase Kinase of Mycobacterium tuberculosis (TMPKm),Confirmatory,12930144.0,
1665,210901,3,10,,103188975,35370,Unspecified,23503074.0,7083.0,,,In Vitro inhibition of Thymidine Monophosphatase Kinase (TMPKh); not determined,Other,12930144.0,
1666,210904,9,5,,103188975,35370,Active,614088749.0,888740.0,28.0,Ki,Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis,Confirmatory,12941330.0,
1667,211064,3,6,,103188975,35370,Unspecified,,,,,In vitro percent of phosphorolysis after incubation with Escherichia coli thymidine phosphorylase for 10 min at 37 degree C,Other,7996541.0,
1668,211485,6,2,,103188975,35370,Active,,,29.0,IC50,Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated Vero cells,Confirmatory,15027854.0,
1669,211648,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated human Peripheral blood mononuclear (PBM) cells,Confirmatory,15027854.0,
1670,211649,6,2,,103188975,35370,Active,,,14.3,IC50,Compounds were evaluated for their potential toxic effect on uninfected PHA-stimulated human T-lymphoblastoid cell line (CEM),Confirmatory,15027854.0,
1671,214060,6,2,,103188975,35370,Active,,,0.03,EC50,Effective concentration required for antiviral activity against Macrophage cell line of U937 cells of Human by XTT assay,Confirmatory,7932526.0,
1672,214083,6,2,,103188975,35370,Active,,,25.0,EC50,Antiviral activity was determined in chronically infected U1 cell line with HIV-1,Confirmatory,11170632.0,
1673,214084,4,4,,103188975,35370,Unspecified,,,,,Effect against HIV-1 chronically infected promonocytic cell line U1,Other,7543578.0,
1674,214085,4,5,,103188975,35370,Unspecified,,,,,Effect against HIV-1 chronically infected promonocytic cell line U1 in the presence of PMA(phorbol 12-myristate 13-acetate),Other,7543578.0,
1675,214213,3,4,,103188975,35370,Unspecified,,,,,inhibition of HIV-1 induced RT production in U1 cells,Other,1901911.0,
1676,214214,3,4,,103188975,35370,Unspecified,,,,,inhibition of infectious virus production in U1 cells,Other,1901911.0,
1677,214215,3,4,,103188975,35370,Unspecified,,,,,inhibition of p24 core antigen synthesis in U1 cells,Other,1901911.0,
1678,214413,6,2,,103188975,35370,Unspecified,,,110.0,CC50,Cytotoxic concentration against HIV-1 infected U937 cell lines,Confirmatory,7837220.0,
1679,214422,6,2,,103188975,35370,Active,,,0.04,IC50,Inhibitory concentration against HIV-1 infected U937 cell lines,Confirmatory,7837220.0,
1680,214558,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against U937 cell lines,Other,2165162.0,
1681,214559,5,1,,103188975,35370,Unspecified,,,,,In vitro antiviral activity against U937 cell lines,Other,2165162.0,
1682,216020,6,2,,103188975,35370,Active,,,29.0,IC50,Cytotoxic concentration against Vero cells was determined on day 3,Confirmatory,8057301.0,
1683,216044,6,2,,103188975,35370,Active,,,29.0,IC50,Inhibitory activity was evaluated in Vero cells.,Confirmatory,10197975.0,
1684,216188,6,2,,103188975,35370,Active,,,29.0,IC50,Tested in vitro for cytotoxicity against Vero cells,Confirmatory,10072683.0,
1685,216718,8,1,,103188975,35370,Active,,,,,Compound was evaluated for anti-retrovirus activity against Visna virus (K184) strain in infected sheep choroid plexus cells.,Other,8496903.0,
1686,217433,6,2,,103188975,35370,Unspecified,,,100.0,EC50,"Antiviral activity against Vero cells, infected with HSV-1",Confirmatory,1720175.0,
1687,217718,6,3,,103188975,35370,Active,,,27.7,IC50,Compound was evaluated for cytotoxicity against Vero cells,Confirmatory,,
1688,217719,6,2,,103188975,35370,Active,,,27.7,IC50,Compound was evaluated for its cytotoxicity against vero cells.,Confirmatory,9873395.0,
1689,217720,6,3,,103188975,35370,Active,,,29.0,IC50,Compound was evaluated for the toxicity in rapidly dividing Vero cells (African Green monkeys kidney cells),Confirmatory,,
1690,217728,6,2,,103188975,35370,Active,,,29.0,IC50,Cytotoxicity against Vero cells was determined.,Confirmatory,11882000.0,
1691,217730,6,3,,103188975,35370,Active,,,27.7,IC50,Cytotoxicity in Vero cells,Confirmatory,,
1692,217731,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity was determined in the vero cells infected with HIV-I,Confirmatory,8423591.0,
1693,217732,6,2,,103188975,35370,Active,,,29.0,IC50,"Cytotoxicity was determined in Vero cells, relative to RVT",Confirmatory,15081000.0,
1694,217733,6,2,,103188975,35370,Active,,,14.3,IC50,Evaluated in vitro for their potential toxic effects against Vero cells,Confirmatory,12540238.0,
1695,217737,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Inhibition of cell growth in vero cells,Confirmatory,8410975.0,
1696,217742,6,2,,103188975,35370,Active,,,29.0,IC50,In vitro cytotoxicity in vero cells.,Confirmatory,11689085.0,
1697,217743,6,2,,103188975,35370,Active,,,26.0,IC50,The compound was tested for toxicity in Vero cells,Confirmatory,1720175.0,
1698,218239,6,3,,103188975,35370,Active,,,28.0,IC50,Cytotoxic activity against HIV-1 in rapidly dividing vero cells,Confirmatory,,
1699,218240,6,2,,103188975,35370,Active,,,28.0,IC50,Cytotoxicity against Vero cells,Confirmatory,12383014.0,
1700,218498,6,2,,103188975,35370,Unspecified,,,50.0,EC50,Antiviral activity against HSV-1 strain F in Vero cells on day 2,Confirmatory,8057301.0,
1701,218515,5,3,,103188975,35370,Inconclusive,,,,,In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay; not determined,Other,,
1702,218517,5,3,,103188975,35370,Inconclusive,,,,,In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay; not determined,Other,,
1703,218531,6,2,,103188975,35370,Active,,,29.0,IC50,Compound was evaluated for its toxicity by Calorimetric assay in vero cells,Confirmatory,9357530.0,
1704,221610,3,3,,103188975,35370,Unspecified,,,,,In Vitro detection by Gray and Whittaker method for % of internalization by comparing with external nucleoside of 2000 nM/g,Other,1501232.0,
1705,222386,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 0.5 hr,Other,1501232.0,
1706,222387,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 1 hr,Other,1501232.0,
1707,222388,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 24 hr,Other,1501232.0,
1708,222389,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 2 hr,Other,1501232.0,
1709,222390,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 48 hr,Other,1501232.0,
1710,222391,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 4 hr,Other,1501232.0,
1711,222392,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 8 hr,Other,1501232.0,
1712,222393,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 0.5 hr,Other,1501232.0,
1713,222394,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 1 hr,Other,1501232.0,
1714,222395,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 24 hr,Other,1501232.0,
1715,222396,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 2 hr,Other,1501232.0,
1716,222397,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 48 hr,Other,1501232.0,
1717,222398,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 4 hr,Other,1501232.0,
1718,222399,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice plasma after oral administration of 20 mg/kg detected in the form of AZT after 8 hr,Other,1501232.0,
1719,222490,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 0.5 hr,Other,1501232.0,
1720,222491,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 1 hr,Other,1501232.0,
1721,222492,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 24 hr,Other,1501232.0,
1722,222493,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 2 hr,Other,1501232.0,
1723,222494,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 48 hr,Other,1501232.0,
1724,222495,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 4 hr,Other,1501232.0,
1725,222496,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT 5`-P after 8 hr,Other,1501232.0,
1726,222497,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 0.5 hr,Other,1501232.0,
1727,222498,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 1 hr,Other,1501232.0,
1728,222499,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 24 hr,Other,1501232.0,
1729,222500,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 2 hr,Other,1501232.0,
1730,222501,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 48 hr,Other,1501232.0,
1731,222502,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 4 hr,Other,1501232.0,
1732,222503,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection in Mice brains after oral administration of 20 mg/kg detected in the form of AZT after 8 hr,Other,1501232.0,
1733,222675,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 0.5 hr,Other,1501232.0,
1734,222676,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 1 hr,Other,1501232.0,
1735,222677,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 24 hr,Other,1501232.0,
1736,222678,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 2 hr,Other,1501232.0,
1737,222679,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 48 hr,Other,1501232.0,
1738,222680,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 4 hr,Other,1501232.0,
1739,222681,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice brains after oral administration of 20 mg/kg after 8 hr,Other,1501232.0,
1740,222686,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 0.5 hr,Other,1501232.0,
1741,222687,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 1 hr,Other,1501232.0,
1742,222688,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 24 hr,Other,1501232.0,
1743,222689,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 2 hr,Other,1501232.0,
1744,222690,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 48 hr,Other,1501232.0,
1745,222691,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 4 hr,Other,1501232.0,
1746,222692,3,4,,103188975,35370,Unspecified,,,,,In Vivo detection of total AZT in Mice plasma after oral administration of 20 mg/kg after 8 hr,Other,1501232.0,
1747,222817,7,1,,103188975,35370,Unspecified,,,,,In Vitro detection by Gray and Whittaker method for the total internal nucleoside,Other,1501232.0,
1748,224946,6,2,,103188975,35370,Active,,,2.0,IC50,Compound was tested for anti-HIV activity in normal peripheral blood mononuclear cells infected with HIV-1(RTMDR-1) virus by inhibition of reverse transcriptase activity,Confirmatory,9873688.0,
1749,224947,6,2,,103188975,35370,Active,,,2.4,IC50,Compound was tested for anti-HIV activity in normal peripheral blood mononuclear cells infected with HIV-2 virus by inhibition of reverse transcriptase activity,Confirmatory,9873688.0,
1750,225321,6,2,,103188975,35370,Active,,,7.8,CC50,Concentration required to reduce viability of mock-infected MT-4 cells,Confirmatory,1469700.0,
1751,226220,5,3,,103188975,35370,Unspecified,,,,,Concentration of external nucleoside in mouse brain,Other,1501232.0,
1752,226232,3,3,,103188975,35370,Unspecified,,,,,Fold increase of EC50 HIV M184v to that of EC90 HIV-1xxBRU was determined,Other,15027854.0,
1753,226233,3,3,,103188975,35370,Unspecified,,,,,Fold increase ratio of HIV-1M184V to HIV-1XXBRU,Other,12852755.0,
1754,226288,3,3,,103188975,35370,Unspecified,,,,,ratio of Ki (Ki TMPKh / KiTMPKmt); not determined,Other,12930144.0,
1755,226670,6,2,,103188975,35370,Unspecified,,,,,Compound was evaluated for its cytotoxicity.,Other,9871553.0,
1756,227258,3,4,,103188975,35370,Unspecified,,,,,Ratio of CD50 to ID50 was determined,Other,15214788.0,
1757,228281,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Compound was evaluated for the cytotoxic activity by using Microculture Tetrazolium assay (MTA),Confirmatory,10509923.0,
1758,228862,6,3,,103188975,35370,Unspecified,,,1000.0,EC50,Antioxidant activity was evaluated by measuring the inhibition of oxidation of ABTS to ABTS+ by metmyoglobin in the presence of H2O2.,Confirmatory,10636251.0,
1759,229048,6,2,,103188975,35370,Active,,,28.0,IC50,Cytotoxic effect against vero cells.,Confirmatory,8496934.0,
1760,229051,6,2,,103188975,35370,Active,,,28.0,IC50,Cytotoxicity against uninfected PHA-stimulated vero cells was determined.,Confirmatory,8421287.0,
1761,229224,6,2,,103188975,35370,Active,,,28.0,IC50,Cytotoxicity in vero cells.,Confirmatory,1597854.0,
1762,229420,4,4,,103188975,35370,Unspecified,,,,,Selectivity ratio CD50 to ED50,Other,3499515.0,
1763,230127,3,5,,103188975,35370,Unspecified,,,,,Tested for the ratio between CC50 (MT-4) to EC50 (MT-4),Other,7527463.0,
1764,230269,3,3,,103188975,35370,Unspecified,,,,,Ratio of TICD50 to that of IC50 of Rauscher-Murine leukemia virus (R-MuLv),Other,2754712.0,
1765,230271,3,3,,103188975,35370,Unspecified,,,,,Ratio of TICD50 to that of IC50 of human immunodeficiency virus (HIV-1),Other,2754712.0,
1766,231375,3,4,,103188975,35370,Unspecified,,,,,Ratio of CD50/ED50,Other,2033586.0,
1767,231665,3,4,,103188975,35370,Unspecified,,,,,CC50/EC50 ratio expressed as selectivity index(SI),Other,2016729.0,
1768,231790,3,9,,103188975,35370,Unspecified,46577576.0,7852.0,,,Ratio of cytotoxic concentration (CC50) in test-I to that of EC50 of compound,Other,11128640.0,
1769,231792,3,9,,103188975,35370,Unspecified,46577576.0,7852.0,,,Ratio of cytotoxic concentration (CC50) in test-II to that of EC50 of compound,Other,11128640.0,
1770,232050,3,4,,103188975,35370,Unspecified,,,,,Selectivity index expressed as the ratio of CC50/ EC50,Other,8558522.0,
1771,232053,3,6,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50 to EC50,Other,9154967.0,
1772,232058,3,4,,103188975,35370,Unspecified,,,,,Selectivity index reported as ratio of CC50 to EC50,Other,,
1773,232296,3,3,,103188975,35370,Unspecified,,,,,Differential selectivity measured as the ratio of CEM-SS cell growth IC50 vs HIV plaque formation IC50.,Other,2016713.0,
1774,232315,3,3,,103188975,35370,Unspecified,,,,,EC50 of HIV-2 in CEM/TK versus EC50 of HIV-2 in CEM/0,Other,8478904.0,
1775,232354,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50 in CEM-CL13 cells to EC50 in HIV-1 LA1 infected CEM-CL13 cells.,Other,9154976.0,
1776,232355,3,3,,103188975,35370,Unspecified,,,,,Ratio of CC50 value that of EC50 value(HIV-1),Other,7523675.0,
1777,232356,3,3,,103188975,35370,Unspecified,,,,,Ratio of CC50 value that of EC50 value(HIV-2),Other,7523675.0,
1778,232507,3,4,,103188975,35370,Inconclusive,,,,,Selectivity ratio of EC50(HIV-1) against TC50(C8166 cell line) was determined; ND denotes no data,Other,,
1779,232738,3,7,,103188975,35370,Unspecified,,,,,Selectivity index expressed as ratio of IC50 (CEM-C113) to EC50 from RT assay,Other,8385224.0,
1780,232746,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is calculated by dividing the TC25(CEM) by ID50(CEM),Other,1738145.0,
1781,232747,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is calculated by dividing the TC25(MT2) by ID50(MT2),Other,1738145.0,
1782,232753,3,4,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of EC50 and CC50 in MT-4 cells,Other,9925728.0,
1783,232754,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of IC50 value to that of EC50 value,Other,7932583.0,
1784,232758,4,4,,103188975,35370,Unspecified,,,,,Selectivity index measured as the ratio of CC50/IC50 values.,Other,1995896.0,
1785,232764,3,4,,103188975,35370,Unspecified,,,,,Selectivity index of HIV-1 and HIV-2 with respect to CEM cells,Other,9046339.0,
1786,232765,3,3,,103188975,35370,Unspecified,,,,,Selectivity index of HIV-1 and HIV-2 with respect to MT-4 cells,Other,9046339.0,
1787,232768,3,3,,103188975,35370,Unspecified,,,,,Selectivity index of IC50 and CD50 of the compound,Other,2165161.0,
1788,232916,3,3,,103188975,35370,Unspecified,,,,,Selective index is the ratio of cytotoxic concentration to effective concentration against MT-4 cell line,Other,8478904.0,
1789,233026,3,3,,103188975,35370,Unspecified,,,,,Selective index was evaluated from inhibitory concentrations of compound,Other,9873515.0,
1790,233408,3,5,,103188975,35370,Unspecified,,,,,Ratio of EC50 to CC50 against HIV-1/C8166 cells was evaluated,Other,,
1791,233700,4,4,,103188975,35370,Unspecified,,,,,"Selectivity ratio to IC50 of HL60 cells and EC50, anti-HIV activity of MT-4 cells",Other,1695683.0,
1792,233701,4,5,,103188975,35370,Unspecified,,,,,"Selectivity ratio to IC50 of MT4 cells and EC50, anti-HIV activity of MT-4 cells",Other,1695683.0,
1793,234033,3,4,,103188975,35370,Unspecified,,,,,Therapeutic Index (IC50/EC50) of the compound,Other,11206454.0,
1794,234114,3,4,,103188975,35370,Unspecified,,,,,Specific index of IC50 and CC50 on HIV-1 IIIB wild type,Other,7473595.0,
1795,234204,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index (Ratio = ID50/ED50).,Other,3497272.0,
1796,235006,3,3,,103188975,35370,Unspecified,,,,,Compound was tested for anti HIV activity by measuring therapeutic index in H9 lymphocytes; IC50/EC50,Other,9873504.0,
1797,235014,3,4,,103188975,35370,Unspecified,,,,,In vitro therapeutic index was measured from IC50 to EC50 towards HIV-1 replication in cell growth in H9 lymphocytes,Other,12699758.0,
1798,235027,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index (IC50/EC50) of compound was determined in acutely infected H9 cell,Other,11527717.0,
1799,235028,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index (IC50/EC50) was determined,Other,14736256.0,
1800,235201,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index expressed as IC50/EC50,Other,15149703.0,
1801,235202,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index for inhibition of uninfected H9 cell growth to that of inhibition of HIV-1 replication in H9 lymphocyte cells.,Other,10843202.0,
1802,235212,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio of IC50 to EC50 in H9 lymphocytes,Other,11262077.0,
1803,235220,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index of IC50 to EC50,Other,7996541.0,
1804,235230,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index was determined,Other,,
1805,235232,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index was determined,Other,11720855.0,
1806,235238,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index was evaluated as ratio of IC50 to that of EC50,Other,9871747.0,
1807,235243,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index value was evaluated as the ratio of IC50/EC50,Other,9873374.0,
1808,235253,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index(TI) was evaluated (IC50/EC50),Other,10021911.0,
1809,235254,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index(TI) was measured as ratio of TD50 and MIC50 (Retrovirus),Other,1322989.0,
1810,235289,4,4,,103188975,35370,Unspecified,,,,,CC50/EC50 was measured,Other,11520210.0,
1811,235310,3,4,,103188975,35370,Unspecified,,,,,SI (selectivity index) is the ratio of TC50 to EC50,Other,,
1812,235314,3,3,,103188975,35370,Unspecified,,,,,Selective index is the ratio between IC50 and EC50,Other,8709096.0,
1813,235319,3,4,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value against CEM cells.,Other,7837220.0,
1814,235383,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index (IC50/EC50) was determined,Other,10956199.0,
1815,235439,3,4,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value against H9 cells.,Other,7837220.0,
1816,235440,3,4,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value against Jurkat cells.,Other,7837220.0,
1817,235441,3,4,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value against MT-4 cells.,Other,7837220.0,
1818,235442,3,4,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value against U937 cells.,Other,7837220.0,
1819,235443,3,3,,103188975,35370,Unspecified,,,,,Selective index as the ratio of CC50 to that of IC50 value.,Other,7837220.0,
1820,235458,4,3,,103188975,35370,Unspecified,,,,,Selectivity index (SI) is determined as the ratio of CC50/EC50,Other,11958995.0,
1821,235462,3,4,,103188975,35370,Unspecified,,,,,Selectivity index based on the ratio of CC50 to EC50,Other,,
1822,235472,3,9,,103188975,35370,Unspecified,82310930.0,,,,Selectivity index expressed as CC50/EC50,Other,11087576.0,
1823,235474,4,4,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio between CD50 and ED50,Other,8691437.0,
1824,235475,3,4,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio between CD50 and IC50 values of the compound,Other,9457243.0,
1825,235480,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50 to EC50,Other,1697345.0,
1826,235484,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50 to IC50,Other,11052800.0,
1827,235486,3,9,,103188975,35370,Unspecified,82310930.0,,,,Selectivity index is the ratio of ED50 and CD50 values against inhibition of HIV-1 in MT-4 cells,Other,2754700.0,
1828,235487,3,4,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of IC50 to EC50 of F-MuLV.,Other,1992143.0,
1829,235503,4,3,,103188975,35370,Unspecified,,,,,Selectivity index calculated as the ratio between CC50 and EC50,Other,7650679.0,
1830,235557,3,4,,103188975,35370,Unspecified,,,,,Ratio of the EC50 against HIV-1 infected MT-4 cells and CC50 against mock infected MT-4 cells.,Other,1469700.0,
1831,235562,3,3,,103188975,35370,Unspecified,,,,,Selectivity Index measured as ratio of CC50 to that of EC50 in PBMCs,Other,9240351.0,
1832,235616,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index is the ratio of IC50 of compound to that of EC50,Other,,
1833,235628,3,3,,103188975,35370,Unspecified,,,,,Selectivity index determined for CC50 (test I) to EC50 x 10e3,Other,11459656.0,
1834,235631,3,3,,103188975,35370,Inconclusive,,,,,Selectivity index determined for CC50 (test II) to EC50 x 10e3; Not tested,Other,11459656.0,
1835,235634,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50/EC50,Other,2479745.0,
1836,235641,4,3,,103188975,35370,Unspecified,,,,,Selectivity index in the HIV-1 infected cell cultures.,Other,8765527.0,
1837,235678,3,4,,103188975,35370,Unspecified,,,,,Selectivity Index measured as ratio of CC50 to that of EC50.,Other,9240351.0,
1838,235681,3,3,,103188975,35370,Unspecified,,,,,Selectivity Index measured as the ratio of CC50 to that of EC50(HIV-1) values.,Other,7562935.0,
1839,235682,3,3,,103188975,35370,Unspecified,,,,,Selectivity Index measured as the ratio of CC50 to that of EC50(HIV-2) values.,Other,7562935.0,
1840,235683,3,4,,103188975,35370,Unspecified,,,,,Selectivity Index measured as the ratio of EC50 to that of CC50 values.,Other,1992136.0,
1841,235684,3,3,,103188975,35370,Unspecified,,,,,Selectivity Index measured as the ratio of EC50(CEM-SS) to that of CC50(CEM-SS).,Other,7562927.0,
1842,235686,3,3,,103188975,35370,Unspecified,,,,,Selectivity Index measured as the ratio of EC50(MT-4) to that of CC50(MT-4).,Other,7562927.0,
1843,235695,4,3,,103188975,35370,Unspecified,,,,,Selectivity index is defined as CC25(A3.01 cells) / CC50(A3.01 cells),Other,1573638.0,
1844,235697,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is defined as CC25(H9 cells) / CC50(H9 cells),Other,1573638.0,
1845,235698,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is defined as CC25(MT2 cells) / CC50(MT2 cells),Other,1573638.0,
1846,235699,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is defined as CC25(PBLcells) / CC50(PBL cells),Other,1573638.0,
1847,235700,3,3,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50 and EC50 in MT-4 cells,Other,7540208.0,
1848,235702,3,4,,103188975,35370,Unspecified,,,,,Selectivity index is the ratio of CC50 and EC50 in peripheral blood lymphocytes (PBL).,Other,7540208.0,
1849,235704,3,4,,103188975,35370,Unspecified,,,,,Selectivity index of CD50 to ED50 of MT-4 cells,Other,2342078.0,
1850,235739,3,3,,103188975,35370,Unspecified,,,,,Therapeutic index determined by ratio of IC50 to EC50,Other,12729671.0,
1851,235745,2,5,,103188975,35370,Unspecified,,,,,Therapeutic index (IC50/EC50),Other,,
1852,235793,3,4,,103188975,35370,Unspecified,,,,,Selectivity index was determined in C8166 cells,Other,11462972.0,
1853,235794,3,4,,103188975,35370,Unspecified,,,,,Selectivity index was determined in CEM-SS cells,Other,11462972.0,
1854,235795,3,3,,103188975,35370,Unspecified,,,,,Selectivity index was measured as the ratio of CC50(HIV-1) to that of EC50(HIV-1),Other,9767646.0,
1855,235799,4,3,,103188975,35370,Unspecified,,,,,Selectivity index which is the ratio between CC50 and EC50,Other,8642557.0,
1856,235800,3,4,,103188975,35370,Unspecified,,,,,Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.,Other,1992143.0,
1857,235801,4,3,,103188975,35370,Unspecified,,,,,Selectivity index (CC50/EC50).,Other,11262088.0,
1858,235811,3,4,,103188975,35370,Unspecified,,,,,Selectivity by CC50 of CEM cells/EC50 of CEM cells against HIV-1,Other,10229629.0,
1859,235871,2,5,,103188975,35370,Unspecified,,,,,Ratio of CC50 to that of IC50 was determined,Other,,
1860,235872,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50/EC50 was calculated,Other,,
1861,235873,4,4,,103188975,35370,Unspecified,,,,,Ratio of CD50 to ED50 based on MTT assay,Other,1712047.0,
1862,235875,3,4,,103188975,35370,Unspecified,,,,,Ratio of CD50 to ED50 rvaluated for inhibition of HIV replication in MT-4 cells,Other,3172142.0,
1863,235876,3,3,,103188975,35370,Unspecified,,,,,Ratio of CD50 value to that of ED50 value was determined and expressed as selectivity index,Other,2299647.0,
1864,235878,3,3,,103188975,35370,Unspecified,,,,,Ratio of EC50/CC50,Other,1732552.0,
1865,235904,3,3,,103188975,35370,Unspecified,,,,,Selectivity index expressed as ratio of IC50 (CEM-C113) to EC50 from MTT assay,Other,8385224.0,
1866,244675,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index expressed as ratio of IC50 for 50% toxicity to EC50 for 50% inhibition,Other,15501054.0,
1867,244677,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index expressed as ratio of IC50 for 50% growth inhibition to EC50 for 50% replication inhibition,Other,15501055.0,
1868,245918,6,2,,103188975,35370,Unspecified,,,57.0,CC50,Cytotoxic concentration against the mock infected MT-4 cells,Confirmatory,15658852.0,
1869,246047,6,3,,103188975,35370,Active,,,0.1,EC50,Effective concentration against HIV-I RTMDR1 in MT-4 cells,Confirmatory,15267246.0,
1870,246139,6,2,,103188975,35370,Active,,,0.04,EC50,Effective concentration against HIV IIIB replication in H9 lymphocytes,Confirmatory,15267246.0,
1871,246175,6,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Effective concentration against HIV-induced cytopathogenicity in MT-4 cells,Confirmatory,15658852.0,
1872,246192,6,2,,103188975,35370,Active,,,0.0018,EC50,Effective concentration to inhibit HIV-1 activity in human peripheral blood mononuclear cells,Confirmatory,15916425.0,
1873,246263,6,2,,103188975,35370,Active,,,0.04,EC50,Concentration required to inhibit 50% of HIV (human immunodeficiency virus) replication,Confirmatory,15501055.0,
1874,246296,6,2,,103188975,35370,Active,,,0.0062,EC50,Concentration required to inhibit 50% of HIV-1 (human immunodeficiency virus-1) replication,Confirmatory,15501054.0,
1875,247698,6,3,,103188975,35370,Unspecified,,,37.5,IC50,Inhibitory concentration against HIV-I RTMDR1 in MT-4 cells,Confirmatory,15267246.0,
1876,247769,6,2,,103188975,35370,Active,,,14.3,IC50,Inhibitory concentration against CEM cell line,Confirmatory,15916425.0,
1877,247880,6,2,,103188975,35370,Unspecified,,,1872.0,IC50,Concentration required to inhibit 50% growth of uninfected H9 cells,Confirmatory,15501055.0,
1878,247943,6,2,,103188975,35370,Active,,,28.0,IC50,Inhibitory concentration against uninfected Vero cells,Confirmatory,15916425.0,
1879,247978,6,2,,103188975,35370,Unspecified,,,1872.0,IC50,Inhibitory concentration against HIV IIIB replication in H9 lymphocytes,Confirmatory,15267246.0,
1880,248082,6,2,,103188975,35370,Unspecified,,,1873.0,IC50,Concentration required to produce 50% toxicity against mock-infected H9 cells,Confirmatory,15501054.0,
1881,248294,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Inhibitory concentration was determined against PHA stimulated human peripheral blood mononuclear cells,Confirmatory,15916425.0,
1882,252633,3,3,,103188975,35370,Unspecified,,,,,Mean retention time in reversed phase HPLC (RP-18),Other,15715485.0,
1883,253092,7,1,,103188975,35370,Active,,,,,Mean phosphorylation rate of 100 uM compound by recombinant human thymidine kinase 2 (mitochondrial),Other,15715485.0,
1884,253093,7,1,,103188975,35370,Unspecified,,,,,Mean phosphorylation rate of 10 uM compound by recombinant human thymidine kinase 1 (cytosolic) expressing wild type L929 tumor cells,Other,15715485.0,
1885,253314,4,3,,103188975,35370,Unspecified,,,,,Therapeutic index was determined,Other,15267246.0,
1886,257166,6,2,,103188975,35370,Active,,,0.003,EC50,Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method,Confirmatory,16335924.0,
1887,257167,6,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method,Confirmatory,16335924.0,
1888,257168,6,2,,103188975,35370,Active,,,0.003,EC50,Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method,Confirmatory,16335924.0,
1889,257169,6,2,,103188975,35370,Active,,,0.003,EC50,Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method,Confirmatory,16335924.0,
1890,257173,6,2,,103188975,35370,Active,,,3.7,CC50,Cytotoxicity against MT4 cells by MTT method,Confirmatory,16335924.0,
1891,257926,6,2,,103188975,35370,Active,,,0.00014,IC50,Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM,Confirmatory,16420027.0,
1892,257928,6,2,,103188975,35370,Active,,,0.00018,IC50,Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM,Confirmatory,16420027.0,
1893,257929,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index (TI=CC50/IC50) in HIV1 TEKI at 1 uM,Other,16420027.0,
1894,257930,3,4,,103188975,35370,Unspecified,,,,,Therapeutic index (TI=CC50/IC50) in HIV1 NL4-3 at uM,Other,16420027.0,
1895,257931,3,4,,103188975,35370,Active,,,,,Anti HIV activity against HIV1 NL4-3 in HeLa-CD4-LTR-beta-gal cells in MAGI-X4 assay,Other,16420027.0,
1896,259181,6,2,,103188975,35370,Active,,,0.0055,EC50,Antiviral activity against HIV1 IIIB in CEM cells,Confirmatory,16392791.0,
1897,259182,6,2,,103188975,35370,Active,,,0.0055,EC50,Antiviral activity against HIV2 ROD in CEM cells,Confirmatory,16392791.0,
1898,259183,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity in CEM cells,Confirmatory,16392791.0,
1899,261442,7,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1 in human PBMC,Confirmatory,16509580.0,
1900,261443,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC,Confirmatory,16509580.0,
1901,261444,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells,Confirmatory,16509580.0,
1902,261445,6,2,,103188975,35370,Active,,,29.0,IC50,Cytotoxicity against Vero cells,Confirmatory,16509580.0,
1903,267854,6,7,,103188975,35370,Active,82310930.0,,0.003,EC50,Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay,Confirmatory,16621553.0,
1904,267855,6,7,,103188975,35370,Active,82310930.0,,0.008,EC50,Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay,Confirmatory,16621553.0,
1905,267856,6,7,,103188975,35370,Active,82310930.0,,0.003,EC50,Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay,Confirmatory,16621553.0,
1906,267858,6,7,,103188975,35370,Active,82310930.0,,0.003,EC50,Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay,Confirmatory,16621553.0,
1907,267859,6,2,,103188975,35370,Active,,,3.7,CC50,Cytotoxicity against MT4 cells by MTT assay,Confirmatory,16621553.0,
1908,269763,8,1,,103188975,35370,Active,,,0.00198,IC50,Antiviral activity against HIV1 TEKI,Confirmatory,16698265.0,
1909,269764,8,1,,103188975,35370,Active,,,0.00175,IC50,Antiviral activity against HIV1 NL4-3,Confirmatory,16698265.0,
1910,269765,8,1,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against human PBMC,Confirmatory,16698265.0,
1911,270072,6,2,,103188975,35370,Active,,,3.4,IC50,Antileishmanial activity against Leishmania donovani LV9 promastigotes by MTT method,Confirmatory,16879965.0,
1912,271054,6,2,,103188975,35370,Unspecified,,,37.5,IC50,Cytotoxicity against human MT4 cells,Confirmatory,16942019.0,
1913,271058,6,2,,103188975,35370,Active,,,0.013000000000000001,EC50,Antiviral activity against HIV1 NL4-3 replication in human MT4 cells,Confirmatory,16942019.0,
1914,271059,6,2,,103188975,35370,Active,,,0.019,EC50,Antiviral activity against HIV1 PI-R replication in human MT4 cells,Confirmatory,16942019.0,
1915,271060,6,2,,103188975,35370,Active,,,0.019,EC50,Antiviral activity against HIV1 FHR2 replication in MT4 cells,Confirmatory,16942019.0,
1916,273054,6,2,,103188975,35370,Active,,,0.02,EC50,Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay,Confirmatory,17004726.0,
1917,273055,6,2,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against MT2 cells,Confirmatory,17004726.0,
1918,275065,6,2,,103188975,35370,Active,,,0.025,EC50,Antiviral activity against HIV1 in MAGI-CCR5 cells,Confirmatory,17181162.0,
1919,275090,6,3,,103188975,35370,Unspecified,,,400.0,CC50,Cytotoxicity against MAGI-CCR5 cells,Confirmatory,17181162.0,
1920,278016,6,2,,103188975,35370,Unspecified,,,5746.1,CC50,Cytotoxicity against C8166 cells by MTT assay,Confirmatory,17315963.0,
1921,278017,6,2,,103188975,35370,Active,,,0.0147,EC50,Antiviral activity against HIV1,Confirmatory,17315963.0,
1922,278018,3,3,,103188975,35370,Unspecified,,,,,"Selectivity index, CC50 against C8166 cell/ EC50 against HIV1",Other,17315963.0,
1923,279914,3,3,,103188975,35370,Unspecified,,,,,Increase in body weight in lean Wistar rat at 70 mg/kg/day after 4 weeks,Other,17158934.0,
1924,279915,3,3,,103188975,35370,Unspecified,,,,,Increase in body weight in cafteria-fed Wistar rat at 70 mg/kg/day after 4 weeks,Other,17158934.0,
1925,279916,3,3,,103188975,35370,Unspecified,,,,,Increase in triglyceride level in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1926,279917,3,3,,103188975,35370,Unspecified,,,,,Increase in triglyceride level in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1927,279918,3,3,,103188975,35370,Unspecified,,,,,Increase in total cholesterol level in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1928,279919,3,3,,103188975,35370,Unspecified,,,,,Increase in total cholesterol level in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1929,279920,3,3,,103188975,35370,Unspecified,,,,,Effect on HDL cholesterol level in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1930,279921,3,3,,103188975,35370,Unspecified,,,,,Effect on HDL cholesterol level in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1931,279922,3,3,,103188975,35370,Unspecified,,,,,Effect on LDL cholesterol level in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1932,279923,3,3,,103188975,35370,Unspecified,,,,,Effect on LDL cholesterol level in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1933,279924,3,3,,103188975,35370,Unspecified,,,,,Effect on ratio of total cholesterol to HDL cholesterol in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1934,279925,3,3,,103188975,35370,Unspecified,,,,,Effect on ratio of total cholesterol to HDL cholesterol in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1935,279926,3,3,,103188975,35370,Unspecified,,,,,Increase in plasma insulin level in lean Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1936,279927,3,3,,103188975,35370,Unspecified,,,,,Increase in plasma insulin level in cafteria-fed Wistar rat at 70 mg/kg/day relative to control,Other,17158934.0,
1937,279928,3,3,,103188975,35370,Unspecified,,,,,Increase in cellularity in cafteria-fed Wistar rat inguinal tissue assessed as DNA content at 70 mg/kg/day,Other,17158934.0,
1938,279929,6,1,,103188975,35370,Unspecified,,,,,Decrease in inguinal adipocyte size in cafteria-fed Wistar rat at 70 mg/kg/day,Other,17158934.0,
1939,279930,3,3,,103188975,35370,Inactive,,,,,Decrease in epididymal adipocyte size in cafteria-fed Wistar rat at 70 mg/kg/day,Other,17158934.0,
1940,279931,6,1,,103188975,35370,Unspecified,,,,,Decrease in cytochrome c oxidase activity in lean Wistar rat inguinal adipose tissue at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1941,279932,6,1,,103188975,35370,Unspecified,,,,,Decrease in cytochrome c oxidase activity in cafteria-fed Wistar rat inguinal adipose tissue at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1942,279933,6,1,,103188975,35370,Unspecified,2506136.0,50671.0,,,Decrease in fatty acid synthase activity in lean Wistar rat inguinal adipose tissue assessed at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1943,279934,6,1,,103188975,35370,Unspecified,2506136.0,50671.0,,,Decrease in fatty acid synthase activity in Wistar cafteria-fed rat inguinal adipose tissue at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1944,279935,3,4,,103188975,35370,Active,,,,,Increase in AMPK phosphorylation level in rat inguinal adipose cells at 70 mg/kg/day,Other,17158934.0,
1945,279936,3,4,,103188975,35370,Active,,,,,Effect on AMPK phosphorylation level in rat epididymal adipose cell at 70 mg/kg/day,Other,17158934.0,
1946,279937,3,10,,103188975,35370,Inactive,2506136.0,50671.0,,,Decrease in fatty acid synthase activity in lean Wistar rat epididymal adipose tissue assessed at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1947,279938,3,10,,103188975,35370,Inactive,2506136.0,50671.0,,,Decrease in fatty acid synthase activity in Wistar cafteria-fed rat epididymal adipose tissue at 70 mg/kg/day by DNA quantification assay,Other,17158934.0,
1948,282658,6,2,,103188975,35370,Active,,,0.02,EC50,Inhibition of HIV1 LAI replication in MT2 by CPE assay,Confirmatory,15615545.0,
1949,282659,6,2,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against MT2 cells,Confirmatory,15615545.0,
1950,282742,6,2,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against C8166 cells by MTT assay,Confirmatory,16279773.0,
1951,282743,6,2,,103188975,35370,Active,,,0.0019,EC50,Inhibition of HIV1-3B replication in C8166 cells,Confirmatory,16279773.0,
1952,282744,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for C8166 cells to IC50 for HIV-3B infected C8166 cells",Other,16279773.0,
1953,282749,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against macrophages,Confirmatory,16279773.0,
1954,282750,6,2,,103188975,35370,Active,,,0.053,EC50,Reduction of HIV1-p24 antigen production in HIV1-3 Ba-L infected macrophages,Confirmatory,16279773.0,
1955,282751,3,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for monocyte-macrophages to EC50 for HIV1-3 Ba-L infected macrophages",Other,16279773.0,
1956,283692,6,2,,103188975,35370,Active,,,0.017,EC50,Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days,Confirmatory,17291043.0,
1957,283693,6,2,,103188975,35370,Unspecified,,,4552.1,CC50,Cytotoxicity against C8166 cells by MTT method,Confirmatory,17291043.0,
1958,283694,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for C8166 cells to IC50 for HIV1 infected C8166 cells",Other,17291043.0,
1959,284150,6,2,,103188975,35370,Active,,,0.0122,EC50,Inhibition of SIV-induced cytopathogenicity in CEM174 cells,Confirmatory,17055732.0,
1960,284151,8,1,,103188975,35370,Unspecified,,,100.0,TC50,Cytotoxicity against CEM174 cells,Confirmatory,17055732.0,
1961,284317,8,2,,103188975,35370,Unspecified,,,,,Antiviral activity against bovine rotavirus RF in MA104 cells,Other,17079149.0,
1962,284318,8,2,,103188975,35370,Unspecified,,,,,Antiviral activity against bovine rotavirus RF in MA 104 cells assessed as neutralization of virus in solution before cell attachment,Other,17079149.0,
1963,284319,8,2,,103188975,35370,Unspecified,,,,,Inhibition of bovine rotavirus RF infectivity following virus attachment to MA 104 cells,Other,17079149.0,
1964,284320,8,2,,103188975,35370,Unspecified,,,,,Growth inhibition of human Caco-2 cells after 72 hrs,Other,17079149.0,
1965,284321,8,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human Caco-2 cells after 72 hrs,Other,17079149.0,
1966,284448,7,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1 LA1 in human PBM cells,Confirmatory,17085053.0,
1967,284449,6,3,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against PBM cells,Confirmatory,17085053.0,
1968,284450,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against CEM cells,Confirmatory,17085053.0,
1969,284451,6,2,,103188975,35370,Unspecified,,,50.6,IC50,Cytotoxicity against Vero cells,Confirmatory,17085053.0,
1970,285189,6,2,,103188975,35370,Active,,,24.4,IC50,Inhibition of [3H]thymidine phosphorylation in isolated perfused Sprague-Dawley rat heart after 30 mins,Confirmatory,17220403.0,
1971,287282,7,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1 LAI replication in human PBMC after 5 days,Confirmatory,17158051.0,
1972,287284,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC after 6 days,Confirmatory,17158051.0,
1973,287285,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells after 6 days,Confirmatory,17158051.0,
1974,287286,6,2,,103188975,35370,Unspecified,,,50.0,IC50,Cytotoxicity against Vero cells after 3 days,Confirmatory,17158051.0,
1975,287871,9,1,,103188975,35370,Unspecified,,,,IC50,Antiviral activity against rotavirus RF in human Caco-2 cells after neutralization of virus in solution pre-incubated with compound for 12 hrs before infection,Confirmatory,17337193.0,
1976,287872,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human Caco-2 cells to IC50 for rotavirus RF in human Caco2 cells after neutralization of virus in solution before infection",Other,17337193.0,
1977,287873,9,1,,103188975,35370,Active,,,22.45,IC50,Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs,Confirmatory,17337193.0,
1978,287874,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human Caco-2 cells to IC50 for rotavirus RF infected human Caco2 cells after viral attachment",Other,17337193.0,
1979,288631,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B in C8166 cells,Other,17489633.0,
1980,288632,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against C8166 cells after 72 hrs by MTT method,Other,17489633.0,
1981,289141,6,2,,103188975,35370,Active,,,0.16,EC50,Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days,Confirmatory,17562366.0,
1982,289142,6,2,,103188975,35370,Active,,,0.05,IC50,Inhibition of HIV1 reverse transcriptase,Confirmatory,17562366.0,
1983,289143,6,2,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against MT2 cells,Confirmatory,17562366.0,
1984,289144,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with reverse transcriptase 6TAM mutation assessed as reduction of potency relative to wild type,Other,17562366.0,
1985,289145,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with reverse transcriptase K65R mutation assessed as reduction of potency relative to wild type,Other,17562366.0,
1986,289146,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV with reverse transcriptase M184V mutation assessed as reduction of potency relative to wild type,Other,17562366.0,
1987,290119,6,2,,103188975,35370,Active,,,0.0008,EC50,Antiviral activity against HIV1 in MT4 cells,Confirmatory,17188402.0,
1988,290120,6,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HSV1 in CCL81 cells,Confirmatory,17188402.0,
1989,290121,6,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HSV2 in CCL81 cells,Confirmatory,17188402.0,
1990,290122,6,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HCMV AD169,Confirmatory,17188402.0,
1991,291759,5,3,,103188975,35370,Inconclusive,,,,,Inhibition of HIV1 reverse transcriptase at 200 ug/mL,Other,17574419.0,
1992,291760,6,2,,103188975,35370,Inconclusive,,,,IC50,Inhibition of HIV1 reverse transcriptase,Confirmatory,17574419.0,
1993,291761,6,2,,103188975,35370,Unspecified,,,5092.0,CC50,Cytotoxicity in human C8166 cells,Confirmatory,17574419.0,
1994,291762,8,1,,103188975,35370,Active,,,0.0108,EC50,Antiviral activity against HIV1 assessed as syncytium reduction,Confirmatory,17574419.0,
1995,291763,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, Ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,17574419.0,
1996,291847,7,1,,103188975,35370,Active,,,,,Inhibition of HTLV1 reverse transcriptase,Other,17580846.0,
1997,291848,7,1,,103188975,35370,Active,,,,,Antiviral activity against HTLV1 in human PBMC,Other,17580846.0,
1998,291849,7,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against PBMC after 1 week by trypan blue exclusion test,Other,17580846.0,
1999,291850,3,3,,103188975,35370,Active,,,,,Antiviral activity against HTLV1 in human PBMC at 100 uM,Other,17580846.0,
2000,291851,3,3,,103188975,35370,Active,,,,,Antiviral activity against HTLV1 in human PBMC at 25 uM,Other,17580846.0,
2001,291852,3,3,,103188975,35370,Active,,,,,Antiviral activity against HTLV1 in human PBMC at 1 uM,Other,17580846.0,
2002,291853,3,3,,103188975,35370,Active,,,,,Antiviral activity against HTLV1 in human PBMC at 5 uM,Other,17580846.0,
2003,295755,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay,Confirmatory,17416522.0,
2004,295757,9,1,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay,Confirmatory,17416522.0,
2005,300146,6,2,,103188975,35370,Unspecified,,,74.62,IC50,Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs,Confirmatory,17555969.0,
2006,300147,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Caco-2 cells to IC50 for Rotavirus RF",Other,17555969.0,
2007,300148,6,2,,103188975,35370,Active,,,22.39,IC50,Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs,Confirmatory,17555969.0,
2008,300149,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human Caco-2 cells to IC50 for Rotavirus RF after attachment to Caco2 cells",Other,17555969.0,
2009,300150,6,2,,103188975,35370,Unspecified,,,74.62,IC50,Antiviral activity against Rotavirus RF infected in rhesus monkey MA104 cells assessed as neutralization of virus in solution before its attachment after 72 hrs,Confirmatory,17555969.0,
2010,300151,3,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for rhesus monkey MA104 cells to IC50 for Rotavirus RF",Other,17555969.0,
2011,300152,6,2,,103188975,35370,Active,,,22.39,IC50,Antiviral activity against Rotavirus RF in rhesus monkey MA104 cells assessed as inhibition of infectivity following virus attachment after 72 hrs,Confirmatory,17555969.0,
2012,300153,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for rhesus monkey MA104 cells to IC50 for Rotavirus RF after attachment to Caco-2 cells",Other,17555969.0,
2013,304872,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells after 5 days by MTT method relative to wild type NL4-3,Other,18052319.0,
2014,308282,6,2,,103188975,35370,Unspecified,,,500.0,IC50,Cytotoxicity against H9 cells assessed as growth inhibition,Confirmatory,17533128.0,
2015,308283,6,2,,103188975,35370,Active,,,0.0137,EC50,Antiviral activity against HIV replication in H9 cells,Confirmatory,17533128.0,
2016,308284,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, IC50 for H9 cells to EC50 for HIV",Other,17533128.0,
2017,309232,6,2,,103188975,35370,Active,,,0.05,EC50,Antiviral activity against HIV1 3B replication in H9 cells,Confirmatory,17719228.0,
2018,309233,6,2,,103188975,35370,Unspecified,,,1900.0,IC50,Reduction in cell viability of human H9 cells,Confirmatory,17719228.0,
2019,309234,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B",Other,17719228.0,
2020,310349,6,2,,103188975,35370,Active,,,0.34,EC50,Antiviral activity against HIV1,Confirmatory,17935987.0,
2021,310350,6,2,,103188975,35370,Unspecified,,,1870.0,IC50,Cytotoxicity against MT2 cells by XTT assay,Confirmatory,17935987.0,
2022,310351,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for MT2 cells to EC50 for HIV1",Other,17935987.0,
2023,311524,4,3,,103188975,35370,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
2024,318738,3,4,,103188975,35370,Active,,,,,Inhibition of HIV1 in sup T1 cells assessed as total reverse transcribed viral DNA at 2 uM by PCR,Other,17488811.0,
2025,319042,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 in C8166 cells after 72 hrs,Other,18088099.0,
2026,319043,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT method,Other,18088099.0,
2027,319044,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,18088099.0,
2028,320325,6,2,,103188975,35370,Active,,,0.16,EC50,Antiviral activity against wild type HIV1 3B in MT2 cells,Confirmatory,18164198.0,
2029,320326,6,2,,103188975,35370,Active,,,0.05,IC50,Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells,Confirmatory,18164198.0,
2030,320327,6,2,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against human MT2 cells,Confirmatory,18164198.0,
2031,320328,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV with reverse transcriptase K65R mutation assessed as fold resistance relative to wild type,Other,18164198.0,
2032,320329,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV with reverse transcriptase 6TAMs mutation assessed as fold resistance relative to wild type,Other,18164198.0,
2033,320330,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV with reverse transcriptase M184V mutation assessed as fold resistance relative to wild type,Other,18164198.0,
2034,322392,6,2,,103188975,35370,Active,,,0.0007,EC50,Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay,Confirmatory,17964796.0,
2035,322393,6,2,,103188975,35370,Active,,,35.6,CC50,Cytotoxicity against human MT4 cells after 4 days by MTT assay,Confirmatory,17964796.0,
2036,322394,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,17964796.0,
2037,325392,7,1,,103188975,35370,Unspecified,56405325.0,1841.0,,,Activity of TMPK in human CEM cells assessed as level of triphosphate metabolites per 10^6 cells at 2 uM after 12 hrs,Other,17353236.0,
2038,326389,6,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay,Confirmatory,18316190.0,
2039,326390,6,2,,103188975,35370,Unspecified,,,749.0,CC50,Cytotoxicity against human C8166 cells after 72 hrs by MTT method,Confirmatory,18316190.0,
2040,326391,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for C8166 cells to EC50 for HIV1 3B",Other,18316190.0,
2041,330485,6,2,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against HIV1 3B infected in MT4 cells by MTT,Confirmatory,18267363.0,
2042,330487,6,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells,Confirmatory,18267363.0,
2043,330488,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,18267363.0,
2044,330489,6,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT,Confirmatory,18267363.0,
2045,330490,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES053",Other,18267363.0,
2046,332929,6,3,,103188975,35370,Active,,,0.04,EC50,Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay,Confirmatory,8158164.0,
2047,332930,6,3,,103188975,35370,Unspecified,,,2000.0,IC50,Cytotoxicity against human H9 cells after 3 days,Confirmatory,8158164.0,
2048,333020,3,5,,103188975,35370,Unspecified,,,,,"Therapeutic index, IC50 for human H9 cells to EC50 for HIV1 3B",Other,8176401.0,
2049,333022,6,3,,103188975,35370,Unspecified,,,2000.0,IC50,Cytotoxicity against human H9 cells after 3 days,Confirmatory,8176401.0,
2050,333023,6,3,,103188975,35370,Active,,,0.04,EC50,Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay,Confirmatory,8176401.0,
2051,333024,6,4,,103188975,35370,Unspecified,,,150.0,IC50,Inhibition of PKC beta2,Confirmatory,8176401.0,
2052,333025,6,4,,103188975,35370,Unspecified,,,150.0,IC50,Inhibition of PKC epsilon,Confirmatory,8176401.0,
2053,334753,8,1,,103188975,35370,Active,,,0.1,ED50,Antiviral activity against Feline leukemia virus infected in cat CRFK cells assessed as inhibition of viral replication after 7 days by ELISA,Confirmatory,1324982.0,
2054,334754,3,4,,103188975,35370,Unspecified,,,,,Ratio of ID50 for cat CRFK cells to ED50 for Feline leukemia virus,Other,1324982.0,
2055,334755,8,1,,103188975,35370,Unspecified,,,1517.0,ID50,Cytotoxicity against cat CRFK cells assessed as reduction in cell viability after 5 days by MTT assay,Confirmatory,1324982.0,
2056,335637,3,5,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B replication in human C8166 cells at 100 uM after 5 to 7 days by MTT-formazan method,Other,1279126.0,
2057,335638,3,5,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B replication in human C8166 cells at 0.016 ug/ml after 5 to 7 days by MTT-formazan method,Other,1279126.0,
2058,336314,5,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells after 5 to 7 days by MTT-formazan method,Other,1279126.0,
2059,341179,6,2,,103188975,35370,Active,,,0.015,EC50,Antiviral activity against R5-HIV1Ba-L assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA,Confirmatory,17548498.0,
2060,341180,6,2,,103188975,35370,Active,,,0.34,EC50,Antiviral activity against R5-HIV1MDR/MM assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA,Confirmatory,17548498.0,
2061,341181,6,2,,103188975,35370,Active,,,0.033,EC50,Antiviral activity against X4-HIV1 NL4-3 assessed as inhibition of p24 Gag protein production in human MT4 cells by MTT assay,Confirmatory,17548498.0,
2062,341182,6,2,,103188975,35370,Active,,,0.39,EC50,Antiviral activity against R5-HIV1MDR/C assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA,Confirmatory,17548498.0,
2063,341183,6,2,,103188975,35370,Active,,,0.38,EC50,Antiviral activity against R5-HIV1MDR/G assessed as inhibition of p24 Gag protein production in human PHA-PBMC by ELISA,Confirmatory,17548498.0,
2064,341184,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,17548498.0,
2065,341185,6,3,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against human PHA-PBMC cells by MTT assay,Confirmatory,17548498.0,
2066,341187,3,4,,103188975,35370,Unspecified,,,,,"Drug level in human CD4+CEM cells assessed as increase in 3'-azido-2',3'-dideoxythymidine triphosphate level at 0.1 uM after 6 hrs",Other,17548498.0,
2067,341191,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CD4+ CEM cells assessed as 3'-azido-2',3'-dideoxythymidine monophosphate intracellular levels at 200 nM after 8 hrs",Other,17548498.0,
2068,341350,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CD4+ CEM cells assessed as 3'-azido-2',3'-dideoxythymidine diphosphate intracellular levels at 200 nM after 8 hrs",Other,17548498.0,
2069,341351,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CD4+ CEM cells assessed as 3'-azido-2',3'-dideoxythymidine triphosphate intracellular levels at 200 nM after 8 hrs",Other,17548498.0,
2070,341352,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CEM cells assessed as 3'-azido-2',3'-dideoxythymidine monophosphate intracellular levels at 200 nM after 24 hrs",Other,17548498.0,
2071,341353,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CEM cells assessed as 3'-azido-2',3'-dideoxythymidine diphosphate intracellular levels at 200 nM after 24 hrs",Other,17548498.0,
2072,341354,3,4,,103188975,35370,Unspecified,,,,,"Metabolic stability of the compound in human CEM cells assessed as 3'-azido-2',3'-dideoxythymidine triphosphate intracellular levels at 200 nM after 24 hrs",Other,17548498.0,
2073,341358,3,4,,103188975,35370,Unspecified,,,,,"Drug uptake in human CD4+CEM cells assessed as 3'-azido-2',3'-dideoxythymidine monophosphate half life at 200 nM",Other,17548498.0,
2074,341359,3,4,,103188975,35370,Unspecified,,,,,"Drug uptake in human CD4+CEM cells assessed as 3'-azido-2',3'-dideoxythymidine diphosphate half life at 200 nM",Other,17548498.0,
2075,341360,3,4,,103188975,35370,Unspecified,,,,,"Drug uptake in human CD4+CEM cells assessed as 3'-azido-2',3'-dideoxythymidine triphosphate half life at 200 nM",Other,17548498.0,
2076,341365,7,1,,103188975,35370,Unspecified,,,,,Drug level in human CD4+CEM cells per 10'9 cells at 0.1 uM,Other,17548498.0,
2077,341368,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4-3 replication in human MT4 cells at 0.01 uM pretreated 24 hrs before infection assessed as protection at 1 uM by MTT assay,Other,17548498.0,
2078,341369,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4-3 replication in human MT4 cells at 0.01 uM pretreated 48 hrs before infection assessed as protection at 1 uM by MTT assay,Other,17548498.0,
2079,341370,3,4,,103188975,35370,Unspecified,,,,,Ratio of EC50 for R5-HIV1MDR/MM in human PHA-PBMC to EC50 for R5-HIV1Ba-L in human PHA-PBMC,Other,17548498.0,
2080,341371,3,5,,103188975,35370,Unspecified,,,,,Ratio of EC50 for X4-HIV1MDR/C in human PHA-PBMC to EC50 for X4-HIV1NL4-3 in human MT4 cells,Other,17548498.0,
2081,341372,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against R5-HIV1MDR/G assessed as inhibition of p24 Gag protein in human PHA-PBMC by ELISA relative to X4-HIV1NL4-3,Other,17548498.0,
2082,341995,8,1,,103188975,35370,Active,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 after 20 hrs,Other,17526755.0,
2083,341996,8,1,,103188975,35370,Unspecified,,,,,Antimicrobial activity against Streptococcus sp. 07941-1 after 20 hrs,Other,17526755.0,
2084,341997,8,1,,103188975,35370,Unspecified,,,,,Antimicrobial activity against Streptococcus sp. 07706-1 after 20 hrs,Other,17526755.0,
2085,341998,8,1,,103188975,35370,Unspecified,,,,,Antimicrobial activity against Streptococcus sp. 07686-2 after 20 hrs,Other,17526755.0,
2086,341999,8,1,,103188975,35370,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 20 hrs,Other,17526755.0,
2087,342000,8,1,,103188975,35370,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CCM 885 after 20 hrs,Other,17526755.0,
2088,342001,8,1,,103188975,35370,Inconclusive,,,,,Antimicrobial activity against Streptococcus pyogenes AP1 after 20 hrs,Other,17526755.0,
2089,342004,7,1,,103188975,35370,Active,,,,,Antibacterial activity against deoxyribonucleotide kinase-deficient Escherichia coli KY895 expressing Staphylococcus aureus recombinant thymidine kinase,Other,17526755.0,
2090,342005,7,1,,103188975,35370,Active,,,,,Antibacterial activity against deoxyribonucleotide kinase-deficient Escherichia coli KY895 expressing Streptococcus pyogenes recombinant thymidine kinase,Other,17526755.0,
2091,342006,7,1,,103188975,35370,Inactive,,,,,Antibacterial activity against deoxyribonucleotide kinase-deficient Escherichia coli KY895 expressing Staphylococcus aureus recombinant deoxyadenosine kinase,Other,17526755.0,
2092,342007,3,3,,103188975,35370,Inactive,,,,,Antibacterial activity against deoxyribonucleotide kinase-deficient Escherichia coli KY895 expressing Staphylococcus aureus recombinant deoxyguanosine kinase,Other,17526755.0,
2093,342008,7,1,,103188975,35370,Inactive,,,,,Antibacterial activity against deoxyribonucleotide kinase-deficient Escherichia coli KY895 expressing Streptococcus pyogenes recombinant deoxyadenosine kinase,Other,17526755.0,
2094,342009,7,1,,103188975,35370,Unspecified,123324380.0,,,Km,Activity of Staphylococcus aureus CCM 885 recombinant thymidine kinase,Confirmatory,17526755.0,
2095,342010,7,6,,103188975,35370,Unspecified,123324380.0,,944.0,Ki,Inhibition of Staphylococcus aureus CCM 885 recombinant thymidine kinase,Confirmatory,17526755.0,
2096,342011,8,1,,103188975,35370,Unspecified,123324380.0,,,,Ratio of kcat to Km for Staphylococcus aureus CCM 885 recombinant thymidine kinase,Other,17526755.0,
2097,342548,6,2,,103188975,35370,Active,,,0.003,EC50,Antiviral activity against HIV1 infected human CEM-SS cells,Confirmatory,18585917.0,
2098,342549,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human CEM-SS cells,Confirmatory,18585917.0,
2099,342550,6,2,,103188975,35370,Active,,,0.015,EC50,Antiviral activity against HIV1 infected human MT4 cells,Confirmatory,18585917.0,
2100,342551,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells,Confirmatory,18585917.0,
2101,342552,6,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity against HIV1 infected human thymidine kinase-deficient CEM cells,Confirmatory,18585917.0,
2102,342553,6,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human thymidine kinase-deficient CEM cells,Confirmatory,18585917.0,
2103,342717,5,2,,103188975,35370,Unspecified,,,,,Aqueous solubility of the compound,Other,18585917.0,
2104,346970,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay,Other,19091580.0,
2105,346971,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay,Other,19091580.0,
2106,346972,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against mock-infected human MT4 cells by MTT assay,Other,19091580.0,
2107,346973,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV 3B",Other,19091580.0,
2108,346974,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV ROD",Other,19091580.0,
2109,350155,6,2,,103188975,35370,Active,,,0.055999999999999994,EC50,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA,Confirmatory,19388685.0,
2110,350157,6,2,,103188975,35370,Unspecified,,,1870.0,CC50,Cytotoxicity against human MT2 cells by XTT assay,Confirmatory,19388685.0,
2111,350158,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human MT2 cells to EC50 for HIV1 3B",Other,19388685.0,
2112,354614,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA,Other,8946749.0,
2113,354615,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against mock-infected human H9 cells after 4 days,Other,8946749.0,
2114,354616,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for mock-infected human H9 cells to EC50 for HIV1 3B",Other,8946749.0,
2115,355253,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Antiviral activity against HIV1 LAV-1 in PHA-stimulated human PBMC after 6 days,Confirmatory,9322359.0,
2116,355254,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against uninfected PHA-stimulated human PBMC assessed as thymidine incorporation after 24 hrs by trypan blue exclusion method,Confirmatory,9322359.0,
2117,355255,3,5,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of IC50 for human PBMC to EC50 for HIV1 LAV-1",Other,9322359.0,
2118,357032,6,2,,103188975,35370,Unspecified,,,1875.0,IC50,Cytotoxicity against human H9 cells,Confirmatory,11473435.0,
2119,357033,9,1,,103188975,35370,Active,,,0.045,EC50,Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication,Confirmatory,11473435.0,
2120,357034,9,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1",Other,11473435.0,
2121,357410,3,4,,103188975,35370,Active,,,,,Inhibition of HIV1 delta env/VSV-G replication in human sup T1 T-lymphoid H9 cells assessed as inhibition of total viral DNA at 2 uM after 2 hrs by RT-PCR,Other,17403681.0,
2122,357960,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human H9 cells,Other,11678650.0,
2123,357961,7,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA,Other,11678650.0,
2124,357962,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 of HIV1 3B",Other,11678650.0,
2125,358594,6,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against Human immunodeficiency virus,Confirmatory,11720540.0,
2126,360655,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA,Other,11374977.0,
2127,360656,5,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against uninfected human C8166 cells by XTT-formazan method,Other,11374977.0,
2128,361400,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Other,12444692.0,
2129,361401,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Other,12444692.0,
2130,361402,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Other,12444692.0,
2131,363846,6,2,,103188975,35370,Unspecified,,,74.84,IC50,Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs,Confirmatory,18037195.0,
2132,363847,6,2,,103188975,35370,Active,,,22.45,IC50,Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs,Confirmatory,18037195.0,
2133,363848,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50 for human Caco-2 cells to IC50 for rotavirus RF assessed by neutralization of virus before its attachment,Other,18037195.0,
2134,363850,6,2,,103188975,35370,Unspecified,,,56.1,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,18037195.0,
2135,363858,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50 for human Caco-2 cells to IC50 for rotavirus RF assessed by inhibition of infectivity following virus attachment,Other,18037195.0,
2136,364088,3,4,,103188975,35370,Active,,,,,Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production at 5 uM by ELISA,Other,18693022.0,
2137,365483,3,4,,103188975,35370,Active,,,,,Antiviral activity against HIV1 3B in MT4 cells assessed as virus p24 antigen production administered at 5 hrs post infection by ELISA,Other,18710207.0,
2138,365484,3,4,,103188975,35370,Active,,,,,Antiviral activity against HIV1 3B in MT4 cells assessed as virus p24 antigen production administered at 16 hrs post infection by ELISA,Other,18710207.0,
2139,369078,7,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1 LAI infected in CEM cells,Confirmatory,19153047.0,
2140,369079,6,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBM cells after 3 days by MTT assay,Confirmatory,19153047.0,
2141,369080,6,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells after 3 days by MTT assay,Confirmatory,19153047.0,
2142,369081,6,2,,103188975,35370,Unspecified,,,50.6,IC50,Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay,Confirmatory,19153047.0,
2143,370731,6,2,,103188975,35370,Active,,,0.0019,EC50,Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay,Confirmatory,19170521.0,
2144,370732,8,1,,103188975,35370,Active,,,1.0,TC50,Cytotoxicity against human C8166 cells by MTT method,Confirmatory,19170521.0,
2145,370733,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for HIV1 3B to TC50 for human C8166 cells",Other,19170521.0,
2146,373351,7,1,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine monophosphate accumulation at 2 uM after 2 hrs assessed per 10'6 cells,Other,17724147.0,
2147,373352,7,1,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine diphosphate accumulation at 2 uM after 2 hrs assessed per 10'6 cells,Other,17724147.0,
2148,373353,7,1,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine triphosphate accumulation at 2 uM after 2 hrs assessed per 10'6 cells,Other,17724147.0,
2149,373354,7,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine monophosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells",Other,17724147.0,
2150,373355,7,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine diphosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells",Other,17724147.0,
2151,373356,7,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine triphosphate accumulation at 2 uM after 12 hrs assessed per 10'6 cells",Other,17724147.0,
2152,373360,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine monophosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2153,373361,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine diphosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2154,373362,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive zidovudine triphosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2155,373363,3,4,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine monophosphate accumulation at 2 uM assessed per 10'6 cells",Other,17724147.0,
2156,373364,3,4,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine diphosphate accumulation at 2 uM assessed per 10'6 cells",Other,17724147.0,
2157,373365,3,4,,103188975,35370,Unspecified,,,,,"Drug metabolism in human CEM cells assessed as radioactive 2', 3'-didehydro-3'-deoxy-4'-ethynylthymidine triphosphate accumulation at 2 uM assessed per 10'6 cells",Other,17724147.0,
2158,373366,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive stavudine monophosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2159,373367,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive stavudine diphosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2160,373368,3,4,,103188975,35370,Unspecified,,,,,Drug metabolism in human CEM cells assessed as radioactive stavudine triphosphate accumulation at 2 uM assessed per 10'6 cells,Other,17724147.0,
2161,373381,7,1,,103188975,35370,Unspecified,,,,,Stability in human CEM cells assessed as intracellular radioactive phosphorylated metabolite accumulation at 2 uM incubated for 24 hrs measured after 8 hrs of compound removal assessed per 10'6 cells,Other,17724147.0,
2162,373382,3,4,,103188975,35370,Unspecified,,,,,Stability in human CEM cells assessed as total intracellular radioactive phosphorylated metabolite remaining at 2 uM incubated for 24 hrs measured after 24 hrs of compound removal assessed per 10'6 cells relative to 0 hrs after compound removal,Other,17724147.0,
2163,373383,3,4,,103188975,35370,Unspecified,,,,,Stability in human CEM cells assessed as intracellular radioactive triphosphate metabolite remaining at 2 uM incubated for 24 hrs measured after 4 hrs of compound removal assessed per 10'6 cells relative to 0 hrs after compound removal,Other,17724147.0,
2164,373384,7,1,,103188975,35370,Unspecified,,,,,Stability in human CEM cells assessed as intracellular radioactive triphosphate metabolite accumulation at 2 uM incubated for 24 hrs measured after 24 hrs of compound removal assessed per 10'6 cells,Other,17724147.0,
2165,373386,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.13 uM after 24 hrs by luciferase assay,Other,17724147.0,
2166,373387,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.18 uM after 24 hrs by luciferase assay,Other,17724147.0,
2167,373388,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.22 uM after 24 hrs by luciferase assay,Other,17724147.0,
2168,373554,4,3,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication after 24 hrs by luciferase assay,Other,17724147.0,
2169,373564,4,3,,103188975,35370,Inactive,,,,,Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 24 hrs post drug removal assessed as inhibition of viral replication at 0.04 to 0.22 uM measured 24 hrs postinfection by luciferase assay,Other,17724147.0,
2170,373569,3,3,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.02 uM after 24 hrs by luciferase assay,Other,17724147.0,
2171,373570,4,3,,103188975,35370,Inactive,,,,,Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 48 hrs post drug removal assessed as inhibition of viral replication at 0.04 to 0.22 uM measured 24 hrs postinfection by luciferase assay,Other,17724147.0,
2172,373572,6,7,,103188975,35370,Active,23503074.0,7083.0,2.9,Km,Binding affinity to TK1 in human H9 cells assessed as conversion of [14C]thyminide to [14C]thymidine monophosphate by scintillation counting,Confirmatory,17724147.0,
2173,373573,6,7,,103188975,35370,Active,23503074.0,7083.0,3.0,Km,Binding affinity to TK1 in human H9 cells assessed as conversion of [3H]azidothymidine to [3H]azidothymidine monophosphate by scintillation counting,Confirmatory,17724147.0,
2174,373867,6,3,,103188975,35370,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
2175,376300,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT method,Other,16643044.0,
2176,376301,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathic effect,Other,16643044.0,
2177,376302,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, CC50 for human C8166 cells to EC50 for HIV1 3B",Other,16643044.0,
2178,376815,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human H9 cells,Other,9584397.0,
2179,376816,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV infected in human H9 cells assessed as viral replication,Other,9584397.0,
2180,376817,6,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV",Other,9584397.0,
2181,377702,7,2,,103188975,35370,Inconclusive,,,,,Antibacterial activity against Staphylococcus aureus,Other,16872140.0,
2182,377703,7,2,,103188975,35370,Inconclusive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus,Other,16872140.0,
2183,377704,7,2,,103188975,35370,Inconclusive,,,,,Antifungal activity against Cryptococcus neoformans,Other,16872140.0,
2184,377705,7,2,,103188975,35370,Inconclusive,,,,,Antibacterial activity against Mycobacterium intracellular by alamar blue assay,Other,16872140.0,
2185,377706,7,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B assessed as reverse transcriptase activity by enzyme immunoassay,Other,16872140.0,
2186,377971,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA,Other,9917290.0,
2187,377972,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human H9 cells,Other,9917290.0,
2188,377973,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B",Other,9917290.0,
2189,378286,6,2,,103188975,35370,Unspecified,,,1871.0,IC50,Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days,Confirmatory,11141100.0,
2190,378287,6,2,,103188975,35370,Active,,,0.045,EC50,Cytotoxicity against mock-infected human H9 cells,Confirmatory,11141100.0,
2191,378288,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, IC50 for human T-lymphoid H9 cells to EC50 for HIV1 3B isolate",Other,11141100.0,
2192,378446,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against mock-infected human H9 lymphocytes,Other,16989518.0,
2193,378447,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected human H9 lymphocytes assessed as suppression of viral replication,Other,16989518.0,
2194,378448,3,3,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 lymphocytes to EC50 for HIV1",Other,16989518.0,
2195,379612,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human H9 cells,Other,10757718.0,
2196,379613,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication,Other,10757718.0,
2197,379614,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1",Other,10757718.0,
2198,379883,6,2,,103188975,35370,Active,,,0.023,EC50,Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA,Confirmatory,17190445.0,
2199,379884,6,2,,103188975,35370,Unspecified,,,1870.0,IC50,Cytotoxicity against human H9 cells after 4 days,Confirmatory,17190445.0,
2200,379885,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B",Other,17190445.0,
2201,380077,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT assay,Other,16499331.0,
2202,380078,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect,Other,16499331.0,
2203,380205,7,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MT4 cells by MTT assay,Other,10425115.0,
2204,380207,7,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Other,10425115.0,
2205,382980,6,2,,103188975,35370,Active,,,22.45,IC50,Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as inhibition of infectivity following virus attachment,Confirmatory,17548129.0,
2206,382981,6,2,,103188975,35370,Unspecified,,,74.84,IC50,Antiviral activity against gastrointestinal rotavirus in human Caco-2 cells assessed as neutralization of virus in the solution before attachment,Confirmatory,17548129.0,
2207,382982,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50 for Caco-2 cells to IC50 for rotavirus infected human Caco2 cells assessed as neutralization of virus in the solution before attachment,Other,17548129.0,
2208,382983,3,4,,103188975,35370,Unspecified,,,,,Ratio of CC50 for Caco-2 cells to IC50 for rotavirus infected human Caco2 cells assessed as inhibition of infectivity following virus attachment,Other,17548129.0,
2209,382985,6,2,,103188975,35370,Unspecified,,,56.1,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,17548129.0,
2210,384987,6,2,,103188975,35370,Active,,,0.0108,EC50,Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay,Confirmatory,18396905.0,
2211,384988,6,2,,103188975,35370,Unspecified,,,5091.0,CC50,Cytotoxicity against human C8166 cells after 72 hrs by MTT assay,Confirmatory,18396905.0,
2212,384989,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,18396905.0,
2213,386623,4,8,,103188975,35370,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
2214,389378,6,2,,103188975,35370,Active,,,0.0151,EC50,Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity,Confirmatory,18824350.0,
2215,389379,6,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells,Confirmatory,18824350.0,
2216,389380,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,18824350.0,
2217,392513,10,1,,103188975,35370,Active,,,0.005,IC50,Antiviral activity against HIV1,Confirmatory,19112024.0,
2218,392514,8,1,,103188975,35370,Active,,,0.005,IC50,Antiviral activity against HIV2,Confirmatory,19112024.0,
2219,393069,6,2,,103188975,35370,Active,,,0.05,IC50,Inhibition on HIV1 reverse transcriptase p66/p51,Confirmatory,19179082.0,
2220,393070,6,2,,103188975,35370,Active,,,0.16,EC50,Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay,Confirmatory,19179082.0,
2221,393071,6,2,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against human MT2 cells after 5 days,Confirmatory,19179082.0,
2222,393072,3,5,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3a with reverse transcriptase K65R mutation in human MT2 cells assessed as inhibition of viral-induced cytopathic effect by XTT assay relative to wild type,Other,19179082.0,
2223,393073,3,5,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3a with reverse transcriptase M184V mutation in human MT2 cells assessed as inhibition of viral-induced cytopathic effect by XTT assay relative to wild type,Other,19179082.0,
2224,394136,3,3,,103188975,35370,Unspecified,,,,,Inhibition of polymerase activity of HIV1 recombinant reverse transcriptase expressed in Escherichia coli at 50 uM,Other,18486994.0,
2225,394137,6,2,,103188975,35370,Unspecified,,,126.0,CC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18486994.0,
2226,395817,6,3,,103188975,35370,Active,,,0.58,EC50,Cytotoxicity against human PG cells after 48 hrs by MTT assay,Confirmatory,18313175.0,
2227,395818,6,3,,103188975,35370,Active,,,4.62,EC50,Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay,Confirmatory,18313175.0,
2228,397589,6,2,,103188975,35370,Active,,,0.001,EC50,Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique,Confirmatory,11430019.0,
2229,397590,6,2,,103188975,35370,Active,,,0.001,EC50,Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique,Confirmatory,11430019.0,
2230,397591,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of cytotoxicity against human H9 cells to EC50 for HIV1 3B",Other,11430019.0,
2231,397592,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of cytotoxicity against human H9 cells to EC50 for HIV1 RF",Other,11430019.0,
2232,398465,6,3,,103188975,35370,Active,,,0.05,IC50,Inhibition of HIV1 reverse transcriptase p66/p51,Confirmatory,7561895.0,
2233,398466,9,2,,103188975,35370,Unspecified,,,20.0,IC50,Inhibition of DNA polymerase beta,Confirmatory,7561895.0,
2234,398467,6,3,,103188975,35370,Active,,,0.2,IC50,Inhibition of HIV2 reverse transcriptase p66/p51,Confirmatory,7561895.0,
2235,398468,6,3,,103188975,35370,Active,,,0.43,IC50,Inhibition of AMV reverse transcriptase,Confirmatory,7561895.0,
2236,398469,6,3,,103188975,35370,Unspecified,,,20.0,IC50,Inhibition of RNA polymerase,Confirmatory,7561895.0,
2237,401232,6,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HSV1,Confirmatory,15104498.0,
2238,401233,6,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HSV2,Confirmatory,15104498.0,
2239,401234,6,2,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against HIV1,Confirmatory,15104498.0,
2240,402091,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA,Other,9748372.0,
2241,402092,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against mock-infected human H9 cells after 4 days,Other,9748372.0,
2242,402093,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B",Other,9748372.0,
2243,404304,3,10,,103188975,35370,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
2244,405332,3,3,,103188975,35370,Unspecified,,,,,Toxicity in human HepG2/C3A cells assessed as induction of cell death at 10 uM after 4 days,Other,17470651.0,
2245,405333,3,3,,103188975,35370,Unspecified,,,,,Toxicity in human HepG2/C3A cells assessed as induction of cell death at 50 uM after 4 days,Other,17470651.0,
2246,405334,3,3,,103188975,35370,Unspecified,,,,,Toxicity in human HepG2/C3A cells assessed as induction of cell death at 50 uM after 10 days,Other,17470651.0,
2247,405335,3,3,,103188975,35370,Unspecified,,,,,Toxicity in human HepG2/C3A cells assessed as induction of cell death at 50 uM after 14 days,Other,17470651.0,
2248,405336,3,4,,103188975,35370,Unspecified,,,,,Toxicity in human H9c2 cells assessed as induction of cell death at 50 uM after 12 days,Other,17470651.0,
2249,405337,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as inhibition of cell proliferation at 50 uM after 6 days by SRB assay,Other,17470651.0,
2250,405339,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as elevation of lactate levels at 10 uM after 6 days by NAD+ reduction assay,Other,17470651.0,
2251,405340,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as elevation of lactate levels at 50 uM after 6 days by NAD+ reduction assay,Other,17470651.0,
2252,405341,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human H9c2 cells assessed as elevation of lactate levels at 10 uM after 6 days by NAD+ reduction assay,Other,17470651.0,
2253,405342,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human H9c2 cells assessed as elevation of lactate levels at 50 uM after 6 days by NAD+ reduction assay,Other,17470651.0,
2254,405343,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as increase in mitochondrial superoxide production at 50 uM by flow cytometry,Other,17470651.0,
2255,405344,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human H9c2 cells assessed as increase in mitochondrial superoxide production at 50 uM by flow cytometry,Other,17470651.0,
2256,405345,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as effect on mitochondrial DNA copy numbers at 50 uM after 4 days,Other,17470651.0,
2257,405346,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human HepG2/C3A cells assessed as effect on mitochondrial DNA copy numbers at 50 uM after 10 days,Other,17470651.0,
2258,405347,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human H9c2 cells assessed as effect on mitochondrial DNA copy numbers after 12 days,Other,17470651.0,
2259,405412,6,2,,103188975,35370,Active,,,0.023,EC50,Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR,Confirmatory,17470654.0,
2260,405581,3,4,,103188975,35370,Unspecified,,,,,Toxicity against human H9c2 cells assessed as inhibition of cell proliferation at 50 uM after 6 days by SRB assay,Other,17470651.0,
2261,405582,6,3,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method,Confirmatory,17470654.0,
2262,406050,3,3,,103188975,35370,Unspecified,,,,,Oral bioavailability in rhesus monkey at 60 mg/kg,Other,17485498.0,
2263,406056,3,3,,103188975,35370,Unspecified,,,,,Terminal phase half life in rhesus monkey,Other,17485498.0,
2264,409954,4,9,,103188975,35370,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
2265,409956,4,9,,103188975,35370,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
2266,416385,6,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Antiviral activity against HIV1 BH10 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS method,Confirmatory,19254848.0,
2267,416386,6,2,,103188975,35370,Unspecified,,,61.0,CC50,Cytotoxicity against human MT4 cells by MTS method,Confirmatory,19254848.0,
2268,417049,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine diphosphate level at 600 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2269,417050,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine triphosphate level at 600 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2270,417051,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine diphosphate level at 600 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2271,417052,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine monophosphate level at 600 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2272,417053,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine monophosphate level at 600 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2273,417054,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine parent-drug level at 600 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2274,417055,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine parent-drug level at 600 mg administered in two courses, first QD for 7 days followed by BID for 7 to 14 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2275,417056,3,3,,103188975,35370,Unspecified,,,,,"Half life in HIV-infected human at 300 mg, po bid",Other,17664328.0,
2276,417057,3,3,,103188975,35370,Unspecified,,,,,"Half life in HIV-infected human at 600 mg, po qd",Other,17664328.0,
2277,417058,4,5,,103188975,35370,Unspecified,,,,,"Drug metabolism in HIV-infected human PBMC assessed as zidovudine triphosphate level at 600 mg administered in two courses, first BID for 7 to 14 days followed by QD for 7 days and second course the subjects were switched to the other regimen measured per 10'6 cells in presence of Lamivudine",Other,17664328.0,
2278,417236,5,1,,103188975,35370,Unspecified,,,,,Half life in HIV-infected human assessed as zidovudine triphosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2279,417241,5,1,,103188975,35370,Unspecified,,,,,AUC in HIV-infected human assessed as zidovudine triphosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2280,417242,5,1,,103188975,35370,Unspecified,,,,,AUC in HIV-infected human assessed as zidovudine diphosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2281,417243,5,1,,103188975,35370,Unspecified,,,,,AUC in HIV-infected human assessed as zidovudine monophosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2282,417247,3,4,,103188975,35370,Unspecified,,,,,Tmax in HIV-infected human assessed as zidovudine triphosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2283,417248,3,4,,103188975,35370,Unspecified,,,,,Tmax in HIV-infected human assessed as zidovudine diphosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2284,417249,3,4,,103188975,35370,Unspecified,,,,,Tmax in HIV-infected human assessed as zidovudine monophosphate level in PBMC at 600 mg QD for 7 days in presence of Lamivudine,Other,17664328.0,
2285,417253,4,5,,103188975,35370,Unspecified,,,,,Cmin in HIV-infected human assessed as zidovudine triphosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2286,417254,4,5,,103188975,35370,Unspecified,,,,,Cmin in HIV-infected human assessed as zidovudine diphosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2287,417255,4,5,,103188975,35370,Unspecified,,,,,Cmin in HIV-infected human assessed as zidovudine monophosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2288,417259,7,2,,103188975,35370,Active,,,,,Cmax in HIV-infected human assessed as zidovudine triphosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2289,417260,7,2,,103188975,35370,Active,,,,,Cmax in HIV-infected human assessed as zidovudine diphosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2290,417262,7,2,,103188975,35370,Active,,,,,Cmax in HIV-infected human assessed as zidovudine monophosphate level in PBMC at 600 mg QD for 7 days measured per 10'6 cells in presence of Lamivudine,Other,17664328.0,
2291,417264,3,3,,103188975,35370,Unspecified,,,,,Half life in HIV-infected human plasma at 1500 mg,Other,17664328.0,
2292,419085,8,1,,103188975,35370,Active,,,0.048,IC50,Inhibition of HIV1 replication in human 293T cells preincubated 15 mins prior to infection measured after 48 hrs postinfection by luciferase reporter gene assay,Confirmatory,19269831.0,
2293,422691,3,3,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 with reverse transcriptase K70E/M184V mutation to IC50 for wild type HIV1,Other,17876005.0,
2294,422692,3,3,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 with reverse transcriptase K70G/M184V mutation to IC50 for wild type HIV1,Other,17876005.0,
2295,422693,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by antivirogram biological cutoffs assay relative to wild type HIV1,Other,17876005.0,
2296,422694,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with reverse transcriptase K70E M184V and K70G M184V mutation by vircotype clinical cutoffs assay relative to wild type HIV1,Other,17876005.0,
2297,422695,3,3,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 with reverse transcriptase K70G mutation to IC50 for wild type HIV1,Other,17876005.0,
2298,423157,6,2,,103188975,35370,Active,,,0.16,EC50,Antiviral activity against wild type HIV1 NL4-3 produced from full length pR9deltaApa infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs,Confirmatory,17967913.0,
2299,423158,6,2,,103188975,35370,Active,,,0.12,EC50,Antiviral activity against wild type HIV2 ROD produced from full length pROD9 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs,Confirmatory,17967913.0,
2300,423278,6,2,,103188975,35370,Active,,,0.071,EC50,Antiviral activity against recombinant HIV2 ROD carrying HIV2 UC2 reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs,Confirmatory,17967913.0,
2301,423279,3,3,,103188975,35370,Active,,,,,Antiviral activity against wild type HIV2 CDC310319 infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs,Other,17967913.0,
2302,423280,6,2,,103188975,35370,Active,,,7.0,EC50,"Antiviral activity against multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase infected in human MAGIC-5A cells assessed as inhibition of Lac+ foci expression after 40 hrs",Confirmatory,17967913.0,
2303,423281,3,3,,103188975,35370,Unspecified,,,,,"Selectivity ratio of EC50 for multinucleoside-resistant HIV1 NL4-3 harboring A62V, V75I, F77L, F116Y, Q151M mutation in viral reverse transcriptase to EC50 for wild type HIV1 NL4-3",Other,17967913.0,
2304,423782,6,2,,103188975,35370,Unspecified,,,60.0,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,19282192.0,
2305,423783,6,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,19282192.0,
2306,423784,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,19282192.0,
2307,423785,6,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase N119 (Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,19282192.0,
2308,423786,6,2,,103188975,35370,Active,,,0.01,EC50,"Antiviral activity against non-nucleoside reverse transcriptase inhibitor-resistant HIV1 bearing reverse transcriptase A17 (K103N, Y181C) mutation infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,19282192.0,
2309,423787,6,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against efavirenz-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,19282192.0,
2310,423788,6,2,,103188975,35370,Active,,,0.6,EC50,Antiviral activity against azidothymidine-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,19282192.0,
2311,423789,6,2,,103188975,35370,Active,,,0.1,EC50,Antiviral activity against MDR1-resistant HIV1 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,19282192.0,
2312,425652,7,2,,103188975,35370,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
2313,425653,7,2,,103188975,35370,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
2314,426888,3,4,,103188975,35370,Unspecified,,,,,Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA relative to untreated control,Other,19581097.0,
2315,426889,6,2,,103188975,35370,Active,,,0.05,EC50,Inhibition of HIV1 viral replication infected in human PBMC cells assessed as viral p24Ag concentration after 7 days postinfection by ELISA,Confirmatory,19581097.0,
2316,426890,6,2,,103188975,35370,Unspecified,,,126.0,CC50,Cytotoxicity against human PBMC by XTT assay,Confirmatory,19581097.0,
2317,426891,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human PBMC cells to EC50 for HIV1",Other,19581097.0,
2318,427971,3,4,,103188975,35370,Inactive,,,,,Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression at > 0.5 uM followed by drug wash out and viral infection measured after 48 hrs by MAGI assay,Other,17967909.0,
2319,429824,6,2,,103188975,35370,Unspecified,,,1000.0,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,19413342.0,
2320,429825,8,1,,103188975,35370,Active,,,0.00195,EC50,Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity,Confirmatory,19413342.0,
2321,429826,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B",Other,19413342.0,
2322,431619,6,2,,103188975,35370,Active,,,0.0151,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay,Confirmatory,19643613.0,
2323,431621,6,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,19643613.0,
2324,431622,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,19643613.0,
2325,434955,1,2,,855980,35370,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
2326,434959,1,1,,85788843,35370,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
2327,434962,1,2,,855980,35370,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
2328,434973,1,3,,49718184,35370,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
2329,434989,1,1,,855980,35370,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2330,435003,1,3,,49718184,35370,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
2331,435005,1,1,,855980,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
2332,435022,2,2,,49718184,35370,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
2333,435030,1,2,,855980,35370,Active,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2334,435030,1,2,,855980,35370,Active,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2335,439728,5,2,,103188975,35370,Active,,,0.069,IC50,Antiviral activity against HIV2 KR X3 infected in human TZM-b1 cells assessed as reduction in luciferase activity after 2 days by luciferase reporter gene assay,Confirmatory,19526990.0,
2336,439729,4,2,,103188975,35370,Unspecified,,,78.0,TC50,Cytotoxicity against human TZM-b1 cells after 2 days,Confirmatory,19526990.0,
2337,439736,5,2,,103188975,35370,Active,,,0.011000000000000001,IC50,Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry,Confirmatory,19537689.0,
2338,439738,5,2,,103188975,35370,Active,,,0.012,IC50,Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry,Confirmatory,19537689.0,
2339,439740,3,4,,103188975,35370,Unspecified,,,,,Inhibition of Vesicular stomatitis virus envelope glycoprotein-mediated viral entry into human A549 cells assessed as infectivity at 10 uM after 48 hrs postinfection by luciferase assay relative to control,Other,19537689.0,
2340,449349,5,2,,103188975,35370,Active,,,1.4,IC50,Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay,Confirmatory,19678643.0,
2341,449351,5,3,,103188975,35370,Active,,,3.6,IC50,Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay,Confirmatory,19678643.0,
2342,449422,5,2,,103188975,35370,Active,,,20.1,IC50,Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay,Confirmatory,19678643.0,
2343,449424,5,2,,103188975,35370,Active,,,39.6,IC50,Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay,Confirmatory,19678643.0,
2344,449489,5,2,,103188975,35370,Active,,,0.0151,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay,Confirmatory,19628308.0,
2345,449491,5,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay,Confirmatory,19628308.0,
2346,449492,3,4,,103188975,35370,Unspecified,,,,,"Selective index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,19628308.0,
2347,449728,1,2,,855980,35370,Active,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
2348,449739,1,2,,855980,35370,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
2349,449762,1,2,,855980,35370,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
2350,449763,1,3,,49718184,35370,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2351,449768,1,1,,855980,35370,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
2352,452269,5,2,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against HIV1 LAI infected in human PBM cells after 5 days,Confirmatory,19948402.0,
2353,452270,5,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC after 5 days,Confirmatory,19948402.0,
2354,452271,5,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells after 5 days,Confirmatory,19948402.0,
2355,452272,5,2,,103188975,35370,Unspecified,,,50.6,IC50,Cytotoxicity against african green monkey Vero cells after 5 days,Confirmatory,19948402.0,
2356,454923,3,3,,103188975,35370,Active,,,0.06,IC50,Antiviral activity against HIV1 Ba-L(R5) infected in human PBMC by p24 antigen capture assay,Confirmatory,20005712.0,
2357,455986,3,5,,103188975,35370,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
2358,456303,5,2,,103188975,35370,Active,,,0.01,IC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity by MTT assay,Confirmatory,19944610.0,
2359,456304,5,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,19944610.0,
2360,456306,5,2,,103188975,35370,Active,,,0.0051,IC50,Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay,Confirmatory,19944610.0,
2361,456307,5,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human CEM-SS cells by MTT assay,Confirmatory,19944610.0,
2362,456309,5,2,,103188975,35370,Active,,,0.0077,IC50,Antiviral activity against HIV1 BaL infected in human PBMC assessed as inhibition of viral replication by MTT assay,Confirmatory,19944610.0,
2363,456310,5,2,,103188975,35370,Unspecified,,,75.0,CC50,Cytotoxicity against human PBMC by MTT assay,Confirmatory,19944610.0,
2364,458192,6,1,,103188975,35370,Unspecified,20454871.0,42273.0,,,Activity at Drosophila melanogaster dNK by spectrophotometry,Other,20060716.0,
2365,458874,5,2,,103188975,35370,Active,,,0.0024,IC50,Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay,Confirmatory,20112915.0,
2366,458875,5,2,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against human CEM-SS cells by MTT assay,Confirmatory,20112915.0,
2367,458876,5,2,,103188975,35370,Active,,,0.018000000000000002,IC50,Antiviral activity against HIV1 3B in human MT4 cells assessed as RT activity after 5 days by single passage assay,Confirmatory,20112915.0,
2368,458877,5,2,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,20112915.0,
2369,460291,3,4,,103188975,35370,Active,,,,,Cytotoxicity against GFP expressing human CEM cells assessed as maximal non-toxic concentration after 48 to 72 hrs by MTT assay,Other,20137956.0,
2370,460292,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral p24 antigen production at non-toxic concentration after 7 days postinfection by ELISA,Other,20137956.0,
2371,460293,5,2,,103188975,35370,Active,,,1.05,IC50,Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry,Confirmatory,20137956.0,
2372,460294,5,2,,103188975,35370,Active,,,24.06,CC50,Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay,Confirmatory,20137956.0,
2373,463073,1,2,,855980,35370,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
2374,463075,1,1,,855980,35370,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
2375,463079,1,2,,855980,35370,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
2376,463082,1,1,,855980,35370,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
2377,463104,1,2,,49718184,35370,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
2378,463106,1,2,,90341185,35370,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2379,463111,1,1,,855980,35370,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
2380,463115,1,1,,855980,35370,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
2381,463141,1,2,,855980,35370,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
2382,463165,1,1,,855980,35370,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
2383,463187,1,1,,855980,35370,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
2384,463189,1,1,,855980,35370,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
2385,463190,1,2,,49718184,35370,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
2386,463193,1,1,,855980,35370,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
2387,463195,1,2,,49718184,35370,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
2388,463210,1,2,,855980,35370,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
2389,463212,1,1,,49718184,35370,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
2390,463254,1,1,,855980,35370,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
2391,466208,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1-infected human C8166 cells,Other,20146529.0,
2392,466209,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT assay,Other,20146529.0,
2393,470647,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect,Other,19685905.0,
2394,470648,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT assay,Other,19685905.0,
2395,471325,6,2,,103188975,35370,Active,,,0.05,IC50,Antiviral activity against HIV-1 NL4-3 expressing VSV-G envelope infected in human 293T cells assessed as inhibition of viral replication after 48 hrs by Luciferase reporter gene assay,Confirmatory,19702283.0,
2396,472248,5,2,,103188975,35370,Active,,,0.048,IC50,Antiviral activity against HIV1 NL4-3 co-transfected with VSV glycoprotein plasmid in human 293T cells after 48 hrs by luciferase reporter gene assay,Confirmatory,19453174.0,
2397,472647,5,2,,103188975,35370,Active,,,1.04,IC50,Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA,Confirmatory,20350812.0,
2398,472671,3,4,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP at 4.98 uM measured up to 8 days postinfection by p24 antigen capture ELISA,Other,20350812.0,
2399,472672,5,2,,103188975,35370,Active,,,24.0,CC50,Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay,Confirmatory,20350812.0,
2400,472673,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human CEM cells expressing GFP to IC50 for Human immunodeficiency virus 1 NL4.3",Other,20350812.0,
2401,473139,5,2,,103188975,35370,Active,,,0.034,EC50,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA,Confirmatory,20329730.0,
2402,473141,5,2,,103188975,35370,Unspecified,,,1870.0,IC50,Cytotoxicity against human MT2 cells by XTT assay,Confirmatory,20329730.0,
2403,473142,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, IC50 for human MT2 cells to EC50 for HIV1 3B",Other,20329730.0,
2404,476929,3,3,,103188975,35370,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
2405,481800,3,9,,103188975,35370,Unspecified,38258258.0,,,,Activity of Ureaplasma parvum thymidine kinase relative to dThd,Other,20378362.0,
2406,481801,3,9,,103188975,35370,Unspecified,23503074.0,7083.0,,,Activity of human TK1 relative to ATP,Other,20378362.0,
2407,481802,5,7,,103188975,35370,Unspecified,38258258.0,,,Km,Activity of Ureaplasma parvum thymidine kinase by Michaelis-Menten plot,Confirmatory,20378362.0,
2408,481803,5,7,,103188975,35370,Unspecified,23503074.0,7083.0,,Km,Activity of human TK1 by Michaelis-Menten plot,Confirmatory,20378362.0,
2409,481804,3,9,,103188975,35370,Unspecified,38258258.0,,,,Ratio of Vmax to Km for Ureaplasma parvum thymidine kinase,Other,20378362.0,
2410,481805,3,9,,103188975,35370,Unspecified,38258258.0,,,,Ratio of Vmax to Km for Ureaplasma parvum thymidine kinase relative to dThd,Other,20378362.0,
2411,481806,3,9,,103188975,35370,Unspecified,23503074.0,7083.0,,,Ratio of Vmax to Km for human TK1,Other,20378362.0,
2412,481807,3,9,,103188975,35370,Unspecified,23503074.0,7083.0,,,Ratio of Vmax to Km for human TK1 relative to ATP,Other,20378362.0,
2413,481808,8,5,,103188975,35370,Active,38258258.0,,12.5,IC50,Inhibition of Ureaplasma parvum thymidine kinase by liquid scintillation counting,Confirmatory,20378362.0,
2414,482025,8,5,,103188975,35370,Active,23503074.0,7083.0,3.0,IC50,Inhibition of human TK1 by liquid scintillation counting,Confirmatory,20378362.0,
2415,482690,3,5,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as time-of-addition prolongation at 0.5 ug/ml after 31 hrs post infection by ELISA,Other,20377249.0,
2416,484741,6,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Other,20488700.0,
2417,484742,6,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in C8166 cells assessed as inhibition of syncytia formation,Other,20488700.0,
2418,484743,3,3,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 to EC50 for HIV1 3B",Other,20488700.0,
2419,485270,1,1,,855980,35370,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
2420,485272,1,1,,855980,35370,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
2421,485273,2,1,,49718184,35370,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
2422,485275,1,3,,855980,35370,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
2423,485281,1,1,,855980,35370,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
2424,485290,1,1,,855980,35370,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2425,485290,1,1,,17390027,35370,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2426,485290,1,1,,26751584,35370,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
2427,485294,1,1,,855980,35370,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
2428,485295,1,2,,90341185,35370,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
2429,485297,1,1,,855980,35370,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2430,485297,1,1,,90341185,35370,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
2431,485298,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2432,485298,1,1,,90341185,35370,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
2433,485313,1,2,,855980,35370,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2434,485313,1,2,,90341185,35370,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
2435,485314,1,1,,855980,35370,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
2436,485341,1,1,,855980,35370,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
2437,485342,1,2,,90341185,35370,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2438,485344,1,1,,855980,35370,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
2439,485345,1,2,,90341185,35370,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2440,485346,1,1,,49718184,35370,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2441,485346,1,1,,49718184,35370,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
2442,485347,1,2,,855980,35370,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
2443,485349,1,1,,855980,35370,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
2444,485350,1,2,,92124444,35370,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
2445,485353,2,1,,855980,35370,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
2446,485358,1,1,,855980,35370,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
2447,485360,1,1,,855980,35370,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
2448,485364,1,1,,855980,35370,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
2449,485366,1,2,,90341185,35370,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2450,485367,1,2,,855980,35370,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2451,485368,1,2,,90341185,35370,Inconclusive,72386991.0,3656265.0,0.8492,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
2452,487828,5,2,,103188975,35370,Active,,,0.044000000000000004,EC50,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA,Confirmatory,20537902.0,
2453,487830,5,2,,103188975,35370,Unspecified,,,1872.0,IC50,Cytotoxicity against human MT2 cells after 6 days by XTT assay,Confirmatory,20537902.0,
2454,487831,3,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MT2 cells to EC50 for HIV1 3B infected in human MT2 cells",Other,20537902.0,
2455,488772,1,1,,90341185,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2456,488773,1,2,,90341185,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
2457,488806,1,2,,855980,35370,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
2458,488816,1,1,,90341185,35370,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
2459,488837,1,1,,855980,35370,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2460,488837,1,1,,90341185,35370,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
2461,488839,1,1,,49718184,35370,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2462,488839,1,1,,49718184,35370,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2463,488847,1,3,,855980,35370,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
2464,488862,1,1,,49718184,35370,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2465,488890,1,2,,855980,35370,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
2466,488895,1,2,,49718184,35370,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2467,488896,1,1,,49718184,35370,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2468,488899,1,1,,49718184,35370,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2469,488922,1,2,,855980,35370,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
2470,488942,1,1,,855980,35370,Active,15645703.0,899625.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
2471,488942,1,1,,855980,35370,Active,15646160.0,899738.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
2472,488949,1,2,,90341185,35370,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2473,488953,1,1,,90341185,35370,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2474,488955,1,1,,855980,35370,Active,16130723.0,947287.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
2475,488955,1,1,,855980,35370,Active,16130724.0,947286.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
2476,488955,1,1,,855980,35370,Active,16130726.0,947294.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
2477,488956,1,1,,855980,35370,Active,,,,,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Screening,,
2478,488965,1,2,,49718184,35370,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2479,488966,1,1,,49718184,35370,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
2480,488975,1,2,,855980,35370,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
2481,488977,1,2,,855980,35370,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
2482,488978,1,1,,90341185,35370,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
2483,488981,1,1,,90341185,35370,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
2484,488982,1,1,,90341185,35370,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
2485,488983,1,1,,90341185,35370,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
2486,489030,2,1,,49718184,35370,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
2487,489031,2,1,,49718184,35370,Active,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
2488,489452,5,2,,103188975,35370,Active,,,0.047,IC50,Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay,Confirmatory,20542430.0,
2489,489453,5,2,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against human MT2 cells by MTT assay,Confirmatory,20542430.0,
2490,491830,3,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human H9 cells to EC50 for HIV1 3B",Other,20527972.0,
2491,491831,5,2,,103188975,35370,Unspecified,,,1873.0,CC50,Cytotoxicity against human H9 cells after 6 days by XTT assay,Confirmatory,20527972.0,
2492,491832,5,2,,103188975,35370,Active,,,0.052000000000000005,EC50,Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay,Confirmatory,20527972.0,
2493,492209,3,4,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against HIV1 BAL by p24 assay,Confirmatory,20542438.0,
2494,492522,5,2,,103188975,35370,Active,,,0.044000000000000004,EC50,Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA,Confirmatory,20187635.0,
2495,492947,1,1,,855980,35370,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2496,492953,1,1,,49718184,35370,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
2497,492956,1,1,,49718184,35370,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
2498,492961,1,1,,26751584,35370,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
2499,492967,1,2,,99301612,35370,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2500,492972,1,1,,49718184,35370,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
2501,493005,1,1,,49718184,35370,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2502,493008,1,1,,49718184,35370,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2503,493008,1,1,,49718184,35370,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2504,493008,1,1,,49718184,35370,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2505,493008,1,1,,49718184,35370,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2506,493011,1,1,,49718184,35370,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2507,493012,1,1,,49718184,35370,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
2508,493014,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2509,493027,1,2,,49718184,35370,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2510,493027,1,2,,49718184,35370,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2511,493033,1,2,,92124444,35370,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2512,493035,1,2,,49718184,35370,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2513,493035,1,2,,49718184,35370,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2514,493036,1,2,,49718184,35370,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
2515,493056,1,1,,855980,35370,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2516,493084,1,1,,855980,35370,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2517,493087,1,1,,49718184,35370,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
2518,493091,1,1,,49718184,35370,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
2519,493098,1,1,,49718184,35370,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
2520,493106,1,1,,90341185,35370,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2521,493107,1,1,,90341185,35370,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2522,493131,1,1,,49718184,35370,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
2523,493153,1,1,,90341185,35370,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2524,493153,1,1,,90341185,35370,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2525,493160,1,1,,49718184,35370,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
2526,493162,1,2,,99301612,35370,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2527,493164,1,2,,90341185,35370,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2528,493164,1,2,,90341185,35370,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2529,493164,1,2,,90341185,35370,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2530,493187,1,2,,49718184,35370,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
2531,493244,1,1,,49718184,35370,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2532,493244,1,1,,49718184,35370,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2533,493244,1,1,,49718184,35370,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2534,493244,1,1,,49718184,35370,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2535,493722,5,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Other,20598530.0,
2536,493723,5,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral replication,Other,20598530.0,
2537,493724,2,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B",Other,20598530.0,
2538,493817,2,4,,103188975,35370,Active,,,,,Cytotoxicity against human CEM cells expressing green fluorescent protein assessed as oncytotoxic concentration by MTT assay,Other,20598537.0,
2539,493818,4,2,,103188975,35370,Active,,,1.04,IC50,Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP cells assessed as inhibition p24 antigen production after 8 days by ELISA,Confirmatory,20598537.0,
2540,493819,2,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human CEM cells expressing green fluorescent protein to IC50 for HIV1 NL4.3",Other,20598537.0,
2541,493820,4,2,,103188975,35370,Active,,,23.04,CC50,Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay,Confirmatory,20598537.0,
2542,499275,4,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells after 4 days by MTT assay,Confirmatory,20638854.0,
2543,499276,4,2,,103188975,35370,Active,,,0.005,IC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Confirmatory,20638854.0,
2544,499278,2,5,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B",Other,20638854.0,
2545,501754,4,2,,103188975,35370,Active,,,0.027000000000000003,EC50,Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of viral replication after 4 days by p24 antigen based ELISA assay,Confirmatory,20673723.0,
2546,501755,4,2,,103188975,35370,Unspecified,,,37.4,IC50,Cytotoxicity against human MT4 cells after 4 days,Confirmatory,20673723.0,
2547,501756,2,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MT4 cells to EC50 for HIV1 NL4-3",Other,20673723.0,
2548,504326,1,2,,49718184,35370,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2549,504326,1,2,,49718184,35370,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2550,504327,1,1,,855980,35370,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2551,504327,1,1,,26751584,35370,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2552,504327,1,1,,90341185,35370,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2553,504329,1,1,,49718184,35370,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
2554,504332,1,1,,855980,35370,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2555,504332,1,1,,26751584,35370,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2556,504332,1,1,,90341185,35370,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2557,504333,1,1,,855980,35370,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2558,504339,1,1,,49718184,35370,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
2559,504357,1,1,,49718184,35370,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2560,504357,1,1,,49718184,35370,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2561,504406,1,1,,855980,35370,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
2562,504408,2,1,,855980,35370,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
2563,504411,1,1,,49718184,35370,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
2564,504414,1,1,,49718184,35370,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2565,504414,1,1,,49718184,35370,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2566,504423,1,1,,49718184,35370,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2567,504441,1,1,,49718184,35370,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2568,504444,1,1,,49718184,35370,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
2569,504454,1,3,,49718184,35370,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
2570,504459,1,3,,855980,35370,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
2571,504462,1,1,,49718184,35370,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
2572,504466,1,1,,855980,35370,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2573,504467,1,1,,855980,35370,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2574,504490,1,2,,49718184,35370,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
2575,504523,1,1,,49718184,35370,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2576,504523,1,1,,49718184,35370,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2577,504536,1,1,,90341185,35370,Inconclusive,5453898.0,5300.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
2578,504541,1,1,,855980,35370,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
2579,504547,1,1,,90341185,35370,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2580,504548,1,2,,90341185,35370,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
2581,504558,1,1,,49718184,35370,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2582,504577,2,2,,49718184,35370,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2583,504582,2,1,,49718184,35370,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2584,504594,1,1,,49718184,35370,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2585,504600,1,2,,855980,35370,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2586,504616,1,1,,49718184,35370,Inactive,187952397.0,317.0,,,uHTS Fluorescent Interference Counterscreen assay for validation of Activators of Apaf-1,Screening,,
2587,504617,1,1,,49718184,35370,Inactive,187952397.0,317.0,,,Single concentration confirmation of uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
2588,504621,1,1,,49718184,35370,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2589,504634,1,1,,49718184,35370,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2590,504648,1,1,,49718184,35370,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
2591,504651,1,1,,855980,35370,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2592,504652,1,1,,855980,35370,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2593,504660,1,1,,855980,35370,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2594,504690,1,3,,49718184,35370,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
2595,504692,2,2,,49718184,35370,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2596,504700,1,1,,49718184,35370,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2597,504700,1,1,,49718184,35370,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2598,504706,1,1,,855980,35370,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
2599,504707,1,1,,49718184,35370,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2600,504707,1,1,,49718184,35370,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2601,504720,1,1,,49718184,35370,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2602,504734,1,1,,49718184,35370,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2603,504749,1,3,,26751584,35370,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2604,504749,1,3,1.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2605,504749,1,3,2.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2606,504749,1,3,3.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2607,504749,1,3,4.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2608,504749,1,3,5.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2609,504749,1,3,6.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2610,504749,1,3,7.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2611,504749,1,3,8.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2612,504749,1,3,9.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2613,504749,1,3,10.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2614,504749,1,3,11.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2615,504749,1,3,12.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2616,504749,1,3,13.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2617,504749,1,3,14.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2618,504749,1,3,15.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2619,504749,1,3,16.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2620,504749,1,3,17.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2621,504749,1,3,18.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2622,504749,1,3,19.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2623,504749,1,3,20.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2624,504749,1,3,21.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2625,504749,1,3,22.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2626,504749,1,3,23.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2627,504749,1,3,24.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2628,504749,1,3,25.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2629,504749,1,3,26.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2630,504749,1,3,27.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2631,504749,1,3,28.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2632,504749,1,3,29.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2633,504749,1,3,30.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2634,504749,1,3,31.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2635,504749,1,3,32.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2636,504749,1,3,33.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2637,504749,1,3,34.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2638,504749,1,3,35.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2639,504749,1,3,36.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2640,504749,1,3,37.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2641,504749,1,3,38.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2642,504749,1,3,39.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2643,504749,1,3,40.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2644,504749,1,3,41.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2645,504749,1,3,42.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2646,504749,1,3,43.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2647,504749,1,3,44.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2648,504749,1,3,45.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2649,504749,1,3,46.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2650,504749,1,3,47.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2651,504749,1,3,48.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2652,504749,1,3,49.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2653,504749,1,3,50.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2654,504749,1,3,51.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2655,504749,1,3,52.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2656,504749,1,3,53.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2657,504749,1,3,54.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2658,504749,1,3,55.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2659,504749,1,3,56.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2660,504749,1,3,57.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2661,504749,1,3,58.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2662,504749,1,3,59.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2663,504749,1,3,60.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2664,504749,1,3,61.0,26751584,35370,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2665,504766,2,1,,49718184,35370,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2666,504770,1,2,,92124444,35370,Active,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2667,504775,1,1,,49718184,35370,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2668,504803,1,1,,49718184,35370,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2669,504810,1,2,,855980,35370,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2670,504810,1,2,,90341185,35370,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2671,504812,1,2,,855980,35370,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2672,504812,1,2,,90341185,35370,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2673,504832,1,1,,855980,35370,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2674,504832,1,1,,26751584,35370,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2675,504834,1,1,,855980,35370,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2676,504834,1,1,,26751584,35370,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2677,504836,1,2,,90341185,35370,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2678,504842,1,1,,855980,35370,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2679,504845,1,1,,49718184,35370,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2680,504845,1,1,,90341185,35370,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2681,504847,1,1,,26751584,35370,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2682,504847,1,1,,49718184,35370,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2683,504847,1,1,,90341185,35370,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2684,504865,1,1,,26751584,35370,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2685,504865,1,1,,90341185,35370,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2686,504884,1,2,,49718184,35370,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2687,504891,1,1,,49718184,35370,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2688,504894,1,1,,49718184,35370,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2689,504937,1,2,,49718184,35370,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2690,511694,4,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay,Confirmatory,20086159.0,
2691,511695,3,1,,103188975,35370,Unspecified,,,0.5,TC50,Cytotoxicity against human CEM-SS cells infected with HIV1 3B after 6 days by XTT assay,Confirmatory,20086159.0,
2692,511696,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human CEM-SS cells infected with HIV1 3B to EC50 for HIV1 3B infected in human CEM-SS cells",Other,20086159.0,
2693,512142,4,2,,103188975,35370,Active,,,35.6,IC50,Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay,Confirmatory,20691339.0,
2694,512143,4,2,,103188975,35370,Active,,,0.7,EC50,Cytotoxicity against african human CEM cells after 6 days by XTT assay,Confirmatory,20691339.0,
2695,512144,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CEM cells to EC50 for HIV1",Other,20691339.0,
2696,515879,2,4,,103188975,35370,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum 3D7 at 100 uM by SYBR green assay,Other,20833052.0,
2697,515880,4,3,,103188975,35370,Unspecified,,,100.0,EC50,Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs by SYBR green assay,Confirmatory,20833052.0,
2698,515989,4,3,,103188975,35370,Unspecified,,,500.0,IC50,Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay,Confirmatory,20846868.0,
2699,515990,4,3,,103188975,35370,Active,,,0.01,EC50,Cytotoxicity against human H9 cells after 6 days by MTT assay,Confirmatory,20846868.0,
2700,515991,1,5,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV1 3B",Other,20846868.0,
2701,516489,6,2,,103188975,35370,Inconclusive,,,,EC50,Displacement of [125I]-SDF-1-alpha from CXCR4 expressed in CHO cells,Confirmatory,20728351.0,
2702,516490,4,2,,103188975,35370,Active,,,0.0493,IC50,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay,Confirmatory,20728351.0,
2703,516491,4,2,,103188975,35370,Inconclusive,,,,CC50,Cytotoxicity against human MT2 cells by MTT assay,Confirmatory,20728351.0,
2704,516492,1,4,,103188975,35370,Inconclusive,,,,,"Selectivity index, ratio of CC50 for human PM1 cells expressing CCR5 to IC50 for HIV1 MNA",Other,20728351.0,
2705,519856,4,2,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay,Confirmatory,18316521.0,
2706,519858,4,2,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2707,519859,4,2,,103188975,35370,Active,,,0.0029,EC50,Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2708,519860,4,2,,103188975,35370,Active,,,0.0063,EC50,Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2709,519861,4,2,,103188975,35370,Active,,,0.0012,EC50,Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2710,519862,4,2,,103188975,35370,Active,,,0.0038,EC50,Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2711,519863,4,2,,103188975,35370,Active,,,0.0049,EC50,Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2712,519864,4,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HIV1 subtype B-NL4-3 infected in 2 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2713,519865,4,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against HIV1 subtype B-NL4-3 infected in 3 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA,Confirmatory,18316521.0,
2714,519866,4,2,,103188975,35370,Active,,,0.034,EC50,Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA,Confirmatory,18316521.0,
2715,519867,4,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA,Confirmatory,18316521.0,
2716,519868,4,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA,Confirmatory,18316521.0,
2717,519869,4,2,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA,Confirmatory,18316521.0,
2718,519870,4,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2719,519871,4,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2720,519872,4,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2721,519873,4,2,,103188975,35370,Active,,,0.043,EC50,Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2722,519874,4,2,,103188975,35370,Active,,,0.051,EC50,Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2723,519875,4,2,,103188975,35370,Active,,,0.075,EC50,Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2724,519876,4,2,,103188975,35370,Active,,,0.209,EC50,Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2725,519877,4,2,,103188975,35370,Active,,,0.249,EC50,Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA,Confirmatory,18316521.0,
2726,519881,4,2,,103188975,35370,Active,,,0.027000000000000003,EC50,Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2727,519882,4,2,,103188975,35370,Active,,,0.038,EC50,Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2728,519883,4,2,,103188975,35370,Active,,,0.054000000000000006,EC50,Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2729,519884,4,2,,103188975,35370,Active,,,0.087,EC50,Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2730,519885,4,2,,103188975,35370,Active,,,0.11699999999999999,EC50,Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2731,519886,4,2,,103188975,35370,Active,,,0.14400000000000002,EC50,Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2732,519887,4,2,,103188975,35370,Active,,,0.223,EC50,Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2733,519888,4,2,,103188975,35370,Active,,,0.302,EC50,Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay,Confirmatory,18316521.0,
2734,519889,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay,Other,18316521.0,
2735,519890,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay,Other,18316521.0,
2736,519891,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay,Other,18316521.0,
2737,519892,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay,Other,18316521.0,
2738,519893,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay,Other,18316521.0,
2739,519960,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay,Other,18316521.0,
2740,519961,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.02 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay,Other,18316521.0,
2741,519962,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by MTS assay to EC50 for 0.05 MOI HIV1 NL4-3 infected in 2 hrs pretreated human MT2 cells by RT assay,Other,18316521.0,
2742,519963,4,2,,103188975,35370,Unspecified,,,10.0,EC50,Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay,Confirmatory,18316521.0,
2743,519964,4,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells,Confirmatory,18316521.0,
2744,519965,4,2,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells,Confirmatory,18316521.0,
2745,519966,4,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells by phenosense assay,Confirmatory,18316521.0,
2746,519967,4,2,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells by phenosense assay,Confirmatory,18316521.0,
2747,519971,2,4,,103188975,35370,Unspecified,,,,,Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT to EC50 for 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells,Other,18316521.0,
2748,520604,4,2,,103188975,35370,Unspecified,,,100.0,EC50,Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis,Confirmatory,18285481.0,
2749,520605,4,3,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human WI38 cells by neutral red assay,Confirmatory,18285481.0,
2750,520606,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human WI38 cells to EC50 for BK polyomavirus ATCC VR837",Other,18285481.0,
2751,521220,3,3,,103188975,35370,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2752,523345,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2753,523346,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain T369V mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2754,523347,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2755,523348,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2756,523349,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain K103N mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2757,523350,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain K103N/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2758,523351,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain K103N/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2759,523352,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain K103N/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2760,523353,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain Y181C mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2761,523354,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain Y181C/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2762,523355,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain Y181C/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2763,523356,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain Y181C/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2764,523357,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190A mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2765,523358,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190A/N348Ib mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2766,523477,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190A/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2767,523478,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190A/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2768,523479,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190S mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2769,523480,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190S/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2770,523481,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190S/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2771,523482,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain G190S/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2772,523483,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain L100I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2773,523484,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain L100I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2774,523485,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain L100I/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2775,523486,1,6,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 with RT connection domain L100I/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3,Other,20194692.0,
2776,525102,4,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2777,525104,4,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound,Confirmatory,18378713.0,
2778,525105,4,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound,Confirmatory,18378713.0,
2779,525106,4,2,,103188975,35370,Active,,,0.006999999999999999,EC50,"Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound",Confirmatory,18378713.0,
2780,525107,4,2,,103188975,35370,Active,,,0.018000000000000002,EC50,Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2781,525108,4,2,,103188975,35370,Active,,,0.022000000000000002,EC50,Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound,Confirmatory,18378713.0,
2782,525109,4,2,,103188975,35370,Active,,,0.022000000000000002,EC50,Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound,Confirmatory,18378713.0,
2783,525110,4,2,,103188975,35370,Active,,,0.022000000000000002,EC50,Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound,Confirmatory,18378713.0,
2784,525111,4,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV 1 NL4.3 assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2785,525112,4,2,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2786,525113,4,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2787,525114,4,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18378713.0,
2788,538997,4,4,,103188975,35370,Unspecified,,,20.0,IC50,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs,Confirmatory,21044845.0,
2789,538998,4,3,,103188975,35370,Unspecified,,,20.0,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 48 hrs,Confirmatory,21044845.0,
2790,538999,4,2,,103188975,35370,Unspecified,,,20.0,IC50,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by FACS analysis in presence of 10 % human serum,Confirmatory,21044845.0,
2791,539770,4,3,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against Human immunodeficiency virus 1 infected in human CEM-SS cells assessed as virus induced cytopathic effects,Confirmatory,21035347.0,
2792,539772,4,3,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay,Confirmatory,21035347.0,
2793,539774,1,5,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human CEM-SS cells to EC50 for Human immunodeficiency virus 1 infected in human CEM-SS cells",Other,21035347.0,
2794,540209,4,3,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2795,540210,4,3,,103188975,35370,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2796,540211,2,5,,103188975,35370,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2797,540212,4,3,,103188975,35370,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2798,540213,4,3,,103188975,35370,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2799,540214,4,3,,103188975,35370,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
2800,540215,3,2,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
2801,540216,4,3,,103188975,35370,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
2802,540217,4,3,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
2803,540218,4,3,,103188975,35370,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
2804,540219,4,3,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
2805,540220,4,3,,103188975,35370,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
2806,540221,4,3,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
2807,540235,1,3,,103188975,35370,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
2808,540253,1,1,,49718184,35370,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2809,540253,1,1,,49718184,35370,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2810,540253,1,1,,49718184,35370,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2811,540256,1,2,,855980,35370,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2812,540256,1,2,,90341185,35370,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2813,540263,1,1,,49718184,35370,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2814,540263,1,1,,49718184,35370,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2815,540267,1,1,,49718184,35370,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2816,540275,1,1,,855980,35370,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2817,540276,1,2,,855980,35370,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2818,540276,1,2,,90341185,35370,Inconclusive,420597.0,,32.6294,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2819,540277,1,1,,855980,35370,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2820,540295,1,1,,49718184,35370,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2821,540299,1,2,,92124444,35370,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2822,540303,1,1,,49718184,35370,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2823,540303,1,1,,49718184,35370,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2824,540303,1,1,,49718184,35370,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2825,540308,1,1,,49718184,35370,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2826,540317,1,1,,49718184,35370,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2827,540336,1,1,,49718184,35370,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2828,540336,1,1,,49718184,35370,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2829,540364,1,2,,49718184,35370,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2830,542924,2,4,,103188975,35370,Active,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation,Other,18474584.0,
2831,542925,2,3,,103188975,35370,Active,,,,,Antiproliferative activity against human subcutaneous preadipocyte assessed as [3H]thymidine incorporation at 6 uM,Other,18474584.0,
2832,542926,2,3,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3-F442A cells assessed as triglyceride accumulation at 6 uM after 9 days by oil red O staining relative to control,Other,18474584.0,
2833,542927,2,3,,103188975,35370,Inactive,,,,,Induction of preadipocyte differentiation in mouse 3T3-F442A cells assessed as triglyceride accumulation at 3 uM after 9 days by oil red O staining relative to control,Other,18474584.0,
2834,542928,2,3,,103188975,35370,Inactive,,,,,Induction of preadipocyte differentiation in mouse 3T3-F442A cells assessed as triglyceride accumulation at 0.1 uM after 9 days by oil red O staining relative to control,Other,18474584.0,
2835,542929,2,4,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3L1 cells assessed as PPARgamma mRNA expression on day 6 by RT-PCR analysis,Other,18474584.0,
2836,542930,2,4,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3L1 cells assessed as PPARgamma mRNA expression on day 4 by RT-PCR analysis,Other,18474584.0,
2837,542931,2,4,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3L1 cells assessed as C/EBPalpha mRNA expression on day 6 by RT-PCR analysis,Other,18474584.0,
2838,542932,2,4,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3L1 cells assessed as C/EBPalpha mRNA expression on day 4 by RT-PCR analysis,Other,18474584.0,
2839,542933,2,3,,103188975,35370,Active,,,,,Induction of preadipocyte differentiation in mouse 3T3-F442A cells assessed as adiponectin mRNA expression on day 9 by RT-PCR analysis,Other,18474584.0,
2840,542934,2,4,,103188975,35370,Unspecified,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation at 1 uM,Other,18474584.0,
2841,542935,2,4,,103188975,35370,Unspecified,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation at 3 uM,Other,18474584.0,
2842,542936,2,4,,103188975,35370,Unspecified,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation at 6 uM,Other,18474584.0,
2843,542937,2,4,,103188975,35370,Unspecified,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation at 180 uM,Other,18474584.0,
2844,542938,2,4,,103188975,35370,Inactive,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as [3H]thymidine incorporation at 0.1 uM,Other,18474584.0,
2845,542939,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against mouse 3T3-F442A cells at 1 uM after 24 hrs by trypan blue staining,Other,18474584.0,
2846,542940,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against mouse 3T3-F442A cells at 6 uM after 24 hrs by trypan blue staining,Other,18474584.0,
2847,542941,2,3,,103188975,35370,Inactive,,,,,Induction of adipocyte differentiation in mouse 3T3-F442A cells assessed as triglyceride accumulation at 6 uM on day 9 by oil red O staining relative to control,Other,18474584.0,
2848,542942,2,3,,103188975,35370,Inactive,,,,,Induction of adipocyte differentiation in mouse 3T3-F442A cells assessed as triglyceride accumulation at 1 uM on day 9 by oil red O staining relative to control,Other,18474584.0,
2849,542943,2,3,,103188975,35370,Inactive,,,,,Induction of adipocyte differentiation in mouse 3T3-F442A cells assessed as PPARgamma mRNA expression on day 6 by RT-PCR analysis,Other,18474584.0,
2850,543109,2,3,,103188975,35370,Inactive,,,,,Induction of adipocyte differentiation in mouse 3T3-F442A cells assessed as C/EBPalpha mRNA expression on day 6 by RT-PCR analysis,Other,18474584.0,
2851,543110,2,4,,103188975,35370,Inactive,,,,,Antiproliferative activity against mouse 3T3-F442A cells assessed as mtDNA depletion,Other,18474584.0,
2852,548302,2,3,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 subtype A isolate 92RW009 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2853,548303,2,3,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 subtype A isolate 92UG029 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2854,548304,2,3,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 subtype A isolate 92UG037 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2855,548305,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 subtype B isolate Ba-L infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2856,548306,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 subtype B isolate ADA infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2857,548307,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 subtype B isolate 92BR014 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2858,548308,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 subtype B isolate 96USHIPS7 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2859,548309,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 isolate JR-CSF infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2860,548310,2,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 subtype B isolate 92TH026 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2861,548311,2,3,,103188975,35370,Active,,,0.0049,EC50,Antiviral activity against HIV1 subtype C isolate 92BR025 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2862,548312,2,3,,103188975,35370,Active,,,0.0049,EC50,Antiviral activity against HIV1 subtype C isolate 91IN101 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2863,548313,2,3,,103188975,35370,Active,,,0.0049,EC50,Antiviral activity against HIV1 subtype C isolate 93MW959 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2864,548314,2,3,,103188975,35370,Active,,,0.0063,EC50,Antiviral activity against HIV1 subtype D isolate 92UG001 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2865,548315,2,3,,103188975,35370,Active,,,0.0063,EC50,Antiviral activity against HIV1 subtype D isolate 92UG024 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2866,548316,2,3,,103188975,35370,Active,,,0.0063,EC50,Antiviral activity against HIV1 subtype D isolate 92UG046 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2867,548317,2,3,,103188975,35370,Active,,,0.0055,EC50,Antiviral activity against HIV1 subtype E isolate 93TH073 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2868,548318,2,3,,103188975,35370,Active,,,0.0055,EC50,Antiviral activity against HIV1 subtype E isolate CMU06 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2869,548319,2,3,,103188975,35370,Active,,,0.0055,EC50,Antiviral activity against HIV1 subtype E isolate CMU08 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2870,548320,2,3,,103188975,35370,Active,,,0.0096,EC50,Antiviral activity against HIV1 subtype F isolate 93BR019 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2871,548321,2,3,,103188975,35370,Active,,,0.0096,EC50,Antiviral activity against HIV1 subtype F isolate 93BR020 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2872,548322,2,3,,103188975,35370,Active,,,0.0096,EC50,Antiviral activity against HIV1 subtype F isolate 93BR029 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2873,548323,2,3,,103188975,35370,Active,,,0.0047,EC50,Antiviral activity against HIV1 subtype G isolate JV1038 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2874,548535,2,3,,103188975,35370,Active,,,0.0047,EC50,Antiviral activity against HIV1 subtype G isolate RU132 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2875,548536,2,3,,103188975,35370,Active,,,0.0047,EC50,Antiviral activity against HIV1 subtype G isolate G3 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2876,548537,2,3,,103188975,35370,Active,,,0.0017,EC50,Antiviral activity against HIV1 group O isolate BCF01 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2877,548538,2,3,,103188975,35370,Active,,,0.0017,EC50,Antiviral activity against HIV1 group O isolate BCF02 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2878,548539,2,3,,103188975,35370,Active,,,0.0017,EC50,Antiviral activity against HIV1 group O isolate BCF03 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2879,548540,2,3,,103188975,35370,Active,,,0.0093,EC50,Antiviral activity against HIV2 isolate CDC310319 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2880,548541,2,3,,103188975,35370,Active,,,0.0093,EC50,Antiviral activity against HIV2 isolate CBL-20 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2881,548542,2,3,,103188975,35370,Active,,,0.0093,EC50,Antiviral activity against HIV2 isolate CDC310342 infected in human PBMC after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2882,548543,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human PBMC up to 1000 nM by MTS assay,Other,20439609.0,
2883,548544,2,3,,103188975,35370,Active,,,0.0012,EC50,Antiviral activity against HIV1 subtype A isolate 92UG029 infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2884,548545,2,3,,103188975,35370,Active,,,0.0013,EC50,Antiviral activity against HIV1 subtype A isolate 92UG037 infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2885,548546,2,3,,103188975,35370,Active,,,0.0027,EC50,Antiviral activity against HIV1 subtype B isolate Ba-L infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2886,548547,2,3,,103188975,35370,Active,,,0.0027,EC50,Antiviral activity against HIV1 subtype B isolate ADA infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2887,548548,2,3,,103188975,35370,Active,,,0.0027,EC50,Antiviral activity against HIV1 isolate JR-CSF infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2888,548549,2,3,,103188975,35370,Active,,,0.0027,EC50,Antiviral activity against HIV1 subtype B isolate 92TH014 infected in human MDM after 48 to 72 hrs by MTS assay,Confirmatory,20439609.0,
2889,548550,2,3,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MDM up to 1000 nM by MTS assay,Other,20439609.0,
2890,548556,2,3,,103188975,35370,Active,,,0.00053,EC50,Antiviral activity against HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC by ELISA,Confirmatory,20439609.0,
2891,548557,2,3,,103188975,35370,Active,,,0.33,EC50,Antiviral activity against HIV1 7324-1 harboring reverse transcriptase 41L/67N/69N/70R/215F/219E mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2892,548558,2,3,,103188975,35370,Active,,,0.1,EC50,Antiviral activity against HIV1 4755-5 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y/184V mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2893,548559,2,3,,103188975,35370,Active,,,3.0,EC50,Antiviral activity against HIV1 7303-3 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2894,548560,2,3,,103188975,35370,Unspecified,,,0.34,EC50,Antiviral activity against HIV1 1617-1 harboring reverse transcriptase 69K/70G/75I/77L/116Y/151M/184V mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2895,548561,2,3,,103188975,35370,Active,,,0.35,EC50,Antiviral activity against HIV1 52534-2 harboring reverse transcriptase 41L//74V/210W/215Y/184V/69SSS mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2896,548562,2,3,,103188975,35370,Active,,,0.0027,EC50,Antiviral activity against HIV1 71361-1 harboring reverse transcriptase 65R mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2897,548563,2,3,,103188975,35370,Active,,,0.0018,EC50,Antiviral activity against HIV1 8415-2 harboring reverse transcriptase 65R/184V mutant gene infected in human PBMC by ELISA,Confirmatory,20439609.0,
2898,548564,2,3,,103188975,35370,Active,,,0.62,EC50,Selectivity ratio of EC50 for HIV1 7324-1 harboring reverse transcriptase 41L/67N/69N/70R/215F/219E mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2899,548565,2,3,,103188975,35370,Active,,,0.19,EC50,Selectivity ratio of EC50 for HIV1 4755-5 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y/184V mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2900,548566,2,3,,103188975,35370,Active,,,5.7,EC50,Selectivity ratio of EC50 for HIV1 7303-3 harboring reverse transcriptase 41L/44D/67N/69D/118I/210W/215Y mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2901,548567,2,3,,103188975,35370,Unspecified,,,0.64,EC50,Selectivity ratio of EC50 for HIV1 1617-1 harboring reverse transcriptase 69K/70G/75I/77L/116Y/151M/184V mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2902,548568,2,3,,103188975,35370,Active,,,0.66,EC50,Selectivity ratio of EC50 for HIV1 52534-2 harboring reverse transcriptase 41L//74V/210W/215Y/184V/69SSS mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2903,548569,2,3,,103188975,35370,Active,,,0.0051,EC50,Selectivity ratio of EC50 for HIV1 71361-1 harboring reverse transcriptase 65R mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2904,548570,2,3,,103188975,35370,Active,,,0.0034,EC50,Selectivity ratio of EC50 for HIV1 8415-2 harboring reverse transcriptase 65R/184V mutant gene infected in human PBMC to EC50 for HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC,Confirmatory,20439609.0,
2905,548571,4,2,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against HIV1 isolate 056 expressing wild type reverse transcriptase gene by phenosense assay,Confirmatory,20439609.0,
2906,548572,4,2,,103188975,35370,Active,,,0.017,EC50,Antiviral activity against HIV1 isolate 057 expressing wild type reverse transcriptase gene by phenosense assay,Confirmatory,20439609.0,
2907,548573,4,2,,103188975,35370,Active,,,9.6,EC50,Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay,Confirmatory,20439609.0,
2908,548574,4,2,,103188975,35370,Active,,,16.0,EC50,Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay,Confirmatory,20439609.0,
2909,548575,4,2,,103188975,35370,Active,,,2.2,EC50,Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay,Confirmatory,20439609.0,
2910,548576,4,2,,103188975,35370,Active,,,1.6,EC50,Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay,Confirmatory,20439609.0,
2911,548577,4,2,,103188975,35370,Active,,,0.017,EC50,Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2912,548578,4,2,,103188975,35370,Unspecified,,,25.0,EC50,Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay,Confirmatory,20439609.0,
2913,548579,4,2,,103188975,35370,Active,,,8.7,EC50,Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2914,548580,4,2,,103188975,35370,Active,,,0.012,EC50,Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay,Confirmatory,20439609.0,
2915,548581,4,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2916,548582,4,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay,Confirmatory,20439609.0,
2917,548583,4,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2918,548584,4,2,,103188975,35370,Active,,,2.5,EC50,Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay,Confirmatory,20439609.0,
2919,548585,4,2,,103188975,35370,Active,,,4.2,EC50,Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2920,548586,4,2,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay,Confirmatory,20439609.0,
2921,548587,4,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay,Confirmatory,20439609.0,
2922,548588,4,2,,103188975,35370,Active,,,0.013999999999999999,EC50,Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay,Confirmatory,20439609.0,
2923,548798,4,2,,103188975,35370,Active,,,1.0,EC50,Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2924,548799,4,2,,103188975,35370,Active,,,0.071,EC50,Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2925,548800,4,2,,103188975,35370,Active,,,0.56,EC50,Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2926,548801,4,2,,103188975,35370,Active,,,0.18,EC50,Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2927,548802,4,2,,103188975,35370,Active,,,2.7,EC50,Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2928,548803,4,2,,103188975,35370,Active,,,2.7,EC50,Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2929,548804,4,2,,103188975,35370,Active,,,0.087,EC50,Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2930,548805,4,2,,103188975,35370,Active,,,0.11,EC50,Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2931,548806,4,2,,103188975,35370,Active,,,0.77,EC50,Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay,Confirmatory,20439609.0,
2932,548807,4,2,,103188975,35370,Active,,,0.19,EC50,Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2933,548808,4,2,,103188975,35370,Active,,,0.21,EC50,Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay,Confirmatory,20439609.0,
2934,548809,4,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay,Confirmatory,20439609.0,
2935,548810,4,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2936,548811,4,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay,Confirmatory,20439609.0,
2937,548812,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 058 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215F/K219Q mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2938,548813,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 060 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2939,548814,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 061 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2940,548815,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 063 harboring reverse transcriptase M41L/D67N/K70R/M184V/L210W/T215Y/K219E mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2941,548816,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 066 harboring reverse transcriptase 184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2942,548817,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 067 harboring reverse transcriptase A62V/D67G/T69SVG/V75I/T215I mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2943,548818,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 069 harboring reverse transcriptase D67E/T69SSG/V75M/M184V/L210W/T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2944,548819,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 070 harboring reverse transcriptase 65R/S68G mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2945,548820,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 071 harboring reverse transcriptase 65R/S68N/184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2946,548821,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 153 harboring reverse transcriptase L74V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2947,548822,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 157 harboring reverse transcriptase L74V/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2948,548823,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 160 harboring reverse transcriptase S68G/V75(I/T)/F77L/Y115F/F116Y /Q151M mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2949,548824,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 162 harboring reverse transcriptase A62V/V75I/F77L/Y115F/F116Y/Q151M/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2950,548825,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 166 harboring reverse transcriptase L74V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type,Other,20439609.0,
2951,548826,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 174 harboring reverse transcriptase M184V mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type,Other,20439609.0,
2952,548827,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 180 harboring reverse transcriptase K65R mutant gene obtained as site-directed mutant of NL4-3 by phenosense assay relative to wild type,Other,20439609.0,
2953,548828,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 185 harboring reverse transcriptase T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2954,548829,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 188 harboring reverse transcriptase T215Y/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2955,548830,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 192 harboring reverse transcriptase M41L/T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2956,548831,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 194 harboring reverse transcriptase M41L/T215Y/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2957,548832,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 200 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2958,548833,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 201 harboring reverse transcriptase M41L/L210W/T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2959,548834,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 203 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2960,548835,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 204 harboring reverse transcriptase M41L/L210W/T215Y/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2961,548836,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 206 harboring reverse transcriptase D67N/K70R mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2962,548837,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 211 harboring reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2963,548838,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 212 harboring reverse transcriptase L210W/T215Y mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2964,548839,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 215 harboring reverse transcriptase D67N/K70E mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2965,548840,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 217 harboring reverse transcriptase D67N/K70E/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2966,548841,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 isolate 220 harboring reverse transcriptase K70E/M184V mutant gene by phenosense assay relative to wild type,Other,20439609.0,
2967,549088,4,3,,103188975,35370,Active,,,0.89,CC50,Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay,Confirmatory,20439609.0,
2968,549089,4,3,,103188975,35370,Active,,,0.5,CC50,Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay,Confirmatory,20439609.0,
2969,551042,4,2,,103188975,35370,Active,,,21.43,IC50,Inhibition of HIV1 reverse transcriptase activity after 1 hr by ELISA,Confirmatory,21095125.0,
2970,551464,4,2,,103188975,35370,Unspecified,,,5041.0,CC50,Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days,Confirmatory,21194939.0,
2971,551465,2,4,,103188975,35370,Active,,,0.01135,EC50,Cytotoxicity against human C1866 cells after 72 hrs by MTT assay,Confirmatory,21194939.0,
2972,551466,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C1866 cells to EC50 for HIV1 3B infected in human C8166 cells",Other,21194939.0,
2973,553574,4,2,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against HIV1 ERS104pre infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2974,553575,4,2,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against HIV1 MOKW infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2975,553576,4,2,,103188975,35370,Active,,,0.89,EC50,Antiviral activity against HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2976,553577,4,2,,103188975,35370,Active,,,0.45,EC50,Antiviral activity against HIV1 MM harboring L10I/K43T/M46L/I54V/L63P/A71V/V82A/L90M/Q92K in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2977,553578,4,2,,103188975,35370,Active,,,0.18,EC50,Antiviral activity against HIV1 JSL harboring L10I/L24I/L33F/E35D/M36I/N37S/M46L/I54V/R57K/I62V/L63P/A71V/G73S/82A in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2978,556524,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type",Other,19223644.0,
2979,556525,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type",Other,19223644.0,
2980,556526,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type",Other,19223644.0,
2981,556527,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type",Other,19223644.0,
2982,557273,4,2,,103188975,35370,Active,,,0.12,EC50,Antiviral activity against HIV1 A harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2983,557274,4,2,,103188975,35370,Unspecified,,,1.0,EC50,Antiviral activity against HIV1 B harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2984,557275,4,2,,103188975,35370,Active,,,0.28,EC50,Antiviral activity against HIV1 C harboring L10I/I15V/K20R/L24I/M36I/M46L/I54V/I62V/L63P/K70Q/V82A/L89M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2985,557276,4,2,,103188975,35370,Active,,,0.6,EC50,Antiviral activity against HIV1 G harboring L10I/V11I/T12E/I15V/L19I/R41K/M46L/L63P/A71T/V82A/L90M in protease encoding region infected in human PHA-PBC assessed as inhibition of p24 Gag protein production by ELISA,Confirmatory,18955518.0,
2986,557277,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 TM harboring L10I/K14R/R41K/M46L/I54V/L63P/A71V/V82A/L90M/I93L in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2987,557278,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 MM harboring L10I/K43T/M46L/I54V/L63P/A71V/V82A/L90M/Q92K in protease encoding region infected to EC50 for HIV1 ERS104pre,Other,18955518.0,
2988,557279,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 JSL harboring L10I/L24I/L33F/E35D/M36I/N37S/M46L/I54V/R57K/I62V/L63P/A71V/G73S/82A in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2989,557280,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 A harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2990,557281,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 B harboring L10I/I15V/E35D/N37E/K45R/I54V/L63P/A71V/V82T/L90M/I93L/C95F in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2991,557282,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 C harboring L10I/I15V/K20R/L24I/M36I/M46L/I54V/I62V/L63P/K70Q/V82A/L89M in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2992,557283,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 G harboring L10I/V11I/T12E/I15V/L19I/R41K/M46L/L63P/A71T/V82A/L90M in protease encoding region to EC50 for HIV1 ERS104pre,Other,18955518.0,
2993,558367,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-infected pregnant woman maternal blood plasma at 300 mg, po BID by LC/MS/MS analysis",Other,19307360.0,
2994,558374,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-infected pregnant woman cord blood plasma at 300 mg, po BID by LC/MS/MS analysis",Other,19307360.0,
2995,558381,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-infected pregnant woman amniotic fluid at 300 mg, po BID by LC/MS/MS analysis",Other,19307360.0,
2996,558388,2,4,,103188975,35370,Unspecified,,,,,"Ratio of drug level in HIV-infected pregnant woman cord blood plasma to maternal blood plasma at 300 mg, po BID by LC/MS/MS analysis",Other,19307360.0,
2997,558395,2,4,,103188975,35370,Unspecified,,,,,"Ratio of drug level in HIV-infected pregnant woman amniotic fluid to maternal blood plasma at 300 mg, po BID by LC/MS/MS analysis",Other,19307360.0,
2998,559935,2,3,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 NL4-3 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
2999,559936,2,3,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV1 X4 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3000,559937,2,3,,103188975,35370,Active,,,0.0074,EC50,Antiviral activity against HIV1 89.6 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3001,559938,2,3,,103188975,35370,Inconclusive,,,,,Antiviral activity against HIV1 R5X4 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Other,19451305.0,
3002,559939,2,3,,103188975,35370,Active,,,0.0009599999999999999,EC50,Antiviral activity against HIV1 JRCSF infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3003,559940,2,3,,103188975,35370,Active,,,0.0062,EC50,Antiviral activity against HIV1 R5 infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3004,559941,2,3,,103188975,35370,Active,,,0.0019,EC50,Antiviral activity against HIV1 A018H infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3005,559942,2,3,,103188975,35370,Unspecified,,,87.0,EC50,Antiviral activity against HIV1 A018G infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA,Confirmatory,19451305.0,
3006,563936,4,2,,103188975,35370,Active,,,0.023,EC50,Antiviral activity against wild-type HIV1 pNL4-3 infected in TZM-bl cells by luciferase assay,Confirmatory,19704131.0,
3007,563937,4,2,,103188975,35370,Active,,,0.017,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3008,563938,4,2,,103188975,35370,Active,,,0.022000000000000002,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3009,563939,4,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3010,563940,4,2,,103188975,35370,Active,,,0.026000000000000002,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3011,563941,4,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3012,563942,4,2,,103188975,35370,Active,,,0.024,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3013,563943,4,2,,103188975,35370,Active,,,0.053,EC50,Antiviral activity against HIV1 pNL4-3 harboring Reverse transcriptase P119S/T165A/M184V mutant gene infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3014,563944,4,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV1 pNL4-3 harboring chimeric pTKD infected in TZM-bl cells after 72 hrs by luciferase assay,Confirmatory,19704131.0,
3015,565571,3,4,,103188975,35370,Inactive,,,,,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production at 10 uM after 8 hrs by ELISA,Other,19786602.0,
3016,568182,2,3,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against R5 tropic HIV1 Ba-L infected in human PBMC assessed as inhibition of HIN p24 antigen expression,Confirmatory,21256008.0,
3017,568183,2,3,,103188975,35370,Active,,,0.25,IC50,Antiviral activity against multidrug-resistant R5 tropic HIV1 MM infected in human PBMC assessed as inhibition of HIN p24 antigen expression,Confirmatory,21256008.0,
3018,569161,2,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production at highest non cytotoxic concentration after 7 days by ELISA,Other,21227704.0,
3019,569222,4,2,,103188975,35370,Active,,,1.1,EC50,Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA,Confirmatory,21227704.0,
3020,569223,4,2,,103188975,35370,Active,,,24.1,CC50,Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay,Confirmatory,21227704.0,
3021,569224,1,3,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human CEM-GFP cells to EC50 for HIV1 NL4.3",Other,21227704.0,
3022,569229,2,3,,103188975,35370,Inactive,,,,,Inhibition of HIV1 reverse transcriptase,Other,21227704.0,
3023,569230,2,4,,103188975,35370,Active,,,,,Cytotoxicity against human CEM-GFP cells assessed as highest non cytotoxic concentration after 48 hrs by MTT assay,Other,21227704.0,
3024,569565,5,3,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C1866 cells,Other,21232955.0,
3025,569566,5,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1-3B infected in human C1866 cells assessed as inhibition of virus-induced cytopathic effect,Other,21232955.0,
3026,569567,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C1866 cells to EC50 for HIV1-3B",Other,21232955.0,
3027,571588,1,3,,103188975,35370,Unspecified,,,,,Tmax in HIV-1 infected patient on day 10 by LC-MS/MS analysis,Other,20038617.0,
3028,571589,4,2,,103188975,35370,Unspecified,,,,,Cmax in HIV-1 infected patient on day 10 by LC-MS/MS analysis,Other,20038617.0,
3029,571590,3,2,,103188975,35370,Unspecified,,,,,AUC (0 to 12 hrs) in HIV-1 infected patient on day 10 by LC-MS/MS analysis,Other,20038617.0,
3030,571591,4,2,,103188975,35370,Unspecified,,,,,Apparent oral clearance in HIV-1 infected patient on day 10 by LC-MS/MS analysis,Other,20038617.0,
3031,571592,1,3,,103188975,35370,Unspecified,,,,,Half life in HIV-1 infected patient on day 10 by LC-MS/MS analysis,Other,20038617.0,
3032,571593,1,3,,103188975,35370,Unspecified,,,,,Ratio of AUC (0 to 12 hrs) in HIV-1 infected patient on day 10 to AUC ( 0 to 12 hrs) in HIV-1 infected patient on day 1,Other,20038617.0,
3033,571594,1,3,,103188975,35370,Unspecified,,,,,"Tmax in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3034,571595,4,2,,103188975,35370,Unspecified,,,,,"Cmax in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3035,571596,3,2,,103188975,35370,Unspecified,,,,,"AUC (0 to 12 hrs) in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3036,571597,4,2,,103188975,35370,Unspecified,,,,,"Apparent oral clearance in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3037,571598,1,3,,103188975,35370,Unspecified,,,,,"Half life in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3038,571599,1,3,,103188975,35370,Unspecified,,,,,"Ratio of AUC (0 to 12 hrs) in HIV-1 infected patient at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir to AUC (0 to 12 hrs) in HIV-1 infected patient at 200 mg, po bid on day 1 coadministered with 500 mg, po bid amdoxovir",Other,20038617.0,
3039,571600,1,3,,103188975,35370,Unspecified,,,,,"Tmax in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3040,571601,4,2,,103188975,35370,Unspecified,,,,,"Cmax in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3041,571602,3,2,,103188975,35370,Unspecified,,,,,"AUC (0 to 12 hrs) in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3042,571603,4,2,,103188975,35370,Unspecified,,,,,"Apparent oral clearance in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3043,571604,1,3,,103188975,35370,Unspecified,,,,,"Half life in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3044,571605,1,3,,103188975,35370,Unspecified,,,,,"Ratio of AUC (0 to 12 hrs) in HIV-1 infected patient at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir to AUC (0 to 12 hrs) in HIV-1 infected patient at 300 mg, po bid on day 1 coadministered with 500 mg, po bid amdoxovir",Other,20038617.0,
3045,571612,4,2,,103188975,35370,Unspecified,,,,,Cmax in HIV-1 infected patient on day 1 by LC-MS/MS analysis,Other,20038617.0,
3046,571619,2,4,,103188975,35370,Unspecified,,,,,Drug level in HIV-1 infected patient urine on day 10 by LC-MS/MS analysis,Other,20038617.0,
3047,571620,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-1 infected patient urine at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3048,571621,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-1 infected patient urine at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3049,571622,2,4,,103188975,35370,Unspecified,,,,,Drug level in HIV-1 infected patient urine on day 10 assessed as zidovudine-5-O-glucoronide level by LC-MS/MS analysis,Other,20038617.0,
3050,571623,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-1 infected patient urine assessed as zidovudine-5-O-glucoronide level at 200 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3051,571624,2,5,,103188975,35370,Unspecified,,,,,"Drug level in HIV-1 infected patient urine assessed as zidovudine-5-O-glucoronide level at 300 mg, po bid on day 10 coadministered with 500 mg, po bid amdoxovir by LC-MS/MS analysis",Other,20038617.0,
3052,572767,4,2,,103188975,35370,Active,,,0.19,IC50,Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3053,572768,4,2,,103188975,35370,Active,,,0.031,IC50,Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3054,572769,4,2,,103188975,35370,Active,,,0.01,IC50,Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication,Confirmatory,19596885.0,
3055,572774,4,2,,103188975,35370,Active,,,0.21,IC50,Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3056,572775,4,2,,103188975,35370,Active,,,0.21,IC50,Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3057,572776,4,2,,103188975,35370,Active,,,0.18,IC50,Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3058,572777,4,2,,103188975,35370,Unspecified,,,213.7,IC50,Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3059,572778,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3060,572779,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3061,572780,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3062,572781,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3063,572782,4,2,,103188975,35370,Active,,,10.4,IC50,Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3064,572783,4,2,,103188975,35370,Unspecified,,,96.7,IC50,Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3065,572784,4,2,,103188975,35370,Active,,,11.9,IC50,Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3066,572785,4,2,,103188975,35370,Unspecified,,,58.6,IC50,Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3067,572972,4,2,,103188975,35370,Unspecified,,,204.6,IC50,Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication,Confirmatory,19596885.0,
3068,572973,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3069,572974,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3070,572975,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3071,572976,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3072,572977,1,4,,103188975,35370,Unspecified,,,,,Ratio of IC50 for HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells,Other,19596885.0,
3073,572981,4,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human PBMC after 2 to 4 days by MTT assay,Confirmatory,19596885.0,
3074,572982,4,2,,103188975,35370,Unspecified,,,150.0,CC50,Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay,Confirmatory,19596885.0,
3075,572983,4,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay,Confirmatory,19596885.0,
3076,572984,4,2,,103188975,35370,Unspecified,,,86.2,CC50,Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay,Confirmatory,19596885.0,
3077,572985,4,2,,103188975,35370,Unspecified,,,270.0,CC50,Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay,Confirmatory,19596885.0,
3078,573975,4,2,,103188975,35370,Active,,,0.027000000000000003,EC50,Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3079,573976,4,2,,103188975,35370,Active,,,0.021,EC50,Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3080,573977,4,4,,103188975,35370,Active,,,0.067,EC50,Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3081,573978,4,2,,103188975,35370,Active,,,0.055999999999999994,EC50,Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3082,573979,4,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3083,573981,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Human immunodeficiency virus 2 EHO,Other,18541726.0,
3084,573982,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Simian immunodeficiency virus MAC 251,Other,18541726.0,
3085,573985,4,2,,103188975,35370,Active,,,0.2,EC50,Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3086,573986,4,2,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3087,573987,4,2,,103188975,35370,Active,,,0.026000000000000002,EC50,Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,18541726.0,
3088,573988,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1,Other,18541726.0,
3089,573989,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1,Other,18541726.0,
3090,573990,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for non nucleoside Protease inhibitor-resistant Human immunodeficiency virus 1,Other,18541726.0,
3091,573995,1,3,,103188975,35370,Unspecified,,,,,"Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-708,906-resistant Human immunodeficiency virus harboring T66I, L74M and S230R mutations in integrase",Other,18541726.0,
3092,573996,1,3,,103188975,35370,Unspecified,,,,,"Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-870,810-resistant Human immunodeficiency virus harboring L74M, E92Q and S230N mutations in integrase",Other,18541726.0,
3093,573997,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for MK-0518-resistant Human immunodeficiency virus harboring G140S and Q148H mutations in integrase,Other,18541726.0,
3094,573998,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for CHI/1043-resistant Human immunodeficiency virus harboring T66I and Q146K mutations in integrase,Other,18541726.0,
3095,573999,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus in presence of 10% FCS to EC50 for Human immunodeficiency virus in presence of 50% human serum,Other,18541726.0,
3096,574002,1,3,,103188975,35370,Unspecified,,,,,Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for wild-type Human immunodeficiency virus 2 ROD,Other,18541726.0,
3097,574186,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 2 by RT-PCR relative to untreated control,Other,18541728.0,
3098,574187,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as increase in mitochondrial DNA on day 5 by RT-PCR relative to untreated control,Other,18541728.0,
3099,574189,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCYB mitochondrial RNA level on day 2 by RT-PCR relative to untreated control,Other,18541728.0,
3100,574190,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in MTCO3 mitochondrial RNA level on day 2 by RT-PCR relative to untreated control,Other,18541728.0,
3101,574194,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 2 by RT-PCR relative to untreated control,Other,18541728.0,
3102,574195,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 2 by RT-PCR relative to untreated control,Other,18541728.0,
3103,574196,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control,Other,18541728.0,
3104,574197,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control,Other,18541728.0,
3105,574198,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myotube assessed as change in POLG mitochondrial RNA level on day 5 by RT-PCR relative to untreated control,Other,18541728.0,
3106,574199,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myotube assessed as change in Tfam mitochondrial RNA level on day 5 by RT-PCR relative to untreated control,Other,18541728.0,
3107,574200,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myoblast at 100 uL on day 5 by WST-1 assay,Other,18541728.0,
3108,574201,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human skeletal muscle Myotube at 100 uL on day 5 by WST-1 assay,Other,18541728.0,
3109,575950,4,2,,103188975,35370,Active,,,0.003,IC50,Antiviral activity against Human immunodeficiency virus 1 ROJO infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3110,575951,4,2,,103188975,35370,Active,,,0.003,IC50,Antiviral activity against Human immunodeficiency virus 1 SLKA infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3111,575952,4,2,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against Human immunodeficiency virus 1 TEKI infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3112,575953,4,2,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against Human immunodeficiency virus 1 WEJO infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3113,575954,4,2,,103188975,35370,Active,,,1.84,IC50,Antiviral activity against Human immunodeficiency virus 1 MDR 769 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3114,575955,4,2,,103188975,35370,Active,,,0.0008,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype A RW/92/016 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3115,575956,4,2,,103188975,35370,Active,,,0.006,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype B 302056 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3116,575957,4,2,,103188975,35370,Active,,,0.003,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype C BR/92/025 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3117,575958,4,2,,103188975,35370,Active,,,0.0007,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype D UG/92/046 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3118,575959,4,2,,103188975,35370,Active,,,0.004,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype E CMU02 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3119,575960,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype F BR/93/020 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3120,576141,4,2,,103188975,35370,Active,,,0.0001,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype G JV 1083 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3121,576142,4,2,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype O BCF01 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3122,576143,4,2,,103188975,35370,Active,,,0.0005,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype O BCF02 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3123,576144,4,2,,103188975,35370,Active,,,0.0001,IC50,Antiviral activity against Human immunodeficiency virus 1 subtype O BCF03 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3124,576145,4,2,,103188975,35370,Active,,,0.0002,IC50,Antiviral activity against Human immunodeficiency virus 2 CDC 310319 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3125,576146,4,2,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against Human immunodeficiency virus 2 CDC 310342 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3126,576147,4,2,,103188975,35370,Active,,,0.01,IC50,Antiviral activity against simian immunodeficiency virus Mac251 infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3127,576148,4,2,,103188975,35370,Active,,,0.0005,IC50,Antiviral activity against simian immunodeficiency virus 69R infected in phytohemagglutininin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3128,576149,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human PBMC assessed as cell viability at 10 uM by MTS assay,Other,20086149.0,
3129,576150,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human PBMC assessed as cell viability at 1 uM by MTS assay,Other,20086149.0,
3130,576152,4,2,,103188975,35370,Unspecified,,,0.1,IC50,Cytotoxicity against human CEM-SS cells by MTS assay,Confirmatory,20086149.0,
3131,576157,4,2,,103188975,35370,Unspecified,,,0.1,IC50,Cytotoxicity against human H9 cells by MTS assay,Confirmatory,20086149.0,
3132,576191,4,2,,103188975,35370,Active,,,0.004,IC50,Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3133,576192,4,2,,103188975,35370,Active,,,0.015,IC50,Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3134,576193,4,2,,103188975,35370,Active,,,0.027999999999999997,IC50,Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3135,576194,4,2,,103188975,35370,Active,,,0.08,IC50,"Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay",Confirmatory,20086149.0,
3136,576195,4,2,,103188975,35370,Active,,,0.04,IC50,"Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay",Confirmatory,20086149.0,
3137,576199,4,2,,103188975,35370,Unspecified,,,0.1,IC50,Cytotoxicity against human AA5 cells by MTS assay,Confirmatory,20086149.0,
3138,576200,4,2,,103188975,35370,Active,,,0.0004,IC50,Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3139,576201,4,2,,103188975,35370,Active,,,0.008,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3140,576202,4,2,,103188975,35370,Active,,,0.01,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3141,576203,4,2,,103188975,35370,Active,,,0.006,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3142,576204,4,2,,103188975,35370,Active,,,0.027000000000000003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3143,576378,4,2,,103188975,35370,Unspecified,,,0.1,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3144,576379,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3145,576380,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3146,576381,4,2,,103188975,35370,Active,,,0.009000000000000001,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3147,576382,4,2,,103188975,35370,Active,,,0.006,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3148,576383,4,2,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3149,576384,4,2,,103188975,35370,Active,,,0.003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3150,576385,4,2,,103188975,35370,Active,,,0.003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3151,576386,4,2,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3152,576387,4,2,,103188975,35370,Active,,,0.002,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3153,576388,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3154,576389,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay,Confirmatory,20086149.0,
3155,576390,4,2,,103188975,35370,Unspecified,,,0.1,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3156,576391,4,2,,103188975,35370,Active,,,0.001,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3157,576392,4,2,,103188975,35370,Active,,,0.0003,IC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA,Confirmatory,20086149.0,
3158,578847,4,2,,103188975,35370,Active,,,0.0025,EC50,Antiviral activity against Human immunodeficiency virus 1 LAI infected in human PBMC assessed as inhibition of viral replication after 5 days by reverse transcriptase assay,Confirmatory,21371895.0,
3159,578849,4,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC after 5 days by trypan blue assay,Confirmatory,21371895.0,
3160,578850,4,2,,103188975,35370,Unspecified,,,56.1,IC50,Cytotoxicity against human CEM cells after 5 days by trypan blue assay,Confirmatory,21371895.0,
3161,581050,2,4,,103188975,35370,Unspecified,,,,,Increase in mitochondrial DNA level in differentiated mouse 3T3-F442A cells at 10 uM by real-time PCR,Other,19104011.0,
3162,581051,2,4,,103188975,35370,Unspecified,,,,,Increase in mitochondrial DNA level in differentiated mouse 3T3-F442A cells at 1 uM by real-time PCR,Other,19104011.0,
3163,581052,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as effect on total deoxynucleotides content at 1 uM after 2 to 10 days,Other,19104011.0,
3164,581053,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as effect on total deoxynucleotides content at 10 uM after 2 to 10 days,Other,19104011.0,
3165,581055,2,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against differentiated mouse 3T3-F442A cells assessed as increase in TTP content after 10 days,Other,19104011.0,
3166,581774,4,2,,103188975,35370,Active,,,0.013999999999999999,IC50,Antiviral activity against HIV-1 SF2 infected in human PBMC assessed as inhibition of viral replication by ELISA,Confirmatory,18212100.0,
3167,581776,4,2,,103188975,35370,Active,,,0.06,IC50,Antiviral activity against HIV-1 3B infected in human PBMC assessed as inhibition of viral replication by ELISA,Confirmatory,18212100.0,
3168,581777,4,2,,103188975,35370,Active,,,0.05,IC50,Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay,Confirmatory,18212100.0,
3169,581778,5,5,,103188975,35370,Inconclusive,51702775.0,5478.0,,Ki,Inhibition of human recombinant cyclophilin-associted cis-trans propyl isomerase activity,Confirmatory,18212100.0,
3170,582311,4,2,,103188975,35370,Active,,,2.47,EC50,Antiviral activity against HIV1 Brazilian isolate 93BR021 infected in PHA-stimulated human PBMC assessed as inhibition of viral replication after 7 days,Confirmatory,18625767.0,
3171,583436,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in viable cells at 50 uM after 15 days by trypan blue dye exclusion assay relative to control,Other,20805401.0,
3172,583437,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in viable cells at 50 uM after 6 days by trypan blue dye exclusion assay relative to control,Other,20805401.0,
3173,583441,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as slight increase in mitochondrial size at 50 uM after 15 days by electron microscopy relative to control,Other,20805401.0,
3174,583445,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as increase in extracellular lactate secretion at 50 uM after 15 days relative to control,Other,20805401.0,
3175,583449,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in mitochondrial DNA content at 50 uM after 15 days by RT-PCR method relative to control,Other,20805401.0,
3176,583456,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex I activity at 50 uM after 15 days relative to control,Other,20805401.0,
3177,583457,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex II activity at 50 uM after 15 days relative to control,Other,20805401.0,
3178,583458,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex III activity at 50 uM after 15 days relative to control,Other,20805401.0,
3179,583459,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as inhibition of mitochondrial respiratory chain complex IV activity at 50 uM after 15 days relative to control,Other,20805401.0,
3180,583847,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K mutant infected in human SupT1 cells derived from 9 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3",Other,20660667.0,
3181,583848,2,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4-3 infected in human SupT1 cells derived from 11 viral passages assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3,Other,20660667.0,
3182,584080,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K, F227F/L mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3",Other,20660667.0,
3183,584081,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, H221Y, F227F/L, M230M/I mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3",Other,20660667.0,
3184,584082,2,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase L100I, K103Q, H221H/Y mutant infected in human SupT1 cells derived from 11 viral passages with efavirenz assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3",Other,20660667.0,
3185,584603,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of mitochondrial DNA abundance at 6 uM after 30 days by RT-PCR analysis,Other,19805555.0,
3186,584610,3,4,,103188975,35370,Inactive,,,,,Inhibition of electron transport protein complex 1/3 in human subcutaneous preadipocytes at 6 uM after 30 to 60 days by photometric analysis,Other,19805555.0,
3187,584611,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of insulin-sensitizing adipokine expression at 6 uM after 30 days by RT-PCR analysis,Other,19805555.0,
3188,584612,2,3,,103188975,35370,Unspecified,,,,,Toxicity in fully differentiated human subcutaneous preadipocytes assessed as cell death at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3189,584613,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as cell death at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3190,584614,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of cell viability measured every 5 days at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3191,584615,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of cell cultures at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3192,584616,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as triacylglyceride droplets at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3193,584617,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as acquisition of adipocyte shape at 6 uM after 30 days using oil red O fluorescence staining by conventional fluorescence microscopy,Other,19805555.0,
3194,584634,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of C/EBPalpha expression at 6 uM after 18 days by RT-PCR analysis,Other,19805555.0,
3195,584635,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of PPARgamma expression at 6 uM after 18 days by RT-PCR analysis,Other,19805555.0,
3196,584639,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as decrease of adiponectin expression at 6 uM after 30 days by ELISA,Other,19805555.0,
3197,584641,3,4,,103188975,35370,Inactive,,,,,Inhibition of electron transport protein complex 2/3 in human subcutaneous preadipocytes at 6 uM after 30 to 60 days by photometric analysis,Other,19805555.0,
3198,584801,3,4,,103188975,35370,Inactive,,,,,Inhibition of electron transport protein complex 4 in human subcutaneous preadipocytes at 6 uM after 30 to 60 days by photometric analysis,Other,19805555.0,
3199,584802,3,4,,103188975,35370,Inactive,,,,,Inhibition of electron transport protein complex 5 in human subcutaneous preadipocytes at 6 uM after 30 to 60 days by photometric analysis,Other,19805555.0,
3200,584803,3,4,,103188975,35370,Inactive,,,,,Inhibition of citrate synthase in human subcutaneous preadipocytes at 6 uM after 30 to 60 days by photometric analysis,Other,19805555.0,
3201,584814,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial membrane potential at 6 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis,Other,19805555.0,
3202,584817,2,4,,103188975,35370,Unspecified,,,,,Toxicity in human subcutaneous preadipocytes assessed as effect on mitochondrial mass at 6 uM after 30 days using JC-1 red/green fluorescence dye by flow cytometry analysis,Other,19805555.0,
3203,586313,1,3,,103188975,35370,Unspecified,,,,,Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression at 0.27 ug/ml after 3 weeks post infection by quantitative real time RT-PCR,Other,21334901.0,
3204,586317,1,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression at 0.27 ug/ml after 5 days post infection by quantitative real time RT-PCR,Other,21334901.0,
3205,586319,4,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression after 3 weeks post infection by quantitative real time RT-PCR,Other,21334901.0,
3206,586320,4,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression after 5 days post infection by quantitative real time RT-PCR,Other,21334901.0,
3207,586325,5,3,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay,Other,21334901.0,
3208,586326,4,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay,Other,21334901.0,
3209,587737,1,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as time required to cause 50% loss in compound potency at 10 times EC95 by time-of-addition assay",Other,21060108.0,
3210,587738,4,2,,103188975,35370,Active,,,0.0084,EC50,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as luciferase activity after 48 hrs by exogenous RT assay",Confirmatory,21060108.0,
3211,587739,4,3,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human HeLaT4 cells by WST-1 assay,Confirmatory,21060108.0,
3212,587740,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HeLa-T4 cells to EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef",Other,21060108.0,
3213,587742,2,4,,103188975,35370,Active,,,,,Drug uptake in human HeLaT4 cells assessed as compound persist measured after 3 times washout at 100 time EC95 for HIV1 for 24 hrs,Other,21060108.0,
3214,587743,1,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed by exposed to virus immediately after 3 times compound washout relative to untreated control cells",Other,21060108.0,
3215,587744,1,4,,103188975,35370,Unspecified,,,,,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed by exposed to virus after 2 to 4 hrs of 3 times compound washout relative to untreated control cells",Other,21060108.0,
3216,587745,1,4,,103188975,35370,Inactive,,,,,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed by exposed to virus after 8 hrs of 3 times compound washout relative to untreated control cells",Other,21060108.0,
3217,587747,4,2,,103188975,35370,Active,,,4.6,EC50,"Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to virus immediately after 3 times compound washout",Confirmatory,21060108.0,
3218,587748,1,4,,103188975,35370,Unspecified,,,,,"Ratio of EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to virus immediately after 3 times compound washout to standard EC50 for HIV1 NLX.Lux-R",Other,21060108.0,
3219,588208,2,3,,103188975,35370,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
3220,588209,2,3,,103188975,35370,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
3221,588210,2,4,,103188975,35370,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
3222,588211,2,3,,103188975,35370,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
3223,588212,2,3,,103188975,35370,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
3224,588213,2,3,,103188975,35370,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
3225,588214,2,3,,103188975,35370,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
3226,588215,2,3,,103188975,35370,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
3227,588216,2,3,,103188975,35370,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
3228,588217,2,3,,103188975,35370,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
3229,588218,2,3,,103188975,35370,Active,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
3230,588219,2,3,,103188975,35370,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
3231,588220,2,3,,103188975,35370,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
3232,588334,1,1,,49718184,35370,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
3233,588335,1,1,,49718184,35370,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
3234,588342,1,1,,855980,35370,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
3235,588349,1,1,,90341185,35370,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
3236,588352,1,2,,49718184,35370,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
3237,588354,1,1,,49718184,35370,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
3238,588358,1,2,,49718184,35370,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
3239,588368,1,2,,855980,35370,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
3240,588378,1,1,,90341185,35370,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
3241,588391,1,1,,49718184,35370,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3242,588405,1,1,,49718184,35370,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
3243,588413,1,2,,49718184,35370,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
3244,588436,1,1,,49718184,35370,Active,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
3245,588453,1,1,,49718184,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
3246,588453,1,1,,90341185,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
3247,588456,1,1,,49718184,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
3248,588456,1,1,,90341185,35370,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
3249,588458,1,1,,49718184,35370,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
3250,588459,1,2,,855980,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
3251,588459,1,2,,855980,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
3252,588459,1,2,,855980,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
3253,588460,1,2,,855980,35370,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
3254,588460,1,2,,855980,35370,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
3255,588460,1,2,,855980,35370,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
3256,588461,1,2,,855980,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
3257,588461,1,2,,855980,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
3258,588461,1,2,,855980,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
3259,588473,1,1,,49718184,35370,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
3260,588473,1,1,,49718184,35370,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
3261,588475,1,2,,49718184,35370,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
3262,588475,1,2,,49718184,35370,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
3263,588478,1,2,,124800927,35370,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
3264,588489,1,1,,49718184,35370,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
3265,588492,1,1,,49718184,35370,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
3266,588493,1,2,,49718184,35370,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
3267,588497,1,2,,49718184,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
3268,588497,1,2,,49718184,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
3269,588497,1,2,,49718184,35370,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
3270,588499,1,3,,49718184,35370,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
3271,588499,1,3,,49718184,35370,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
3272,588499,1,3,,49718184,35370,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
3273,588501,1,2,,49718184,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
3274,588501,1,2,,49718184,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
3275,588501,1,2,,49718184,35370,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
3276,588506,1,2,,855980,35370,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
3277,588511,1,2,,855980,35370,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
3278,588513,1,1,,17390027,35370,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
3279,588513,1,1,,26751584,35370,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
3280,588514,1,1,,17390027,35370,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
3281,588514,1,1,,26751584,35370,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
3282,588515,1,1,,17390027,35370,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
3283,588515,1,1,,26751584,35370,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
3284,588516,1,1,,17390027,35370,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
3285,588516,1,1,,26751584,35370,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
3286,588519,1,2,,92124444,35370,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
3287,588526,1,1,,17390027,35370,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
3288,588526,1,1,,26751584,35370,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
3289,588527,1,1,,17390027,35370,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
3290,588527,1,1,,26751584,35370,Inconclusive,325495553.0,9971.0,0.0013,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
3291,588532,1,1,,17390027,35370,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
3292,588532,1,1,,26751584,35370,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
3293,588533,1,1,,17390027,35370,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
3294,588533,1,1,,26751584,35370,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
3295,588534,1,1,,17390027,35370,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
3296,588534,1,1,,26751584,35370,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
3297,588535,1,1,,17390027,35370,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
3298,588535,1,1,,26751584,35370,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
3299,588536,1,1,,17390027,35370,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
3300,588536,1,1,,26751584,35370,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
3301,588537,1,1,,17390027,35370,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
3302,588537,1,1,,26751584,35370,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
3303,588541,1,1,,17390027,35370,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
3304,588541,1,1,,26751584,35370,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
3305,588543,1,1,,17390027,35370,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
3306,588543,1,1,,26751584,35370,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
3307,588544,1,1,,17390027,35370,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
3308,588544,1,1,,26751584,35370,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
3309,588545,1,1,,17390027,35370,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
3310,588545,1,1,,26751584,35370,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
3311,588546,1,1,,17390027,35370,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
3312,588546,1,1,,26751584,35370,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
3313,588547,1,1,,17390027,35370,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
3314,588547,1,1,,26751584,35370,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
3315,588549,1,1,,49718184,35370,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3316,588550,1,1,,855980,35370,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
3317,588579,1,1,,26751584,35370,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
3318,588579,1,1,,49718184,35370,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
3319,588579,1,1,,90341185,35370,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
3320,588590,1,1,,49718184,35370,Inactive,154350220.0,11201.0,89.1251,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
3321,588591,1,1,,49718184,35370,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
3322,588621,1,1,,49718184,35370,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
3323,588627,1,1,,855980,35370,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
3324,588664,1,2,,49718184,35370,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
3325,588664,1,2,,49718184,35370,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
3326,588674,1,2,,49718184,35370,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3327,588675,1,1,,855980,35370,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
3328,588676,1,1,,855980,35370,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
3329,588685,1,1,,855980,35370,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
3330,588689,1,1,,49718184,35370,Inconclusive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
3331,588692,2,1,,49718184,35370,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3332,588726,1,2,,49718184,35370,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
3333,588727,1,1,,49718184,35370,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
3334,588795,1,1,,49718184,35370,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
3335,588795,1,1,,90341185,35370,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
3336,588814,1,3,,49718184,35370,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
3337,588819,1,4,,49718184,35370,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
3338,588834,2,1,,17390027,35370,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
3339,588834,2,1,,144203613,35370,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
3340,588834,2,1,,144204445,35370,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
3341,588850,1,1,,49718184,35370,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
3342,588852,1,3,,49718184,35370,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
3343,588855,1,1,,49718184,35370,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
3344,588856,1,1,,49718184,35370,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
3345,588964,1,10,,103188975,35370,Unspecified,74762955.0,9356.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1",Other,20190787.0,
3346,589078,1,10,,103188975,35370,Unspecified,136727.0,7364.0,,,Substrate of human UDP-glucuronosyltransferase UGT2B7,Other,,
3347,590165,3,2,,103188975,35370,Active,,,24.06,CC50,Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay,Confirmatory,21295891.0,
3348,590166,3,2,,103188975,35370,Active,,,1.05,EC50,Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA,Confirmatory,21295891.0,
3349,590167,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human CEM cells expressing green fluorescent protein to EC50 for Human immunodeficiency virus 1 NL4.3",Other,21295891.0,
3350,590345,1,4,,103188975,35370,Unspecified,,,,,Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production at 5 uM measured 7 days post infection by ELISA,Other,21295891.0,
3351,591001,1,4,,103188975,35370,Active,,,0.12,IC50,Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay,Confirmatory,21414776.0,
3352,592681,1,4,,103188975,35370,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
3353,595594,3,2,,103188975,35370,Active,,,0.0044,EC50,Antiviral activity against Human immunodeficiency virus 1 LAV1 assessed as reduction in RT activity by [3H]-dTTP incorporation assay,Confirmatory,21376429.0,
3354,595595,3,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human PBMC infected with Human immunodeficiency virus 1 LAV1 by MTS assay,Confirmatory,21376429.0,
3355,595596,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human PBMC infected with Human immunodeficiency virus 1 LAV1 to EC50 for Human immunodeficiency virus 1 LAV1",Other,21376429.0,
3356,597658,4,2,,103188975,35370,Unspecified,,,,,Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay,Other,21515046.0,
3357,597659,4,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human mock-infected MT4 cells after 4 days by MTT assay,Other,21515046.0,
3358,600420,4,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay,Other,19515569.0,
3359,600422,4,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 NL4-3 infected human C8166-CCR5 cells assessed as decrease in virus-induced cytopathicity after 72 hrs by cell associated dehydrogenase activity assay,Other,19515569.0,
3360,600423,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166-CCR5 cells to EC50 for HIV1 NL4-3",Other,19515569.0,
3361,602123,1,1,,49718184,35370,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
3362,602141,1,1,,49718184,35370,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
3363,602162,1,1,,49718184,35370,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
3364,602163,1,1,,49718184,35370,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
3365,602179,1,2,,49718184,35370,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
3366,602229,1,1,,49718184,35370,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
3367,602233,1,1,,49718184,35370,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
3368,602244,1,2,,49718184,35370,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
3369,602247,1,2,,49718184,35370,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
3370,602248,1,2,,49718184,35370,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
3371,602250,1,2,,49718184,35370,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
3372,602252,1,1,,49718184,35370,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3373,602252,1,1,,49718184,35370,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3374,602261,1,1,,49718184,35370,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
3375,602274,1,2,,49718184,35370,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
3376,602276,1,1,,855980,35370,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,Screening,,
3377,602277,1,1,,855980,35370,Inactive,20140422.0,7098.0,,,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,Screening,,
3378,602281,1,1,,49718184,35370,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
3379,602281,1,1,,49718184,35370,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
3380,602310,1,2,,49718184,35370,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
3381,602313,1,1,,49718184,35370,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
3382,602314,1,2,,92124444,35370,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
3383,602329,1,1,,49718184,35370,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3384,602332,1,1,,26751584,35370,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3385,602332,1,1,,49718184,35370,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3386,602332,1,1,,90341185,35370,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
3387,602340,1,2,,49718184,35370,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
3388,602342,2,1,,49718184,35370,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3389,602346,1,1,,49718184,35370,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3390,602363,1,1,,49718184,35370,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
3391,602393,1,1,,49718184,35370,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3392,602396,1,2,,49718184,35370,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
3393,602399,1,2,,49718184,35370,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
3394,602405,1,1,,49718184,35370,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3395,602410,1,1,,49718184,35370,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
3396,602429,1,1,,49718184,35370,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
3397,602438,1,1,,49718184,35370,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
3398,602440,1,1,,49718184,35370,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
3399,602449,1,2,,49718184,35370,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
3400,602481,1,1,,49718184,35370,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3401,604020,1,4,,103188975,35370,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3402,604021,3,1,,103188975,35370,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3403,604022,1,4,,103188975,35370,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3404,604023,1,3,,103188975,35370,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3405,604024,1,3,,103188975,35370,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
3406,604025,1,4,,103188975,35370,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
3407,604026,1,4,,103188975,35370,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
3408,606415,3,2,,103188975,35370,Active,,,0.05,IC50,Antiviral activity against HIV1 harboring vesicular stomatitis virus glycoprotein infected in human 293T cells assessed as inhibition of viral replication after 48 hrs by luciferase activity based luminometer analysis,Confirmatory,21534583.0,
3409,607806,1,4,,103188975,35370,Active,,,0.01059,EC50,Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,21689939.0,
3410,607807,3,2,,103188975,35370,Active,,,0.00812,EC50,Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,21689939.0,
3411,607808,3,4,,103188975,35370,Active,,,0.1293,EC50,Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,21689939.0,
3412,607809,3,2,,103188975,35370,Unspecified,,,5601.71,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,21689939.0,
3413,607810,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 IIIB infected in C8166 cells",Other,21689939.0,
3414,607873,3,2,,103188975,35370,Active,,,0.015,EC50,Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay,Confirmatory,21683601.0,
3415,607875,3,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay,Confirmatory,21683601.0,
3416,607876,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type Human immunodeficieny virus 1 3B infected in human MT4 cells",Other,21683601.0,
3417,610675,3,2,,103188975,35370,Active,,,4e-06,EC50,Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect,Confirmatory,21534540.0,
3418,610676,3,2,,103188975,35370,Active,,,4.07,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,21534540.0,
3419,610677,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for C8166 cells to EC50 for Human immunodeficiency virus 1",Other,21534540.0,
3420,611571,3,2,,103188975,35370,Unspecified,,,4071.9,CC50,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Confirmatory,21561060.0,
3421,611572,5,1,,103188975,35370,Active,,,0.0045,EC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay,Confirmatory,21561060.0,
3422,611573,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for Human immunodeficiency virus 1 3B infected in human C8166 cells",Other,21561060.0,
3423,611608,1,4,,103188975,35370,Active,,,0.012819999999999998,EC50,Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope,Confirmatory,21719299.0,
3424,611609,3,2,,103188975,35370,Active,,,0.023,EC50,Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope,Confirmatory,21719299.0,
3425,611661,3,2,,103188975,35370,Unspecified,,,5401.4,CC50,Cytotoxicity against human C8166 cells by MTT colorimetric assay,Confirmatory,21719299.0,
3426,611662,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B infected in human C8166 cells",Other,21719299.0,
3427,611663,3,4,,103188975,35370,Active,,,39.0,EC50,Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope,Confirmatory,21719299.0,
3428,611664,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV2 ROD infected in human C8166 cells",Other,21719299.0,
3429,611910,3,2,,103188975,35370,Active,,,4.07,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,21650224.0,
3430,611911,1,4,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for against human C8166 cells to EC50 for HIV-1",Other,21650224.0,
3431,611912,3,2,,103188975,35370,Active,,,4e-06,EC50,Antiviral activity against Human immunodeficiency virus 1 assessed as inhibition of virus-induced cytopathic effects by cell based assay,Confirmatory,21650224.0,
3432,612003,1,3,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against R5 tropic HIV1 Ba-L infected PBMC assessed as inhibition of viral p24 antigen expression,Confirmatory,21658961.0,
3433,612004,1,3,,103188975,35370,Active,,,0.25,IC50,Antiviral activity against R5 tropic multidrug-resistant HIV1 MM infected PBMC assessed as inhibition of viral p24 antigen expression,Confirmatory,21658961.0,
3434,612668,3,2,,103188975,35370,Active,,,0.0128,EC50,Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay,Confirmatory,21788138.0,
3435,612669,3,2,,103188975,35370,Active,,,0.023,EC50,Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay,Confirmatory,21788138.0,
3436,612670,3,2,,103188975,35370,Unspecified,,,5401.4,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,21788138.0,
3437,612671,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 3B",Other,21788138.0,
3438,614139,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 IIIB infected in human MT4 cells",Other,21824782.0,
3439,614140,3,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells after 4 days by MTT assay,Confirmatory,21824782.0,
3440,614141,3,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,21824782.0,
3441,614142,3,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,21824782.0,
3442,614143,3,4,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,21824782.0,
3443,616199,1,4,,103188975,35370,Active,,,0.047,EC50,Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay,Confirmatory,21745701.0,
3444,617754,2,1,,103188975,35370,Active,,,0.001,ED50,Antiviral activity against HIV,Confirmatory,21840722.0,
3445,617764,3,2,,103188975,35370,Active,,,0.037000000000000005,IC50,Antiviral activity against HIV1 HxB2 infected in human TZM-bl cells assessed as inhibition of virus neutralization after 48 hrs by luciferase assay,Confirmatory,21840722.0,
3446,617765,3,2,,103188975,35370,Active,,,0.078,IC50,Antiviral activity against HIV1 SF162 infected in human TZM-bl cells assessed as inhibition of virus neutralization after 48 hrs by luciferase assay,Confirmatory,21840722.0,
3447,618793,3,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity against HIV1 LAV1 infected in phytohemagglutininin-stimulated human PBMC assessed as RT level after 6 days by microdilution plate assay,Confirmatory,21700368.0,
3448,618794,3,2,,103188975,35370,Unspecified,,,100.0,EC50,Antiviral activity against Hepatitis B virus infected in human HepAD38 assessed as reduction of viral DNA level on day 7 by quantitative-PCR assay analysis,Confirmatory,21700368.0,
3449,618858,3,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against phytohemagglutininin-stimulated human PBMC after 6 days by trypan blue exclusion assay,Confirmatory,21700368.0,
3450,618859,3,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay,Confirmatory,21700368.0,
3451,618860,3,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometry,Confirmatory,21700368.0,
3452,618866,1,4,,103188975,35370,Unspecified,,,,,Cytotoxicity against human HepAD38 cells,Other,21700368.0,
3453,619511,3,3,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against human CEM-T4 cells assessed as cell viability after 7 days by MTT assay,Confirmatory,21834513.0,
3454,619513,3,2,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV1 infected in human CEM-T4 cells assessed as reduction in viral protein p24 production preincubated for 24 hrs measured after 8 days by MTT assay,Confirmatory,21834513.0,
3455,619514,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human CEM-T4 cells to EC50 for HIV1 infected human CEM-T4 cells",Other,21834513.0,
3456,619629,3,2,,103188975,35370,Active,,,0.0076,EC50,Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3457,619630,3,4,,103188975,35370,Active,,,0.0033,EC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3458,619631,3,2,,103188975,35370,Unspecified,,,88.26,CC50,Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay,Confirmatory,21872971.0,
3459,619632,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells",Other,21872971.0,
3460,619633,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-2 ROD infected in human MT4 cells",Other,21872971.0,
3461,619634,3,2,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3462,619635,3,2,,103188975,35370,Active,,,0.011000000000000001,EC50,Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3463,619636,3,2,,103188975,35370,Active,,,0.0049,EC50,Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3464,619637,1,4,,103188975,35370,Inactive,,,,,Antiviral activity against HIV-1 3B harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Other,21872971.0,
3465,619638,1,4,,103188975,35370,Inactive,,,,,Antiviral activity against HIV-1 3B harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Other,21872971.0,
3466,619639,1,4,,103188975,35370,Inactive,,,,,Antiviral activity against HIV-1 3B harboring RT F227L and V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Other,21872971.0,
3467,619640,3,2,,103188975,35370,Inactive,,,,EC50,Antiviral activity against HIV-1 3B harboring RT K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,21872971.0,
3468,619641,1,4,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV-1 3B harboring RT K103N mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells,Other,21872971.0,
3469,619642,1,4,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV-1 3B harboring RT E138K mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells,Other,21872971.0,
3470,619643,1,4,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV-1 3B harboring RT L100I mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells,Other,21872971.0,
3471,623870,1,1,,49718184,35370,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3472,623870,1,1,,49718184,35370,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3473,623877,1,1,,49718184,35370,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
3474,623901,1,1,,49718184,35370,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
3475,624030,1,2,,26751584,35370,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
3476,624031,1,2,,26751584,35370,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
3477,624032,1,2,,26751584,35370,Inconclusive,8393992.0,24660.0,25.5748,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
3478,624037,1,3,,49718184,35370,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3479,624038,1,3,,49718184,35370,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3480,624040,1,3,,49718184,35370,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
3481,624044,1,2,,26751584,35370,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
3482,624125,1,4,,49718184,35370,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3483,624126,1,3,,49718184,35370,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3484,624127,1,2,,49718184,35370,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
3485,624146,1,1,,90341185,35370,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
3486,624147,1,1,,90341185,35370,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
3487,624148,1,2,,90341185,35370,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
3488,624149,1,1,,90341185,35370,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
3489,624156,1,1,,85788843,35370,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
3490,624168,1,1,,49718184,35370,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
3491,624169,1,1,,49718184,35370,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
3492,624170,1,1,,26751584,35370,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
3493,624170,1,1,,49718184,35370,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
3494,624171,1,1,,49718184,35370,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
3495,624172,1,1,,26751584,35370,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
3496,624172,1,1,,49718184,35370,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
3497,624173,1,3,,26751584,35370,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
3498,624173,1,3,,49718184,35370,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
3499,624178,1,1,,49718184,35370,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
3500,624202,1,1,,49718184,35370,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
3501,624204,1,2,,49718184,35370,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
3502,624246,1,1,,49718184,35370,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
3503,624256,1,2,,49718184,35370,Active,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
3504,624263,1,1,,49718184,35370,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
3505,624263,1,1,,49718184,35370,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
3506,624267,1,2,,49718184,35370,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
3507,624267,1,2,,49718184,35370,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
3508,624268,1,3,,49718184,35370,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
3509,624288,1,1,,49718184,35370,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
3510,624296,1,1,,855980,35370,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
3511,624296,1,1,,26751584,35370,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
3512,624296,1,1,,49718184,35370,Inactive,7705682.0,51053.0,7.3078,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
3513,624297,1,1,,855980,35370,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
3514,624297,1,1,,26751584,35370,Inconclusive,7705682.0,51053.0,29.8554,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
3515,624297,1,1,,49718184,35370,Inconclusive,7705682.0,51053.0,3.6626,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
3516,624304,1,2,,49718184,35370,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
3517,624330,1,2,,49718184,35370,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
3518,624349,1,2,,92124444,35370,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3519,624349,1,2,,92307576,35370,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3520,624349,1,2,,92309127,35370,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3521,624349,1,2,,121362495,35370,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3522,624349,1,2,,121363002,35370,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
3523,624352,1,1,,49718184,35370,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
3524,624354,1,1,,49718184,35370,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
3525,624377,1,1,,49718184,35370,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
3526,624414,1,1,,49718184,35370,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
3527,624415,1,2,,49718184,35370,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
3528,624416,1,1,,49718184,35370,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
3529,624417,1,1,,49718184,35370,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
3530,624418,1,1,,49718184,35370,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
3531,624455,1,1,,90341185,35370,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
3532,624463,1,1,,49718184,35370,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
3533,624464,1,1,,49718184,35370,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
3534,624465,1,1,,49718184,35370,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
3535,624466,1,3,,49718184,35370,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
3536,624467,1,1,,49718184,35370,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
3537,624483,1,1,,49718184,35370,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
3538,624606,1,9,,103188975,35370,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
3539,624609,1,9,,103188975,35370,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
3540,624612,1,9,,103188975,35370,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
3541,624640,3,7,,103188975,35370,Unspecified,136727.0,7364.0,770.0,Km,Drug glucuronidation reaction catalyzed by human recombinant UGT2B7,Confirmatory,15781124.0,
3542,625144,5,5,,103188975,35370,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
3543,625145,4,7,,103188975,35370,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
3544,625146,5,5,,103188975,35370,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
3545,625147,4,7,,103188975,35370,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3546,625148,4,7,,103188975,35370,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3547,625149,4,7,,103188975,35370,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
3548,625150,5,5,,103188975,35370,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
3549,625151,4,7,,103188975,35370,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3550,625152,4,7,,103188975,35370,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3551,625153,4,7,,103188975,35370,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3552,625154,4,7,,103188975,35370,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3553,625155,4,7,,103188975,35370,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3554,625156,1,9,,103188975,35370,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
3555,625157,6,2,,103188975,35370,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
3556,625158,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
3557,625159,5,5,,103188975,35370,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
3558,625160,1,9,,103188975,35370,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
3559,625161,4,7,,103188975,35370,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
3560,625162,4,7,,103188975,35370,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3561,625163,4,7,,103188975,35370,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3562,625164,1,6,,103188975,35370,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
3563,625165,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3564,625166,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3565,625167,5,5,,103188975,35370,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
3566,625168,4,7,,103188975,35370,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
3567,625169,1,6,,103188975,35370,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
3568,625170,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
3569,625171,4,7,,103188975,35370,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
3570,625172,4,7,,103188975,35370,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
3571,625173,5,5,,103188975,35370,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
3572,625174,5,5,,103188975,35370,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
3573,625175,5,5,,103188975,35370,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
3574,625176,1,9,,103188975,35370,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
3575,625177,5,5,,103188975,35370,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3576,625178,5,5,,103188975,35370,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3577,625179,1,9,,103188975,35370,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
3578,625180,5,5,,103188975,35370,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3579,625181,5,5,,103188975,35370,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3580,625182,5,5,,103188975,35370,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3581,625183,5,5,,103188975,35370,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
3582,625184,5,5,,103188975,35370,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3583,625185,5,5,,103188975,35370,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3584,625186,5,5,,103188975,35370,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3585,625187,5,5,,103188975,35370,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3586,625188,1,9,,103188975,35370,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
3587,625189,1,7,,103188975,35370,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
3588,625190,4,5,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
3589,625191,4,7,,103188975,35370,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3590,625192,4,7,,103188975,35370,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
3591,625193,5,5,,103188975,35370,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
3592,625194,4,7,,103188975,35370,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
3593,625195,4,7,,103188975,35370,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
3594,625196,5,6,,103188975,35370,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
3595,625197,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
3596,625198,4,7,,103188975,35370,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3597,625199,4,7,,103188975,35370,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3598,625200,4,7,,103188975,35370,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3599,625201,4,7,,103188975,35370,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
3600,625202,4,7,,103188975,35370,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
3601,625203,4,7,,103188975,35370,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
3602,625204,4,7,,103188975,35370,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3603,625205,4,7,,103188975,35370,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
3604,625206,4,7,,103188975,35370,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3605,625207,4,7,,103188975,35370,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3606,625208,5,5,,103188975,35370,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
3607,625209,4,7,,103188975,35370,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
3608,625210,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
3609,625211,1,6,,103188975,35370,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
3610,625212,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
3611,625213,4,7,,103188975,35370,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
3612,625214,1,9,,103188975,35370,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
3613,625215,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
3614,625216,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
3615,625217,4,7,,103188975,35370,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3616,625218,4,7,,103188975,35370,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
3617,625219,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
3618,625220,4,7,,103188975,35370,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
3619,625221,4,7,,103188975,35370,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3620,625222,4,7,,103188975,35370,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
3621,625223,4,7,,103188975,35370,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
3622,625224,3,4,,103188975,35370,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
3623,625225,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
3624,625226,4,7,,103188975,35370,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
3625,625227,4,7,,103188975,35370,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
3626,625228,4,7,,103188975,35370,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
3627,625229,5,5,,103188975,35370,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
3628,625230,1,6,,103188975,35370,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
3629,625231,4,7,,103188975,35370,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
3630,625232,1,9,,103188975,35370,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
3631,625233,4,7,,103188975,35370,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
3632,625234,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
3633,625235,4,7,,103188975,35370,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
3634,625236,5,5,,103188975,35370,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
3635,625237,4,7,,103188975,35370,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
3636,625238,4,7,,103188975,35370,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
3637,625239,4,7,,103188975,35370,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
3638,625240,1,9,,103188975,35370,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
3639,625241,4,7,,103188975,35370,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
3640,625242,4,7,,103188975,35370,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
3641,625243,5,5,,103188975,35370,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3642,625244,5,5,,103188975,35370,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3643,625245,5,5,,103188975,35370,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3644,625246,1,9,,103188975,35370,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
3645,625247,5,5,,103188975,35370,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3646,625248,5,5,,103188975,35370,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3647,625249,5,5,,103188975,35370,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3648,625250,5,5,,103188975,35370,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3649,625251,5,5,,103188975,35370,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
3650,625252,4,7,,103188975,35370,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
3651,625253,4,7,,103188975,35370,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3652,625254,4,7,,103188975,35370,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3653,625255,4,7,,103188975,35370,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3654,625256,4,7,,103188975,35370,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3655,625257,4,7,,103188975,35370,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
3656,625258,4,7,,103188975,35370,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3657,625259,4,7,,103188975,35370,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3658,625260,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
3659,625261,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
3660,625262,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
3661,625263,4,7,,103188975,35370,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
3662,625264,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
3663,625265,1,6,,103188975,35370,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
3664,625266,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
3665,625267,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
3666,625268,4,2,,103188975,35370,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3667,625268,4,2,,103188975,35370,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3668,625268,4,2,,103188975,35370,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3669,625268,4,2,,103188975,35370,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3670,625269,4,7,,103188975,35370,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
3671,625270,4,7,,103188975,35370,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
3672,625271,5,5,,103188975,35370,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
3673,625272,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
3674,625273,4,6,,103188975,35370,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
3675,625274,1,6,,103188975,35370,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
3676,625275,3,4,,103188975,35370,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
3677,625276,1,3,,103188975,35370,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI,Other,21624500.0,
3678,625279,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
3679,625280,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
3680,625281,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
3681,625282,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
3682,625283,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
3683,625284,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
3684,625285,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
3685,625286,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
3686,625287,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
3687,625288,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
3688,625289,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
3689,625290,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
3690,625291,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
3691,625292,1,3,,103188975,35370,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
3692,626424,3,2,,103188975,35370,Active,,,0.084,EC50,Antiviral activity against Human immunodeficiency virus 1 assessed as inhibition of viral replication by MTT assay,Confirmatory,21974951.0,
3693,630371,3,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay,Other,21945463.0,
3694,630372,3,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay,Other,21945463.0,
3695,630377,1,4,,103188975,35370,Unspecified,,,,,Apparent permeability from apical to basolateral side of the human Caco2 cells at 100 uM after 30 mins by HPLC method,Other,21945463.0,
3696,630379,1,4,,103188975,35370,Unspecified,,,,,Oral bioavailability in human,Other,21945463.0,
3697,635301,3,2,,103188975,35370,Active,,,0.0075,EC50,Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,22037050.0,
3698,635302,3,2,,103188975,35370,Active,,,0.013000000000000001,EC50,Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,22037050.0,
3699,635345,3,4,,103188975,35370,Active,,,0.0075,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,22037050.0,
3700,635346,3,2,,103188975,35370,Unspecified,,,46.44,CC50,Cytotoxicity against human MT4 cells measured by MTT assay,Confirmatory,22037050.0,
3701,635347,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,22037050.0,
3702,635864,5,5,,103188975,35370,Active,614088749.0,888740.0,28.0,Ki,Competitive inhibition of Mycobacterium tuberculosis TMPK by Lineweaver-Burk analysis,Confirmatory,22061826.0,
3703,644273,3,2,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against X4 tropic HIV1 NL4-3 in MT4 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,22277590.0,
3704,644280,3,2,,103188975,35370,Active,,,0.45899999999999996,EC50,Antiviral activity against R5 tropic HIV1 NL(AD8) in PM1/CCR5 cells assessed as protection from virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,22277590.0,
3705,644281,3,2,,103188975,35370,Active,,,0.17,EC50,Antiviral activity against R5 tropic HIV1 JR-CSF in PM1/CCR5 cells assessed as protection from virus-induced cytopathogenicity measuring capsid p24 level after 5 days by ELISA,Confirmatory,22277590.0,
3706,644283,3,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,22277590.0,
3707,645267,1,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 harboring VSV glycoprotein-G co-transfected with luciferase gene infected in human TZM-bl cells assessed as inhibition of viral replication at 10 uM after 48 hrs by microplate luminometer based luciferase assay,Other,22369862.0,
3708,645268,5,1,,103188975,35370,Active,,,0.03,IC50,Antiviral activity against HIV1 harboring VSV glycoprotein-G co-transfected with luciferase gene infected in human TZM-bl cells assessed as inhibition of viral replication after 48 hrs by microplate luminometer based luciferase assay,Confirmatory,22369862.0,
3709,646699,3,4,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs,Confirmatory,22014549.0,
3710,646700,3,2,,103188975,35370,Unspecified,,,10.0,EC50,Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR,Confirmatory,22014549.0,
3711,646707,3,2,,103188975,35370,Unspecified,,,56.0,IC50,Cytotoxicity against african green monkey Vero cells after 3 days by hemocytometer analysis,Confirmatory,22014549.0,
3712,646708,3,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method,Confirmatory,22014549.0,
3713,646709,3,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method,Confirmatory,22014549.0,
3714,646711,3,2,,103188975,35370,Active,,,0.0033,EC50,Antiviral activity against HIV1 LAV1 infected in PHA-stimulated human PBMC assessed as reduction in RT activity after 6 days by micromethod-based beta scintillation counting,Confirmatory,22014549.0,
3715,647165,3,2,,103188975,35370,Active,,,0.0028,IC50,Antiviral activity against HIV1 3B infected human TZM-bl cells assessed as inhibition of viral replication by luciferase reporter assay,Confirmatory,22226654.0,
3716,647166,3,2,,103188975,35370,Inconclusive,,,,CC50,Cytotoxicity in human TZM-bl cells by MTT assay,Confirmatory,22226654.0,
3717,647168,3,2,,103188975,35370,Inconclusive,113576.0,213.0,,,Binding affinity to human serum albumin by fluorescence quenching assay,Other,22226654.0,
3718,647174,1,3,,103188975,35370,Active,,,,,Antiviral activity against HIV1 3B infected human TZM-bl cells assessed as inhibition of viral replication at 10 uM treated 8 hrs after viral infection by luciferase reporter assay,Other,22226654.0,
3719,648420,2,3,,103188975,35370,Active,,,0.0206,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay,Confirmatory,22405288.0,
3720,648421,3,2,,103188975,35370,Unspecified,,,249.5,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,22405288.0,
3721,648422,1,4,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,22405288.0,
3722,648424,3,2,,103188975,35370,Active,,,0.0086,EC50,Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay,Confirmatory,22405288.0,
3723,651550,1,1,,49718184,35370,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
3724,651560,1,1,,49718184,35370,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
3725,651572,1,2,,49718184,35370,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
3726,651582,1,1,,49718184,35370,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
3727,651602,1,1,,49718184,35370,Active,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3728,651602,1,1,,49718184,35370,Active,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3729,651602,1,1,,49718184,35370,Active,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3730,651631,4,1,,144203613,35370,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3731,651631,4,1,,144204445,35370,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3732,651631,4,1,,144209401,35370,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3733,651631,4,1,,144210895,35370,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3734,651632,4,1,,144203613,35370,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3735,651632,4,1,,144204445,35370,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3736,651632,4,1,,144209401,35370,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3737,651632,4,1,,144210895,35370,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3738,651633,4,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3739,651633,4,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3740,651633,4,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3741,651633,4,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3742,651634,4,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3743,651634,4,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3744,651634,4,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3745,651634,4,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3746,651635,1,3,,49718184,35370,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3747,651635,1,3,,90341185,35370,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3748,651636,1,1,,49718184,35370,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
3749,651640,1,1,,49718184,35370,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
3750,651644,1,1,,49718184,35370,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
3751,651647,1,1,,49718184,35370,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
3752,651654,1,1,,49718184,35370,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3753,651658,1,1,,49718184,35370,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3754,651660,1,1,,49718184,35370,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3755,651661,2,1,,49718184,35370,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3756,651687,1,1,,49718184,35370,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3757,651699,1,1,,49718184,35370,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3758,651699,1,1,,49718184,35370,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3759,651702,1,2,,49718184,35370,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
3760,651704,2,1,,49718184,35370,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3761,651710,1,1,,49718184,35370,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3762,651711,2,1,,49718184,35370,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3763,651718,1,2,,49718184,35370,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
3764,651723,1,1,,49718184,35370,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
3765,651724,1,1,,49718184,35370,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
3766,651725,1,1,,49718184,35370,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
3767,651741,1,1,,17390027,35370,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3768,651741,1,1,,144204445,35370,Inconclusive,20149576.0,4780.0,61.1306,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3769,651743,1,1,,17390027,35370,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3770,651743,1,1,,144204445,35370,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3771,651749,1,1,,17390027,35370,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3772,651749,1,1,,144204445,35370,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3773,651751,1,1,,17390027,35370,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3774,651751,1,1,,144204445,35370,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3775,651754,1,1,,17390027,35370,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
3776,651755,1,1,,17390027,35370,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
3777,651757,1,1,,17390027,35370,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
3778,651758,1,1,,17390027,35370,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
3779,651768,1,2,,49718184,35370,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3780,651777,1,1,,17390027,35370,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3781,651777,1,1,,144204445,35370,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3782,651778,1,1,,17390027,35370,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3783,651778,1,1,,144204445,35370,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3784,651784,1,1,,17390027,35370,Inconclusive,4826730.0,2475.0,28.9633,Potency,"Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Hit Validation",Confirmatory,,
3785,651789,1,1,,17390027,35370,Inactive,4826730.0,2475.0,,Potency,Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in WT MEF Cells: Hit Validation,Confirmatory,,
3786,651800,1,1,,49718184,35370,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3787,651802,1,1,,17390027,35370,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3788,651819,1,1,,49718184,35370,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3789,651820,1,1,,855980,35370,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3790,651820,1,1,,49718184,35370,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3791,651821,2,4,,49718184,35370,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3792,651828,1,2,,92309127,35370,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3793,651828,1,2,,121362495,35370,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3794,651838,1,1,,17390027,35370,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3795,651838,1,1,,144204445,35370,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3796,651838,1,1,1.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3797,651838,1,1,1.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3798,651838,1,1,2.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3799,651838,1,1,2.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3800,651838,1,1,3.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3801,651838,1,1,3.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3802,651838,1,1,4.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3803,651838,1,1,4.0,144204445,35370,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3804,651838,1,1,5.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3805,651838,1,1,5.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3806,651838,1,1,6.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3807,651838,1,1,6.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3808,651838,1,1,7.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3809,651838,1,1,7.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3810,651838,1,1,8.0,17390027,35370,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3811,651838,1,1,8.0,144204445,35370,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3812,651957,1,1,,49718184,35370,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3813,651958,1,1,,49718184,35370,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3814,651965,1,1,,49718184,35370,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3815,651982,1,1,,49718184,35370,Active,16130723.0,947287.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3816,651982,1,1,,49718184,35370,Active,16130724.0,947286.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3817,651982,1,1,,49718184,35370,Active,16130726.0,947294.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3818,651983,1,1,,49718184,35370,Active,,,,,Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,Screening,,
3819,651984,1,1,,49718184,35370,Active,15645703.0,899625.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
3820,651984,1,1,,49718184,35370,Active,15646160.0,899738.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
3821,651999,1,1,,49718184,35370,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3822,652010,1,1,,49718184,35370,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3823,652017,1,1,,49718184,35370,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3824,652025,1,1,,49718184,35370,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3825,652039,1,1,,49718184,35370,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3826,652048,1,2,,49718184,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3827,652048,1,2,,144203613,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3828,652048,1,2,,144204445,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3829,652051,1,1,,49718184,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3830,652051,1,1,,144203613,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3831,652051,1,1,,144204445,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3832,652054,1,1,,49718184,35370,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3833,652067,1,4,,49718184,35370,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3834,652104,1,1,,49718184,35370,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3835,652105,1,1,,49718184,35370,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3836,652106,1,1,,49718184,35370,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3837,652106,1,1,,90341185,35370,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3838,652115,1,1,,49718184,35370,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3839,652126,1,3,,49718184,35370,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3840,652154,1,1,,49718184,35370,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3841,652162,2,1,,49718184,35370,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3842,652163,1,1,,49718184,35370,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3843,652197,1,1,,49718184,35370,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3844,652257,1,1,,49718184,35370,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3845,658564,1,2,,103188975,35370,Active,,,0.2,EC50,Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay,Confirmatory,22148316.0,
3846,658565,1,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay,Confirmatory,22148316.0,
3847,658566,1,2,,103188975,35370,Unspecified,,,,,"Resistance factor, ratio of EC50 for multidrug-resistant HIV1 695-RT infected in HEK293T cells to wildtype HIV1 infected in HEK293T cells",Other,22148316.0,
3848,658567,1,2,,103188975,35370,Unspecified,,,,,"Resistance factor, ratio of EC50 for multidrug-resistant HIV1 106-PR infected in HEK293T cells to wildtype HIV1 infected in HEK293T cells",Other,22148316.0,
3849,662533,1,6,,103188975,35370,Inconclusive,46577576.0,7852.0,,,Displacement of [125I]-CXCL12 from CXCR4 expressed in human Jurkat cells at 10 uM relative to T140,Other,22579418.0,
3850,662534,2,2,,103188975,35370,Active,,,0.057999999999999996,EC50,Antiviral activity against X4-tropic HIV1 NL4.3 infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity,Confirmatory,22579418.0,
3851,662535,2,2,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells assessed as reduction of cell viability,Confirmatory,22579418.0,
3852,664466,2,2,,103188975,35370,Active,,,10.8,EC50,Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay,Confirmatory,22352809.0,
3853,664467,2,2,,103188975,35370,Active,,,14.2,EC50,Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay,Confirmatory,22352809.0,
3854,664468,2,2,,103188975,35370,Unspecified,,,374.0,EC50,Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay,Confirmatory,22352809.0,
3855,664469,1,3,,103188975,35370,Active,,,0.0024,IC50,Antiviral activity against wild type HIV1 clade B 94US3393IN clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay,Confirmatory,22352809.0,
3856,664470,1,3,,103188975,35370,Active,,,0.00195,IC50,Antiviral activity against wild type HIV1 clade C 98USMSC5016 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay,Confirmatory,22352809.0,
3857,664471,1,3,,103188975,35370,Active,,,0.0217,IC50,Antiviral activity against NNRTI-resistant HIV1 clade B A-17 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay,Confirmatory,22352809.0,
3858,664472,1,3,,103188975,35370,Active,,,2.425,IC50,Antiviral activity against multidrug-resistant HIV1 clade B 4775-5 clinical isolate infected in PHA-P-stimulated human PBMC assessed as reverse transcriptase activity incubated for 6 hrs followed by incubated in drug-free medium for 6 days by multiround infection assay,Confirmatory,22352809.0,
3859,665271,2,2,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22575532.0,
3860,665272,2,2,,103188975,35370,Active,,,0.013000000000000001,EC50,Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22575532.0,
3861,665273,2,4,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22575532.0,
3862,665274,2,2,,103188975,35370,Unspecified,,,46.0,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,22575532.0,
3863,665275,1,3,,103188975,35370,Unspecified,,,,,Selectivity index ratio of CC50 for human MT4 cells to EC50 for HIV1 3B,Other,22575532.0,
3864,665547,1,3,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22591854.0,
3865,665548,2,4,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22591854.0,
3866,665549,2,2,,103188975,35370,Unspecified,,,49.77,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,22591854.0,
3867,665550,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B",Other,22591854.0,
3868,665551,2,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,22591854.0,
3869,665552,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant",Other,22591854.0,
3870,665553,1,2,,103188975,35370,Unspecified,,,,,"Fold resistance, ratio of EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant to EC50 for wild type HIV1 3B",Other,22591854.0,
3871,665832,1,3,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV infected in human TZM-bl cells at 10 uM after 48 hrs by luciferase-based reporter gene assay,Other,22546200.0,
3872,666132,2,2,,103188975,35370,Active,,,7.7,IC50,Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay,Confirmatory,22549138.0,
3873,666134,2,3,,103188975,35370,Active,,,12.1,CC50,Cytotoxicity against human MOLT3 cells by MTS assay,Confirmatory,22549138.0,
3874,666135,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MOLT3 cells to IC50 for HIV1",Other,22549138.0,
3875,666971,2,2,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days,Confirmatory,22652226.0,
3876,666972,2,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Other,22652226.0,
3877,666973,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3",Other,22652226.0,
3878,668361,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV infected in human TZM-bl cells at 10 uM after 48 hrs by measuring luciferase activity by luminometer analysis,Other,22608761.0,
3879,671653,2,2,,103188975,35370,Active,,,0.16,EC50,Antiviral activity against R5-tropic Human immunodeficiency virus 1 Ba-L subtype B infected in human PBMC assessed as inhibition of viral replication after 7 days by ELISA,Confirmatory,22763201.0,
3880,671654,2,2,,103188975,35370,Unspecified,,,128.0,CC50,Cytotoxicity against human PBMC after 7 days by XTT assay,Confirmatory,22763201.0,
3881,671655,1,3,,103188975,35370,Unspecified,,,,,Selectivity ratio of CC50 for human PBMC to EC50 for R5-tropic Human immunodeficiency virus 1 Ba-L subtype B,Other,22763201.0,
3882,675187,1,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV-1 subtype B US/92/727 infected in PBMC assessed as inhibition of viral replication after 7 days by XTT assay,Confirmatory,22858097.0,
3883,675188,1,3,,103188975,35370,Active,,,0.002,EC50,Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay,Confirmatory,22858097.0,
3884,675189,2,1,,103188975,35370,Unspecified,,,0.5,TC50,Cytotoxicity against human CEM-SS cells by XTT method,Confirmatory,22858097.0,
3885,675190,1,3,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human CEM-SS cells to EC50 for HIV-1 subtype 3B infected in CEM-SS cells",Other,22858097.0,
3886,675191,2,1,,103188975,35370,Unspecified,,,1.0,TC50,Cytotoxicity against human PBMC,Confirmatory,22858097.0,
3887,675192,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of TC50 for human PBMC to EC50 for HIV-1 subtype B US/92/727 infected in PBMC",Other,22858097.0,
3888,676992,2,3,,103188975,35370,Inactive,,,,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage cells assessed as reduction parasitemia by Malstat assay,Confirmatory,22858300.0,
3889,676994,2,2,,103188975,35370,Active,,,0.04,IC50,Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry,Confirmatory,22858300.0,
3890,676995,1,3,,103188975,35370,Inconclusive,,,,,"Selectivity index, ratio of CC50 for human HeLa cells to IC50 for Plasmodium falciparum 3D7 ring stage cells",Other,22858300.0,
3891,676996,2,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,22858300.0,
3892,676998,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human HeLa cells to IC50 for VSV-G pseudotyped HIV1 lentiviral particles",Other,22858300.0,
3893,676999,1,3,,103188975,35370,Active,,,0.0008,IC50,Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microscopy,Confirmatory,22858300.0,
3894,678712,1,8,,103188975,35370,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
3895,678713,1,8,,103188975,35370,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
3896,678714,1,8,,103188975,35370,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3897,678715,1,8,,103188975,35370,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3898,678716,1,8,,103188975,35370,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
3899,678717,1,8,,103188975,35370,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
3900,678721,1,5,,103188975,35370,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
3901,678722,1,5,,103188975,35370,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
3902,678793,2,7,,103188975,35370,Unspecified,313104182.0,6582.0,,Km,TP_TRANSPORTER: uptake in OCT2A-expressing HEK293 cells,Confirmatory,12089365.0,
3903,678818,2,7,,103188975,35370,Unspecified,81871841.0,89776.0,26.0,Km,TP_TRANSPORTER: uptake in Oat2-expressing LLC PK1 cells,Confirmatory,,
3904,678994,2,7,,103188975,35370,Unspecified,81872095.0,24904.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,10825466.0,
3905,679158,2,7,,103188975,35370,Unspecified,313104182.0,6582.0,,Km,TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells,Confirmatory,12089365.0,
3906,679291,1,7,,103188975,35370,Unspecified,81872789.0,29503.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,10825466.0,
3907,679320,2,7,,103188975,35370,Unspecified,74762955.0,9356.0,45.9,Km,TP_TRANSPORTER: uptake in OAT1-expressing S2 cells,Confirmatory,11861798.0,
3908,679515,1,8,,103188975,35370,Unspecified,74762955.0,9356.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 5 uM, AZT: 1000 uM) in OAT1-expressing S2 cells",Other,11861798.0,
3909,679629,1,8,,103188975,35370,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: Anti-HIV-1 activity in MT-4 and MT-4/DOX500,Other,12488537.0,
3910,679673,2,7,,103188975,35370,Unspecified,74730587.0,9376.0,145.1,Km,TP_TRANSPORTER: uptake in OAT3-expressing S2 cells,Confirmatory,11861798.0,
3911,680202,1,7,,103188975,35370,Unspecified,74734337.0,55867.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, AZT: 1000 uM) in OAT4-expressing S2 cells",Other,11861798.0,
3912,680771,2,7,,103188975,35370,Unspecified,74753520.0,10864.0,26.8,Km,TP_TRANSPORTER: uptake in OAT2-expressing S2 cells,Confirmatory,11861798.0,
3913,680951,1,8,,103188975,35370,Unspecified,74753520.0,10864.0,,,"TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2alpha: 0.005 uM, AZT: 1000 uM) in OAT2-expressing S2 cells",Other,11861798.0,
3914,681231,1,7,,103188975,35370,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, AZT: 5 uM) in Xenopus laevis oocytes",Other,11306713.0,
3915,681232,1,7,,103188975,35370,Unspecified,74730587.0,9376.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, AZT: 1000 uM) in OAT3-expressing S2 cells",Other,11861798.0,
3916,681294,1,8,,103188975,35370,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of Calcein efflux (Calcein: 0.05 micro;M, Zidovudine: 0.02 uM) in UMCC-1/VP cells",Other,12218384.0,
3917,681387,2,7,,103188975,35370,Unspecified,81886651.0,29509.0,68.0,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,10945832.0,
3918,681563,1,8,,103188975,35370,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells,Other,12488537.0,
3919,681577,2,7,,103188975,35370,Unspecified,27735248.0,80899.0,76.3,Km,TP_TRANSPORTER: uptake in OAT-K2-expressing MDCK cells,Confirmatory,11561088.0,
3920,681578,2,7,,103188975,35370,Unspecified,27735248.0,80899.0,64.3,Km,TP_TRANSPORTER: uptake in OAT-K1-expressing MDCK cells,Confirmatory,11561088.0,
3921,681676,2,7,,103188975,35370,Unspecified,74734337.0,55867.0,151.8,Km,TP_TRANSPORTER: uptake in OAT4-expressing S2 cells,Confirmatory,11861798.0,
3922,681687,1,7,,103188975,35370,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, AZT: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
3923,682145,1,7,,103188975,35370,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, AZT: 1000 uM) in Xenopus laevis oocytes",Other,10224140.0,
3924,682180,1,8,,103188975,35370,Unspecified,124015184.0,19879.0,,,TP_TRANSPORTER: inhibition of benzylpenicillin uptake by 3'-Azido-3'-deoxythymidine at a concentration of 1000uM in Oat3-expressing oocyte cells,Other,14762099.0,
3925,685330,2,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay,Confirmatory,22883027.0,
3926,685331,2,2,,103188975,35370,Active,,,6.0,EC50,Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay,Confirmatory,22883027.0,
3927,685332,2,4,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay,Confirmatory,22883027.0,
3928,685333,2,2,,103188975,35370,Unspecified,,,50.0,CC50,Cytotoxicity against mock-infected human MT4 cells by MTT assay,Confirmatory,22883027.0,
3929,685335,1,3,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B",Other,22883027.0,
3930,686940,1,1,,49718184,35370,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3931,686947,2,2,,162108254,35370,Inconclusive,4885661.0,7525.0,43.431999999999995,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
3932,686950,1,1,,162108254,35370,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
3933,686964,1,1,,49718184,35370,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3934,686970,1,2,,49718184,35370,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3935,686971,1,2,,49718184,35370,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3936,686978,1,1,,49718184,35370,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3937,686978,1,1,,144203613,35370,Inconclusive,79154014.0,55775.0,21.136,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3938,686978,1,1,,144204445,35370,Active,79154014.0,55775.0,7.4993,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3939,686979,1,1,,49718184,35370,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3940,686979,1,1,,144203613,35370,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3941,686979,1,1,,144204445,35370,Active,79154014.0,55775.0,21.136,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3942,686992,2,1,,49718184,35370,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3943,686996,1,1,,49718184,35370,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3944,687014,1,1,,49718184,35370,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3945,687016,1,1,,49718184,35370,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3946,689101,2,2,,103188975,35370,Active,,,0.003,EC50,Antiviral activity against HIV1 pseudovirus by cell-based assay,Confirmatory,22954898.0,
3947,689102,2,2,,103188975,35370,Active,,,0.09,EC50,Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis,Confirmatory,22954898.0,
3948,693583,2,2,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23159806.0,
3949,693584,2,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23159806.0,
3950,693585,2,4,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23159806.0,
3951,693586,2,2,,103188975,35370,Unspecified,,,93.63,CC50,Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay,Confirmatory,23159806.0,
3952,693587,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells",Other,23159806.0,
3953,693590,2,2,,103188975,35370,Unspecified,,,4913.8,CC50,Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay,Confirmatory,23164656.0,
3954,693591,1,2,,103188975,35370,Active,,,0.0128,EC50,Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,23164656.0,
3955,693592,2,4,,103188975,35370,Active,,,39.0,EC50,Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,23164656.0,
3956,693593,2,2,,103188975,35370,Active,,,0.0228,EC50,Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay,Confirmatory,23164656.0,
3957,693594,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 3B infected in human C8166 cells",Other,23164656.0,
3958,693595,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells",Other,23164656.0,
3959,696750,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,23078294.0,
3960,696751,2,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT assay,Other,23078294.0,
3961,696752,2,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect,Other,23078294.0,
3962,698294,1,2,,103188975,35370,Active,,,0.0038,EC50,"Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay",Confirmatory,22712652.0,
3963,698298,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3",Other,22712652.0,
3964,698299,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3",Other,22712652.0,
3965,698300,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3",Other,22712652.0,
3966,698301,1,2,,103188975,35370,Active,,,0.0016,EC50,Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay,Confirmatory,22712652.0,
3967,698302,1,2,,103188975,35370,Active,,,0.0156,EC50,Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay,Confirmatory,22712652.0,
3968,698303,1,2,,103188975,35370,Unspecified,,,18.71,CC50,Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay,Confirmatory,22712652.0,
3969,698304,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells",Other,22712652.0,
3970,698305,1,2,,103188975,35370,Active,,,0.0078,EC50,Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay,Confirmatory,22712652.0,
3971,698306,1,2,,103188975,35370,Active,,,0.0117,EC50,Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay,Confirmatory,22712652.0,
3972,699539,1,7,,103188975,35370,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
3973,699540,1,7,,103188975,35370,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3974,699541,1,7,,103188975,35370,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3975,701103,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of cytotoxic concentration for human MT4 cells to IC50 for HIV1 3B",Other,22268494.0,
3976,701105,1,2,,103188975,35370,Active,,,0.0015,IC50,Antiviral activity against HIV1 3B infected in MT4 cells,Confirmatory,22268494.0,
3977,706457,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human MT4 cells to IC50 for HIV-1 NL4-3",Other,22978745.0,
3978,706458,2,2,,103188975,35370,Active,,,0.03,IC50,Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as p24 antigen level after 4 days by ELISA,Confirmatory,22978745.0,
3979,706460,2,2,,103188975,35370,Unspecified,,,37.0,CC50,Cytotoxicity against human MT4 cells after 2 days,Confirmatory,22978745.0,
3980,707985,2,2,,103188975,35370,Unspecified,,,4107.39,CC50,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Confirmatory,23046280.0,
3981,707986,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV-1 3B infected in C8166 cells",Other,23046280.0,
3982,707988,2,2,,103188975,35370,Active,,,0.0087,EC50,Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy,Confirmatory,23046280.0,
3983,714356,2,2,,103188975,35370,Active,,,20.52,IC50,Inhibition of HIV1 reverse transcriptase incubated for 1 hr by colorimetric assay,Confirmatory,23067552.0,
3984,717254,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD",Other,23084898.0,
3985,717256,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,23084898.0,
3986,717257,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant",Other,23084898.0,
3987,717258,2,2,,103188975,35370,Unspecified,,,249.0,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,23084898.0,
3988,717259,2,4,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay,Confirmatory,23084898.0,
3989,717260,2,2,,103188975,35370,Active,,,0.009000000000000001,EC50,Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay,Confirmatory,23084898.0,
3990,717261,2,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay,Confirmatory,23084898.0,
3991,717448,1,2,,103188975,35370,Inactive,,,,,Antiviral activity against HCV assessed as inhibition of viral replication at 10 uM,Other,23085031.0,
3992,717449,2,2,,103188975,35370,Unspecified,,,56.0,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,23085031.0,
3993,717450,2,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells,Confirmatory,23085031.0,
3994,717451,2,2,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC,Confirmatory,23085031.0,
3995,717452,2,2,,103188975,35370,Active,,,0.0017,EC50,Antiviral activity against HIV1 LAI infected in human PBMC assessed as inhibition of viral replication,Confirmatory,23085031.0,
3996,718367,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for HIV2 ROD infected in human MT4 cells to EC50 for HIV1 3B",Other,23098609.0,
3997,718368,2,2,,103188975,35370,Unspecified,,,249.0,CC50,Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay,Confirmatory,23098609.0,
3998,718369,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for HIV1 3B infected in human MT4 cells to EC50 for HIV1 3B",Other,23098609.0,
3999,718370,2,2,,103188975,35370,Unspecified,,,249.0,CC50,Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay,Confirmatory,23098609.0,
4000,718371,2,4,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,23098609.0,
4001,718372,2,2,,103188975,35370,Active,,,0.021,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay,Confirmatory,23098609.0,
4002,718519,1,4,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as protection against virus-induced cytopathicity relative to control,Other,23099090.0,
4003,718520,2,2,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability by MTT assay,Confirmatory,23099090.0,
4004,718521,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV-1 3B infected in MT4 cells assessed as protection against virus-induced cytopathicity relative to control,Other,23099090.0,
4005,718522,2,2,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against HIV-1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,23099090.0,
4006,718523,2,4,,103188975,35370,Unspecified,,,0.009000000000000001,IC50,Antiviral activity against HIV-2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathicity,Confirmatory,23099090.0,
4007,718815,2,3,,103188975,35370,Active,,,0.019,EC50,Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days,Confirmatory,23099098.0,
4008,718816,1,3,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B",Other,23099098.0,
4009,718817,2,3,,103188975,35370,Unspecified,,,5110.0,CC50,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Confirmatory,23099098.0,
4010,720504,1,1,,49718184,35370,Inconclusive,21359873.0,5347.0,29.9349,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
4011,720508,1,1,,49718184,35370,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
4012,720509,1,1,,49718184,35370,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
4013,720511,1,1,,49718184,35370,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
4014,720516,2,1,,144203613,35370,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
4015,720516,2,1,,144204445,35370,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
4016,720516,2,1,,144209401,35370,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
4017,720516,2,1,,144210895,35370,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
4018,720532,1,1,,144203613,35370,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
4019,720532,1,1,,144204445,35370,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
4020,720533,1,1,,144203613,35370,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
4021,720533,1,1,,144204445,35370,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
4022,720538,1,2,,90341185,35370,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
4023,720542,1,2,,49718184,35370,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
4024,720543,1,1,,49718184,35370,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
4025,720551,1,2,,49718184,35370,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
4026,720552,2,1,,144203613,35370,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
4027,720552,2,1,,144204445,35370,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
4028,720552,2,1,,144209401,35370,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
4029,720552,2,1,,144210895,35370,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
4030,720553,1,2,,49718184,35370,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
4031,720554,1,3,,121362495,35370,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
4032,720559,1,2,,90341185,35370,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
4033,720572,1,2,,90341185,35370,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
4034,720573,1,2,,90341185,35370,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
4035,720579,2,1,,49718184,35370,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
4036,720580,1,1,,49718184,35370,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
4037,720582,1,1,,49718184,35370,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
4038,720596,1,1,,49718184,35370,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
4039,720634,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
4040,720634,2,1,,144204445,35370,Inactive,,,2.9849,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
4041,720634,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
4042,720634,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
4043,720635,2,1,,144203613,35370,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
4044,720635,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
4045,720635,2,1,,144209401,35370,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
4046,720635,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
4047,720636,1,1,,17390027,35370,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
4048,720636,1,1,,144204445,35370,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
4049,720637,2,1,,144203613,35370,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
4050,720637,2,1,,144204445,35370,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
4051,720637,2,1,,144209401,35370,Inconclusive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
4052,720637,2,1,,144210895,35370,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
4053,720641,1,2,,92307576,35370,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
4054,720641,1,2,,92309127,35370,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
4055,720647,1,2,,49718184,35370,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
4056,720648,1,1,,49718184,35370,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
4057,720652,1,1,,17390027,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4058,720653,1,1,,17390027,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
4059,720653,1,1,,144204445,35370,Inconclusive,,,39.8107,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
4060,720659,1,1,,17390027,35370,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
4061,720659,1,1,,144204445,35370,Inconclusive,325495557.0,8856.0,70.7946,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
4062,720674,2,2,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
4063,720674,2,2,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
4064,720674,2,2,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
4065,720674,2,2,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
4066,720675,2,2,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
4067,720675,2,2,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
4068,720675,2,2,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
4069,720675,2,2,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
4070,720678,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
4071,720678,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
4072,720678,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
4073,720678,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
4074,720679,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
4075,720679,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
4076,720679,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
4077,720679,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
4078,720680,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
4079,720680,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
4080,720680,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
4081,720680,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
4082,720681,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
4083,720681,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
4084,720681,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
4085,720681,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
4086,720682,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
4087,720682,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
4088,720682,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
4089,720682,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
4090,720683,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
4091,720683,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
4092,720683,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
4093,720683,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
4094,720684,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
4095,720684,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
4096,720684,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
4097,720684,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
4098,720685,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
4099,720685,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
4100,720685,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
4101,720685,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
4102,720686,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
4103,720686,2,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
4104,720686,2,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
4105,720686,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
4106,720687,2,2,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
4107,720687,2,2,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
4108,720687,2,2,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
4109,720687,2,2,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
4110,720691,4,1,,144203613,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4111,720691,4,1,,144204445,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4112,720691,4,1,,144209401,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4113,720691,4,1,,144210895,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4114,720692,3,1,,144203613,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4115,720692,3,1,,144204445,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4116,720692,3,1,,144209401,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4117,720692,3,1,,144210895,35370,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
4118,720693,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
4119,720693,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
4120,720693,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
4121,720693,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
4122,720700,1,4,,49718184,35370,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
4123,720702,1,1,,49718184,35370,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
4124,720704,1,4,,49718184,35370,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
4125,720706,1,2,,49718184,35370,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4126,720707,1,2,,49718184,35370,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
4127,720708,1,2,,49718184,35370,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
4128,720709,1,2,,49718184,35370,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
4129,720711,1,2,,49718184,35370,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
4130,720717,1,3,,92124444,35370,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
4131,720717,1,3,,92307576,35370,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
4132,720717,1,3,,92309127,35370,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
4133,720719,2,1,,144203613,35370,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4134,720719,2,1,,144204445,35370,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4135,720719,2,1,,144209401,35370,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4136,720719,2,1,,144210895,35370,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4137,720725,2,1,,144203613,35370,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4138,720725,2,1,,144204445,35370,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4139,720725,2,1,,144209401,35370,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4140,720725,2,1,,144210895,35370,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
4141,727265,1,2,,103188975,35370,Unspecified,,,,,Mitochondrial toxicity in human HepG2 cells assessed as lactate dehydrogenase release up to 200 uM,Other,23237841.0,
4142,732657,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV-1 3B infected in human C8166 cells",Other,23368966.0,
4143,732658,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay,Other,23368966.0,
4144,732659,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days,Other,23368966.0,
4145,734116,1,2,,103188975,35370,Active,,,20.0,EC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathicity treated post-viral infection measured after 5 days by Cell-Titer Glo assay,Confirmatory,23375089.0,
4146,735332,3,1,,103188975,35370,Active,,,0.00395,EC50,Antiviral activity against deltaTat/rev deffective HIV-1 MC99 infected in human 1A2 cells assessed as inhibition of syncytia formation after 3 days,Confirmatory,23550966.0,
4147,735333,3,1,,103188975,35370,Unspecified,,,10000.0,IC50,Cytotoxicity against human 1A2 cells assessed as inhibition of metabolic activity by XTT assay,Confirmatory,23550966.0,
4148,736854,1,2,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,23327759.0,
4149,736855,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 assessed as reduction in virus-induced cytopathogenicity,Other,23327759.0,
4150,736856,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human C8166 cells by MTT assay,Other,23327759.0,
4151,738314,1,2,,103188975,35370,Unspecified,,,,,Inhibition of HIV1 reverse transcriptase at 50 uM relative to control,Other,23415084.0,
4152,738315,1,2,,103188975,35370,Active,,,4.54,IC50,Inhibition of HIV1 reverse transcriptase,Confirmatory,23415084.0,
4153,743012,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
4154,743012,3,1,,144204445,35370,Active,,,6.6824,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
4155,743012,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
4156,743012,3,1,,144210895,35370,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
4157,743014,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
4158,743014,3,1,,144204445,35370,Active,,,7.4978,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
4159,743014,3,1,,144209401,35370,Inconclusive,,,70.5473,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
4160,743014,3,1,,144210895,35370,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
4161,743015,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
4162,743015,3,1,,144204445,35370,Active,,,11.8832,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
4163,743015,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
4164,743015,3,1,,144210895,35370,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
4165,743033,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
4166,743033,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
4167,743033,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
4168,743033,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
4169,743035,2,1,,144203613,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4170,743035,2,1,,144204445,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4171,743035,2,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4172,743035,2,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4173,743036,2,1,,144203613,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4174,743036,2,1,,144204445,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4175,743036,2,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4176,743036,2,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
4177,743040,3,1,,144203613,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4178,743040,3,1,,144204445,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4179,743040,3,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4180,743040,3,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4181,743041,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
4182,743041,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
4183,743041,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
4184,743041,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
4185,743042,3,1,,144203613,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4186,743042,3,1,,144204445,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4187,743042,3,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4188,743042,3,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
4189,743053,2,1,,144203613,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4190,743053,2,1,,144204445,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4191,743053,2,1,,144209401,35370,Inconclusive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4192,743053,2,1,,144210895,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4193,743054,2,1,,144203613,35370,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
4194,743054,2,1,,144204445,35370,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
4195,743054,2,1,,144209401,35370,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
4196,743054,2,1,,144210895,35370,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
4197,743063,2,1,,144203613,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4198,743063,2,1,,144204445,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4199,743063,2,1,,144209401,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4200,743063,2,1,,144210895,35370,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
4201,743064,3,1,,144203613,35370,Inconclusive,,,0.0008,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
4202,743064,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
4203,743064,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
4204,743064,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
4205,743065,3,1,,144203613,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4206,743065,3,1,,144204445,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4207,743065,3,1,,144209401,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4208,743065,3,1,,144210895,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4209,743066,3,1,,144203613,35370,Inactive,399498506.0,24831.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4210,743066,3,1,,144204445,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4211,743066,3,1,,144209401,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4212,743066,3,1,,144210895,35370,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
4213,743067,2,1,,144203613,35370,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
4214,743067,2,1,,144204445,35370,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
4215,743067,2,1,,144209401,35370,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
4216,743067,2,1,,144210895,35370,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
4217,743069,2,1,,144203613,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4218,743069,2,1,,144204445,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4219,743069,2,1,,144209401,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4220,743069,2,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4221,743074,2,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
4222,743074,2,1,,144204445,35370,Inconclusive,,,5.3538,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
4223,743074,2,1,,144209401,35370,Inconclusive,,,22.4947,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
4224,743074,2,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
4225,743075,2,1,,144203613,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4226,743075,2,1,,144204445,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4227,743075,2,1,,144209401,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4228,743075,2,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
4229,743077,2,1,,144203613,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4230,743077,2,1,,144204445,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4231,743077,2,1,,144209401,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4232,743077,2,1,,144210895,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4233,743078,2,1,,144203613,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4234,743078,2,1,,144204445,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4235,743078,2,1,,144209401,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4236,743078,2,1,,144210895,35370,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
4237,743079,3,1,,144203613,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4238,743079,3,1,,144204445,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4239,743079,3,1,,144209401,35370,Active,348019627.0,2099.0,17.7207,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4240,743079,3,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4241,743080,3,1,,144203613,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4242,743080,3,1,,144204445,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4243,743080,3,1,,144209401,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4244,743080,3,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
4245,743081,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
4246,743081,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
4247,743081,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
4248,743081,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
4249,743083,3,1,,144203613,35370,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
4250,743083,3,1,,144204445,35370,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
4251,743083,3,1,,144209401,35370,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
4252,743083,3,1,,144210895,35370,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
4253,743084,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
4254,743084,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
4255,743084,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
4256,743084,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
4257,743085,3,1,,144203613,35370,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
4258,743085,3,1,,144204445,35370,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
4259,743085,3,1,,144209401,35370,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
4260,743085,3,1,,144210895,35370,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
4261,743086,3,1,,144203613,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
4262,743086,3,1,,144204445,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
4263,743086,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
4264,743086,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
4265,743091,2,1,,144203613,35370,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
4266,743091,2,1,,144204445,35370,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
4267,743091,2,1,,144209401,35370,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
4268,743091,2,1,,144210895,35370,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
4269,743094,3,1,,144203613,35370,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4270,743094,3,1,,144204445,35370,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4271,743094,3,1,,144209401,35370,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4272,743094,3,1,,144210895,35370,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4273,743122,2,1,,144203613,35370,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
4274,743122,2,1,,144204445,35370,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
4275,743122,2,1,,144209401,35370,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
4276,743122,2,1,,144210895,35370,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
4277,743126,1,1,,49718184,35370,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
4278,743139,2,1,,144203613,35370,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
4279,743139,2,1,,144204445,35370,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
4280,743139,2,1,,144209401,35370,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
4281,743139,2,1,,144210895,35370,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
4282,743140,2,1,,144203613,35370,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4283,743140,2,1,,144204445,35370,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4284,743140,2,1,,144209401,35370,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4285,743140,2,1,,144210895,35370,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4286,743191,3,1,,144209401,35370,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4287,743191,3,1,,144210895,35370,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4288,743191,3,1,,170464737,35370,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
4289,743194,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
4290,743194,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
4291,743194,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
4292,743199,2,1,,144209401,35370,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4293,743199,2,1,,144210895,35370,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4294,743199,2,1,,170464737,35370,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
4295,743202,4,1,,144209401,35370,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
4296,743202,4,1,,144210895,35370,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
4297,743202,4,1,,170464737,35370,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
4298,743203,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
4299,743203,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
4300,743203,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
4301,743205,1,1,,90341185,35370,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
4302,743205,1,1,,90341185,35370,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
4303,743206,1,1,,90341185,35370,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
4304,743206,1,1,,90341185,35370,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
4305,743207,1,1,,90341185,35370,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
4306,743207,1,1,,90341185,35370,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
4307,743209,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
4308,743209,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
4309,743209,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
4310,743210,4,1,,144209401,35370,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
4311,743210,4,1,,144210895,35370,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
4312,743210,4,1,,170464737,35370,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
4313,743211,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4314,743211,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4315,743211,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4316,743212,3,1,,144209401,35370,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4317,743212,3,1,,144210895,35370,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4318,743212,3,1,,170464737,35370,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4319,743213,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4320,743213,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4321,743213,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
4322,743215,3,1,,144209401,35370,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4323,743215,3,1,,144210895,35370,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4324,743215,3,1,,170464737,35370,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
4325,743217,3,1,,144209401,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4326,743217,3,1,,144210895,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4327,743217,3,1,,170464737,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4328,743218,3,1,,144209401,35370,Inconclusive,,,0.0063,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4329,743218,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4330,743218,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4331,743219,3,1,,144209401,35370,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
4332,743219,3,1,,144210895,35370,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
4333,743219,3,1,,170464737,35370,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
4334,743220,3,1,,144209401,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4335,743220,3,1,,144210895,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4336,743220,3,1,,170464737,35370,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
4337,743221,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4338,743221,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4339,743221,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
4340,743222,3,1,,144209401,35370,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4341,743222,3,1,,144210895,35370,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4342,743222,3,1,,170464737,35370,Inconclusive,216409708.0,7421.0,0.1883,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4343,743223,3,1,,144209401,35370,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4344,743223,3,1,,144210895,35370,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4345,743223,3,1,,170464737,35370,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
4346,743224,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4347,743224,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4348,743224,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4349,743225,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4350,743225,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4351,743225,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
4352,743226,2,1,,144209401,35370,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4353,743226,2,1,,144210895,35370,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4354,743226,2,1,,170464737,35370,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4355,743227,2,1,,144209401,35370,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4356,743227,2,1,,144210895,35370,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4357,743227,2,1,,170464737,35370,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
4358,743228,3,1,,144209401,35370,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4359,743228,3,1,,144210895,35370,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4360,743228,3,1,,170464737,35370,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
4361,743238,1,1,,49718184,35370,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
4362,743239,2,1,,144209401,35370,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4363,743239,2,1,,144210895,35370,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4364,743239,2,1,,170464737,35370,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4365,743240,2,1,,144209401,35370,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4366,743240,2,1,,144210895,35370,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4367,743240,2,1,,170464737,35370,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
4368,743241,2,1,,144209401,35370,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4369,743241,2,1,,144210895,35370,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4370,743241,2,1,,170464737,35370,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4371,743242,2,1,,144209401,35370,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4372,743242,2,1,,144210895,35370,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4373,743242,2,1,,170464737,35370,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
4374,743244,1,1,,90341185,35370,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
4375,743244,1,1,,144203613,35370,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
4376,743244,1,1,,144204445,35370,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
4377,743247,1,2,,49718184,35370,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4378,743255,1,1,,49718184,35370,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
4379,743266,1,2,,49718184,35370,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
4380,743268,1,1,,172080789,35370,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
4381,743269,1,1,,49718184,35370,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
4382,743269,1,1,,49718184,35370,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
4383,743270,1,1,,172080789,35370,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
4384,743271,1,1,,172080789,35370,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
4385,743272,1,1,,172080789,35370,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
4386,743279,1,2,,49718184,35370,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
4387,743287,1,1,,49718184,35370,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
4388,743288,1,1,,17390027,35370,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
4389,743288,1,1,,144204445,35370,Inconclusive,,,50.1187,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
4390,743292,1,1,,17390027,35370,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
4391,743292,1,1,,144204445,35370,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
4392,743344,1,1,,162108254,35370,Inactive,,,5.3045,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
4393,743345,1,1,,162108254,35370,Inactive,,,0.0038,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
4394,743346,1,1,,162108254,35370,Inactive,,,0.6678,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
4395,743347,1,1,,162108254,35370,Inactive,,,0.0038,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
4396,743397,1,1,,49718184,35370,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4397,743398,1,1,,49718184,35370,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
4398,746746,1,1,,103188975,35370,Unspecified,,,25.0,CC50,Cytotoxicity against human MT2 cells by MTT assay,Confirmatory,23570720.0,
4399,746747,1,1,,103188975,35370,Active,,,0.084,EC50,Antiviral activity against HIV1 expressing VSV glycoprotein plasmid infected in human 293T cells treated 15 mins before viral infection measured after 48 hrs by luciferase reporter gene assay,Confirmatory,23570720.0,
4400,747597,1,1,,103188975,35370,Unspecified,,,53.0,CC50,Cytotoxicity against African green monkey Vero cells,Confirmatory,23623492.0,
4401,747598,1,1,,103188975,35370,Active,,,14.3,CC50,Cytotoxicity against human CEM cells,Confirmatory,23623492.0,
4402,747599,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human PBMC,Confirmatory,23623492.0,
4403,747600,1,1,,103188975,35370,Active,,,0.004,EC50,Antiviral activity against Human immunodeficiency virus 1 LAI infected in human PBMC,Confirmatory,23623492.0,
4404,747601,1,3,,103188975,35370,Unspecified,,,10.0,CC50,Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis,Confirmatory,23623492.0,
4405,747602,1,1,,103188975,35370,Unspecified,,,10.0,EC50,Antiviral activity against Hepatitis C virus infected in human HuH7 cells,Confirmatory,23623492.0,
4406,751133,1,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV-1 3B",Other,23738539.0,
4407,751135,1,1,,103188975,35370,Active,,,0.034,EC50,Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay,Confirmatory,23738539.0,
4408,751136,1,1,,103188975,35370,Unspecified,,,200.0,CC50,Cytotoxicity against human C8166 cells after 3 days by MTT assay,Confirmatory,23738539.0,
4409,757622,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,23707918.0,
4410,757623,1,1,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,23707918.0,
4411,757624,1,3,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23707918.0,
4412,757625,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23707918.0,
4413,757626,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,23707918.0,
4414,766740,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B",Other,23916148.0,
4415,766741,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells after 4 days by MTT assay,Confirmatory,23916148.0,
4416,766742,1,1,,103188975,35370,Active,,,0.04,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,23916148.0,
4417,779525,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells",Other,24055077.0,
4418,779526,1,1,,103188975,35370,Unspecified,,,93.56,CC50,Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay,Confirmatory,24055077.0,
4419,779527,1,3,,103188975,35370,Active,,,0.0064,EC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24055077.0,
4420,779528,1,1,,103188975,35370,Active,,,0.0066,EC50,Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24055077.0,
4421,779529,1,1,,103188975,35370,Active,,,0.0059,EC50,Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24055077.0,
4422,780327,1,1,,103188975,35370,Unspecified,,,56.0,IC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,24091080.0,
4423,780328,1,1,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC,Confirmatory,24091080.0,
4424,780329,1,1,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells,Confirmatory,24091080.0,
4425,780330,1,1,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against Human immunodeficiency virus 1 infected in human PBMC assessed as inhibition of viral replication after 5 days by RT-PCR method,Confirmatory,24091080.0,
4426,926185,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020401,Other,,
4427,926186,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020401",Other,,
4428,926187,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020401,Other,,
4429,926188,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020401,Other,,
4430,926189,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020401,Other,,
4431,926190,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020401,Other,,
4432,926191,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020401,Other,,
4433,926192,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020401,Other,,
4434,926193,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020401,Other,,
4435,928196,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020401,Other,,
4436,928197,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020401,Other,,
4437,928198,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020401,Other,,
4438,928199,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020401,Other,,
4439,928200,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020401,Other,,
4440,928201,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020401,Other,,
4441,928202,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020401,Other,,
4442,928203,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020401,Other,,
4443,928204,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020401,Other,,
4444,928205,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020401,Other,,
4445,942269,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020401,Other,,
4446,942270,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020401,Other,,
4447,942271,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020401,Other,,
4448,942272,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020401,Other,,
4449,942273,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020401,Other,,
4450,942274,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020401,Other,,
4451,942275,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020401,Other,,
4452,942276,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020401,Other,,
4453,942277,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020401,Other,,
4454,942278,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020401,Other,,
4455,942279,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020401,Other,,
4456,942280,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020401,Other,,
4457,942281,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020401,Other,,
4458,942282,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020401,Other,,
4459,942283,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020401,Other,,
4460,942284,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020401",Other,,
4461,942285,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020401,Other,,
4462,942914,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020401,Other,,
4463,942915,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020401,Other,,
4464,955799,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020401,Other,,
4465,955800,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020401,Other,,
4466,955801,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020401,Other,,
4467,955802,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020401,Other,,
4468,955803,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020401,Other,,
4469,955804,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020401,Other,,
4470,955805,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020401,Other,,
4471,955806,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020401,Other,,
4472,955807,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020401,Other,,
4473,955808,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020401,Other,,
4474,955809,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020401,Other,,
4475,955810,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020401,Other,,
4476,955811,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020401,Other,,
4477,955812,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020401,Other,,
4478,955813,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020401,Other,,
4479,955814,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020401,Other,,
4480,955815,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020401,Other,,
4481,955816,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020401,Other,,
4482,955817,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020401,Other,,
4483,969887,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020401,Other,,
4484,969888,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020401,Other,,
4485,969889,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020401,Other,,
4486,969890,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020401,Other,,
4487,969891,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020401,Other,,
4488,969892,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020401,Other,,
4489,969893,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020401,Other,,
4490,969894,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020401,Other,,
4491,969895,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020401,Other,,
4492,969896,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020401,Other,,
4493,969897,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020401,Other,,
4494,969898,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020401,Other,,
4495,969899,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020401,Other,,
4496,969900,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020401,Other,,
4497,969901,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020401,Other,,
4498,969902,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020401,Other,,
4499,969903,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020401,Other,,
4500,969904,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020401,Other,,
4501,971907,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020401,Other,,
4502,977599,1,1,,103188975,35370,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4503,977602,1,2,,103188975,35370,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4504,977610,3,1,,310262872,35370,Active,,,410.0,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,24699659.0,
4505,1006131,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4506,1006132,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020401",Other,,
4507,1006133,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
4508,1006134,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
4509,1006135,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
4510,1006136,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
4511,1006137,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020401",Other,,
4512,1006138,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
4513,1006139,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
4514,1006140,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020401",Other,,
4515,1006141,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
4516,1006142,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020401",Other,,
4517,1006143,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020401",Other,,
4518,1006144,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020401",Other,,
4519,1006145,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020401",Other,,
4520,1006146,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020401,Other,,
4521,1006147,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020401,Other,,
4522,1006148,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020401",Other,,
4523,1006149,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
4524,1006150,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4525,1006151,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020401",Other,,
4526,1006152,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020401",Other,,
4527,1006153,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4528,1006154,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4529,1006155,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020401",Other,,
4530,1006156,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4531,1006157,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020401",Other,,
4532,1006158,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020401",Other,,
4533,1006159,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020401,Other,,
4534,1006160,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4535,1006161,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
4536,1006162,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4537,1006163,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020401",Other,,
4538,1006164,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020401,Other,,
4539,1006165,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4540,1006744,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020401",Other,,
4541,1006745,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4542,1006746,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020401",Other,,
4543,1006747,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020401",Other,,
4544,1008613,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020401",Other,,
4545,1008614,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020401",Other,,
4546,1008615,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020401",Other,,
4547,1008616,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4548,1008617,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4549,1008618,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020401",Other,,
4550,1008619,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020401",Other,,
4551,1008620,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020401,Other,,
4552,1008621,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
4553,1008622,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020401",Other,,
4554,1008623,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020401",Other,,
4555,1008624,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020401",Other,,
4556,1008625,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4557,1008626,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4558,1008627,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4559,1008628,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020401",Other,,
4560,1008629,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020401",Other,,
4561,1008630,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020401,Other,,
4562,1008631,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4563,1008632,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020401",Other,,
4564,1008633,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020401",Other,,
4565,1008634,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4566,1008635,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4567,1008636,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020401",Other,,
4568,1008637,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4569,1013543,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4570,1013544,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4571,1013545,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
4572,1013546,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020401",Other,,
4573,1013547,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020401",Other,,
4574,1013548,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020401",Other,,
4575,1013549,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4576,1013550,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
4577,1013551,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020401",Other,,
4578,1013552,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020401",Other,,
4579,1013553,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4580,1013554,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020401,Other,,
4581,1013555,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020401",Other,,
4582,1013556,1,3,,103188975,35370,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020401,Other,,
4583,1013557,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020401",Other,,
4584,1013558,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020401",Other,,
4585,1013559,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020401",Other,,
4586,1013560,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020401",Other,,
4587,1013561,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020401",Other,,
4588,1013562,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020401",Other,,
4589,1013563,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020401",Other,,
4590,1013564,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020401",Other,,
4591,1013565,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020401",Other,,
4592,1013566,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020401",Other,,
4593,1013567,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020401",Other,,
4594,1013568,1,3,,103188975,35370,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020401",Other,,
4595,1053188,2,1,,49718184,35370,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4596,1053197,1,1,,49718184,35370,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4597,1053503,1,1,,103188975,35370,Active,,,,,Binding affinity to HIV1 reverse transcriptase assessed as compound-terminated template/primer translocation from N-site to P-site of enzyme preincubated for 20 mins prior to TTP addition measured after 10 mins by gel electrophoretic analysis,Other,24102161.0,
4598,1053504,1,1,,103188975,35370,Unspecified,,,,,Induction of AZT-resistant HIV1 reverse transcriptase assessed as rate of ATP-mediated excision of chain-terminating nucleotides by phosphorimaging analysis,Other,24102161.0,
4599,1053506,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for NNRTI-resistant Human immunodeficiency virus 1 to EC50 for wild type Human immunodeficiency virus 1 expressing p24,Other,24102161.0,
4600,1053507,1,1,,103188975,35370,Active,,,0.12,EC50,Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1,Confirmatory,24102161.0,
4601,1053508,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for AZT-resistant Human immunodeficiency virus 1 to EC50 for wild type Human immunodeficiency virus 1 expressing p24,Other,24102161.0,
4602,1053509,1,1,,103188975,35370,Active,,,7.9,EC50,Antiviral activity against AZT-resistant Human immunodeficiency virus 1 expressing D67N/K70R/T215F/K219Q reverse transcriptase mutation,Confirmatory,24102161.0,
4603,1053511,1,1,,103188975,35370,Active,,,0.14,EC50,Antiviral activity against wild type Human immunodeficiency virus 1 expressing p24 infected in human HeLa P4/R5 cells preincubated for 16 hrs prior to virus infection measured after 48 hrs by beta-galactosidase-based single replication cycle assay,Confirmatory,24102161.0,
4604,1053512,1,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human CEM-SS cells to EC50 for Human immunodeficiency virus 1 3B",Other,24102161.0,
4605,1053513,1,3,,103188975,35370,Unspecified,,,1.0,CC50,Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay,Confirmatory,24102161.0,
4606,1053514,1,1,,103188975,35370,Active,,,0.0053,EC50,Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay,Confirmatory,24102161.0,
4607,1053517,1,1,,103188975,35370,Active,,,0.0054,Kd,Binding affinity to HIV1 reverse transcriptase assessed as compound incorporation into DNA by primer extension assay,Confirmatory,24102161.0,
4608,1055509,1,2,,103188975,35370,Unspecified,,,250.0,CC50,Cytotoxicity against human CEM cells,Confirmatory,24177359.0,
4609,1055510,1,1,,103188975,35370,Active,,,0.067,EC50,Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,24177359.0,
4610,1055512,1,1,,103188975,35370,Active,,,0.012,EC50,Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis,Confirmatory,24177359.0,
4611,1056504,1,1,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay,Confirmatory,24299567.0,
4612,1056584,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against wild-type HIV-1 infected in HEK293T cells co-transfected with VSVG protein assessed as time required for 50% failure of viral replication at 10 uM by luciferase reporter gene assay,Other,24308675.0,
4613,1060626,1,1,,103188975,35370,Unspecified,,,,,"Fold resistance, ratio of EC50 for HIV1 RES056 expressing K103N/Y181C mutant infected in human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells",Other,24275349.0,
4614,1060627,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells",Other,24275349.0,
4615,1060628,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells",Other,24275349.0,
4616,1060629,1,1,,103188975,35370,Active,,,0.0057,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay,Confirmatory,24275349.0,
4617,1060630,1,3,,103188975,35370,Unspecified,,,94.0,CC50,Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay,Confirmatory,24275349.0,
4618,1060631,1,1,,103188975,35370,Active,,,0.0074,EC50,Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay,Confirmatory,24275349.0,
4619,1060632,1,1,,103188975,35370,Active,,,0.0072,EC50,Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay,Confirmatory,24275349.0,
4620,1064552,1,2,,103188975,35370,Unspecified,,,89.5,LC50,Cytotoxicity against human CEM-TART cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,24392742.0,
4621,1064553,1,1,,103188975,35370,Active,,,1.3,EC50,Antiviral activity against HIV-1 infected in human CEM-TART cells assessed as protection against virus-induced cytopathicity after 96 hrs by MTT assay,Confirmatory,24392742.0,
4622,1068975,1,1,,103188975,35370,Unspecified,,,14.9,IC50,Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells,Confirmatory,24411122.0,
4623,1068976,1,1,,103188975,35370,Unspecified,,,467.7,CC50,Cytotoxicity against human CEM/0 cells,Confirmatory,24411122.0,
4624,1068977,1,1,,103188975,35370,Active,,,0.04,IC50,Antiviral activity against HIV-2 ROD infected in human CEM/0 cells,Confirmatory,24411122.0,
4625,1068978,1,2,,103188975,35370,Unspecified,,,93.5,CC50,Cytotoxicity against human MT4 cells,Confirmatory,24411122.0,
4626,1068979,1,1,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells,Confirmatory,24411122.0,
4627,1068980,1,1,,103188975,35370,Active,,,0.006999999999999999,IC50,Antiviral activity against HIV-1 3B infected in human MT4 cells,Confirmatory,24411122.0,
4628,1077217,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-2 ROD infected in human MT4 cells",Other,24602795.0,
4629,1077218,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells",Other,24602795.0,
4630,1077219,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells",Other,24602795.0,
4631,1077220,1,3,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay,Confirmatory,24602795.0,
4632,1077221,1,1,,103188975,35370,Active,,,0.012,EC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24602795.0,
4633,1077222,1,1,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24602795.0,
4634,1077223,1,1,,103188975,35370,Active,,,0.0075,EC50,Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24602795.0,
4635,1077413,1,2,,103188975,35370,Unspecified,,,,,Selectivity ratio of CC50 for HIV-2 ROD mock-infected human MT4 cells to EC50 for HIV-2 ROD infected in human MT4 cells,Other,,
4636,1077414,1,2,,103188975,35370,Unspecified,,,,,Selectivity ratio of CC50 for HIV-1 3B mock-infected human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells,Other,,
4637,1077415,1,3,,103188975,35370,Unspecified,,,249.5,CC50,Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay,Confirmatory,,
4638,1077416,1,3,,103188975,35370,Unspecified,,,249.5,CC50,Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay,Confirmatory,,
4639,1077417,1,2,,103188975,35370,Active,,,0.0045,EC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay,Confirmatory,,
4640,1077418,1,2,,103188975,35370,Active,,,0.021,EC50,Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay,Confirmatory,,
4641,1078016,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV-1 3B infected in human MT4 cells",Other,,
4642,1078017,1,3,,103188975,35370,Unspecified,,,93.56,CC50,Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay,Confirmatory,,
4643,1078018,1,2,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay,Confirmatory,,
4644,1078019,1,2,,103188975,35370,Active,,,0.0063,EC50,Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay,Confirmatory,,
4645,1078020,1,2,,103188975,35370,Active,,,0.0064,EC50,Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay,Confirmatory,,
4646,1079722,1,2,,103188975,35370,Unspecified,,,,,"Fold resistance, ratio of IC50 for NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant to wild type HIV-1 isolate infected in human PBMC cells",Other,,
4647,1079723,1,2,,103188975,35370,Unspecified,,,829.1,IC50,"Antiviral activity against NRTI-resistant HIV-1 D67N, T69D, K70R, A98G, V118I, M184V, T215F and K219Q mutant isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA",Confirmatory,,
4648,1079724,1,2,,103188975,35370,Active,,,0.2162,IC50,Antiviral activity against wild type HIV-1 isolate infected in human PBMC cells assessed as inhibition of viral production by p24 antigen production/ELISA,Confirmatory,,
4649,1079931,1,1,,103188975,35370,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4650,1079932,1,1,,103188975,35370,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4651,1079933,1,1,,103188975,35370,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4652,1079934,1,1,,103188975,35370,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4653,1079935,1,1,,103188975,35370,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4654,1079936,1,1,,103188975,35370,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4655,1079937,1,1,,103188975,35370,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4656,1079938,1,1,,103188975,35370,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4657,1079939,1,1,,103188975,35370,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4658,1079940,1,1,,103188975,35370,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4659,1079941,1,1,,103188975,35370,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4660,1079942,1,1,,103188975,35370,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4661,1079943,1,1,,103188975,35370,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4662,1079944,1,1,,103188975,35370,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4663,1079945,1,1,,103188975,35370,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4664,1079946,1,1,,103188975,35370,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4665,1079947,1,1,,103188975,35370,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4666,1079948,1,1,,103188975,35370,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4667,1079949,1,1,,103188975,35370,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4668,1085020,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MT4 cells,Other,,
4669,1085021,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity,Other,,
4670,1085022,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity,Other,,
4671,1087015,1,3,,103188975,35370,Unspecified,,,56.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 5 days celltiter 96 aqueous assay,Confirmatory,,
4672,1087016,1,3,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against Homo sapiens (human) PBMCs after 5 days celltiter 96 aqueous assay,Confirmatory,,
4673,1087017,1,2,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay,Confirmatory,,
4674,1087018,1,2,,103188975,35370,Active,,,,EC50,Antiviral activity against 0.1 MOI of Human immunodeficiency virus 1 LAI infected human PBM cells after 2 to 3 hr by scintillation counting analysis in presence of [3H]thymidine-5'-triphosphate,Confirmatory,,
4675,1095194,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in MT4 cells",Other,,
4676,1095195,1,3,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay,Confirmatory,,
4677,1095197,1,2,,103188975,35370,Active,,,0.0151,EC50,Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay,Confirmatory,,
4678,1096474,1,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,,
4679,1096475,1,2,,103188975,35370,Unspecified,,,50.0,CC50,Cytotoxicity against Homo sapiens (human) MT4 cells containing integrated HTLV-1 genome after 96 hr by MTT assay,Confirmatory,,
4680,1096854,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay,Other,,
4681,1096856,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4682,1096857,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4683,1096924,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay,Other,,
4684,1096925,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4685,1096926,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4686,1097061,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay,Other,,
4687,1097062,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4688,1097063,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay,Other,,
4689,1106963,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV2 ROD",Other,,
4690,1106964,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against human MT4 cells by MTT assay,Other,,
4691,1106965,1,2,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B",Other,,
4692,1106966,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay,Other,,
4693,1106968,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay,Other,,
4694,1107295,1,2,,103188975,35370,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa cells infected with HIV-1 NL4-3 assessed as cell viability at 100 uM by XTT assay,Other,,
4695,1107296,1,2,,103188975,35370,Unspecified,,,,,Antiviral activity against Human immunodeficiency virus 1 NL4-3 infected human HeLa cells assessed as decrease in P24 expression at 100 uM after 72 hr by single cycle replication assay,Other,,
4696,1115255,1,2,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as protection against virus-induced cytopathogenicity treated before viral infection measured after 4 days by MTT assay,Confirmatory,,
4697,1115259,1,3,,103188975,35370,Unspecified,,,50.0,CC50,Cytotoxicity against Homo sapiens (human) MT4 cells assessed as inhibition of cell vaibility after 96 hr by MTT assay,Confirmatory,,
4698,1117298,1,2,,170464737,35370,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4699,1117301,1,2,,170464737,35370,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
4700,1117302,1,2,,170464737,35370,Inactive,,,2.5119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
4701,1117303,1,2,,170464737,35370,Inactive,,,39.82,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
4702,1117304,1,2,,170464737,35370,Inactive,,,3.5481,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4703,1117305,1,2,,170464737,35370,Inactive,,,4.4668,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4704,1117310,1,1,,170464737,35370,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4705,1117311,1,1,,170464737,35370,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
4706,1117312,1,1,,170464737,35370,Inactive,,,4.46684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4707,1117314,1,1,,170464737,35370,Inactive,,,3.5481300000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4708,1117315,1,1,,170464737,35370,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
4709,1117318,1,1,,170464737,35370,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
4710,1117319,1,2,,855980,35370,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4711,1117319,1,2,,855980,35370,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4712,1117326,1,1,,170464737,35370,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4713,1117329,1,1,,170464737,35370,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4714,1117336,1,1,,170464737,35370,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4715,1117340,1,1,,170464737,35370,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4716,1117341,1,1,,170464737,35370,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4717,1117342,1,1,,170464737,35370,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4718,1117343,1,1,,170464737,35370,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4719,1117346,1,1,,170464737,35370,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4720,1126506,1,1,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay,Confirmatory,24680058.0,
4721,1126507,1,1,,103188975,35370,Active,,,0.008,EC50,Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay,Confirmatory,24680058.0,
4722,1126508,1,1,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay,Confirmatory,24680058.0,
4723,1126509,1,1,,103188975,35370,Unspecified,,,93.6,CC50,Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay,Confirmatory,24680058.0,
4724,1126510,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to IC50 for HIV1 3B infected in human MT4 cells",Other,24680058.0,
4725,1140742,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 HTLV-3B infected in human MT4 cells assessed as inhibition of virus proliferation by measuring host cell viability at 25 nM relative to control,Other,24742150.0,
4726,1141959,1,1,,103188975,35370,Unspecified,,,30.595,CC50,Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay,Confirmatory,24769348.0,
4727,1141960,1,1,,103188975,35370,Active,,,0.0037,EC50,Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method,Confirmatory,24769348.0,
4728,1141961,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4.3 infected in human MT4 cells",Other,24769348.0,
4729,1141964,1,1,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method,Confirmatory,24769348.0,
4730,1141965,1,1,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method,Confirmatory,24769348.0,
4731,1141966,1,1,,103188975,35370,Active,,,0.033,EC50,Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method,Confirmatory,24769348.0,
4732,1141968,1,1,,103188975,35370,Active,,,0.016,EC50,Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method,Confirmatory,24769348.0,
4733,1141969,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 harboring reverse transcriptase K103N/Y181C double mutant to EC50 for wild type HIV1 NL4.3,Other,24769348.0,
4734,1141970,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4.3,Other,24769348.0,
4735,1141971,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4.3,Other,24769348.0,
4736,1141972,1,1,,103188975,35370,Unspecified,,,,,Ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4.3,Other,24769348.0,
4737,1152127,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of p24 antigen production by measuring time delay in loss of compound activity at 50 to 100 times EC50 by ELISA,Other,24793360.0,
4738,1152370,1,1,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay,Confirmatory,24794751.0,
4739,1152371,1,1,,103188975,35370,Active,,,0.005,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay,Confirmatory,24794751.0,
4740,1152372,1,1,,103188975,35370,Active,,,0.006999999999999999,EC50,"Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay",Confirmatory,24794751.0,
4741,1152373,1,1,,103188975,35370,Unspecified,,,93.5,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,24794751.0,
4742,1152374,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio CC50 for human MT4 cells to EC50 for HIV 1 3B",Other,24794751.0,
4743,1152845,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against cat CRFK cells assessed as cell viability at 10 uM after 24 hrs by MTT assay,Other,24813732.0,
4744,1152846,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against cat CRFK cells assessed as cell viability after 7 days by MTT assay,Confirmatory,24813732.0,
4745,1152847,1,1,,103188975,35370,Active,,,5.31,EC50,Antiviral activity against Feline immunodeficiency virus infected in cat FL-4 cells assessed as viral RNA production by RT-qPCR,Confirmatory,24813732.0,
4746,1152848,1,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for cat CRFK cells to EC50 for Feline immunodeficiency virus infected in cat FL-4 cells",Other,24813732.0,
4747,1156484,1,1,,103188975,35370,Active,,,0.0066,IC50,Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24952305.0,
4748,1156485,1,1,,103188975,35370,Active,,,0.0077,IC50,Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24952305.0,
4749,1156486,1,1,,103188975,35370,Active,,,0.0017,IC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,24952305.0,
4750,1156487,1,1,,103188975,35370,Unspecified,,,93.5489,CC50,Cytotoxicity against human MT4 cells after 5 days by MTT assay,Confirmatory,24952305.0,
4751,1156488,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for wild type HIV1 3B",Other,24952305.0,
4752,1157580,1,1,,103188975,35370,Unspecified,,,50.0,CC50,Cytotoxicity against human MT4 cells after 96 hrs by MTT assay,Confirmatory,24805780.0,
4753,1157581,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,24805780.0,
4754,1157582,1,1,,103188975,35370,Active,,,0.01,EC50,"Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4755,1157583,1,1,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,24805780.0,
4756,1157584,1,1,,103188975,35370,Active,,,0.01,EC50,"Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4757,1157585,1,1,,103188975,35370,Active,,,0.2,EC50,"Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4758,1157586,1,1,,103188975,35370,Active,,,0.2,EC50,"Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4759,1157587,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay,Confirmatory,24805780.0,
4760,1157592,1,1,,103188975,35370,Active,,,0.01,EC50,"Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4761,1157593,1,1,,103188975,35370,Active,,,0.009000000000000001,EC50,"Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4762,1157594,1,1,,103188975,35370,Active,,,0.01,EC50,"Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4763,1157595,1,1,,103188975,35370,Active,,,0.008,EC50,"Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay",Confirmatory,24805780.0,
4764,1159509,1,1,,144209401,35370,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4765,1159509,1,1,,144210895,35370,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4766,1159509,1,1,,170464737,35370,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4767,1159515,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4768,1159515,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4769,1159515,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4770,1159516,1,1,,144209401,35370,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4771,1159516,1,1,,144210895,35370,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4772,1159516,1,1,,170464737,35370,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4773,1159517,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4774,1159517,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4775,1159517,1,1,,170464737,35370,Inconclusive,,,1.1986,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4776,1159518,1,1,,144209401,35370,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4777,1159518,1,1,,144210895,35370,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4778,1159518,1,1,,170464737,35370,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4779,1159519,1,1,,144209401,35370,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4780,1159519,1,1,,144210895,35370,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4781,1159519,1,1,,170464737,35370,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4782,1159520,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4783,1159520,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4784,1159520,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4785,1159521,1,1,,144209401,35370,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4786,1159521,1,1,,144210895,35370,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4787,1159521,1,1,,170464737,35370,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4788,1159523,1,1,,144209401,35370,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4789,1159523,1,1,,144210895,35370,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4790,1159523,1,1,,170464737,35370,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4791,1159524,1,1,,49718184,35370,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4792,1159525,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4793,1159525,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4794,1159525,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4795,1159526,1,1,,144209401,35370,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4796,1159526,1,1,,144210895,35370,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4797,1159526,1,1,,170464737,35370,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4798,1159527,1,1,,144209401,35370,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4799,1159527,1,1,,144210895,35370,Inconclusive,325495497.0,6256.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4800,1159527,1,1,,170464737,35370,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4801,1159528,1,1,,144209401,35370,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4802,1159528,1,1,,144210895,35370,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4803,1159528,1,1,,170464737,35370,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4804,1159529,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4805,1159529,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4806,1159529,1,1,,170464737,35370,Inconclusive,,,0.0849,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4807,1159531,1,1,,144209401,35370,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4808,1159531,1,1,,144210895,35370,Inconclusive,325495497.0,6256.0,61.6448,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4809,1159531,1,1,,170464737,35370,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4810,1159550,3,1,,252401157,35370,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
4811,1159551,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4812,1159551,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4813,1159551,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4814,1159552,1,1,,144209401,35370,Inactive,325495463.0,5914.0,39.6717,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4815,1159552,1,1,,144210895,35370,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4816,1159552,1,1,,170464737,35370,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4817,1159553,2,1,,144209401,35370,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4818,1159553,2,1,,144210895,35370,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4819,1159553,2,1,,170464737,35370,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4820,1159555,1,1,,144209401,35370,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4821,1159555,1,1,,144210895,35370,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4822,1159555,1,1,,170464737,35370,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4823,1159580,2,1,,268734876,35370,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4824,1159606,1,1,,49718184,35370,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4825,1159607,2,1,,312309786,35370,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4826,1159614,1,2,,170464737,35370,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4827,1159620,1,1,,103188975,35370,Active,,,,,Summary of drug indications.,Other,,
4828,1161592,1,1,,103188975,35370,Active,,,,,Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral entry compound treated at 200 uM at 6 hrs post infection measured 3 to 4 days post infection by time-of-addition assay,Other,25156906.0,
4829,1165074,1,1,,103188975,35370,Active,,,0.0071,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,25240095.0,
4830,1165075,1,1,,103188975,35370,Active,,,0.0067,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,25240095.0,
4831,1165076,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay,Confirmatory,25240095.0,
4832,1165077,1,1,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay,Confirmatory,25240095.0,
4833,1165078,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells",Other,25240095.0,
4834,1166453,1,1,,103188975,35370,Active,,,,,Antiviral activity against HIV1 infected in human A3.01 cells assessed as complete inhibition of viral replication at 20 uM,Other,25260957.0,
4835,1172370,1,1,,103188975,35370,Active,,,13.74,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4836,1172371,1,1,,103188975,35370,Active,,,6.81,IC50,Cytotoxicity against human H460 cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4837,1172372,1,1,,103188975,35370,Active,,,9.17,IC50,Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4838,1172373,1,2,,103188975,35370,Active,,,39.11,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4839,1172374,1,1,,103188975,35370,Active,,,12.25,IC50,Cytotoxicity against human 143B cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4840,1172375,1,1,,103188975,35370,Unspecified,,,148.42,IC50,Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay,Confirmatory,25440502.0,
4841,1172376,1,1,,103188975,35370,Unspecified,,,,,Ratio of IC50 for human thymidine kinase-deficient 143B cells to IC50 for human 143B cells,Other,25440502.0,
4842,1172695,1,2,,103188975,35370,Unspecified,,,479.0,IC50,Cytotoxicity against human KB cells,Confirmatory,25442310.0,
4843,1172696,1,1,,103188975,35370,Unspecified,,,479.0,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,25442310.0,
4844,1174083,1,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1,Confirmatory,25458500.0,
4845,1174084,1,1,,103188975,35370,Unspecified,,,,EC50,Antiviral activity against Hepatitis B virus,Confirmatory,25458500.0,
4846,1174085,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human PBMC,Confirmatory,25458500.0,
4847,1174086,1,1,,103188975,35370,Active,,,14.0,CC50,Cytotoxicity against human CEM cell,Confirmatory,25458500.0,
4848,1174087,1,1,,103188975,35370,Unspecified,,,56.0,CC50,Cytotoxicity against african green monkey Vero cells,Confirmatory,25458500.0,
4849,1174088,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human HepG2 cells,Confirmatory,25458500.0,
4850,1180342,1,2,,103188975,35370,Active,82319964.0,,18.22,IC50,Inhibition of HIV-1 reverse transcriptase after 1 hr by ELISA plate reader analysis,Confirmatory,24953602.0,
4851,1186008,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against HIV1 infected in 293T cells assessed as time of 50% failure,Other,25072874.0,
4852,1189129,1,1,,103188975,35370,Unspecified,,,155.66,IC50,"DNDI: Chagas in Vitro, 96 hour",Confirmatory,,
4853,1189130,1,1,,103188975,35370,Unspecified,,,206.93,IC50,"DNDI: Cytotoxicity in Vitro, 72 hour, in rat skeletal myoblast cells",Confirmatory,,
4854,1189131,1,1,,103188975,35370,Unspecified,,,112.26,IC50,"DNDI: Cytotoxicity in Vitro, 96 hour, in mouse macrophages (infected-amastigotes)",Confirmatory,,
4855,1189133,1,1,,103188975,35370,Unspecified,,,139.57,IC50,"DNDI: HAT in Vitro, 72 hour",Confirmatory,,
4856,1189134,1,1,,103188975,35370,Unspecified,,,374.19,IC50,"DNDI: Leish (axenic) in Vitro, 72 hour",Confirmatory,,
4857,1189135,1,1,,103188975,35370,Unspecified,,,112.26,IC50,"DNDI: Leish (macro) in Vitro, 96 hour",Confirmatory,,
4858,1189136,1,1,,103188975,35370,Unspecified,,,174.75,IC50,"DNDI: Malaria in Vitro, 72 hour",Confirmatory,,
4859,1191399,1,1,,103188975,35370,Active,,,0.0071,EC50,Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25537532.0,
4860,1191400,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25537532.0,
4861,1191401,1,1,,103188975,35370,Active,,,0.0066,EC50,Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25537532.0,
4862,1191402,1,1,,103188975,35370,Unspecified,,,93.55,CC50,Cytotoxicity against human MT4 cells after 5 days MTT assay,Confirmatory,25537532.0,
4863,1191403,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells",Other,25537532.0,
4864,1191971,1,1,,103188975,35370,Active,,,0.0019,EC50,Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay,Confirmatory,25682562.0,
4865,1191972,1,1,,103188975,35370,Active,,,0.0016,EC50,Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay,Confirmatory,25682562.0,
4866,1191973,1,1,,103188975,35370,Unspecified,,,25.0,CC50,Cytotoxicity against mock-infected human HeLa cells by MTT assay,Confirmatory,25682562.0,
4867,1191974,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human HeLa cells to EC50 for HIV2 ROD infected in human MT4 cells",Other,25682562.0,
4868,1193051,1,1,,103188975,35370,Active,,,,EC50,Antiviral activity against HIV1 LAV-1 infected in human PBMC cells after 6 days by RT assay,Confirmatory,25701249.0,
4869,1193052,1,1,,103188975,35370,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay,Confirmatory,25701249.0,
4870,1193053,1,1,,103188975,35370,Active,,,14.3,IC50,Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay,Confirmatory,25701249.0,
4871,1193054,1,1,,103188975,35370,Unspecified,,,56.0,IC50,Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay,Confirmatory,25701249.0,
4872,1193106,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against cat CRFK cells assessed as cell viability at 10 uM after 24 hrs by MTT assay,Other,25702849.0,
4873,1193107,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against IL2-independent cat FL-4 cells assessed as reduction in cell viability after 7 days by MTT assay,Confirmatory,25702849.0,
4874,1193108,1,1,,103188975,35370,Active,,,5.31,EC50,Antiviral activity against Feline immunodeficiency virus infected in cat FL-4 cells assessed as inhibition of viral replication after 7 days by quantitative RT-PCR analysis,Confirmatory,25702849.0,
4875,1193109,1,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for cat FL-4 cells to EC50 for Feline immunodeficiency virus infected in cat FL-4 cells",Other,25702849.0,
4876,1197829,1,1,,103188975,35370,Active,,,0.0071,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25626145.0,
4877,1197830,1,1,,103188975,35370,Unspecified,,,94.0,CC50,Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay,Confirmatory,25626145.0,
4878,1197831,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells",Other,25626145.0,
4879,1197832,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25626145.0,
4880,1197833,1,1,,103188975,35370,Unspecified,,,,,"Resistance index, ratio of EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant to EC50 for wild type HIV1 3B",Other,25626145.0,
4881,1197834,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant",Other,25626145.0,
4882,1199051,1,1,,103188975,35370,Unspecified,,,25.0,CC50,Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay,Confirmatory,24926807.0,
4883,1199052,1,1,,103188975,35370,Active,,,0.0071,IC50,Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay,Confirmatory,24926807.0,
4884,1199053,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for Human immunodeficiency virus 1 3b infected in human MT4 cells",Other,24926807.0,
4885,1199054,1,1,,103188975,35370,Active,,,0.006,IC50,Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay,Confirmatory,24926807.0,
4886,1199055,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to IC50 for Human immunodeficiency virus type 2 ROD infected in human MT4 cells",Other,24926807.0,
4887,1200843,1,1,,103188975,35370,Active,,,0.006999999999999999,EC50,Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25707013.0,
4888,1200844,1,1,,103188975,35370,Active,,,0.01,EC50,Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay,Confirmatory,25707013.0,
4889,1200845,1,1,,103188975,35370,Unspecified,,,94.0,CC50,Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay,Confirmatory,25707013.0,
4890,1200846,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells",Other,25707013.0,
4891,1200847,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant",Other,25707013.0,
4892,1203614,1,1,,103188975,35370,Active,,,,,Antioxidant activity in Wistar rat brain assessed as inhibition of TBARS formation at 200 uM after 60 mins by spectrophotometric method relative to control,Other,25811955.0,
4893,1203615,1,1,,103188975,35370,Unspecified,,,,,Antioxidant activity assessed as thiol peroxidase-like activity assessed as concentration required to oxidize 50% of benzenethiol during reduction of hydrogen peroxide measured for 180 secs by UV spectroscopic analysis,Other,25811955.0,
4894,1203617,1,1,,103188975,35370,Unspecified,,,,,Toxicity in rat liver assessed as effect on cell viability at 50 to 200 uM after 2 hrs by MTT reduction assay relative to control,Other,25811955.0,
4895,1203618,1,1,,103188975,35370,Unspecified,,,,,Toxicity in rat liver assessed as change in AST release relative to control,Other,25811955.0,
4896,1203619,1,1,,103188975,35370,Unspecified,,,,,Toxicity in rat liver assessed as change in ALT release relative to control,Other,25811955.0,
4897,1203620,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against human 5637 cells assessed as growth inhibition at 50 uM after 48 hrs by MTT assay relative to control,Other,25811955.0,
4898,1203621,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against human 5637 cells assessed as growth inhibition at 12.5 to 200 uM after 48 hrs by MTT assay relative to control,Other,25811955.0,
4899,1203623,1,1,,103188975,35370,Active,,,7.0,IC50,Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,25811955.0,
4900,1203625,1,1,,103188975,35370,Unspecified,,,,,Induction of apoptosis in human 5637 cells at 50 uM after 48 hrs by annexin V-PE/7-AAD staining-based flow cytometric analysis (Rvb = 7.36%),Other,25811955.0,
4901,1203626,1,1,,103188975,35370,Inactive,,,,,Induction of apoptosis in human 5637 cells assessed as DNA fragmentation at 50 to 100 uM after 48 hrs by TUNEL assay relative to control,Other,25811955.0,
4902,1203627,1,1,,103188975,35370,Inactive,,,,,Cytotoxicity against human 5637 cells assessed as dead cells at 100 uM after 48 hrs by calcein/ethidium bromide staining-based fluorescence microscopic analysis relative to control,Other,25811955.0,
4903,1203628,1,1,,103188975,35370,Active,,,,,Downregulation of Bcl2 mRNA expression in human 5637 cells at 100 uM after 48 hrs by real-time PCR analysis relative to control,Other,25811955.0,
4904,1203629,1,1,,103188975,35370,Unspecified,,,,,Induction of apoptosis in human 5637 cells assessed as ratio of Bax mRNA to Bcl2 mRNA level at 100 uM after 48 hrs by real-time PCR analysis (Rvb = 0.08 to 0.13 No_unit),Other,25811955.0,
4905,1203630,1,1,,103188975,35370,Unspecified,,,,,Induction of apoptosis in human 5637 cells assessed as ratio of Bax mRNA to Bcl2 mRNA level at 50 uM after 48 hrs by real-time PCR analysis (Rvb = 0.08 to 0.13 No_unit),Other,25811955.0,
4906,1204139,1,1,,103188975,35370,Inactive,,,,,Antimycobacterial activity against Mycobacterium sp.,Other,25933593.0,
4907,1204140,1,2,,103188975,35370,Active,,,34.45,IC50,Cytotoxicity against human DU145 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
4908,1204141,1,1,,103188975,35370,Active,,,16.19,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
4909,1204142,1,1,,103188975,35370,Active,,,34.97,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
4910,1204143,1,1,,103188975,35370,Unspecified,,,65.46,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB method,Confirmatory,25933593.0,
4911,1204144,1,1,,103188975,35370,Unspecified,,,200.0,IC50,Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method,Confirmatory,25933593.0,
4912,1209581,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
4913,1209582,1,1,,103188975,35370,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
4914,1209583,1,1,,103188975,35370,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
4915,1213031,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Drug metabolism assessed as UGT2B7 activity in human liver microsome assessed as of O-glucuronidation at 25 to 200 uM incubated for 60 mins by LC-MS/MS analysis,Other,22028316.0,
4916,1220783,1,1,,103188975,35370,Unspecified,,,,,Drug metabolism in human assessed as glucuronide concentration in bile and urine,Other,21282406.0,
4917,1220784,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in mouse plasma by ultracentrifugation method,Other,21282406.0,
4918,1220785,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in rat plasma by ultracentrifugation method,Other,21282406.0,
4919,1220786,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in monkey plasma by ultracentrifugation method,Other,21282406.0,
4920,1220787,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in dog plasma by ultracentrifugation method,Other,21282406.0,
4921,1220788,1,2,,103188975,35370,Unspecified,,,,,Fraction unbound in human plasma by ultracentrifugation method,Other,21282406.0,
4922,1220789,1,2,,103188975,35370,Unspecified,,,,,Ratio of drug level in blood to plasma in mouse,Other,21282406.0,
4923,1220790,1,2,,103188975,35370,Unspecified,,,,,Ratio of drug level in blood to plasma in rat,Other,21282406.0,
4924,1220791,1,2,,103188975,35370,Unspecified,,,,,Ratio of drug level in blood to plasma in monkey,Other,21282406.0,
4925,1220792,1,2,,103188975,35370,Unspecified,,,,,Ratio of drug level in blood to plasma in dog,Other,21282406.0,
4926,1220793,1,2,,103188975,35370,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,21282406.0,
4927,1220794,1,1,,103188975,35370,Unspecified,,,,,Plasma clearance in human,Other,21282406.0,
4928,1220795,1,1,,103188975,35370,Unspecified,,,,,Plasma clearance in po dosed human,Other,21282406.0,
4929,1220796,1,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
4930,1220797,1,1,,103188975,35370,Unspecified,,,,,Volume of distribution at steady state in human,Other,21282406.0,
4931,1220798,1,1,,103188975,35370,Unspecified,,,,,Half life in human,Other,21282406.0,
4932,1220799,1,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
4933,1220800,1,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
4934,1220801,1,1,,103188975,35370,Unspecified,,,,,"Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
4935,1221956,1,1,,103188975,35370,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4936,1221957,1,1,,103188975,35370,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4937,1221958,1,1,,103188975,35370,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4938,1221966,1,1,,103188975,35370,Unspecified,,,,,Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse,Other,21051535.0,
4939,1221968,1,1,,103188975,35370,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4940,1221969,1,1,,103188975,35370,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4941,1221970,1,1,,103188975,35370,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4942,1221975,1,1,,103188975,35370,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4943,1221976,1,1,,103188975,35370,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4944,1221977,1,1,,103188975,35370,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
4945,1221982,1,1,,103188975,35370,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
4946,1223445,1,2,,103188975,35370,Unspecified,136727.0,7364.0,307.0,Km,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4947,1223446,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4948,1223447,1,2,,103188975,35370,Unspecified,136727.0,7364.0,200.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human liver microsomes assessed as reduction in enzyme-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4949,1223448,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4950,1223449,1,2,,103188975,35370,Unspecified,136727.0,7364.0,519.0,Km,Drug metabolism in diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4951,1223450,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4952,1223451,1,2,,103188975,35370,Unspecified,136727.0,7364.0,150.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in diabetic human kidney microsomes assessed as reduction in enzyme-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4953,1223465,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4954,1223466,1,2,,103188975,35370,Unspecified,136727.0,7364.0,330.0,Km,Drug metabolism in non-diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4955,1223467,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4956,1223468,1,2,,103188975,35370,Unspecified,136727.0,7364.0,200.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human liver microsomes assessed as reduction in enzyme-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4957,1223469,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4958,1223470,1,2,,103188975,35370,Unspecified,136727.0,7364.0,519.0,Km,Drug metabolism in non-diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4959,1223471,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Ratio of Vmax to Km in non-diabetic human kidney microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4960,1223472,1,2,,103188975,35370,Unspecified,136727.0,7364.0,150.0,Ki,Uncompetitive substrate inhibition of UGT2B7 in non-diabetic human kidney microsomes assessed as reduction in enzyme-mediated zidovudine glucuronide formation by HPLC and LC-MS/MS method,Confirmatory,21123165.0,
4961,1223473,1,2,,103188975,35370,Unspecified,136727.0,7364.0,,,Drug metabolism in diabetic human liver microsomes assessed as UGT2B7-mediated zidovudine glucuronide formation per pmol protein by HPLC and LC-MS/MS method,Other,21123165.0,
4962,1224824,1,1,,162108254,35370,Inactive,,,4.6859,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
4963,1224825,1,1,,162108254,35370,Inactive,,,26.3506,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
4964,1224834,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4965,1224834,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4966,1224834,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4967,1224835,1,1,,144209401,35370,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4968,1224835,1,1,,144210895,35370,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4969,1224835,1,1,,170464737,35370,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4970,1224836,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4971,1224836,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4972,1224836,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4973,1224837,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4974,1224837,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4975,1224837,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4976,1224838,1,1,,144209401,35370,Inconclusive,66775687.0,9970.0,0.3151,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4977,1224838,1,1,,144210895,35370,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4978,1224838,1,1,,170464737,35370,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4979,1224839,1,1,,144209401,35370,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4980,1224839,1,1,,144210895,35370,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4981,1224839,1,1,,170464737,35370,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4982,1224840,3,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4983,1224840,3,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4984,1224840,3,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4985,1224841,3,1,,144209401,35370,Inactive,325495545.0,2101.0,35.3574,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4986,1224841,3,1,,144210895,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4987,1224841,3,1,,170464737,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4988,1224842,3,1,,144209401,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4989,1224842,3,1,,144210895,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4990,1224842,3,1,,170464737,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4991,1224843,1,1,,144209401,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4992,1224843,1,1,,144210895,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4993,1224843,1,1,,170464737,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4994,1224844,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4995,1224844,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4996,1224844,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4997,1224845,1,1,,144209401,35370,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4998,1224845,1,1,,144210895,35370,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4999,1224845,1,1,,170464737,35370,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5000,1224846,1,1,,144209401,35370,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5001,1224846,1,1,,144210895,35370,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5002,1224846,1,1,,170464737,35370,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5003,1224847,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5004,1224847,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5005,1224847,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5006,1224848,3,1,,144209401,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5007,1224848,3,1,,144210895,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5008,1224848,3,1,,170464737,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5009,1224849,3,1,,144209401,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5010,1224849,3,1,,144210895,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5011,1224849,3,1,,170464737,35370,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5012,1224857,2,1,,162108254,35370,Inactive,,,7.4266,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5013,1224857,2,1,,170464737,35370,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5014,1224859,2,1,,90341185,35370,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5015,1224859,2,1,,162108254,35370,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5016,1224859,2,1,,170464737,35370,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5017,1224864,1,2,,316935145,35370,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
5018,1224865,1,2,,49718184,35370,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
5019,1224867,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5020,1224867,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5021,1224867,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5022,1224868,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5023,1224868,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5024,1224868,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5025,1224869,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5026,1224869,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5027,1224869,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5028,1224870,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5029,1224870,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5030,1224870,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5031,1224871,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5032,1224871,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5033,1224871,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5034,1224872,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5035,1224872,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5036,1224872,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5037,1224873,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5038,1224873,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5039,1224873,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5040,1224874,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5041,1224874,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5042,1224874,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5043,1224875,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5044,1224875,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5045,1224875,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5046,1224876,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5047,1224876,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5048,1224876,1,1,,170464737,35370,Inconclusive,,,10.6822,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5049,1224877,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5050,1224877,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5051,1224877,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5052,1224878,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5053,1224878,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5054,1224878,1,1,,170464737,35370,Inconclusive,,,13.4481,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5055,1224879,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5056,1224879,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5057,1224879,1,1,,170464737,35370,Inconclusive,,,15.089,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5058,1224880,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5059,1224880,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5060,1224880,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5061,1224881,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5062,1224881,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5063,1224881,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5064,1224882,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5065,1224882,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5066,1224882,1,1,,170464737,35370,Inconclusive,,,13.4481,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5067,1224883,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5068,1224883,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5069,1224883,1,1,,170464737,35370,Inconclusive,,,13.4481,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5070,1224884,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5071,1224884,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5072,1224884,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5073,1224885,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5074,1224885,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5075,1224885,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5076,1224886,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5077,1224886,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5078,1224886,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5079,1224887,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5080,1224887,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5081,1224887,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5082,1224888,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5083,1224888,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5084,1224888,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5085,1224889,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5086,1224889,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5087,1224889,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5088,1224890,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5089,1224890,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5090,1224890,1,1,,170464737,35370,Inconclusive,,,10.6822,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5091,1224892,1,1,,144209401,35370,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5092,1224892,1,1,,144210895,35370,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5093,1224892,1,1,,170464737,35370,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5094,1224893,1,1,,144209401,35370,Active,66775687.0,9970.0,0.518976,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5095,1224893,1,1,,144210895,35370,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5096,1224893,1,1,,170464737,35370,Inconclusive,66775687.0,9970.0,1.18832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5097,1224894,1,1,,144209401,35370,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5098,1224894,1,1,,144210895,35370,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5099,1224894,1,1,,170464737,35370,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5100,1224895,1,1,,144209401,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5101,1224895,1,1,,144210895,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5102,1224895,1,1,,170464737,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5103,1224896,1,1,,144209401,35370,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5104,1224896,1,1,,144210895,35370,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5105,1224896,1,1,,170464737,35370,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5106,1224905,2,1,,92309127,35370,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5107,1224905,2,1,,92309127,35370,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5108,1226478,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against West Nile virus infected in BHK-WII RepRen1B cells assessed as inhibition of viral replication at 10 uM after 3 days by luciferase reporter gene assay relative to control,Other,25909386.0,
5109,1226479,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against BHK cells infected with West Nile virus replicon assessed as cell viability at 10 uM after 3 days by CellTiter 96 aqueous one solution cell proliferation assay relative to control,Other,25909386.0,
5110,1226480,1,1,,103188975,35370,Unspecified,,,,,Antiviral activity against Dengue virus infected in BHK pD2-hRucPac-2ATG cells assessed as inhibition of viral replication at 10 uM after 3 days by luciferase reporter gene assay relative to control,Other,25909386.0,
5111,1226481,1,1,,103188975,35370,Unspecified,,,,,Cytotoxicity against BHK cells infected with Dengue virus replicon assessed as cell viability at 10 uM after 3 days by CellTiter 96 aqueous one solution cell proliferation assay relative to control,Other,25909386.0,
5112,1228734,1,1,,103188975,35370,Unspecified,,,25.0,CC50,Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay,Confirmatory,25946116.0,
5113,1228735,1,1,,103188975,35370,Active,,,0.0071,EC50,Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay,Confirmatory,25946116.0,
5114,1228736,1,1,,103188975,35370,Active,,,0.006,EC50,Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay,Confirmatory,25946116.0,
5115,1228737,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1-3B",Other,25946116.0,
5116,1228738,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2-ROD",Other,25946116.0,
5117,1231485,1,1,,103188975,35370,Active,,,0.0056,EC50,Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay,Confirmatory,25907370.0,
5118,1231486,1,1,,103188975,35370,Active,,,0.0052,EC50,Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay,Confirmatory,25907370.0,
5119,1231487,1,1,,103188975,35370,Inconclusive,,,,IC50,Inhibition of wild-type HIV1 Reverse transcriptase p66/p51 assessed as relative fluorescence signal after 40 mins,Confirmatory,25907370.0,
5120,1231488,1,1,,103188975,35370,Unspecified,,,94.0,CC50,Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay,Confirmatory,25907370.0,
5121,1231489,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells",Other,25907370.0,
5122,1231846,1,1,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days,Confirmatory,25970561.0,
5123,1231847,1,1,,103188975,35370,Inconclusive,,,,,"Selectivity index, CC50 for african green monkey Vero cells to EC50 for chikungunya virus Indian ocean strain 899",Other,25970561.0,
5124,1231848,1,1,,103188975,35370,Active,,,7.1,EC50,Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay,Confirmatory,25970561.0,
5125,1231849,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV1 3B",Other,25970561.0,
5126,1231850,1,1,,103188975,35370,Active,,,6.0,EC50,Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay,Confirmatory,25970561.0,
5127,1231851,1,1,,103188975,35370,Unspecified,,,,,"Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV2 ROD",Other,25970561.0,
5128,1235865,1,1,,103188975,35370,Active,,,0.02,EC50,Antiviral activity against HIV1 assessed as inhibition of cytopathic effect by microtiter syncytium formation infectivity assay,Confirmatory,26214125.0,
5129,1235866,1,1,,103188975,35370,Unspecified,,,4690.0,CC50,Cytotoxicity against human C8166 cells by MTT assay,Confirmatory,26214125.0,
5130,1235867,1,1,,103188975,35370,Unspecified,,,,,"Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1",Other,26214125.0,
5131,1237699,1,1,,103188975,35370,Active,,,0.044000000000000004,EC50,Antiviral activity against HIV1 3B infected in human CEM/0 cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days,Confirmatory,26125628.0,
5132,1237700,1,1,,103188975,35370,Active,,,0.49,EC50,Antiviral activity against HIV2 ROD infected in human CEM/0 cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days,Confirmatory,26125628.0,
5133,1237701,1,1,,103188975,35370,Unspecified,,,250.0,EC50,Antiviral activity against HIV2 ROD infected in human thymidine kinase deficient CEM/TK- cells assessed as reduction in virus-induced giant cell formation incubated for 4 to 5 days,Confirmatory,26125628.0,
5134,1237702,1,1,,103188975,35370,Unspecified,,,250.0,CC50,Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days,Confirmatory,26125628.0,
5135,1238309,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells by MTT assay,Confirmatory,26094944.0,
5136,1238310,1,1,,103188975,35370,Active,,,27.0,CC50,Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine,Confirmatory,26094944.0,
5137,1238311,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine,Confirmatory,26094944.0,
5138,1238312,1,1,,103188975,35370,Active,,,31.0,CC50,Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine,Confirmatory,26094944.0,
5139,1238313,1,1,,103188975,35370,Active,,,0.12,EC50,Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay,Confirmatory,26094944.0,
5140,1238314,1,1,,103188975,35370,Active,,,0.015,EC50,Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine,Confirmatory,26094944.0,
5141,1238315,1,1,,103188975,35370,Active,,,0.013000000000000001,EC50,Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine,Confirmatory,26094944.0,
5142,1238316,1,1,,103188975,35370,Inconclusive,,,,EC50,Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 10 uM of chloroquine,Confirmatory,26094944.0,
5143,1238317,1,1,,103188975,35370,Active,,,0.51,EC50,Antiviral activity against macrophage-tropic HIV1 NL(AD8) infected in human PM1 expressing CCR5 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine,Confirmatory,26094944.0,
5144,1238318,1,1,,103188975,35370,Unspecified,,,100.0,CC50,Cytotoxicity against human PM1 cells expressing CCR5 by MTT assay in presence of 5 uM of chloroquine,Confirmatory,26094944.0,
5145,1238518,1,1,,103188975,35370,Unspecified,,,,,Inhibition of HIV-1 reverse transcriptase in human Jurkat cells assessed as ratio MTT activity to reverse transcriptase activity with compound/reverse transcriptase activity with DMSO at 1 uM after 72 hrs (Rvb = 0.356 No_unit),Other,26112446.0,
5146,1238520,1,1,,103188975,35370,Unspecified,,,,,Inhibition of HIV-1 reverse transcriptase in human Jurkat cells assessed as ratio MTT activity to reverse transcriptase activity with compound/reverse transcriptase activity with DMSO at 10 uM after 72 hrs (Rvb = 0.795 No_unit),Other,26112446.0,
5147,1238542,1,1,,103188975,35370,Active,113576.0,213.0,44.0,Kd,Binding affinity to human serum albumin with excitation at 280 nm after 2 hrs by spectrofluorimetric analysis,Confirmatory,26112446.0,
5148,1242368,1,1,,103188975,35370,Inactive,46577576.0,7852.0,,IC50,Inhibition of CXCR4 in human Jurkat cells assessed as reduction in HIV-Nef-M1-induced mitochondrial membrane depolarization at 0.01 to 100 uM by JC1 dye based fluorescence depolarization assay,Confirmatory,26191361.0,
5149,1248672,1,1,,103188975,35370,Inconclusive,74762365.0,29028.0,,Kd,"Binding affinity to recombinant human ATAD2 (982 to 1108 amino acids) bromodomain radiolabelled at methyl groups of leucine, valine, isoleucine, methionine expressed in Escherichia coli BL21 (DE3) by NMR titration",Confirmatory,,
5150,1259241,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5151,1259241,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5152,1259241,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5153,1259242,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5154,1259242,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5155,1259242,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5156,1259243,1,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5157,1259243,1,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5158,1259243,1,1,,170464737,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5159,1259244,1,1,,144209401,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5160,1259244,1,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5161,1259244,1,1,,170464737,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5162,1259247,1,1,,144209401,35370,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5163,1259247,1,1,,144210895,35370,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5164,1259247,1,1,,170464737,35370,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5165,1259248,1,1,,144209401,35370,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5166,1259248,1,1,,144210895,35370,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5167,1259248,1,1,,170464737,35370,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5168,1259252,1,1,,162108254,35370,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
5169,1259253,1,1,,162108254,35370,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
5170,1259255,1,1,,162108254,35370,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
5171,1259256,1,1,,162108254,35370,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
5172,1259310,1,1,,104170164,35370,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5173,1259310,1,1,,321942150,35370,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5174,1259310,1,1,,333493933,35370,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5175,1259313,1,1,,49718184,35370,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
5176,1259318,1,1,,49718184,35370,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
5177,1259325,1,2,,336954315,35370,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
5178,1259344,1,1,,144203613,35370,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5179,1259344,1,1,,144204445,35370,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5180,1259355,1,1,,144203613,35370,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
5181,1259355,1,1,,144204445,35370,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
5182,1259356,1,1,,144203613,35370,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
5183,1259356,1,1,,144204445,35370,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
5184,1259364,1,1,,144209401,35370,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5185,1259364,1,1,,144210895,35370,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5186,1259364,1,1,,170464737,35370,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5187,1259365,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5188,1259365,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5189,1259365,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5190,1259366,1,1,,144209401,35370,Inconclusive,,,79.1554,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5191,1259366,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5192,1259366,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5193,1259367,1,1,,144209401,35370,Active,,,70.5473,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5194,1259367,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5195,1259367,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5196,1259368,1,1,,144209401,35370,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5197,1259368,1,1,,144210895,35370,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5198,1259368,1,1,,170464737,35370,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5199,1259369,1,1,,144209401,35370,Active,109731339.0,2737.0,17.7207,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5200,1259369,1,1,,144210895,35370,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5201,1259369,1,1,,170464737,35370,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5202,1259377,1,1,,144209401,35370,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5203,1259377,1,1,,144210895,35370,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5204,1259377,1,1,,170464737,35370,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5205,1259378,1,1,,144209401,35370,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5206,1259378,1,1,,144210895,35370,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5207,1259378,1,1,,170464737,35370,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5208,1259379,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5209,1259379,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5210,1259379,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5211,1259380,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5212,1259380,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5213,1259380,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5214,1259381,1,1,,144209401,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5215,1259381,1,1,,144210895,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5216,1259381,1,1,,170464737,35370,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5217,1259382,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5218,1259382,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5219,1259382,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5220,1259383,1,1,,144209401,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5221,1259383,1,1,,144210895,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5222,1259383,1,1,,170464737,35370,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5223,1259384,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5224,1259384,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5225,1259384,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5226,1259385,1,1,,144209401,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5227,1259385,1,1,,144210895,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5228,1259385,1,1,,170464737,35370,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5229,1259386,1,1,,144209401,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5230,1259386,1,1,,144210895,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5231,1259386,1,1,,170464737,35370,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5232,1259387,1,1,,144209401,35370,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5233,1259387,1,1,,144210895,35370,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5234,1259387,1,1,,170464737,35370,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5235,1259388,1,1,,144209401,35370,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5236,1259388,1,1,,144210895,35370,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5237,1259388,1,1,,170464737,35370,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5238,1259389,1,1,,124637746,35370,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
5239,1259390,1,1,,144209401,35370,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5240,1259390,1,1,,144210895,35370,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5241,1259390,1,1,,170464737,35370,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5242,1259391,1,1,,144209401,35370,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5243,1259391,1,1,,144210895,35370,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5244,1259391,1,1,,170464737,35370,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5245,1259392,1,1,,144209401,35370,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5246,1259392,1,1,,144210895,35370,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5247,1259392,1,1,,170464737,35370,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5248,1259393,1,1,,144209401,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5249,1259393,1,1,,144210895,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5250,1259393,1,1,,170464737,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5251,1259394,1,1,,144209401,35370,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5252,1259394,1,1,,144210895,35370,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5253,1259394,1,1,,170464737,35370,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5254,1259395,1,1,,144209401,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5255,1259395,1,1,,144210895,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5256,1259395,1,1,,170464737,35370,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5257,1259396,1,1,,144209401,35370,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5258,1259396,1,1,,144210895,35370,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5259,1259396,1,1,,170464737,35370,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5260,1259400,1,1,,170464737,35370,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
5261,1259401,1,1,,144209401,35370,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5262,1259401,1,1,,144210895,35370,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5263,1259401,1,1,,170464737,35370,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5264,1259402,1,1,,144209401,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5265,1259402,1,1,,144210895,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5266,1259402,1,1,,170464737,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5267,1259403,1,1,,144209401,35370,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5268,1259403,1,1,,144210895,35370,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5269,1259403,1,1,,170464737,35370,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5270,1259404,1,1,,144209401,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5271,1259404,1,1,,144210895,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5272,1259404,1,1,,170464737,35370,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5273,1259406,1,1,,363920339,35370,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
5274,1259406,1,1,1.0,363920339,35370,Inactive,26638650.0,3778.0,-0.00122862,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
5275,1259406,1,1,2.0,363920339,35370,Inactive,4758626.0,3779.0,0.0378606,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5276,1259406,1,1,3.0,363920339,35370,Inactive,5031823.0,10242.0,0.00186346,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5277,1259406,1,1,4.0,363920339,35370,Inactive,26051275.0,27345.0,0.0147683,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5278,1259406,1,1,5.0,363920339,35370,Inactive,160410009.0,389816.0,0.0180802,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5279,1259406,1,1,6.0,363920339,35370,Inactive,26638650.0,3778.0,-0.0156568,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
5280,1259406,1,1,7.0,363920339,35370,Inactive,4758626.0,3779.0,-0.0324137,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5281,1259406,1,1,8.0,363920339,35370,Inactive,5031823.0,10242.0,0.0218671,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5282,1259406,1,1,9.0,363920339,35370,Inactive,26051275.0,27345.0,0.00485424,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5283,1259406,1,1,10.0,363920339,35370,Inactive,5031823.0,10242.0,0.0220488,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
5284,1259407,1,1,,363898055,35370,Active,,,,,CCRIS mutagenicity studies,Other,,
5285,1259411,1,1,,363898055,35370,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
5286,1259413,1,2,,104170164,35370,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
5287,1259415,1,1,,49718184,35370,Inconclusive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
5288,1259416,1,2,,56423125,35370,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5289,1259416,1,2,,375178239,35370,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5290,1259421,1,1,,375178239,35370,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5291,1259423,1,2,,354950733,35370,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5292,1259423,1,2,,354966212,35370,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5293,1259423,1,2,,354990329,35370,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
